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SUMMARY
Cases of AIDS have been reported in the U.S.A. since 1981 and its 
a etiological agent, human inmunodef iciency virus type 1, HIV-1, has 
been spreading in the population for longer. A testing system was 
established at the Hepatitis Reference Laboratory, HRL, to identify 
those infected in the Glasgow and West of Scotland population. The 
performance of commercial screening tests was examined using sera 
locally available at the HRL. Confirmation of reactivity was 
confirmed by western blot analysis: other methods of confirmation
were examined. Hie criteria of positivity on a western blot were 
established from observation of the antibody response in 
seroconversion and weakly reactive samples compared to false reactive 
or indeterminate samples. In this way genuine HIV-1 infection could 
be reliably diagnosed.
Hie prevalence of HIV-1 infection in the conmunity was assessed 
and various risk groups identified and studied in detail. Hie groups 
at high risk of infection were the same as those initially reported 
from the United States, i.e. homosexuals (including bisexuals), 
intravenous drug abusers and haemophiliacs. A prevalence of less than 
2% was found in drug abusers, in narked contrast to the situation in 
Edinburgh, with first infection detected in 1985. Infection in 
haemophiliacs pre-da ted the discovery of HIV-1 with the earliest 
seropositive sample in Glasgow being 1981. Early infection of 
homosexuals was suspected to be around that time or before.
Hie progress of HIV-1 infection was followed in a group of 
patients attending the Infectious Disease clinics at Ruchill Hospital 
and in the HIV-1 infected haemophiliacs. Three marker changes 
associated with progression, i.e. loss of anti-p24, production of p24 
antigen and raised j^-microglobulin were examined along with clinical 
details to establish their usefulness in predicting onset of disease. 
An association with disease progression was observed with each marker. 
However no formula for progression based on marker changes could be 
established and individuality of response was the common theme. A 
association between age and disease progression was noted in the 
haemophiliacs.
ABBREVIATIONS
Ab Antibody
Ag Antigen
AIDS Acquired irnaunodeficiency syndrome, also
acquired immune deficiency syndrome 
anti-gag (env) Antibody to group specific antigen
(envelope protein) 
anti-HIV(1 /2) Antibody to human inmunodef iciency virus
(type1/type2 )
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CHAPTER 1
INTRODUCTION 
1. RETROVIRUSES
What is a Retrovirus?
The study of retroviruses has seen many advances in the past two 
decades, most notably since the detection and isolation of the first 
human retrovirus, Human T-cell Leukaemia Virus Type I (HELV-I) by 
Poiesz et al. (1) in 1980-81 and subsequently Human Iranunodeficiency 
Virus, HIV, (formerly Human T-cell Lymphotropic Virus Type 
III /Lymphadenopa thy Associated Virus), the a etiological agent of 
Acquired Immune Deficiency Syndrome, AIDS (2, 3).
Retroviridae are enveloped, spherical viruses containing two 
copies of single-stranded, positive sense ribonucleic acid (RNA) and 
are distinguished by a viral-coded RNA-dependent DNA polymerase, a 
reverse transcriptase (RT). This reverse transcriptase catalyses the 
synthesis of double-stranded complementary deoxyribonucleic acid 
(cDNA) using RNA as a template. The cDNA circularises and becomes 
integrated into the host genome, thereby establishing latency which is 
an important feature of retroviral infection. Retroviruses were so 
named because they reverse what is the normal flow of genetic 
information as their RNA genome must be converted into DNA before 
viral expression.
Classification of Retroviruses (4,5)
The retroviridae are broadly classified by mechanism of 
transmission as either endogenous or exogenous retroviruses where the 
former are integrated into normal cellular DNA, probably as a remnant 
of an ancient infection and are passed vertically from generation to 
generation via the germ line, in a Mendelian fashion. Exogenous 
retroviruses can be split into two groups:
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( i) those carrying one genes derived from host DNA and 
directly coding for a protein involved in neoplastic transformation. 
Infection with such a virus leads to rapid development of malignancy 
and these are referred to as acute leukaemia viruses.
(ii) those which do not carry an one gene, do not transform 
cells in vitro and are slow to produce disease in vivo. These are 
known as chronic leukaemia viruses.
There are 3 sub-families of retrovirus based on pathogenesis; 
(i) Qnccvirinae: these viruses can induce tumour formation, e.g.
feline leukaemia virus FeLV, bovine leukaemia virus BLV and human 
T-lymphotropic virus HTLV;
(ii) Lentivirinae: these are exogenous retroviruses which 
infect ungulate mammals especially sheep, goat and horses. 
Progression to disease is slow (over many years) and infection often 
results in degenerative diseases of the central nervous system, e.g. 
visna virus of sheep and equine infectious anaemia virus EIAV also 
feline immunodeficiency virus FIV, and human immunodeficiency virus 
HIV, etc. and
(iii) Spuraavirinae, the foamy viruses which induce persistent 
infection but are thought to be non-pathogenic, e.g. simian virus 5 
(SV5).
Retroviruses are also classified by morphology into type A, B, C 
or D particles as observed in electron microscopic studies. Type A 
produces an imnature form and are only found intracellularly while the 
other three types produce particles which bud from the host cell 
membrane; type B have an eccentric core on budding, e.g. mouse 
mammary tumour virus type C the most abundant sub-family, have a
central, spherical core, e.g. FeLV, HTLV, BLV etc. and type D with a 
cylindrical central core, e.g. Mason-Pfizer and related primate 
retroviruses and HIV (6,7).
Hie Retroviral Genome, its Organisation and Gene Products
Sane basic features of the genome organisation are common to all 
retroviruses (4 PP^61-368 ^ p^pl 7-73^
The genome of a retrovirus contains 3 major structural genes,
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gag which codes for the group-specific or core antigen, pol the 
polymerase gene and env the envelope gene which are flanked on either 
side in the proviral DNA by a series of nucleotides forming long 
terminal repeats (LTRs) (Fig.1.1). The LTR region contains the 
binding site for the RNA polymerase and important sequences involved 
in the control of replication of the virus, e.g. promoter and enhancer 
sequences. This region is also responsible for the integration of 
the DNA provirus into host cellular DNA. A number of other open 
reading frames are present between pol and env or env and LTR, 
encoding non-structural genes whose protein products may play a role 
in the regulation of viral expression and maturation.
The gag gene encodes a precursor protein which is cleaved to 
yield 3 or more internal structural proteins. The major core protein 
surrounds the viral RNA and associated nucleic acid-binding proteins. 
The pol gene encodes the enzymes required at various stages of the 
viral life-cycle; an Integrase, reverse transcriptase and a protease. 
The env gene encodes a precursor envelope protein which may be 
glycosylated. This is cleaved to an outer membrane protein (OMP) and 
a smaller transraerabrane protein(TMP), at least one of which is 
glycosylated. The IMP spans the lipid bilayer of the mature virus 
and is linked to the OMP by a disulphide bond. The OMP forms the 
spikes seen by electron microscopy and plays an important role in the 
binding of virus to its receptor and induction of neutralising 
antibody. The lipid bilayer surrounding the virus is derived from 
the host cell by budding of mature virus particles through the 
membrane of the host cell. The retroviral nucleic acid contains 
other open reading frames (orfs) varying in number and gencroe location 
in different viruses. These can be involved in control of gene 
expression, maturation and infectivity of the virus.
Retroviruses and their Association with Disease
The possible involvement of viruses in cancer was first 
postulated by Ellerraan and Bang in 1908 (8 ), who shewed that a 
filterable agent was responsible for the transmission of leukaemia in 
fowl. Peyton Rous (1910-1911) (9) also demonstrated that cell-free
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filtrates were able to transmit tumours in chickens and he isolated 
the first such agent, Rous sarccma virus (RSV). Many scientists did 
not believe that leukaemia was linked to cancer nor in the concept of 
infectivity in cancer so the subject lay dormant for several decades. 
In the 1950s, Gross et al. (10) isolated an RNA tumour virus from 
murine leukaemia cells. Further work followed on simian RNA tumour 
viruses. This fostered the idea that a virus can cause a silent or 
latent infection in its natural host but could be pathogenic in 
another host. E.g. SV40, a papova virus which is non-pathogenic in 
monkeys, its normal host has oncogenic properties when injected into 
baby hamsters.
As the work performed on mice involved using inbred laboratory 
strains there was a possibility that infections could be congenital 
and thus not an effect of the virus. Further progress was not seen 
until the 1960s when a retrovirus of cats, feline leukaemia virus FeLV 
(1 1) was discovered and it was observed that this virus could be 
transmitted horizontally amongst unrelated cats in household 
surroundings. Hence it was possible that a form of cancer could be 
transmitted and this work laid the foundations for the discovery of 
cancer-causing retroviruses in many species.
Retroviruses are the only known RNA viruses that can produce 
cancer and have been isolated from many species including sheep, 
chicken, ccws, goats, horses etc. and new man.
HOMAN T-LYMPHOTROPIC VIRUSES TYPE I AND II (HTLV-1 AND HTLV-II) 
Isolation
The first human retrovirus was not detected until 1980-81 by 
isolation from cultured T cells. HTLV-I was isolated from two black 
US patients with T cell malignancies thought to be an aggressive 
variant of cutaneous T cell lymphoma (1,12).
Research had concentrated on the search for endogenous viruses 
and only those with high replicating activity could be detected with 
the methods available. The search for a human retrovirus was 
facilitated by two important findings in the 1970s. The first was
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the independent and simultaneous discovery of the enzyme, reverse 
transcriptase (RT) by Terain and Mitzutani (13) and by Baltimore (14). 
A sensitive assay was developed to detect RT activity. The second 
finding was the discovery that a growth factor or its receptor were 
produced by T cells on stimulation by an antigen or various mitogens, 
e.g. phytohaemagglutinin (PHA), a plant lectin. Those T cells 
secreting this factor bind to other T cells bearing its specific 
receptor and in such a way promotes their continuous growth (15). 
This was called T cell growth factor (TCGF) now referred to as 
Interleukin-2 (IL-2). In vitro cultures of human lymphocytes could 
now be maintained by the addition of IL-2. In this way T cells from 
leukaemic patients and those with T cell malignancies were examined. 
Some cell lines were able to grow without in vitro activation, the 
membrane already contained IL-2 receptors in contrast to normal T 
cells. It was from these cells that H3LV-I was isolated. A second 
human retrovirus HELV-II was isolated in 1982 from a patient, Mo, with 
a T cell variant of hairy cell leukaemia (16).
HTLV-I shares the qualities of both acute and chronic leukaemia 
viruses. It can transform primary cells in vitro as do the acute 
leukaemia viruses although it lacks an one gene; it also produces 
clonally derived tumours in vivo and has a long incubation time to 
production of disease, similar to chronic leukaemia viruses.
Morphology and Size
The HTLV family derive their name from their tropisra for T4 
cells. HTLV-I and -II have the morphology of a 1'budding" type C 
retrovirus. The average size of HTLV-I is 100nra, but ranges from 
90nm to 140nra in newly established cultures. One copy of proviral 
DNA is found in leukaemic cells and it is able to integrate anywhere 
in the host genome (17). This integration is conserved in the one 
patient but varies from patient to patient. HTLV-I shows greatest 
similarity to bovine leukaemia virus (BLV) (17) suggesting a distant 
evolutionary relationship.
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The Genome, its Organisation and Gene Products (17,18)
The genetic organisation of HTLV-I and II is similar to other 
retroviruses, i.e. gag, pol and env genes but also includes 
regulatory genes rex, regulator of expression of virion proteins, and 
tax (transactivator) designated with a subscript number 1 or 2 
pertaining to the relevant virus, e.g. rex^  and tax^  for HELV-I etc. 
This tax gene is highly conserved in the HTLV family (HTLV-II, BLV and 
simian T lyraphotropic virus type I, STLV-I). The protein product
(p42 in HTLV-I, p38 in HTLV-I I) operates in trans to activate viral 
gene expression and is involved in regulation of cellular genes (19). 
This unique tax sequence is capable of activating the gene for IL-2 
and its receptor and therefore may play a role in the raechanisn of 
oncogenesis of HTLV-I. The gene products of HTLV-I are described in 
Table 1.1. HTLV-H has 65% nucleotide sequence homology to HTLV-I 
and the encoded proteins are closely related (2 0).
HTLV and Disease
HTLV-I is associated with adult T cell leukaemia (AIL) (1,21) 
and mare recently with a neurological disorder called tropical spastic 
paraparesis (TSP) or HTLV-I associated myelopathy (HAM) (22,23). ATT. 
was first described as a new clinical syndrome in the 1970s in Japan 
(24) in particular among the residents of two southern Japanese 
islands, Shikoku and Kyushu. The link between HTLV-I and ATL was 
made when sera from Japanese ATL patients were tested and HTLV-I 
antibodies were present in almost all cases of ATL and in a high 
percentage of normal adults in endemic areas (25). Other
geographical clusters, have been identified, in the Caribbean islands, 
areas of South America, Southern Italy and parts of Africa. The 
virus is also endemic in immigrant populations in Europe, e.g. West 
Indian population in England, Surinam population of Holland, etc. 
(18).
HTLV-I I has not yet been definitely linked with any clinical 
disease state. Serological evidence of HTLV-11 infection has been 
found in intravenous drug abusers in England (26) and New Orleans (27) 
and in an isolated, symptom-free population of Guayami Indians in 
Panama (28).
TABLE 1.1 HTLV-I genes, their protein products and 
related function
Gene
gag
pol
env
rex-;
tax*;
Precursor Protein Location in Virus
Protein(s) Products and/or Function
*p53-- > p36,p32 p19
p28,p26
p24 Major internal core
protein surrounding 
viral RNA
p15 Nucleic-acid associated
protein
p14 Protease
p99 Reverse transcriptase
?p32
gp61 -gp68# gp46 OMP
gp21 IMP
p27 Regulatory
p24 Regulatory
gp - glycoprotein 
OMP - Outer membrane protein 
IMP - Transraembrane protein
* p53 represents a protein of molecular weight 53 kd.
# Molecular weight depends on the cell line used for isolation.
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HOMAN IMMUNODEFICIENCY VIROS TYPE 1 (HIV-1)
Isolation
Hie isolation of the third human retrovirus Human 
Innmuncdeficiency Virus, HIV, (formerly called HELV-III/LAV) was first 
achieved by Luc Montagnier and colleagues at the Pasteur Institute in 
Paris, 1983 (2). They co-cultivated an HTLV-I-like retrovirus from 
the lymph nodes of a homosexual patient with lyraphadenopathy and 
called it Lyn^ phadenopathy Associated Virus, LAV. It was noted that 
although the core proteins were similar in size to HTLV-I they
differed imnunologica lly and no cross-reaction was detected. 
Sufficient quantities of virus could not be produced to allow full 
characterisation of this isolate due to the cytopathic effect of LAV, 
in vitro. So the full impact of this discovery was not realised 
until one year later when Fopovic et al. (3) described the 
establishment of a permissive T-cell population, that could grow 
continuously and produce virus after infection, from a neoplastic, 
aneuploid T-cell line, HP, derived from a patient with lymphoid 
leukaemia. Using clones of these T-cell lines, specifically H9, 
Gallo et al. (29) were able to isolate a 'novel' retrovirus from
patients with AIDS and those at risk for AIDS. Robert Gallo and 
co-workers from the National Cancer Institute (NCI) in Bethesda, 
Maryland, called their virus Human T-Cell Lyraphotropic Virus Type III 
(HTLV-III) because they noted many similarities to the other human 
retroviruses notably T4 tropism, Mg^— dependent reverse transcriptase 
and its cytopathic nature. Samgadharan et al. (30) showed
antibodies in patients at risk for AIDS and that 88% of patients with
AIDS had antibody to this virus. Thus HIV appeared to have a role as
the aetiological agent for AIDS. Hie pioneering work of Robert Gallo
and oo-workers at the NCI on HTLV-I allowed the rapid characterisation 
of HIV and development of immunological reagents for a screening assay 
(30,31). In August 1984, Levy et al. (6 ) isolated a third set of 
viruses, AIDS-associated retroviruses (ARV) from San Francisco AIDS
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patients, which were antigenically and structurally related to LAV. 
The above isolates are all variants of the same virus now called Human 
Imraunodeficiency Virus, HIV, the name proposed by the International 
Committee of Virus Taxonomy and Nomenclature in May 1986 (32).
HIV has been isolated from plasma (33 )f lymphocytes in the 
peripheral blood (6,29) as well as from cells in the bone marrow, 
lynph nodes, brain, semen, cervical secretions, CSF, tears, saliva, 
and tareast-railk of infected persons (34-39). The major routes of 
transmission are through sexual contact; male to male, male to female 
and female to male, parenterally from blood and blood products and 
perinatally, pre-, post- or during delivery.
Morphology and Size
Negative staining electron microscopy revealed no 
information about virus morphology, but by thin sectioning the core of 
HIV-1 could be seen to have type D morphology. As it buds from the 
cell membrane, the core is crescent-shaped, this condenses and becomes 
an eccentric bar-shaped or conic core in the mature particle. 
Extracellular particles are 90-130nrn in diameter. This core contains 
the capsid proteins and two copies of the positive sense 
single-stranded RNA genome and associated with this is the 
viral-enooded reverse transcriptase. The envelope of the virus 
consists of a lipid bilayer, contributed by the membrane of the host 
cell through which the envelope glycoproteins project (40). The 
outer envelope protein appears as projections or spikes on the outer 
surface of mature virions. A close evolutionary relationship exists 
between HIV-1 and the lentivirus family particularly visna virus of 
sheep (7). There are many similarities, e.g. in morphology, budding 
and formulation of electron dense core, variation in env region, 
nucleotide sequence homology in gag and pol regions, neurotropism, 
gencme organisation and the large size of the envelope proteins. In 
vivo lentiviruses are cytopathic and cause debilitating diseases in 
contrast to type C human retroviruses HTLV-I and -II which cause 
lyraphoproliferation of infected cells and T-cell malignancies.
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The Genome, its Organisation and Gene Products (18,41,42)
Hie RNA genome of HTV is 9.2 kilobases, (kb), long and the 
integrated provirus 9.6 kb. Hie integrated genome is flanked on 
either side by LTR regions with the usual U3 R U5 motif which contain 
regulatory sequences recognised by various host transcription factors, 
e.g. NF-KB (43) and by viral regulatory gene products. In addition 
to the three classical retroviral genes, gag, pol and env, there are 
at least six further genes vif (virion infectivity factor), vpr (viral 
protein R), vpu (viral protein u),tat (transactivatar), rev (regulator 
of expression of viral proteins), and nef (negative factor). Hie 
latter three have regulatory functions and the functions of at least 
two are unclear. Hiis level of genomic complexity distinguishes the 
lentiviruses from other retroviruses. All the gene products of HIV-1 
are immunogenic but this thesis is concerned with the detection of 
antibodies to the structural proteins of the virus and these will be 
discussed in greater detail. Hie products of the non-structural 
genes are involved in control of the replication and infection pathway 
of the virus. Their functions and their role in the complex 
regulatory mechanisms of HIV-1 expression and pathogenesis are 
described more fully in a recent review article by W.C. Greene (44).
Structural Genes (18,41)
Hie gag gene encodes a p55 precursor which is cleaved by the 
viral-coded protease into 3 major proteins. A phosphorylated p24 is 
the major core protein and-this surrounds the nucleoprotein core. Hie 
amino-terminal protein p17 is associated with the inner surface of the 
phospholipid bilayer and probably stabilises the exterior and interior 
components of the virion. Hie carbaxy-terrainal p15 is cleaved into 
two proteins p7 and p9, which are nucleoproteins; the p7 binds 
directly to the viral RNA.
Hie pol gene encodes several important viral enzymes; an 
aspartyl protease, the reverse transcriptase, ribonuclease, and an 
Integrase. These functions are so crucial to the virus that the
amino-acid sequences are well conserved amongst all established
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retroviral sequences to date. Hie amino-terminal protein is an 
aspartyl protease which cleaves the precursor proteins. The middle 
region of the pol gene encodes the reverse transcriptase which exists 
as a heterodimer, p66/p51 in its most active farm (45). (Hie old 
numbering p64, p53 on the early version western blot has been used 
throughout this thesis). Hie ribonuclease function is also here and 
is used to digest the snail RNA sequences used as template for DNA 
synthesis. Hie third pol gene product is a 31 kilodaltcn (kd)
endonuclease/integrase which cleaves the closed circular DNA, made 
from the viral RNA and integrates it into the host cell DNA.
Hie envelope proteins of HIV-1 are larger in size than type C 
retroviruses and are more similar to lentiviruses. Hie glycosylated 
precursor, gp160, is cleaved by a cellular protease to an outer 
membrane protein (OMP), gp120 and a transraerabrane protein (TMP), gp41; 
these are linked by disulphide bonds in the mature virion (46). 
There are 31 potential N-linked glycosylation sites on the env 
protein, as predicted from the nucleotide sequence, with greater than 
20 sites on the gp120 and up to six sites on the gp41 • Hie 
carbohydrate moiety, in the farm of oligosaccharide chains is added 
and modified by host cell enzymes and contributes half the molecular 
mass of gp120; gp120 is reduced to p80 on deglycosylaticn (46). 
Gp120 occurs as spikes on the outside of the virus and a rapid loss of 
some of these gp120 molecules has been seen, by electron microscopy, 
to occur in vitro during maturation of HIV virions (40).
Gp120 mediates binding of the virus to its receptor. For HIV 
this is the T helper cell (T4) antigen, referred to as the CD4 antigen 
(47). Hie receptor binding site on the gp120 appears to be conserved 
in different isolates. It was the remarkably selective depletion of 
CD4+ lymphocytes in AIDS patients that led investigators to show the 
tropisra of HIV for GD4+ cells, predominantly T4 cells. Although 
HIV-1 infects predominantly T4 helper/inducer cells, other cell types 
can be infected in vitro, e.g. EBV-transformad B cells, brain cells, 
muscle cells from a rhabdomyosarcoma cell line etc. (41,48) and most 
importantly monocytes and macrophages which are considered to be major 
reservoirs of the virus in the body as they are on the whole 
refractory to the cytopathic effects of HIV-1 • There is evidence to
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suggest that infection is not always madia ted by the CD4 antigen (48). 
In addition another component on the cell surface is required to 
achieve virus entry. It is currently believed that binding of a 
fusogenic domain in the gp41 with another cell-roembrane protein is the 
required secondary event (49). The oligosaccharide side chains may 
also be involved.
Nucleotide sequence data from many isolates of HIV-1 illustrate 
an extensive degree of variation. Not only does variation exist 
amongst geographically distinct isolates and between sequential 
isolates taken from the same individual but also that multiple 
variants co-exist in an individual at any one time (50-52). 
Variation occurs mainly through nucleotide substitutions but also 
through short sequence deletions and insertions. These are usually 
in multiples of three to preserve the reading frame. The 
consequences of such variation may affect the three-dimensional 
protein structure or conformation of an epitope. This diversity is 
greatest in the OMP, gp120, and these are localised to the "hot spots 
of mutation" or hypervariable regions which are interspersed with 
conserved regions. There are five such regions, VI-V5, and
computer-assisted analysis of the predicted env protein gp120 
sequences of seven HIV-1 isolates locates the majority of antigenic 
epitopes in these hypervariable regions (53).
The envelope proteins are the major target of neutralising 
antibodies (54) and cytotoxic T-lymphocytes (CTLs) (55). In addition 
a highly conserved epitope at the 3* end of gp120 is the target of the 
antibody-dependent cellular toxicity (ADCC) process (56). What role 
all these play in establishing an anti-viral or protective state in an 
infected individual is unclear and requires further evaluation. 
Neutralisation sites have been identified on both gp120 and gp41 and 
antibodies can cross-neutralise other strains of HIV-1, however 
neutralisation titres are low. The major neutralisation epitope is 
situated on the immunodominant loop in the V3 region of gp120 (57). 
This antigenic site has been found to vary in different isolates but a 
small GPGR amino acid sequence, i.e. glycine, proline, glycine, 
arginine at the bop of the loop is generally conserved. Sequence 
changes in these regions may be an adaptive response by HIV to evade
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the host immune system and maintain a persistent latent infection as 
proposed for other lentiviruses particularly equine infectious anaemia 
virus, EIAV, (58).
HIV-1 and Disease
It was noted in the late 1970s, early 1980s that young, highly 
promiscuous, homosexual men, in San Francisco and New York, began to 
suffer and die from infections normally considered harmless or 
causing only mild disease. There was also an increase in the
occurrence of uncoaroon types of cancer particularly Kaposi's Sarcoma 
(KS). An endemic form of KS exists in Africa but otherwise it is 
rare in the population especially in young adults. Haeraatological 
studies revealed that certain cells of the immune system were present 
in the wrong proportions and most obvious was the decrease in numbers 
of T helper cells. So it appeared that an immune deficiency was 
allowing opportunistic infections of fungal, protozoal, viral and
bacterial origins to be life-threatening in otherwise healthy, young 
men. This acquired immune deficiency syndrome or AIDS was first 
identified as a new disease in 1981 (59).
AIDS was originally defined by the CDC (60), the Centre for
Disease Control, U.S.A., as occurring in a person:
(i) with reliably diagnosed disease that is moderately indicative 
of a defect in cell-mediated immunity, e.g. KS in a patient less than
60 years old or an opportunistic infection, 01; and
(ii) who has no known underlying cause of cellular immune
deficiency or any other cause of reduced resistance reported to be
associated with disease.
Early epidemiological evidence suggested AIDS was a new 
infectious disease that could be horizontally transmitted by intimate 
contact or blood products (61). The specific finding that
haemophiliacs developed AIDS after transfusions of Factor VIII (FVIII) 
and that plasma is filtered in the preparation of FVIII suggested "a 
filterable agent" was responsible. A virus, specifically a
retrovirus, was suggested because a virus of cats, feline leukaemia 
virus (FeLV) causes an immune deficiency similar to AIDS. The T cell
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tropism and manner of transmission of the agent was reminiscent of 
HTLV-I and HILV-II. These human retroviruses normally induce a 
lymphoproliferative response but can also have imnunosuppressive 
activity in vitro, AIDS appeared to be spreading to the HUiV-I endemic 
areas of Africa, Europe, Haiti, etc. Gelmann et al. (62) looked for 
evidence of HTLV-I in AIDS; only 2 out of 33 AIDS patients contained 
HTLV-I proviral sequences and these were in black homosexuals who may 
have been predisposed to HTLV-I if bom in an endemic area. Essex et 
al. (63) could only detect anti-HTLV-I in approximately 25% of AIDS 
and pre-AIDS patients. This was insufficient evidence to establish a 
causal relationship of HELV-I to AIDS.
Other candidate viruses, e.g. cytomegalovirus, Epstein-Barr 
virus, etc. were also implicated in AIDS due to the high rates of 
infection with these agents in the population with AIDS. However 
these viruses were more opportunist than causal in association. A 
novel retrovirus type, HIV, was subsequently isolated from AIDS and 
pre-AIDS patients as described previously. Serological evidence (30) 
showed that 90% of AIDS patients had antibodies to the viral proteins 
of HIV and that this virus could be isolated from patients with AIDS 
(29).
AIDS has such a devastating effect on the human body due to the 
selective tropism of HIV-1 for the T4-helper cell, a key cell of the 
inmune system. Other cell types, e.g. monocytes and macrophages can 
also be infected and act as reservoirs of HIV-1. Following invasion 
of a foreign body, the T4 cell is involved in the orchestration of 
events leading to an immune response and has been termed the 'leader 
of the immune orchestra'. The pathogenic effects of HIV-1 are 
mediated predominantly through gp120 attachment to the CD4 receptor on 
infected and uninfected T4 cells leading to syncytium formation and 
cell death. Direct or indirect effects on other cells in the inmune 
system also contribute to the development of disease but discussion of 
this is beyond the scope of this thesis. However depletion of the T4 
cell population through the cytopathic effect of HIV allows 
opportunist micro-organisms to spread unhindered and cause death.
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HOMAN IMMUNODEFICIENCY VIRUS TYPE 2 
Isolation
A second human imminodeficiency virus, HIV-2, was first isolated
from two HIV-1 seronegative patients with an AIDS-like illness from
Guinea-Bissau and Cape Verde, West Africa (64) and this virus was more
closely related to a simian immunodeficiency virus, SIV , than to
HIV-1 • This confirmed serological evidence of the emergence of a new
human retrovirus (65).
Initially there was sane confusion due to the apparent isolation
by Kanki et al. (65) of HTLV-IV from asymptomatic Senegalese women.
HTLV IV shared similarities and serological cross-reactivity with a
monkey retrovirus STLV-III^^, isolated by the same group, which was
non-pathogenic in its host, African green monkeys (agm). However
restriction mapping confirmed by sequencing revealed that HTLV-IV and
STLV-IIIg^ were greater than ninety-nine percent similar and that
both were identical to a particular isolate of SIV from a macaque,
SIVraac251 031,363 an AIDS-like illness in captive macaques (66).
This was the isolate used in serological studies performed by Kanki
and Essex and they subsequently readily admitted their mistake to the
scientific community (67) - that their isolates of HTLV-IV and STLV-
III   were a result of laboratory contamination of their cell stocksagm
by SIV • Thus the French isolate of LAV-2 is the virus known 
to-day as HIV-2. It has been proposed that HIV-2 arose from 
horizontal infection of a human, 30-40 years ago, by a retrovirus of 
sooty mangabeys, SIV^ (68). These monkeys are native to West Africa 
and SIV causes an AIDS-type illness in captive macaques, although
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non-pa thogenic in its host.
The Genome, its Organisation and Gene Products (69)
The genome and its organisation are similar to that. of HIV-1 
although it is genetically and antigenically more closely related to 
SIV sharing about 75% homology to SIV^ and only about 45% homology 
to HIV-1 • The gag, pol, env and similar regulatory genes, i.e. tat.
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rev, nef, vif and vpr are present. The vpx region located between 
the pol and env genes is unique to HIV-2 and SIV but the function of 
its gene product(s) are unknown. Serological cross-reactivity exists 
between HIV-1 and HIV-2 and this can be seen on heterologous western 
blots (70). Anti-HIV 2 reacts readily with the core protein and to a 
lesser extent with the envelope proteins of HIV-1. In contrast 
anti-HIV 1 sera react mainly with the gag and pol gene products of 
HIV-2. In addition HIV-2 antibodies will neutralise HIV-1 but HIV-1 
antisera do not neutralise the type 2 virus.
HTV-2 Seroprevalence
HIV-2 is prevalent in many West African countries where it is a
more conmon cause of AIDS than HIV-1. There is evidence that HIV-2
has been present in West Africa as early as 1966 (71) though others
dispute this (72) and are cautious, not wishing to increase the stigma
regarding Africa as the progenitor since it already bears much of the
blame for the emergence and spread of HIV-1 • HIV-2 infection is rare
outside Africa. A few cases have been described in Europe, Brazil,
the USA and Canada (73); the majority of reported cases had West
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African connections ^ either natives of the area or through sexual 
contacts. In the United Kingdom (UK) to date there have been 12 cases 
of HTV-2 identified. Nine of the 12 had connections with Africa, 
predominantly West Africa and each had a risk factor for HIV-2 
infection (74). Since June 1990, the UK Blood Transfusion Service 
has been screening for anti-HIV 2 in (combination with anti-HIV 1 in 
all blood donations. In the first six months of testing one donor was 
found to be infected with HIV-2 (74).
Transmission of HIV-2 occurs in a similar way to HIV-1, i.e. 
sexually, parenterally via blood or blood products and perinatally. 
The predominant mode of spread is through sexual intercourse between 
men and women, as is the situation with HIV-1 transmission in Africa.
HIV-2 and Disease
HIV-2 causes an AIDS-type illness similar to that caused by
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HIV-1. Setae features of HTV-2 infection appear to be different to 
that of HIV-1, most notably that of a longer latency period to disease 
progression, up to sixteen years has been reported (75). Dual 
infection with HIV-1 and HIV-2 has been documented (76) but what 
influence this has on disease progression has yet to be fully 
evaluated. Care must be exercised in interpreting apparent dual 
infection based on serological studies due to the nature of antibody 
cross-reactions to both viruses.
2. SEROLOGICAL MARKERS OF HIV INFECTION AND THEIR DETECTION 
SEROLOGICAL TIME COURSE OF INFECTION
Primary infection with HIV-1 may be syraptoraless but can result 
in an acute illness with a variety of presentations, e.g. fever, rash, 
nausea, diarrhoea, myalgia, sore throat, lyraphadenopathy, etc. (77). 
This is reminiscent of other viral illnesses; influenza, rubella 
etc., but also includes some neurological involvement (78). This 
mononucleosis-type syndrome has been described for all risk groups 
(77-81). No anti-HIV 1 is detectable at this time although symptoms 
have been known to persist until seroconversion (79). An increase in 
the number of circulating T8 cells and therefore a change in the T4:T8 
ratio is seen. The estimated time to development of symptoms is 3 to 
6 weeks (80), however a British nurse developed symptoms 2 weeks after 
a needlestick injury (81). In contrast acute illness is rarely 
documented in haemophiliacs (82). Therefore the incubation time and 
severity of symptoms may vary according to the route and size of the 
virus inoculum.
The first serological marker detected is HIV-1 antigen (Ag) 
(83). This antigen, mainly care (p24) Ag is present in the free 
state and in inmune complexes. Antigenaemia occurs before or at the 
time of primary symptoms (84). In most cases Ag is present early and 
transiently. Goudsnit et al. (85) detected HIV-1 Ag in 11 out of 35 
homosexual men who serooonverted during the period of study, in 5 men 
this was prior to antibody seroconversion. Alla in et al. (86) found 
a similar prevalence (35%) of antigen positivity in a group of
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seroconverting haemophiliacs; antigen was present up to 9 months 
prior to seroconversion in 9 of the antigen positive patients. 
Timing of patient sampling probably precludes detection of HIV-Ag in 
many studies as it is produced transiently. It is also possible that 
antigen may not be produced at all in some cases or that the Ag test 
lacks sensitivity in the acute phase. However, HIV-1 can be
isolated from plasma at the time of primary infection (87,88) and 
reflects a true viraemic phase prior to seroconversion. Persons at 
this stage are potentially highly infectious.
A primary anti-HIV 1 IgM response has been detected; it occurs 
one to two weeks after onset of antigenaemia, it may persist in the 
presence of IgG and may circulate for 8 to 41 weeks (83,89,90). The 
IgM antibody recognises only a limited group of antigens, mainly core 
p17 and p24 (89) proteins, on a western blot. HIV-1 IgM is not 
always detected prior to the Ig£ antibody response even by the most 
sensitive tests and therefore its role in blood donor and clinical 
screening is of very limited value.
Some 6 to 8 weeks elapses between infection with HIV-1 and 
production of IgG antibodies. Analysis of seroconversion samples 
using western blots shewed a predominant anti-p24 reactivity as the 
first evidence of infection followed by other gag proteins then env 
and pol (79,91-93). In contrast radioiramunoprecipitation (RIPA) 
detected anti-env (anti-gp160) before anti-gag reactivity (80,91). 
This illustrated differences in detection ability of the two 
techniques at that time. Western blots now detect anti-env during 
seroconversion (94). Alla in et al. (86) have also shown, using a 
competitive enzyme inniunoassay (Abbott Diagnostics), that anti-env 
antibodies are produced earlier than anti-gag antibodies in HIV-1 
infection.
From the information described above, a diagrammatic 
representation of the putative time course of serological events in 
HIV-1 infection can be constructed and is shown in Fig.1.2. In 
summary HIV-1 antigen is produced around the time of acute infection, 
3-6 weeks after encountering the virus. This acute infection is 
manifested by symptoms of a viral-like illness. An IgM response may 
be detected around this time followed 2-4 weeks later by anti-HIV 1
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IgG, It is important to note that not everyone has a documented 
illness and it may not always be possible to detect serum antigen 
during the acute stage. The best and most reliable marker is still 
the detection of anti-HIV 1 Ic£. Thus antibody negative, virus 
culture positive/plasma viraemia presents a problem when screening. 
In the blood transfusion situation this puts potential recipients at 
risk. Transmission of HIV-1 by antibody negative blood donors has 
been documented (95/96) and occurred in the West of Scotland, where 
two recipients were infected from a single donor (97). Thus reducing 
this window period has been the goal of those involved in development 
and manufacture of screening tests for HIV-1.
Infection with HIV-1 is life-long because once integrated into 
the host genome chronic infection is established. Senm HIV-1 Ag is 
usually undetectable following seroconversion and during the ensuing 
chronic phase, probably due to the formation of immune complexes with 
anti-HIV 1. Persistence of serum antigen after seroconversion has 
been associated with rapid clinical progression (99). HIV-1 
infection is not a truly latent infection as recent evidence has 
shown, by culturing HIV-1 from plasma, that a small amount of viral 
replication occurs throughout all stages of infection and thus such 
body fluids are potentially infectious (33,100).
The end stage of HIV-1 infection is AIDS. Development of 
clinical syndromes associated with AIDS is often, though not always, 
accompanied or preceded by serum antigenaeraia. Goudsrait et al. (85) 
detected HIV-1 serum antigen in 86% of adult and paediatric cases of
AIDS but less often, only 8%, in asymptomatic patients. In addition
early serological studies using western blots had noted a decline or 
loss of core antibody in AIDS patients (92,101,102). A longitudinal 
study by Lange et al. (92) revealed that anti-core reactivity 
decreased before or at the onset of symptoms. In contrast, anti-env 
reactivity was retained without evidence of decline and no association 
of anti-env with other markers and clinical outcome could be 
established (103).
A link between the changes in these two markers, loss of
anti-p24 and appearance of serum Ag with clinical progression was 
further established (104-107). Lange et al. (104) found that
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persistent antigenaetnia and decline of anti-p24 reactivity preceded 
the onset of AIDS. Oomplexing of excess Ag was implicated in the 
mechanism of reduction of anti-p24 reactivity. However Nishanian 
et al. (98) recently reported that the decline of anti-p24 was most 
likely a result of the reduced ability of the inmune system (IS) to 
produce anti-p24 as they could show no excessive Ag production. 
Detection of such changes in antibody and antigen indicated increased 
expression of viral genes and thus a switch from latent to active 
HIV-1 infection. Persistent activation of viral genes would herald 
clinical progression.
A representation of this information is shown in the extended 
part of Fig.1.2. Hcwever it is Important to note that this pattern 
is not standard in all AIDS patients and that deviations do occur, 
e.g. lack of detectable antigen during AIDS, simultaneous presence of 
both antibody and antigen etc. The time to development of AIDS is 
variable and only estimates can be made from following cohorts of 
seropositives. Measurement of serological markers may predict
progression and oould aid in assessing the prognosis of a patient. 
Loss of antibody and/or appearance of antigen may be associated with a 
poor prognosis and may allow earlier intervention of drug therapies.
ANTI-HIV DETECTION
Antibody Screening
Upon infection with a viral agent, the body's inmune system, 
specifically the B-cells are stimulated to produce antibodies. Hence 
detection of antibodies to a specific virus in the blood of a patient 
indicates previous exposure to the virus. As the nature of the 
infectious agent causing AIDS, the methods by which it is transmitted 
and the population most at risk of being infected were elucidated, 
antibody screening tests were developed to identify those who had been 
infected. In this way an attempt oould be made to control the spread 
of virus by education, information and counselling the seropositives 
to adopt a change in life-style towards lcw-risk behaviour and to 
identify infected blood donations and so prevent transfusion of HIV by
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blood and blood products. Transfusion-acquired AIDS was a
particular problem in the USA, early in the epidemic, because of the 
policy in the American blood banks of paying donors for their blood 
donation. Large numbers of the homosexual population made regular 
visits. So there was clearly a need for a reliable test to screen 
out infected blood and prevent it being used in transfusions or the 
manufacture of blood products.
Hie technology and reagents involved in identification and 
characterisation of the virus were used in the development of a 
screening test (30). The first assays were introduced in 1984, and 
early in 1985 the United States Food and Drug Administration (IDA) 
licensed the first commercial kit. Since then there has been a 
profusion of cocmercial kits available for the detection of anti-HIV 
and the majority of tests use enzyme-linked immunosorbent assay 
(ELISA) technology.
A good screening test requires high sensitivity and specificity 
to prevent false negatives and false positives, either of which would 
have disastrous consequences in any screening programme, particularly 
in the Blood Transfusion Service (BTS). Ideally the test would 
detect antibody at all stages of infection, especially new infections 
when a patient seroccnverts and antibodies to only a few proteins are 
present and in the late stages of infection when antibody titres are 
decreasing. The test needs to be robust, user friendly, adaptable 
far screening either large or small numbers depending on requirement, 
with few steps to reduce the possibility of human error and have a 
short performance time to allow high throughput especially for centres 
such as the BTS who are testing large numbers of sera. The design of 
suitable tests can be divided into a few basic types as described by 
Mortimer et al. (108). These are described more fully in Appendix 1.
Screening has been performed at the Hepatitis Reference 
Laboratory (HKL) since April 1985. Prior to this time a snail amount 
of testing was performed by immunofluorescence using LAV-infected and 
uninfected ready-prepared slides (Diagnostics Pasteur). Routine 
screening of all blood donations by the Blood Transfusion Service 
(BTS) began in the United Kingdom on the 14th October 1985. Before 
screening oonmenced an assessment of five commercial kits, using a
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panel of 360 selected sera (including blood donors, high-risk groups 
and sera likely to cause false positive readings) was performed by the 
FHLS Virus Reference Laboratory at Oolindale (108). This evaluation 
identified problems with certain kits especially the performance of 
heat-treated specimens which gave rise to false positive results. 
But, in general, the kits were found to be adequately sensitive with 
the Wellcome and Organon kits being particularly good due to a higher 
specificity. In an evaluation of six first generation ELISAs, 
Reesink et al. (109) also found high values for sensitivity with good 
specificity particularly in the Wellcome and Pasteur tests. The 
Wellcozyme anti-fflLV III EIA (Wellcome Diagnostics) was chosen for use 
in the Scottish BTS.
Frequent evaluations have been performed on the commercial kits 
as they have evolved and improved with appropriate use of 
seroconversion panels, rather than dilutions to assess test 
performance.
First Generation Tests
The first generation of tests used cell culture derived viral 
lysate to coat the solid phase and a number of problems were 
identified with this source of antigen. The first FDA licensed kit, 
the Abbott HTLV III Antibody EIA was found, in use, to lack 
specificity. False positives occurred in testing patients with 
antibodies to human leukocyte antigens (HLA), especially haemophiliacs 
and renal unit patients. T cell-associated HLAs become incorporated 
into the surface of the virus as newly synthesised virus particles are 
released by budding out from the T cell membrane. These are then 
present in the viral preparation used to coat the bead. Testing with 
anti-HLA sera by Kuhnl et al. (110) showed that 37% HLA-ER antisera 
gave positive results in this test; they suggested that ER4 is 
present on the H9 cell, the cell line clone used to grow HIV-1 (3) and 
is therefore present on the antigen-coated beads. The H9 cell line 
has been HLA-typed by Weiss et al. (111) and found to include ER4 and 
DCW3 amongst other HLA specificities. However evaluation of the HLA 
specificity of sera reactive in the HIV ELISA test systems is no
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substitute for a confirmatory test to shew an HIV-specific reaction 
since genuine positives may also have an anti-HLA serotype (112), 
Heat inactivation of the virus (56°C for 30 minutes) in patients* sera 
also interfered with the test, increasing the optical density and 
giving false positive results but the mechanism for this is unknown 
(113).
Sapid Tests
A number of alternative assays were developed which were rapid 
to perform, required minimal equipment and no automation. These 
qualities are important in field studies or in developing countries 
where money and other resources are limited, and conditions for 
storage and testing are far from ideal. In such situations tests
need to be robust, sensitive and easy to perform without necessitating 
the use of electrical equipment or other expensive hardware. These 
tests include the Dipstick and HEVCHEK (Du Pont) and Testpack (Abbott) 
and a particle aggulination test, Serodia-HIV (Fujirebio Inc.). This 
latter test was found to be highly sensitive and specific (114). 
However others were short-lived on the market, e.g. Dipstick (Du Pont) 
which lacked sensitivity. Hcwever more recently, five of these 
rapid, visually-read assays including Serodia-HIV (Fujirebio Inc.) and 
HIVCHEK (Du Pont) were evaluated on fresh clinical samples in Zaire. 
The sensitivity of these assays ranged from 84.6% to 99.1% and the 
specificity from 92.7% to 98.8% (115). The authors suggested these 
tests although less sensitive could be used in developing countries 
particularly for large-scale blood donor screening.
Second Generation Tests
As more information was gleaned about the virus and the immune 
response to it, tests were evaluated and improved in an effort to 
close the window of infection, i.e. that time between infection with 
the virus and production of antibodies. A second generation of
screening assays were developed using recombinant proteins or 
synthetic peptides to avoid the problem of anti-HLA reactivity.
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Sequences from env regions were the predominant epitopes coated onto 
the solid phase. First generation tests detected anti-p24 
predominantly. It was thought to be the first antibody produced 
(92,93,101). However evidence from other serological studies showed 
that anti-env was the most reliable marker of infection as it was 
produced early in response to infection and also retained in the later 
stages of disease (86,91,94).
Second generation tests detected anti-HIV earlier than first 
generation assays. In a comparison of three first and three second 
generation tests (from the same manufacturers), second generation 
tests were far more sensitive than the first generation ELISAs both in 
earlier detection of anti-HIV 1 at seroconversion and in testing 
serial dilutions (116).
Combination Tests
The isolation of HIV-2 from West African AIDS patients and the 
subsequent emergence of HIV-2 infection in the USA and Europe prompted 
the development of anti-HIV 2 ELISAs (Diagnostics Pasteur). Some 
serological cross-reaction occurs between HIV-1 and HIV-2 and it was 
found that the anti-HIV 1 assay could detect HIV-2 seropositivity. 
The type II assay format for HTV-1 (competitive test) was the worst 
performer in detecting anti-HIV 2 (117); the affinity of the
cross-reacting antibodies may not be sufficient to compete with the 
anti-HIV 1 conjugate. Hie prevalence of HIV-2 seropositives detected 
by indirect anti-HIV 1 ELISAs ranged from 70% to 93%, clearly 
demonstrating the serological cross-reactivity of HIV-1 and HIV-2 
(117).
Screening assays for anti-HIV 1 have new incorporated 
recombinant protein or synthetic peptides from HIV-2 onto the solid 
phase and thus anti-HIV 2 reactivity can be assayed in the same sample 
well as anti-HIV 1. Hie second generation anti-HIV 1 assays had 
achieved high degrees of sensitivity and specificity up to this point 
and it was thought that the addition of a second virus might 
compromise this. However 9 out of 9 combination (combi) tests 
retained 100% sensitivity in detecting anti-HIV 1 in a PHLS/Department
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of Health (DH) evaluation (118). Specificity ranged from 94.6% to 
100% in the tests examined. In a supplement (119) to this 
evaluation/ anti-HIV 2 performance was assessed in the same 9 kits. 
All assays examined were found to be adequately sensitive as screening 
tests for the detection of anti-HIV 2. Sensitivity was highest in 
the tests developed by Bio-Stat Diagnostics Ltd. and Wellcome 
Diagnostics. It is interesting to note that the Abbott Anti-HIV 1/2 
Testpack a rapid test, despite low specificity, was as sensitive as 
the conventional ELISAs in detecting anti-HIV 1 and anti-HIV 2.
A lack of readily available HIV-2 antibody positive samples and 
seroconversion panels in the UK prevents a larger evaluation of 
anti-HIV 2 detection performance. However the priority in screening 
is the detection of anti-HIV 1 as HIV 2 infection is still rare in the 
UK. Further serological discriminatory tests and confirmatory tests 
have to be performed to establish the exact nature of the reactivity 
of any test specimens in these combination assays.
Confirmatory Tests for Detection of Antibody
The problem of false negatives (FN) can only be addressed as 
test sensitivities improve since this occurs usually in persons 
infected with the virus who present for testing in the initial 
incubation phase. However false positives (FP) can be tested 
further. A positive HIV test result is devastating and has far 
reaching consequences for the patient. Therefore a screening 
programme for testing members of high and low risk populations must 
attempt to minimise both the FN and the FP rate to give the best 
predictive value for the test result. All ELISA reactives were 
therefore further assayed by a test with a higher specificity which 
was usually of different technology and used an alternative source of 
antigen. Since a positive confirmatory test is a definitive 
diagnosis of HIV infection these tests must be subject to strict 
criteria of interpretation.
Four types of tests have been used in this capacity.
1. An indirect inmunofluorescent (IF) test. Slides were 
coated with HIV-1 infected and uninfected cells. Antibody in the
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test specimen bound to viral antigens on the slide was ; detected with 
a fluorescent conjugate,
2. A competitive enzyme immunoassay using a dual-bead system 
(Abbott Confirmatory EIA, now Abbott ENVACCR HIV-1 EIA) was developed 
by Abbott Laboratories, A recombinant protein from the core sequence 
and from the envelope sequence of the viral genome were coated onto 
individual beads and assayed independently.
Two further test systems examined the antibody response to 
individual viral proteins.
3. Hie western blot assay (WB): viral proteins from a cell
culture derived lysate are electrophoretica lly separated in a 
polyacrylamide gel. Hie proteins, separated according to molecular 
weight are electrophoretica lly blotted onto a nitrocellulose (NC) 
membrane. Hie NC is cut vertically into strips and antibodies in the 
test sera are reacted with the viral proteins bonded to the NC. 
Incubation of the strip with an enzyme conjugate followed by substrate 
reveals an insoluble coloured product at the site where antibody in 
the clinical specimen has bound. Hie nine structural proteins of 
HIV-1 form a distinct separation pattern and it is therefore easy to 
examine the antibody response of an individual to a range of viral 
antigens.
4. In the radioiraraunoprecipitation assay (RIPA) human serum is 
reacted with metabolically radiolabelled viral-infected cell cultures. 
Hie antibody-antigen inmune complexes formed are removed and separated 
onto a gel. Hie result is visualised following autoradiography. 
Those viral antigens recognised by antibodies in the test serumfarm a 
distinct separation pattern on the gel.
Immunofluorescence
Initially imnunofluorescence was favoured as a screening test in 
some laboratories. As a confirmatory test, it performed well in 
comparisons with other confirmatory tests. Carlson et al. (120) 
found 100% agreement with WB results.
In the hands of experienced persons, IF is a good reliable and 
rapid test. Hcwever the differentiation of specific from
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non-specific fluorescence may be a problem for persons with little 
experience of the technique.
Hie Confirmatory EIA
Hie Confirmatory EIA (Abbott Diagnostics) has the advantage of 
being a ready-to-use ELISA requiring no extra specialised equipment 
for a diagnostic laboratory. In a small evaluation the Confirmatory 
EIA results were in complete agreement with IF or WB results in sera 
from high-risk donors, with only two samples, from low-risk blood 
donors, which were discrepant (121). Hcwever as the screening tests 
improved, the sensitivities of the second generation ELISAs bettered 
that of the Confirmatory EIA and its role changed to that of a 
supplementary test for the screening ELISAs rather than confirmatory.
Radioimraunoprecipitation
RIPA has been used primarily as a research tool for
characterising viral proteins (46). Since the viral lysate is
prepared under milder conditions than that for WB, this helps to
preserve the conformational epitopes. Hie antibody-antigen ooraplexing 
reaction occurs in a liquid phase allowing maximal exposure of 
epitopes, and thus it is a sensitive technique, particularly for the
detection of envelope glycoproteins. This is an advantage in the
diagnosis of early HIV-1 infection. Tersmette et al. (122) developed 
a glycoprotein-enriched assay (GRIPA) which they found to be at least 
as sensitive as the WB on seroconversion sanples. In addition those 
samples considered to be false positive (FP) by WB were negative by 
(3HPA (and virus culture). RIPA results would therefore be useful in 
distinguishing between false positivity and seroconversion in an 
indeterminate WB where an isolated p24 reactivity by RIPA was claimed 
to represent a true antibody response in contrast to an isolated p24 
reactivity on WB (122,123).
However to perform RIPA requires facilities to grow virus and 
use radioisotopes. This is often impracticable and beyond the scope 
of most diagnostic and some reference laboratories. RIPA is not
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performed routinely as a confirmatory test for anti-HIV 1; the WB with 
its new enhanced envelope detection performs adequately.
Western Blotting
The technique of western blotting, was first described by Towbin 
et al. in 1979 (124). Its use and development as a tool in the 
confirmation of HIV infection was its first introduction into 
diagnostic virology. The setting up and running of electrophoretic 
gels and blots is a time-consuming process requiring specialised 
equipment and technical expertise. However commercial kits are 
available, only one of which has been licensed by the FDA (Western 
Blot Assay kit for the detection of IgG antibodies to HIV-1, EXi Pont). 
In a comparison of 3 WB tests, an in-house test and two commercial 
kits, the Du Pont test had the highest sensitivity and the highest 
specificity (125).
Pre-blotted nitrocellulose is supplied and the western blot test 
becomes an ELISA, where the product of the enzyme-substrate reaction 
forms an insoluble precipitate at the site of the Ab-Ag complex 
formation on the NC.
The nature of the test requires interpretation of the result 
from a series of bands on the NC strip. Initial problems arose 
because the test, whether in-house or commercial, was not fully 
standardised. Individual laboratories detected different bands in 
the same collections of sera, thus making evaluation and the setting 
of criteria for positivity very difficult. At the start of screening 
and confirmation, the predominant reactivity observed was anti-p24. 
In 1985 the CDC guidelines on the minimum requirement for a positive 
blot was reactivity to p24 and/or gp41 (126). Hcwever caution in 
interpreting an isolated anti-p24 reaction was necessary following 
reports of false positive or indeterminate results. In 1986 
Biberfield et al. (127) first reported the presence of false positive 
WB bands at p24 and p55 in 3 low risk blood donors. These donations 
were reactive in 3 screening ELISAs but negative by 2 or 3 other 
ELISAs and by IF. The same ELISA reactivity and anti-gag WB pattern 
were present in follow-up samples, 1-3 months later. Further reports
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In the literature corroborated this finding and demonstrated that 
bands at p17, p24 and p55 alone or in combination was the motif most 
commonly seen in falsely reactive sera (128,129).
The cause of this FP reaction is unclear. Bloraberg and Klasse 
(125) noted that 3 out of 12 commercial species anti-huraan IgG 
conjugates gave relatively strong bands at p24 and a rabbit 
anti-tubulin serun reacted to proteins indistinguishable from p24 and 
p55. In addition anti-HLA class I and H  sera reacted with proteins 
migrating close to gp41 and p31 respectively. Clearly some cellular 
human proteins from the cell culture which co-migrate with the viral 
proteins are the cause of some FP reactions. The use of WB strips 
prepared from mock-infected cell culture lysates has had some success 
in confirming the cellular nature of FPs.
A variety of criteria have been established and one in 
particular has been recommended by the Centre for Disease Control, 
Atlanta (130), i.e. a positive result is determined by the presence of 
antibodies to any two of p24, gp41 and gp160/120 since this gave the 
highest percentage of positives and the lowest percentage of
indeterminate results.
The western blot test is not the gold standard and various
problems can be identified including the subjective nature of
interpretation, lot-to-lot variability, length of time to perform, and
the occurrence of FPs. Despite these shortcomings the western blot
remains the test of choice in most reference laboratories. More
information regarding antibody specificity can be instantly obtained
from a WB result. Different patterns on the WBs of individual
patients were noted and it was speculated that a WB may give extra
the
information relating to^stage of infection. Both the banding pattern 
and the intensity of reaction can give such an indication, e.g. at
seroconversion, high intensity to few bands and in terminal stages
where lack of anti-p24 is a common feature.
Recombinant Immunoblot Assays (RIBA)
The newest development is that of recombinant immunoblot assays 
(RIBAs). These consist of nitrocellulose strips with lines of
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recombinant proteins painted onto the surface. Obvious advantages 
include the exclusion of human cellular proteins, choosing immunogenic 
regions from which to make peptides and the, addition of HIV-2 specific 
recombinant peptides to allow the simultaneous discrimination of HIV-1 
and HIV-2. These tests, in general, contain a maximum of about 4 
peptides for HIV-1 and only one peptide for HIV-2. Therefore a
decision regarding positivity is based on a reaction to fewer bands 
and these represent linear rather than conformational epitopes.
3. EPIDEMIOLOGY OP AIDS AND HIV-1 INFECTION
AIDS: THE EPIDQCEC
The acquired immune deficiency syndrome, AIDS, was first 
described by Gottlieb et al. in 1981 (59) following their previous 
report of an increased incidence of Pneumocystis carinii pneumonia 
(PCP) in young homosexual males in the U.S.A. (131).
The first report (131) discussed the occurence of PCP in 5 
previously healthy homosexual men in Los Angeles. Prior to this 
time, PCP had only been found in patients with an already impaired 
immune system or in persons undergoing immunosuppressive treatments. 
At the same time there was a report of a rare malignant tumour of 
blood vessel tissue in the skin and internal organs called Kaposi*s 
sarcoma (KS), occurring in twenty-six previously healthy homosexual 
men in New York and California (132), some of whom also had 
Pneumocystis pneumonia. Increased reports after this time described 
patients suffering from overwhelming infections with opportunistic 
micro-organisms either protozoal, fungal, bacterial or viral in 
origin, e.g. Cryptosporidium, Candida, mycobacterium or
cytomegalovirus (CMV) respectively. Something was happening in the 
gay population as increasing numbers fell victim to a devastating 
depression in immune function through an alteration in T cell subsets 
allowing opportunistic infections (01) to ravage the immune system and 
kill otherwise healthy, active, young men. Various physicians, 
immunologists and epidemiologists at the time became aware of this but 
were puzzled; perhaps a new and particularly virulent strain of CMV
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or a new infectious agent was the cause. These patients had acquired 
an underlying iranune deficiency which allowed such infections to 
become established. The cause, however, remained unknown.
The united States Centre for Disease Control (CDC) began a 
national surveillance far these conditions, PCP and KS, in June 1981 
and produced a guideline definition (60). These criteria were 
specified to help detection of AIDS in the population and to identify 
those at risk. A task force (Kaposi's sarcoma and opportunistic 
infection, KSOI, task force) was sent out from the CDC to identify 
what common factors, if any were present in those patients with 
symptoms (133). Various aspects of homosexual behaviour were
examined; a bad batch of nitrate inhalants, a stimulant used
frequently by homosexuals was suspected. However the argument for a 
sexually transmitted infectious agent was strengthened when the 
astonishing numbers of possible sexual contacts (up to 250 or more per 
year) were revealed and indeed it was this factor and the incidence of 
venereal disease associated with increased number of sexual contacts 
which distinguished the cases from the controls.
AIDS was originally thought to be a 'gay-person's' disease and 
the name Gay-Related Immune Deficiency or GRID was coined. The 
increased surveillance of clinical cases and their contacts inplied an 
infectious aetiology. The causative agent was unknown but its spread 
in the gay population was reminiscent of hepatitis B, a blood-borne 
disease. Thus if it could be spread sexually, it could also be 
spread parenterally and thus additional at-risk populations were 
identified. Case reports of unusual opportunistic infections were 
noted in haemophiliacs (Hm), intravenous drug abusers (DA), Haitians, 
recipients of blood and blood products, sexual contacts of these 
groups and in babies particularly in those with a drug abusing mother 
and more frequently in ethnic populations, blacks, hispanics and 
Haitians (60,61).
Although the first case reports came from the U.S.A. in the late 
1970s, early 1980s, it soon became clear that this was not just an 
American health problem. Reports of AIDS soon followed from Europe 
among the same risk groups; homosexuals, drug abusers and 
haemophiliacs. In addition, an AIDS-like illness was reported in
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Negro patients, native to equatorial Africa, who were in hospital in 
Brussels and Paris, Further investigation revealed AIDS in Africa 
itself, particularly Zaire and Rwanda at this time and later in most 
Central and East African countries (134). But for those African 
patients in hospital in Europe, this disease syndrome may have gone 
unnoticed in this continent for longer as multiple infections 
especially of a respiratory nature, e.g. tuberculosis, are a routine 
medical problem in Africa. Various aspects of AIDS in Africa and the 
similarity to a monkey disease have led many to believe that the 
origin of AIDS and its causative agent come from Africa itself.
Thus the world was on the brink of a global epidemic of a killer 
disease with an infectious aetiology in the early 1980s. Until the 
causative agent was identified, a diagnosis of AIDS was based on 
clinical observation of opportunistic infections. In addition 
several prodromal stages or pre-AIDS conditions were noted, i.e. 
persistent generalised lyraphadenqpathy (PGL) and AIDS related complex 
(ARC) (135). Several staging systems have been developed to classify 
patients at the various stages leading to development of AIDS. The 
two most commonly used are: the CDC system (Stages I through IV)
which is based primarily on clinical signs, symptoms and opportunistic 
infections; an alternative method, the Walter Reed (WR) staging 
system involves 6 stages, WR1 to WR6, defined by T4 cell counts, other 
immune indicators, e.g. skin tests, and clinical manifestations (136). 
The CDC definition has been updated and further signs and symptoms 
associated with AIDS have been added (137) including neurological 
involvement (e.g. encephalopathy) and that of a wasting syndrome or 
slim disease which was a major feature of disease presentation in 
Africa (138). Thus cases of AIDS were reported to the CDC allowing 
epidemiologists to examine the dynamics of the epidemic as it changed 
over time. When reporting started in the USA, in 1982, the doubling 
time, i.e. that time for the number of reported cases to double was 5 
months, by 1985 this had increased to 11 months (139).
Since the start of the epidemic case reports and transmission 
dynamics have been analysed and extrapolated to make predictions about 
the numbers of cases expected over a specified time period. The 
reported cases are likely to represent the minimum number of cases at
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any one time due to the many problems in epidemiological surveillance 
of such a disease. Under-reporting and delays in reporting make it 
more difficult to establish trends. The up-dating of the AIDS 
case-definition also affects the numbers and encourages retrospective 
reporting giving a false boost in the total numbers at any one time.
To the end of June 1990 a world total of 266,098 cases of AIDS, 
across 5 continents from 157 countries, had been reported to the 
World Health Organisation (WHO) (140). The WHO estimates that the 
true figure is closer to 700,000 and expects a cumulative total of one 
million cases worldwide by the early 1990s and 5-6 million cases by 
the year 2000. The majority of cases come from the Americas (61%) 
with 50% of the world total in the U.S.A. alone and 25% from the 
African continent with Europe contributing 13% of all cases. The 
numbers quoted from these countries represent absolute numbers and at 
such a high level are worriesome, however they are not rates per 
capita so the extent of the problem is not evident from the bare data. 
To the oid of June 1990, the total number of cases of AIDS reported in 
the UK was 3,433 (141). This represents a rate of 59.8 per million 
population. The majority (80%) were homosexual or bisexual, only 3% 
were drug abusers, 6% were haemophiliacs with between 1-4% in the 
other risk groups. In the same time period, a total of 155 cases of 
AIDS (136 male and 19 female) had been recorded in Scotland; this is 
a rate of 30.3 per million population. A breakdown of the total by 
risk group reveals 51% were homosexuals (or bisexuals) and 28.4% were 
drug abusers. AIDS in Scotland has been recorded in all risk groups 
(Fig.1.3). The mortality rate has always been close to 50%. 
However as patients now live longer once diagnosed with AIDS the rate 
has dropped to around 43%.
In Glasgow the first case of AIDS was a homosexual diagnosed 
retrospectively in 1984. He had travelled to the U.S.A./Caribbean. 
A total of 53 cases (37 deceased) have now been reported in Glasgow 
and the West of Scotland (Mrs. G. Allardice, CDSU, personal 
communication) up to the end of June 1990. The majority (43%) of cases 
are homosexuals, however the nunbers in the other risk groups are 
increasing. This is most probably due to the time of arrival of the 
virus in the different risk groups.
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An average of 9 new cases of AIDS per quarter in Scotland and 
186 new cases in the U.K. have been reported since September 1987. 
However this has increased to 14 per quarter between June 1989 to June 
1990 in Scotland and 265 per quarter in the UK. (Figures extracted 
from the surveillance data published in the CDS weekly report, AIDS 
News Supplements). Again this is probably due to the later arrival of 
the virus in certain at-risk populations who are now contributing to 
the AIDS figures. In addition measures introduced to slow down the 
disease process, e.g. drug therapy, means a longer incubation period 
between infection and AIDS for those infected earlier.
HIV-1 INFECTION
Hcwever, reports of AIDS cases give no information about new 
infections, only about those already infected. In addition the 
numbers of persons with AIDS make up only a small fraction of the 
total who harbour the potential to develop AIDS. An analogy to this 
"tip of an iceberg" phenomenon has frequently been made. The 
discovery and characterisation of the infectious agent causing AIDS 
added a new dimension to the epidemiology. When a screening test was 
developed the numbers who had been exposed to the virus could be 
determined. This is the reservoir from which AIDS cases arise. 
Early serological studies shewed a high prevalence of HIV-1 infection, 
determined by the presence of anti-HIV 1 in patients* sera in the 
population groups with AIDS. Identification of these at-risk groups 
and modes of spread could be helpful in limiting the spread of the 
epidemic through information, education and counselling aimed at 
encouraging behavioural change and therefore reducing viral 
transmission.
Nodes of Transmission (142-144)
HIV-1 is transmitted primarily during sexual contact, through 
parenteral exposure to blood and blood products and perinatally from 
mother to child. Sexual contact between males is the most common 
route of spread reported to date. The epidemic in the U.S.A. began
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in this group. In the U.K. up to the end of June 1990, 52% of 
reported seropositives are homosexual men. Although HIV-1 has been
isolated from semen, additional homosexual practices causing trauma to 
the lining of the rectum facilitate entry of HIV-1. Thus anal 
intercourse transmits HIV efficiently. The risk of infection
increases with the number of sexual partners, i.e. as the chances of 
coming into contact with an infected person increase. The receptive 
partner is at greater risk of acquiring HIV-1. A few cases involving 
arogenital contact have been reported; this is a rather less 
efficient mode of transmission. The frequency of female to female 
transmission is very low; in one case this was reported to have 
resulted from traumatic sex practices.
Male to female and female to male transmission can occur as 
HIV-1 has been isolated from both semen and cervical secretions. 
Heterosexual spread was noted to be on the increase in the U.S.A. 
during the late 1980s, this was originally through contact with high 
risk groups. However heterosexual spread of the virus outwith the 
high risk groups is the worry and concern of the 1990s. This is 
highlighted by the situation in Africa where the HIV-1 infected male 
to female ratio is approximately one. This is principally in the 
sexua lly-active (25-40 years old) age groups suggesting that 
heterosexual contact is the major means of transmission of the virus 
in this continent (134). The ratio of male to female HIV-1 
seropositives in the U.K. is 8.35 up to the end of June 1990 (145) and 
heterosexual contact contributed less than 7% of the total 
seropositives, the majority of whom had known exposure abroad, 
predominantly in Africa (145). More recent reports suggest this is 
increasing, although the total numbers are still small. Current 
surveillance data indicate the greatest increase is in males or 
females with partners from abroad (146). Different rates of 
heterosexual transmission have been noted. There is also varied 
opinion on the role of co-factors and risk factors influencing 
transmission, e.g. numbers of sexual contacts, frequency of contact, 
infection with other sexually-transmitted diseases, disease stage of 
index patient, genetic factors (HLA type) etc. (147). These may 
operate more or less efficiently in different populations and in
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different risk groups.
Parenteral exposure occurs in intravenous drug abusers, DAs, 
through the sharing of needles and syringes contaminated with infected 
blood. Injecting practices such as 'wash-out* coupled with the large 
groups who share together in shooting galleries promote the spread of 
the virus in the drug abusing community. It is important to note 
that the drug abusers are the major reservoir for perinatal
transmission and spread into the heterosexual population through
non-drug abusing sexual contacts.
Transfusion of infected blood and blood products is associated 
with a high rate of seroconversion. All components of blood, e.g.
platelets, concentrated red cells, plasma, etc. can transmit
infection. A more advanced disease stage in the donor is associated 
with a greater risk of seroconversion in the recipient and possibly an 
increased rate of progression to AIDS in the recipient. Transmission 
by this route can now largely be prevented both by appropriate donor 
deferral and blood donor screening. However cases have been reported 
of seroconversion in recipients after transfusion with screened blood. 
The donors, seronegative at the time of donation have subsequently 
developed anti-HIV 1 • All tissue and organ donors are also screened 
for HIV-1 antibodies as transmission has been documented in transplant 
of tissues such as kidney, liver, heart, pancreas and bone. Clotting 
factor concentrates (Factor VIII and Factor IX) were responsible for 
infection in the haemophiliac population. A method of heat treating 
the factor concentrates to inactivate the virus was introduced in 1984 
which resulted in a reduced incidence of infection. The risk is now 
virtually nil, perhaps in time with the current advances in genetic 
engineering, recombinant FVIII will be used routinely thereby removing 
the risk of infection with any blood-borne virus.
The main risk of parenteral exposure to HIV-1 in health-care 
workers (HCW) is through needle-stick injuries and has been associated 
with a 0.9% seroconversion rate. Three health-care workers
serooonverted following non-needlestick exposures of infected blood 
probably via raucous membranes or non-intact skin. Two laboratory 
workers became infected while working with concentrated virus. A 
total of 28 cases of documented seroconversion in HCW has been
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reported world-wide including nurses, surgeons, dentists etc. (148). 
Therefore rates of transmission of HIV-1 in HCW are low and can remain 
so if safety precautions are adhered to and enforced.
The true rate of perinatal transmission is unknown and requires 
close follow-up of children born to seropositive mothers due to the 
passive transfer of maternal antibodies which can persist up to 12-18 
months. Most transmission is thought to occur in utero during 
pregnancy or at birth in the immediate post-partura period as HIV has 
been isolated from foetal tissues and oord-blood. In addition 
breast-feeding is oontra-indicated in seropositive mothers as this may 
be another mode of transmitting the virus. Perinatal transmission 
has been a significant problem in other areas of the world especially 
the U.S.A. and Africa; at one time in New York AIDS was the leading 
cause of paediatric deaths. It was also found in the U.S.A. (New 
York City) that infection rate varied with race and that it was 
greater in negroes and hispanics than Caucasians; why this is so is 
unclear (144). A multi-centre study of paediatric infection in 
Europe (149) has found that the rate of transmission (13%) is now much 
lower than the original estimates. Current surveillance data include 
all antibody positive children no matter whether this is passive 
antibody from the mother cr genuine antibody synthesised in response 
to true infection. Therefore many of those quoted in this risk 
category may not be genuinely infected.
There is no current evidence to suggest that other or more 
unusual modes of transmission of the virus exist. No non-sexual, 
household contacts of HIV-1 infected individuals were shown to 
serooonvert (150). There is no indication that HIV can be 
insect-borne despite the high numbers of cases in Africa where 
arthropod vectors are a common means of disease transmission (134). 
Thus HIV has only been reported in the risk groups described. 
Continued epidemiological surveillance is required to monitor the 
appearance of new risk groups and new modes of viral transmission.
The U.K. surveillance, including Scotland, England, Wales and 
Northern Ireland, of HIV-1 antibody positive reports totalled 14,090 
to the end of June 1990 (145). The largest contribution was from the 
homosexual (including the bisexual) population with 51.2% of the
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total. Fourteen percent were drug abusers, 9% haemophiliacs, 16% 
other or undetermined and the remaining risk groups, i.e. homosexual 
drug abusers, blood transfusion recipients, heterosexual contact and 
children of infected or at risk parent(s) only between 1 and 3%.
On closer examination of the figures, there emerges an 
interesting geographical difference in the seroprevalence of certain 
risk groups throughout the U.K. Forty-three per cent of the total 
homosexual/bisexual seropositives are located within the North West 
Thames reporting region with a further 25% from two other Thames 
regions (North East and South East) (145). In contrast 49% of the 
total drug abusers reported are from Scotland. A breakdown of the 
Scottish figures reveals that one area in particular, Edinburgh, is 
the greatest source of seropositive drug abusers. Evidently 
different behavioural and biological factors promoting transmission 
vary in different areas and allowed a rapid spread of infection in a 
high proportion of risk group members in a relatively short space of 
time. This is particularly so when there is a large pool of at-risk 
persons. The pockets of high prevalence of infection remain, 
although there is evidence that all risk groups in all areas, to a 
greater or lesser extent, are infected.
NATURAL HISTORY OF INFECTION
Since the start of the epidemic it has become evident that 
development of AIDS in HIV-1 seropositives is not an uncommon outcome. 
The numbers of cases of AIDS will increase despite a stabilising or 
slewing down in the incidence of new infection. Provisions for 
health care have to be made available to meet the demands of a growing 
epidemic and therefore estimates of the expected number of new AIDS 
cases are required. In general, estimates represent the woorst-case 
scenario. Most estimates made at the start of the epidemic were not 
fulfilled due to changes in many epidemiological and behavioural 
parameters.
The risk of developing AIDS increases with the duration of 
infection with HIV-1, but the rate at which AIDS develops is variable. 
The incubation period may depend on the route of infection, the size
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of inoculun, iimune response In host, etc. The best estimates can be 
obtained from cohort studies where the length of time of infection is 
known, this is particularly so in transfusion-related cases. Most 
estimates suggest that the incubation period to AIDS is long, in 
general, between 7 and 10 years (151,152). No difference in 
progression rate was found in a study on a snail sanple of 
haemophiliacs and homosexuals from two different areas of the U.S.A. 
(153) and in a comparison of individual studies of these risk groups 
by Moss and Bacchetti (154). Cohort studies on cumulative 
progression rate where date of seroconversion is either known or 
estimated find that 10-20% of seropositives will progress to AIDS in 5 
years (154-157) and 30-40% will have AIDS at 8 years after 
seroconversion (158-160). Thus the studies suggest that the 
probability of progression increases with length of time of 
seropositivity and that in the absence of treatment most persons will 
progress to AIDS within 10 years. Medley et al. (151) noted an 
age-related difference in latency period. In children under 5 years 
of age with transfusion-associated infection rapid progression 
occurred, on average in 1.97 years compared with 8.23 years in those 
aged 5"59 years. Studies on haemophiliacs suggests an older age at 
seroconversion correlated with a more rapid disease progression (158).
An interplay of viral and host co-factors can influence the rate
of progression. This is an inportant consideration for those
infected as behavioural factors, e.g. continuation of JuigW risk 
activities is with in the control of the individual, but other 
biological and genetic variables are not. Co-infection with other 
viruses, intercurrent acute infections, virulence of the infecting 
strain of HIV-1 and host genetic factors have all been thought to 
contribute to progression, however the extent of the contribution of 
such factors is difficult to ascertain. Viruses such as HHiV-1 and 
the herpesvirus family are thought to interact at the molecular level 
enhancing viral replication (161). Other microbial infections and T 
cell mitogens which can stimulate the immune system nay trigger
increased viral replication (162). Variation in the replication 
capacity and cytopathic effect of different strains of HIV-1 in vitro 
has , been noted (163), what significance this has in vivo is
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uncertain. Certain human leukocyte antigen (HLA) phenotypes have 
been associated with development of AIDS particularly HLA-DR3 and
associated antigens (164). Any one or a combination of the above
factors can contribute to the rate of developing AIDS or whether an 
individual develops AIDS at all, however these factors cannot be 
routinely measured in the laboratory to give any indication of onset 
of disease.
Several prognostic indicators of progression have been
identified in a number of European cohort studies (99,104,105,107). 
An association between loss of antibody to the core protein p24, 
production of free viral antigen, and decline in T4 cell counts with 
development of HIV-related symptoms were the most oociaon findings. 
Other markers reflecting the more general state of the immune system, 
e.g.^-ndcroglobulin, neoptwdn,o< - and interferon, interleukin-2, 
inmunoglobulin levels etc. have also been evaluated in predicting
disease progression. These markers may indicate those infected 
persons who will progress more rapidly and would therefore benefit 
from earlier intervention and prophylactic drug therapies as it 
becomes increasingly more likely that AIDS is the end stage for all 
HIV-1 seropositives. Measurement of the viral and some immune 
markers is possible using the caunercial test kits which are 
available.
OBJECTIVES OF STUDY
When this study was begun in October 1985 the first objectives 
were to establish a reliable screening and confirmatory test system 
for HIV-1 to cover Glasgow and the West of Scotland. Using this 
system the epidemiology of HIV infection in the community was studied; 
risk-groups were identified and the prevalence of infection in these 
groups was measured over time.
Public concern about HIV and AIDS led to major health service 
commitments including establishing an outpatient and counselling 
clinic at Ruchill Hospital. It was thus possible to follow patients 
with infection over many years. Virological progression of the 
disease in such patients was investigated to see if there was any 
relationship to clinical progression.
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CHAPTER 2
DETECTION OP HIV-1 ANTIBODY:
SCREENING AND CONFIRMATORY TESTING
A. SCREQTENG FOR ANTI-HIV 1
INTRODUCTION
Antibodies synthesised in response to infection with human 
immunodeficiency virus type 1 (HIV-1) are detected in the serum of 
individuals by enzyme-linked immunosorbent assay (ELISA).
The first HIV-1 antibody test kits were developed in 1984, 
following the isolation of the putative agent for AIDS and its 
characterisation in terms of size, morphology and the nature of its 
structural proteins. Test kits have been commercially available 
since 1985 and the choice has been extensive. The tests discussed 
here comprise two basic designs as described more fully in Appendix 1; 
the Type I or direct binding/antiglobulin assay and the Type II or 
competitive assay.
The kits are evaluated and the performance characteristics e.g. 
sensitivity and specificity, defined by the manufacturers before use 
in routine diagnostic testing (Table 2.1). Since there is no 
recognised gold standard for establishing the presence or absence of 
HIV-1 antibodies in human blood the assumptions in Table 2.1 are 
required, that is,
(a) assuming 100% prevalence of antibodies in AIDS patients
(b) assuming 0% prevalence in random blood donors.
Initial evaluation of the available kits was performed by the 
Public Health Laboratory Service (FHLS), Virus Reference Laboratory, 
Col indale, London (108) prior to the beginning of routine blood donor 
screening in October 1985.
With the development of new technologies and the advent of 
improved tests, regular evaluations have been carried out by the PHLS. 
Hie most recent of these evaluations has been that of the combination 
ELISAs for HIV-1 and HIV-2 (118,119).
A second, related human iimiunodeficiency virus, HIV-2 causing an
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AIDS-like disease in West Africa was isolated from two male patients 
with AIDS in Guinea Bissau and Cape Verde in 1986 (64). This virus 
can be transmitted in the same way as HIV-1. Very few cases of HIV-2 
infection have been identified in the UK; a total of 12 by the end of 
December 1990 (74), but one of these was in a blood donor detected in 
1989. Therefore it was decided by the BTS to screen for previous 
exposure to this virus and so eliminate it from the blood bank 
supplies. HIV-2 has been incorporated into screening tests and the 
ELISAs now take the form of a combined assay for antibodies to HIV-1 
and HIV-2. These combination assays have been available since the 
end of 1988. In the UK Blood Transfusion Services the combined 
screen was introduced on 1st June 1990.
Evaluation of screening assays at the KRL has depended on the 
-testing of a number of samples from high risk individuals. These 
included -
( i) seroconversions, where specimens are available both 
pre- and post- infection;
( ii) weak antibody positives where no previous antibody 
negative sample is available but blood samples have 
been withdrawn shortly after seroconversion before 
the levels of antibody saturate the test system, and 
(iii) dilutions of antibody positive sera, either serial
dilution of a single sample or in the case of pooled 
sera where one or more samples in the pool may be 
positive.
The results presented here are not intended as an evaluation of 
the test kits, but simply a look at the improvement in performance 
characteristics (i.e. sensitivity and specificity) of the tests 
available ever the first four years of anti-HIV 1 screening.
The following results demonstrate how the different ELISAs 
performed with the array of samples at the HKL.
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METHODS
Hie test kits used throughout this study were:
Abbott HHiV III Antibody EIA 
Wellcozyme anti-HTLV III EIA 
Abbott Recombinant HIV-1 EIA 
Wellcozyme HIV Monoclonal EIA
Type I First Generation
Type II First Generation
Type I Second Generation
Type II Second Generation
An alternative ELISA, the Dipstick assay (DuPont), is discussed 
and an introduction to the combination anti-HIV 1 plus anti-HIV 2 
assays is made. The tests employed have been more fully described in 
Appendix 2.
Prior to commercial kits being introduced a selection of samples 
were tested by immunofluorescence (IF) using ready-prepared slides 
coated with LAV infected and uninfected cells (Pasteur). After April 
1985, enzyme-linked immunosorbent assays (ELISAs) were used to screen 
for anti-HIV 1.
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RESULTS
1. DETECTION OF HIV-1 ANTIBODY BY FIRST GENERATION TESTS
Hie first oonmercial test used at the HRL in April 1985 was the 
Abbott HTLV III Antibody EIA (Abbott Laboratories). Sanples found 
seropositive were confirmed by IF using the slides, described above, 
at this time.
Hie haemophiliacs farm a discrete population and stored sera 
were available from the mid-70s. Hius, retrospective screening was
performed using the Abbott ELISA. At this time 14 out of 111 adults
and 16 out of 57 children were found seropositive in 1982-84 samples. 
Hie test was used in a semi-quantitative fashion, as an increase in 
optical density (0D) was observed in those with serial samples. A 
lew OD reading implies low antibody load. This may be an indication 
of recent infection or a property of the antibody species itself where 
only high avidity antibodies have bound to the solid phase and have 
therefore been detected. Table 2.2 shows the results from testing 
serial samples from 7 haemophilia patients. A slow rise in HIV 
antibody titre occurs in these patients. Hie results demonstrated 
that the Abbott ELISA could detect seroconverting patients and that 
low CD values oould represent genuine, specific HIV-1 antibody.
Hie second test which came into operation at the HRL in October 
1985 was the Wellcozyme anti-HTLV HI ELISA (Wellcome Diagnostics). 
During the period of overlap, when both tests were being used, a few 
available samples demonstrated the increased sensitivity and reduced 
number of false positives in the Wellcome test at this time (Table 
2.3). Sample 3 was from a hepatitis B surface antigen positive 
blood donor in 1986 identified through retrospective testing of such 
donors by the BTS. Hie ELISA result, when tested by the Abbott and 
Wellcome first generation tests at the HRL was negative at this time. 
Further testing was performed for the BTS, since their screening 
result by the Wellcozyme anti-HTLV III EIA was initially reactive and 
repeated within a 10-20% cut-off range. Hie sample gave three bands 
(p17, p24, gp41) on a western blot and the ENV bead was positive on
TABLE 2.2
Abbott HTLV III Antibody EIA results 
from serial samples of seven haemophiliacs
ELISA Result
Patient Date OP Cut-off
Ha 21. 5.82 0.045
2. 7.84 1.570
8. 8.84 1.830
1. 4.85 >2.000
Hb 24. 2.82 0.045
6. 4.83 1.236
29.10.84 >2.000
He 29. 1.82 0.059
6. 8.82 0.126
10. 3.83 1.349
26.10.83 1.909
2. 7.84 >2.000
Hd 18. 1.82 1.654
17. 9.82 1.905
5. 7.83 >2.000
He 11. 1.82 0.092
26. 5.82 0.488
18. 1.83 1.286
24. 6.83 1.376
3. 9.84 1.826
25. 2.85 >2.000
Hf 31. 8.82 0.093
4. 2.83 0.284
9. 6.84 1.580
Hg 29.11.82 0.830
22. 2.83 1.127
13. 8.84 1.607
c/o 0.134
c/o 0.134
c/o 0.134
c/o 0.133
c/o 0.133
c/o 0.135
c/o 0.135
TABLE 2.3
First generation ELISA results and confirmatory results 
on several interesting samples.
Patient Abbott Wellcozyme Confirmed
Category HTLV III Ab EIA anti-HTLV III EIA Result*
1. LP1 # N P Positive
2. Drug Abuser N Eg** Positive
3. Blood Donor N N Positive
4. Blood Donor WP N Negative
5. Renal Unit WP N Negative
N - Negative
P - Positive
* - Confirmed by western blot (DuPont) and the Abbott
Confirmatory EIA
§ - Low Positive Control 1 (Virus Reference Laboratory, PHLS,
Colindale, England)
**Eq - A cut-off range (c/o i 10%) was defined in the Wellcome
test. Samples with ODs within this range were defined as
equivocal until confirmed.
WP - Weakly Reactive by ELISA
Patient 4 - s/co 1.33 
Patient 5 - s/co 2.32
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the Abbott Confirmatory EIA. At this time the sample was considered 
a confirmed positive and has subsequently retested positive by the 
third generation screening ELISAs and by a GACELISA developed by Parry 
et al. (165)
Many lessons were learned from the use and performance of these 
tests in the field. The rapid developments occurring in this area 
and the need far improvement meant that second generation tests 
quickly became available for use.
2. DETECTION OF HIV-1 ANTIBODY BY SECOND GENERATION TESTS
Weakly reactive serum samples and those fran patients who 
serooonverted, which were originally screened by the Wellcozyme 
anti-HTLV III EIA and confirmed by western blot, were tested by the 
second generation assays from Abbott and Wellcome Diagnostics.
In order to compare intra- and inter-assay results, the optical 
density (OD) readings were assigned a score on a scale of 1-20. The 
optical density distance, i.e. the difference between the maximum and 
the minimum readings was divided into 20 equal intervals, 10 parts on 
either side of the cut-off (166). The interval size was determined 
thus:
cut-off ~ ODminiraum 
____________________ far intervals 1-10 (i.e. Ab negative)
10
and
^^ Baxiraum “ cut-off
____________________ for intervals 11-20 (i.e. Ab positive)
10
If the OD was greater than 2.00 (>2.00) in the Abbott test, a 
category, 21, was used. The test system is saturated at this point 
and the spectrophotometer is unable to give an OD greater than 2 units
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at this wavelength. Since the Wellcome tests are competitive ELISAs 
these formulae were reversed, i.e. the lower interval 1-10 represents
oPmaxiraunr00 cut-off/10 303 uPPer interval,
Q P c n t - o f  f - Q D ^ I  n j  n n n y /1 0 ,  to allow the test scares to be comparable to 
those for the Abbott ELISA.
Performance of Second Generation Antibody Tests:
Seroconversion Samples
The scores for a group of patients who seroconverted over the 
period of the study have been represented in a graphic form in 
Fig.2.1. Tbe results of the two second generation tests are
comparable and the scores are higher than those of the same sample in 
the first generation test in 14 of the 23 individuals. The best 
separation of negative and positive ODs around the cut-off is achieved 
using the HIV Monoclonal EIA (Wellcome). It is clear, with reference 
to certain marked specimens in Fig.2.1 that the second generation 
tests are more sensitive than the first generation test shown here.
Weak Positive Samples
Table 2.4 shows the results for the same 3 ELISAs on a group of 
patients, where the original ODs of the sera were judged to be weakly 
reactive in the screening ELISA and shewed a pattern associated with 
recent infection on western blot. Certain results (patients 3, 4, 7, 
8, 10) which had been borderline on previous testing were clearly 
positive by the second generation tests. Weak positives were now 
apparently strong positives. This can also be seen from the plots of 
the OD scores (Fig.2.2). Again the monoclonal test from Wellcome 
gives the clearest results with good separation of positives and 
negatives and there are fewer samples near the cut-off.
Serial Dilutions
A panel of dilutions from HIV antibody positive blood donations 
provided a good set of samples to examine the performance of the same
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TABLE 2.4
Optical density scores in samples from patients 
with weakly reactive ODs on initial testing
TEST
Patient No. A B C
1. 19 18 17
2. 21 19 20
20 20 20
20 20 19
21 20 19
3. 11 12 10
NT NT 13
13 15 11
15 17 14
21 20 20
4. 16 16 10
16 15 13
20 18 17
5.
6.
7.
8.
9.
10.
11.
12.
19
17
19
21
15
21
12
12
19
17
21
21
14
17
20 
20
12
17
16
19
16
20
18
20
20
17
20
18
17
NT
19
19
NT
16
19
19
20
16
19
20
17
20
18
19 
18
20
9
20
11
11
16
15
19
20
9
13
19
20
13
14 
20
15 
NT
A - Abbott Recombinant HIV-1 EIA (2nd Generation) 
B - Wellcozyme HIV Monoclonal EIA (2nd Generation) 
C - Wellcozyme anti-HTLV III EIA (1st Generation)
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3 ELISA systems. Table 2.5 shews the dilutions and their test 
results. This also gives an indication of the sensitivity of the 
tests. However, there is a drawback: the ELISA only picks up that
species of antibody which is present in the highest concentration in 
the serum and remains when the sanple is diluted. This is not always 
the same species that would be present in a genuine early sample from 
a seroconversion. The result also depends on the viral antigens 
present on the solid phase.
A marked difference in the results between the first and second 
generation ELISAs can be seen in S3 and S4, Table 2.5. Overall, the 
Abbott Recombinant HIV-1 EIA is able to detect antibody at higher 
dilutions. Certain narked samples in Table 2.5 were sufficiently 
close to the cut-off, in the various tests, to have been noted and 
retested or confirmed if this were a clinical situation.
Pooled Sera
A number of biochemistry quality control (QC) sera were tested 
for HIV. This QC material was produced from large pools of human and 
bovine sera for use in the calibration of a variety of clinical
biochemistry tests.
Human-derived material carried the risk of being anti-HIV
positive prior to the implementation of blood product screening. Only 
one single donor was required to be infected with HIV to contaminate a 
whole batch.
This pooled material was screened for HIV in 1985 and 1986; one 
company in particular actively pursued this testing facility in order 
to ensure customers that their products were safe to handle and 
unlikely to contaminate other material or machinery.
The QC material was supplied lyophilised and was reconstituted 
in deionised water, except in those samples where a diluent was 
supplied. The reconstituted samples were screened in three ELISA 
systems and confirmed by western blot. Table 2.6 shows typical
results obtained on this set of samples. It was noted that this
material performed less well in the competitive ELISAs: however the
second generation tests were better than the first generation test 
used. Although, in general, the pooled material showed low ELISA
TABLE 2.5
Serial dilutions of seropositives tested by 3 ELISA systems
Abbott Recombinant
HIV-1 EIA
(2nd Generation)
SI. Neat +
1:2 +
1:4 +
1:8 +
1:16 +*
1:32 -
S2. 1:30 +
1:100 +
1:300 +
1:1000
1:3000 -
S3. 1:1000 +
1:2000 +
1:4000 +
1:8000 +
1:16000 -
S4. 1:100 +
1:300 +
1:1000 +
1:3000 -
1:10000 -
S5. Neat +
1:10 +
1:30 +
1:100 +
1:300 +
1:1000 +
S6. 1:30 +
1:100 +
1:300 +
1:1000
1:3000 -
♦ - within 
/ within 
** - within 
§ - within
Wellcozyme Wellcozyme
HIV Monoclonal anti-HTLV III
EIA EIA
(2nd Generation) (1st Generation)
+ +
+
c/o + 10% 
c/o + 20% 
c/o - 20% 
c/o - 10%
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reactivities, multiple bands were present on WB described later in 
this Chapter (Fig. 2.11).
All non-human-derived material that was tested was anti-HIV 
negative.
These results give no information regarding the infectivity of 
the product.
3. DETECTION OF HIV-1 ANTIGEN IN SEROOONVERSIONS AND 
WEAK POSITIVE SAMPLES
HIV-1 antigen (Ag) is the first serological marker to be 
produced on infection. When the first antigen test became available 
(January 1987) a number of samples from patients who were suspected of 
being recently infected were tested. No serum Ag was detected in 13 
samples from 10 patients prior to seroconversion where the time 
interval from the last HIV-1 antibody negative sample to the first 
antibody positive sample ranged from 35 days to 196 days. In 
addition, Ag was detected and confirmed in only one out of six 
patients with equivocal antibody ELISA reactive (but WB confirmed) 
samples, i.e. at seroconversion (data not shown).
Table 2.7 shows the results of Ag testing in two patients in 
whom the time course of HIV-1 infection was followed by testing 
sequential samples. This gives a clearer indication of when 
antigenaemia occurs in acute infection. The Ab serology is discussed 
later in this Chapter along with western blot results (Table 2.14). 
In one case (Tx) the date of infection with the virus was known. HIV 
Ag was detectable in the first serum sample available for screening, 
after infection at day +38 and was present in a further two samples up 
to day +42. These results, however, were unconfirmed due to the low 
sample volumes in each case. No HIV-1 Ab was detected in these 
samples by ELISA or WB. Thus Ag was detected 19-23 days prior to the 
first specimen found to contain antibody. In contrast in patient Ho 
the date of infection with HIV was unknown (Table 2.7), but several 
samples around the time of antibody seroconversion were available for 
testing. The patient was found to be both antibody and antigen 
negative three months earlier (day -101). One sample, 6 days prior
TABLE 2.7
Antigen results in sequential samples fran two patients.
HIV-1 Antigen 
Patient Day Result (Abbott)#
Tx -35 N
0* No sanple
+3 N
+38 R (s/co 1.46)
+40 R (s/co 1.68)
+42 R (s/co 1.54)
+61 N
+80 N
+308 N
Ho
HIV-1 Antigen 
Result (DuPont)#
101 N N
-6 R (s/co 1.32) R (s/co 10.51)
-2 N (s/co 0.90) R (s/co >17.09)
0* N (s/co 0.92) R (s/co >17.09)
+2 N (s/co 0.96) R (s/co 11.75)
+22 N N
§ The sample to cut-off ratio of reactive and high negative 
results are indicated
* In patient Tx, day 0 represents the date of infection with 
HIV-1, i.e. the date of the platelet transfusion. In patient Ho, 
day 0 represents the first specimen with detectable anti-HIV-1 
since the exact date of infection with the virus was unknown.
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to the appearance of HIV-1 antibody, was reactive in the antigen test. 
Three further samples at day -2, day 0 and day +2, where day 0 was the 
first specimen with detectable, but unconfirraable anti-HIV 1, gave 
negative CD readings in the antigen test. However the ODs were close 
to the cut-off (c/o minus 10%) giving sample to cut-off (s/co) ratios 
between 0.90 and 0.96 and clearly stood out from the other negative 
samples on that test run. These were referred to as high negative 
results and it appeared that the antigen level was decreasing. A 
sample at day +22 was HIV-1 Ag negative. These results were 
interesting and the Du Pont p24 core antigen EIA was also performed. 
Discrepant results were found and this is indicated in Table 2.7. 
All the samples were reactive in this test apart from day +22 and in 
two cases there was sufficient antigen to saturate the test system. 
No neutralisation confirmatory tests were performed at this time. 
This difference in the results may be explained by the use of Triton 
X-100 in the DuPont assay. This detergent disrupts HIV-1 virions and 
releases Ag in the sample. The Triton X-100 treatment step was later 
introduced into the Abbott antigen test protocol. The day +2 sample 
then retested positive by the Abbott test and was confirmed by 
neutralisation.
4. RAPID ANTIBODY SCREENING TESTS
A number of sera from different risk groups, whose reactivity in 
other test systems was known, were tested using the Dipstick assay (Du 
Pont). A limited amount of testing was performed using this assay 
and the results are shewn in Table 2.8. The negative and strong 
positive sera gave clear results and presented no problems, although 
one AIDS patient gave a weak one plus (1+) reading. The remaining 
three out of the seven weak ELISA reactives did give equivocal 
results, namely a tinge of colour. In addition five of the nine 
false positives gave equivocal results and clearly these sera would 
have to be tested further.
TABLE 2.8
HIV-1 antibody test results using the 
Dipstick Assay (DuPont)
Category 
of Sera
No. Sera 
Tested
Du Pont Dipstick 
Positive
HIV-1 Ab 
positive 10 10 (100%)
HIV-1 Ab 
negative 0 (100%)
Weak ELISA Ab 
positive
False positive
6 (66.7%) 
2 (22.2%)
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5. COMBINATION ANTI-HIV 1 AND ANTI-HIV 2 SCREQUNS TESTS
The first combination test in use at the HRL was the Abbott 
Recombinant HIV-1/HIV-2 EIA (Abbott Diagnostics) in March 1989 
(Appendix 2). A number of sera were examined and the results 
compared to the test in use at that time (Abbott Recombinant HIV-1 
EIA). The results are shown in Table 2.9.
Anti-HIV 1 Detection by Combination Tests
All strong HIV-1 positives were detected by the combination 
test; but three samples from patients considered to be at an early 
stage of infection were apparently missed. The reason far this is 
unknown. Sane problems had previously been noted when testing older 
stored sera indicating that there could be loss or deterioration of 
antibody in such samples. Sera are stared in plastic vials at -20°C; 
the effects on serum proteins of repeated freezing and thawing are 
unknown, however contamination, proteolytic degradation and some 
binding of proteins to the plastic vials has led to discrepant results 
after a period of storage.
A number of sera from low risk individuals which had reacted
falsely by different ELISAs including the Abbott Recombinant HIV-1
EIA, were tested. A reduced number of false positives was found
using the combination EIA. This was not unexpected as past
experience in testing low risk sera by different ELISAs showed that 
the various tests flag a different set of samples as falsely reactive.
Four internal quality control sera and nine biochemistry quality 
controls were tested and compared to the results of the HIV-1 assay. 
Three results in the HIV-1/HIV-2 tests were discrepant; two quality 
control sera were negative by the test criteria, but the CD was within 
10% of the cut-off, and one biochemistry serumwas negative.
The lack of sensitivity noted in the above results was also seen 
with respect to testing serial sanple dilutions of HIV-1 seropositives 
(Table 2.10).
TABLE 2.9
Results of screening various groups of sera with the 
combination, HIV-1 plus HIV-2, assay versus the 
HIV-1 antibody assay.
Category of 
Specimen
Total Nos. 
Tested
Abbott 
Recombinant 
HIV-1 EIA 
Positive
Abbott 
Recombinant 
HIV-1 /HIV-2 EIA 
Positive
HIV-1 Ab 
positive
HIV-1 Ab 
negative
WPs 11 11 8
FPs
QC
19
13#
11
13
2
10
HIV-2 Ab 
positive 10
# - Including 9 biochemistry quality control sera 
described earlier.
WPs - Weak Positives 
FPs - False Positives 
QC - Quality Controls
TABLE 2.10
Performance of single Sample dilutions in the 
combination test versus the HIV-1 antibody assay.
Abbott Abbott
Recombinant Recombinant
Dilutions HIV-1 EIA HIV-1 /HIV-2 EIA
51. Neat + +
1:2 + +
1:4 + +
1:8 + +
1:16  - *
1:32
52. 1:30 + +
1:100 + +
1:300 + +
1:1000
1:3000
S7. 1:1000 + +
1 :2000 - *
1:4000 
1:8000 
1:16000
* within c/o -20%
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Anti-HIV 2 Detection by Combination Tests
Nine out of ten sera, brought from Portugal, and taken from 
patients with HIV-2 infection, were detected by the combination HEV-1 
and -2 test (Table 2.9). All these samples are positive far HIV-2 
antibody by ELISA (ELAVIA Ac-Ab-Ak II, Diagnostics Pasteur). 
Unfortunately, little is known about these samples and it may be that 
the negative sample was from a patient who was seroconverting or 
possibly even at a terminal stage. Six out of the 10 sera were 
detected by the HIV-1 screen, indicating the cross-reactive nature of 
proteins from related viruses.
Although no increased sensitivity or specificity was seen with 
this combination test, it did provide a means of testing for HIV-2 
antibodies in the population being screened. There have been no 
persons found to be HIV-2 antibody positive in 18 months of routine 
screening with the combination HIV-1/-2 test.
6. HIV-2 ANTIBODY DETECTION
An HIV-2 Ab ELISA (Diagnostics Pasteur) was used prior to the 
introduction of the combination tests, for specific anti-HIV 2 
requests. In addition, some testing was performed on a snail number 
of HIV-1 Ab positive persons who came from Africa or were infected in 
Africa. Ten out of 15 HIV-1 Ab positives reacted in the HIV-2 ELISA. 
To establish the nature of this reactivity, whether simply 
cross-reaction with HIV-2 encoded proteins or more interestingly a 
genuine HIV-2 infection or dual infection, an HIV-2 Western Blot 
(Du-Pont) was performed. The results are shewn in Table 2.11. The 
major HTV-2 structural proteins were identified as follows - 
(Instruction Manual, Western Blot IgG Assay Kit for the Detection of 
HIV-2 Antibodies, Du-Pont, March 1988):
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gag proteins : p56 (gag precursor)
p26, p16
pol proteins : p68 (reverse transcriptase)
p36 (endonuclease)
env proteins : gp140, gp105
gp41 (transraembrane protein)*
♦The molecular weight of the transraembrane protein 
of HIV-2 is usually quoted as gp36.
Comparison with the positive control indicated that the 
predominant reactivity was to the core proteins. Two samples (MJH 
and BV, Table 2.11) required further investigation because of the 
presence of a band in the high molecular weight regions, gp105 in BV 
and gp140 in MJH. The samples were sent to the Research and 
Diagnostics Unit, Diagnostics Pasteur, France, where a peptide test 
had been developed. Synthetic peptides (Genetic Systems, Seattle, 
USA) mimicking the gp41 HIV-1 and the gp36 HIV-2 transraerabrane 
glycoprotein specific epitopes were coated onto strips of 
nitrocellulose and detected by an ELISA method thus discriminating 
between anti-HIV 1 and anti-HIV 2 reactivity. BV was positive on the 
HIV-1 peptide only but MJH reacted against both peptides and it was 
suggested that he was infected with an HIV-1 isolate more closely 
related to HIV-2 than the prototype HIV-1 (Diagnostics Pasteur, 
personal communication). This test is now available commercially as 
the Pepti-LAV 1/2 (Diagnostics Pasteur).
7. HTLV-I/-II ANTIBODY DETECTION
An ELISA (Abbott HTLV-I EIA) is only performed on those samples 
for which there is a specific request. Some screening has been 
performed on HIV-1 risk groups, predominantly DAs and this is 
discussed in Chapter 3. No evaluation of the commercially available 
ELISAs can be performed due to a lack of HTLV-I and HILV-II antibody 
positive sera.
TABLE 2.11
HIV-2 western blot results on HIV-1 antibody positive 
sera reactive in an Anti-HIV 2 ELISA (Diagnostics Pasteur)
Patient Reason Dilutions Western Blot
OC ex-Malawi 1:100 p26, (gp41), p56, p68
MUH ex-Africa 1:100 p26, p36, gp41, p56,
p68, gp140
GR Sexual contact
with African 1:100 p26
SR - 1:100 p26, p36
PN ex-Uganda 1:100 p26, gp41, p56
BV Contact in
Zambia 1:20 p26, gp41, p56, p68,
gp105
A3/86 BTS reference 1:100 p26, p36, (gp41)
A6/86 BTS reference 1:100 p26, gp41
A7/87 BTS reference 1:100 p26, p36
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DISCUSSION
Hie presence of specific antibody to HIV means that an 
individual has been exposed to HIV at some time in the past. 
Antibody positive persons are potentially capable of transmitting the 
virus; this implies that an individual is continually or chronically 
infected with HIV. Hie ability to transmit HIV may not always be 
present, the potential is, however.
Although the result of a screening test does not give any 
measure of the infectivity nor any information on the prognosis of an 
individual a positive result is devastating for the patient. 
Therefore, the test has to achieve a high degree of sensitivity and 
specificity to ensure confidence in the result. Hie consequences of 
a wrong result to a patient, especially with such an emotive subject 
as HIV are disastrous.
There is no gold standard test for anti-HIV so the 
characteristics of an assay are assessed on certain populations. 
There have been no large scale evaluations performed at the HRL 
principally because a proper evaluation of specificity requires the 
testing of thousands of samples. However, several groups of 
interesting clinical samples have been examined over the period of the 
study and useful information produced on specificity and sensitivity.
A good screening test has to be robust, easy to install, easy to 
operate with minimal handling, i.e. user-friendly, give reproducible 
results, available at a low cost per test, and adaptable for either 
large scale automated use or limited numbers, in addition to the 
essential qualities of high sensitivity and specificity. Hie 
occurrence of false negatives is a problem because they pass through 
the system and are not retested or tested by another system. False 
positives can be eliminated by further tests and the numbers in this 
category were reduced when confirmatory testing was used, either 
immunofluorescence or western blotting.
Some ELISAs have traded one quality, e.g. high sensitivity at 
the expense of another, e.g. that of specificity and many tests had 
their teething problems in the beginning which have been ironed out 
with use. It is important that test performance is subject to
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rigorous criteria of validity each run.
First Generation Tests
The first test, the Abbott fULV III EIA, was subject to both 
false negatives (FN) and false positives (FP).
False positive reactions with human sera occurred through 
cross-reactions of antibodies to human leukocyte antigens (HLAs) 
specifically the ER locus of the Class II HLAs which are expressed on 
the surface of the HIV-infected H9 cell culture material used as an 
antigen source (110-112). This was seen in a few multiply-transfused 
renal unit patients tested at the HRL. It was also noted in the 
literature that heat inactivation of the virus (56°C for 30 rain) in 
patients' sera led to an increase in absorbance and in some cases to 
false positive reactivity (113). The mechanism for this is unknown. 
However this was not routine practice at the HRL and was therefore not 
a problem.
The Wellcozyme anti-HELV III EIA also used human cell culture 
derived material as an antigen source. The cut-off value was based 
on the OD of a weak positive serum and a grey zone for retesting was 
identified as 10% either side of this value. This test was also 
subject to false negative (167) and false positive results (168). In 
addition an edge effect was noticed when the microtitre plate was 
incubated on a heating block. The CDs at the edge were higher than 
those in the centre of the plate and was a potential source of error 
(169). The edge effect was overcome by the use of a water bath or 
incubator. This test was highly favoured by the BTS and most centres 
used it for screening. The Glasgow and West of Scotland BTS achieved 
an increased sensitivity by an extra 30 min incubation of sera prior 
to addition of the enzyme-labelled HIV antigen conjugate (170). Any 
donor sera with an OD repeatedly outwith 3.2 standard deviations of 
the test negative mean, i.e. that of the saiqples under test and/or 
repeatedly reactive were sent for confirmation to the HRL.
The Wellcome test appeared to be able to detect recent 
infections with a higher degree of accuracy (Fig.2.1; Fig.2.2). A 
different epitope may be exposed on the solid phase in different tests
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and therefore different antibodies are being detected. It was
initially thought that antibodies to core proteins were the first 
species produced after infection as they are present in abundance. 
As time progressed it was established from seroconversion studies that 
antibodies to envelope glycoproteins were produced early in infection 
(86) and reliable detection of seroconversion required these epitopes 
to be present as capture antigen on the solid phase. Epitopes on the 
envelope proteins used in the development of the Wellcome test were 
perhaps exposed in such a way as to be better able to detect early 
infection.
Second Generation Tests
Lessons learned from the first generation assays helped to 
improve the tests, e.g. the false positives due to anti-HLA 
cross-reactions were reduced by using recombinant peptides on the 
solid phase (Abbott) instead of cell culture derived viral lysate. 
The use of recombinant protein(s) derived from sequences of HIV-1 
proteins permitted a choice of which epitopes to include on the solid 
phase and this was the prerogative of the manufacturer. Thus the
solid phase could be coated with a choice of antigens of different 
specificities and in different proportions. The second generation 
Wellcome test used the same first generation test antigen on the solid 
phase but it was bound to the microtitre well by monoclonal antibody. 
The tests evolved with the aim of detecting HIV-1 antibody at its 
earliest production in an infected person and therefore closing down 
the window of infection, i.e. that time between exposure to the virus 
and the first production of antibodies.
The sera used in studies at the HRL were chosen to assess how 
efficient the new assays were at picking up anti-HIV 1 when it is 
present in those patients recently infected. The results show that 
the new generation of tests were indeed an improvement; the test 
signals were amplified and CDs were more positive in the second 
generation tests. A sample previously considered a weak positive now 
gave a strong positive result and the tests showed a greater 
separation of negative and positive results, therefore permitting
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greater faith in the result being genuine. Although there was the 
added danger of anplifying false positive reactions and introducing a 
further new set of specimens which reacted falsely in the second 
generation tests, confirmatory testing was available to screen out the 
problems.
It can be seen using these panels of pedigreed anti-HIV 1 
positive samples that different tests do show variation in their 
ability to detect antibody to different parts of the virus and at 
different time points in infection; competitive assays appear better 
than the antiglobulin kits in detecting antibody at seroconversion 
whereas the latter have the edge in endpoint dilution studies. It is 
important to note that although dilution studies may give an 
indication of sensitivity of a test, where the antibody species 
present in highest concentration is measured, this will vary in 
different people and will depend also on disease stage. A test 
giving a high sensitivity in this situation does not indicate its use 
in the diagnostic laboratory where sensitivity depends on being able 
to detect genuine HIV antibody early in infection. Specimens from 
recent infections give a better, more true picture of test performance 
than dilutions since this is the situation in a genuine clinical 
setting.
A subtle difference existed between the serial dilutions, tested 
and presented in Table 2.5 and those of the pooled sera containing HIV 
shown in Table 2.6 The latter were originally thought to be ELISA 
false positives but multiple bands were shown by western blot. In 
contrast the western blots of single sanple dilutions could eventually 
show a single band at higher dilutions (Fig.2.10). The pooled 
material is assumed to be a dilution of an HIV positive; it is not 
known exactly what is in these samples or what they are diluted in, if 
anything, prior to lyophi 1 i sat ion. It would appear that there was 
more than one infected donor in the pool.
Antigen Testing
The initial testing with the antigen assay(s) was performed to 
establish its usefulness in the diagnostic laboratory. HIV-1 Ag
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has been detected in sera and CSF prior to antibody production (85,86) 
and has also been detected at the time of acute illness (84). In one 
of the two patients studied, Tx, antigen was present 3 weeks prior to 
the production of antibody. This fits with the putative time course 
of HIV-1 infection and is comparable with other studies of incubation 
times. Patient Ho was more unusual in that antigen was present at 
antibody seroconversion. Hie patient had a documented illness 
consistent with acute HIV-1 infection, i.e. lyraphadenopathy, pyrexia 
etc. in the 3 to 4 weeks prior to seroconversion.
Such a test would be useful in detecting infection early and thus 
closing the window of infection. A programme of HIV-Ag screening of 
blood donors in Germany failed to detect additional HIV-infected 
individuals in over 150,000 donations (171). Thus its lack of 
sensitivity for this marker, even although it can detect picograrane 
quantities, and the transient nature of early antigenaemia meant that 
it could not be used routinely to detect infected persons prior to the 
production of antibody. However it may prove useful in situations 
such as needlestick injuries where a known exposure has occurred and 
regular samples are being withdrawn from the patient. The test was 
used for some time as part of a battery of tests on reference samples 
sent from the Regional Transfusion Centres (RTC) in Scotland and 
Northern Ireland. However, its major use at the HRL is in the 
follow-up of anti-HIV 1 seropositives. This is discussed further in 
Chapter 4.
Rapid Tests
A number of alternative antibody screening tests, including the 
DuPont Dipstick Assay, were developed to appeal to a variety of users. 
These were designed for use 'in the field' or 'at the patient's 
bedside' and particularly in developing countries where problems such 
as maintaining test kits at 4°C are as much a challenge as performing 
and reading the results of the assay. The results indicate that the 
Dipstick test lacked sensitivity and therefore confirmation of a 
result was still required, especially in those samples giving only a 
tinge of colour in the final substrate solution. This test was
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s h o r t - l iv e d  o n  th e  m a rk e t. No f u r t h e r  w o rk  h a s  b e e n  p e r fo rm e d  o n  
th e s e  r a p id  t e s t s  a t  th e  H R L.
Combination Tests
The arrival of the combination (combi) tests where both HIV-1 
and HIV-2 proteins were present on the solid phase brought with it a 
new challenge. A specimen reactive in such a test would have to be 
tested further to distinguish between anti-HIV 1 and anti-HIV 2 or to 
confirm a dual infection. In addition, it was thought the
sensitivity of anti-HIV 1 detection would be compromised by the 
presence of HIV-2 on the bead. Strong positives were flagged easily 
but in other clinically relevant cases (WPs, Table 2.9) it was 
suspected that the use of older, stored sera which had been frozen and 
thawed numerous times may have affected the test performance. In 
practice the test has proved sufficiently sensitive for the detection 
of HIV-1 Ab with respect to seroconversion samples. The combi test 
detected all but one of 10 serum sanples from HIV-2 infected 
individuals from Portugal. No assessment of test performance with 
respect to HIV-2 Ab detection could be made due to the lack of HIV-2 
Ab positive samples available locally.
HIV-1 and HIV-2 share a 45% homology both at the genomic level 
and in amino-acid sequence (69) and it is not surprising that antibody 
cross-reactions do occur. The simplest method of distinguishing 
between HTV-1 and HIV-2 reactivity would be by using individual ELISAs 
specific far anti-HIV 1 only or anti-HIV 2 only, i.e. ELISAs 
incorporating nan-conserved epitopes.
HIV-2 Antibody Screening
The results with the HIV-2 antibody ELISA used at the HRL 
(Diagnostics Pasteur) indicates that it lacks specificity since 75% of 
the HIV-1 seropositive samples tested did react but were not confirmed 
as HIV-2 Ab positive. Again sensitivity could not be assessed due to 
a lack of HTV-2 seropositive samples. Therefore, a problem exists in 
finding a reliable method of determining the nature of the reactivity
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in the combi test. The answer nay lie in the use of recombinant 
imraunoblots containing more than one epitope from each of HIV-1 and 
HIV-2. This is discussed further at the end of this Chapter.
CONCLUSION
The phenomenal pace of AIDS research has allowed constant and 
continued advancement and updating of diagnostic screening. The 
tests available are always improving as technology and test
development keep up with current research.
Questions to be asked on developing an antibody assay for 
testing clinical samples and blood donors include which antibodies are 
produced during both early and late infection and are the
corresponding antigens represented on the solid phase? This question 
has been effectively answered as the sensitivity and specificity 
improved in the second generation tests. The window period between 
infection and production of antibody has been narrowed.
The tests have now incorporated screening for a second
retrovirus, HIV-2, and epitopes from the envelope protein are included 
on the solid phase. Although this virus was first isolated in 
regions of West Africa, cases have new been reported in Europe (74) 
and America (73). Inevitably the virus will spread either through 
direct transmission in one geographical area or as infected persons 
travel round the world and it is therefore necessary to be able to 
detect such persons and limit the spread. Future developments nay 
include adding epitopes of the human T-cell leukaemia virus family 
into the primary screening stage. One of the major considerations is 
protecting the blood supply and prevent transmission of such viruses 
by this route.
Great variation exists within each retrovirus family. The 
envelope proteins of HIV-1 are highly variable; isolates obtained 
from a single patient from patients infected from the same source and 
from geographically diverse areas are different (50-52) so it is 
important that tests are continually evaluated especially on local 
samples to ensure that antibody to emerging strains of virus can be 
detected.
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B. CONFIRMATORY SCREENING
INTRODUCTION
If screening tests were perfect, there would be no need for 
confirmatory tests. However, although there has been a great 
improvement, screening tests are not 100% sensitive and 100% specific, 
so confirmation of a result is required. The more important quality 
of a confirmatory assay is specificity, since samples which have 
reacted in the screening test are to be tested by this method. The 
sensitivity should preferably be much better than but must be at least 
as high as the screening test. An ideal confirmatory test would be 
able to detect antibody to a range of viral proteins, e.g. core and 
envelope and to detect antibody to a variety of strains of HIV.
Initially inraunofluorescence was used as a screening test prior 
to the advent of a commercial ELISA in April 1985 and then as a 
confirmatory test for the ELISA results, for some months during 1985. 
This was rapidly superseded by western blotting at the end of 1985.
Two tests, in particular were used at the HRL; the Western Blot 
(Du Pont) and the Confirmatory EIA (Abbott Diagnostics).
RESULTS
1. CONFIRMATORY EIA
This dual-bead confirmatory ELISA was developed by Abbott 
Laboratories in 1986 for use with their antibody screening test 
(Appendix 2). The core bead is coated with a protein which contains 
part of p17, all the amino acids of p24 and part of p15 and thus 
detects anti-p24 and anti-p55. The env bead is coated with all the 
amino acids of gp41 and part of gp120 and detects anti-gp41 and 
anti-gp160 according to the manufacturer1 s instructions.
Initial evaluation of the test showed that the core bead lacked 
sensitivity. Table 2.12 shows that 14 of the 53 seropositives were 
negative with the core bead and positive on the env bead. These 
samples would be considered positive by the manufacturer's criteria,
TABLE 2.12
Performance of confirmed HIV-1 seropositive and HIV-1 
seronegative samples on the Abbott Confirmatory EIA
HIV-1 Seropositive HIV-1 Seronegative
No. tested 53 52*
No. ENV bead
Positive 53 0
No. CERE bead
Positive 39 0
* Low risk blood donors sent to the HRL for confirmatory testing. 
These had been found to be reactive by ELISA in this or a 
previous specimen. All were found to be HIV-1 Ab negative.
TABLE 2.13
Comparison of core antibody reactivities on both the 
Abbott Core bead and Western Blot (Du Pont) on the 
HIV-1 seropositives in Table 2.12
Western Blot 
p24 and/or p55 
Positive Negative
Core
Bead
Positive
Negative
38
11*
1# 39
14
49
# Seropositive haemophiliac
* Including 2 with p55 only and no p24 
band on a western blot
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1.e. repeatedly positive on one bead. These 14 core bead negatives 
consisted of:
(a) 3 who were symptomatic or at a late stage of infection 
(two of whom had no p24 or p55 on a western blot).
(Table 2.13).
one
(b) 5 early infections^with a follow-up sample which remained 
core negative, and
(c) 6 whose stage of infection was unknown, one of whom was 
p24/p55 negative on a WB. This also included two samples 
from one patient at different times both of which were 
core negative.
However, the env bead was sensitive in detecting Ab early in 
infection (Table 2.14) and because of this the ELISA was included as 
part of a battery of tests on sanples sent far confirmation frcm the 
BTS for a number of years.
The test was subsequently called the Abbott ENVAOOR HIV-1 EIA 
and was intended to supplement the screening result rather than being 
a confirmatory test since the second generation Abbott Recombinant 
HIV-1 EIA was equally, if not more, sensitive.
Serial specimens frcm a number of patients were tested and 
showed loss of core antibody as time progressed although an anti-core 
reaction was often still visible on a western blot. The negative 
anti-core result, in some cases, correlated with the production of p24 
antigen in the serum and in some cases preceded the onset of symptoms 
and/or antigenaeraia. The role of this core bead ELISA in association 
with other markers of progression, e.g. presence of p24 antigen will 
be discussed in Chapter 4.
2. WESTERN BLOTTING
Viral proteins are electropharetically separated on a 
polyacrylamide gel and then blotted onto a nitrocellulose membrane. 
This is subsequently divided into strips for each individual sample. 
Antibodies to specific viral proteins are then detected by type I 
ELISA methodology using the nitrocellulose strip as the solid phase.
Although all the gene products of HIV are immunogenic in vivo it
TABLE 2.14
Development of markers of HIV-1 infection in a 
transfusion recipient (Tx) and a homosexual (Ho)
Patient Day ELISA ENV Core Western Blot
Tx 0* NS NS NS NS
+3 N NT NT No bands visible
+38 N N NT No bands visible
+40 N N NT No bands visible
+42 N N NT No bands visible
+61 P P NT p24, p55, gp160/120
+75 P NT NT p24, p55, gp160/120
+78 P NT NT p24, p55, gp160/120
+80 P P NT p24, p55, gp160/120
+103 P P N P17, p24, p55, gp160/120
+115 P P N p17, p24, gp41, p55, 
gp160/120
+308 P P P p17, p24, p31, gp41, p53, 
p55, p64, gp160/120
Ho -101 N NT NT NT
-6 N N N No bands visible
-2 NT NT NT No bands visible
0* P N N p24, gp160/120
+2 P P N p24, p55, gp160/120
+22 P P Bd p17, p24, p55, gp160/120
+40 P P P p17, p24, p31, gp41, p53, 
p55, p64, gp160/120
N = Negative; P = Positive; Bd = Borderline; NT = Not Tested
NS = N o S am p le
* = In patient Tx, day 0 represents the date of infection with HIV-1, i.e. 
the date of the platelet transfusion. In patient Ho, day 0 represents 
the first specimen with detectable but unoonfiiraable anti-HIV 1 because 
the exact date of infection with the virus was unknown.
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is the structural proteins which are detected by western blot strips 
prepared frcm cell culture derived viral lysate. Nine proteins, 
seven structural and two precursor proteins are separated according to 
molecular weight from a viral lysate prepared frcm HIV-infected cells. 
The molecular weights of these proteins are p55, p24, p17 (gag), p64, 
p53, p31 (pol) and gp160, gp120, gp41 (env) (Fig.2.3). When arranged 
according to molecular weight on a strip they form a distinct and 
unique pattern. Hence the antibody specificity of an individual for 
HIV can be examined by western blot and a decision made as to the 
specificity of the reaction seen in the ELISA test.
Initially both an "in-house" western blot (WB) and a commercial 
Western Blot kit (Du Pont) were available. Hie high molecular weight 
env proteins were not present on the original WB kits from Du Pont in 
late 1985. However, by March 1986, gp160/120 were detected on these 
strips, often as a single smeared band, characteristic of envelope 
glycoprotein transfer to nitrocellulose. Hie unreliability of 
detecting high molecular weight envelope proteins on the in-house 
strips, and its lack of sensitivity, meant that the commercial kit was 
used routinely far confirmation of samples reactive by ELISA. These 
were designated as strong positive cr weak positive by OD readings in 
the ELISA test. Weak positives implied low levels of antibody and 
were tested at a dilution of 1:20. Strong positives were tested at a 
dilution of 1:100.
Strong Positives
Those sera which reacted strongly by ELISA produced 8 or 9 bands 
and were therefore easy to confirm. Fig.2.4 shows western blot 
strips from different risk groups tested at 1:100, demonstrating an 
antibody reactivity to all the viral proteins. These strips were 
taken frcm the same batch and so the bands could be easily aligned. 
No difficulty was found in confirming samples which reacted in a 
similar way.
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Figure 2.4. Strong ELISA reactives confirmed by western blot at 
1:100 dilution
a Contact in Africa 
b Homosexual 
c Homosexual 
d Drug Abuser 
e Drug Abuser
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Weak Positives
Hie decision was taken to test weak ELISA reactives at 1:20
dilution to ensure detection of antibody even at very low levels,
because of the role of the HRL as an HIV Reference Laboratory. This
dilution was chosen to maximise sensitivity without producing too high
a background. Fig.2.5 shows 3 weak ELISA positives and the weak 
positive WB control (Du Pont) at 1:20 and 1:100 dilution. In general 
the strongest bands are present at both dilutions but the 1:20 blot 
gives more information.
Problems arose when weak ELISA reactives showed only a few 
bands, even when tested at 1:20, on a western blot. Therefore strict 
criteria about what constituted a positive WB had to be established.
Establishing the Criteria of Positivity
Initial criteria of positivity for this test system, in the USA, 
were the presence of antibodies to p24 and/or gp41 (126). However the 
occurrence of false positives producing bands at either p17, p24 or 
p55 alone or a combination of any two was noted in several reference
samples in the HRL and noted in the literature (127-129). These
criteria would mean that such samples would be wrongly reported as 
positive with all the consequences far the patient.
An important distinction could be made by examining those sera 
from expected low-risk individuals flagged by the strict criteria 
attached to screening at the BTS and those from high risk groups being 
screened in a clinical situation at the HRL. Initially, the criteria 
of positivity at HRL were established from the observation of 
serooonversions in the drug abusing population in Glasgow and the West 
of Scotland in 1986. Fig. 2.6 illustrates the pattern found in early 
infections in drug abusers; all samples were tested at 1:20 dilution 
except numbers 5, 8, 10 and 11.
The samples were tested at different times using different 
batches of strips. It can be seen that there is batch variation in 
the exact positions of the bands. They are not always at the same
electrophoretic distance from the top of the gel but their relative
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Figure 2.5. Weak ELISA reactives tested at 1:20 versus 1:100 
dilution by western blot.
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Figure 2.6. Early infection with HIV-1 in 12 DAs confirmed 
by western blot.
All samples tested at 1:20 dilution except 
nos. 5, 8, 10 and 11.
Strips aligned on the p24 band.
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positions are the same. In Fig. 2.6 the p24 band has been aligned in 
all the samples and this has resulted in the other bands being 
slightly out of line in most oases.
All strips shew gp120 with at least two other bands. Even on 
the weakest reacting strip (2) three bands are visible. No earlier 
samples from these patients were available which would have shown 
which band or bands were the first to be detected. It was therefore 
decided that the criteria of positivity would be 3 bands one of which 
had to be gp120. In early infections the pattern was most commonly 
p24, p55, gp120, a pattern reported by others (94,123). Antibodies 
to p17, p24, gp41, p55 and gp120 are the major bands represented on 
the WB strips in Fig. 2.6 and this is indicated on the left hand side 
of the diagram. Sample 11 also shews anti-p53 and anti-p64. 
(Symptomatic patients at advanced stages of HIV-related disease are 
also noted to have few bands on a western blot but the pattern is 
different and is described later (Western Blot and Disease 
Progression)).
Some time later serial samples became available from two further 
serooonversions which permitted confirmation and refinement of the
above criteria. A set of samples was made available to us by Dr.
leukaemic
Sheila Cameron from a^patient who received a transfusion of platelets 
and subsequently became infected with HIV-1. These platelets were 
from a donor whose donation contained no detectable antibody but who 
was in the seroconversion window, was infectious and infected two 
recipients. Sequential samples were available from the platelet 
recipient and the time course of HIV-1 infection, with respect to 
production of markers, could be determined.
The results are shown in Table 2.14 (patient Tx) and Fig.2.7. 
The first detectable antibody response was found in the sample on day 
61, by two ELISAs (Abbott Recombinant HIV-1 and Abbott Confirmatory 
EIA) and WB (p24, p55 and gp160/120). Antibody to the envelope 
glycoprotein was detected by the confirmatory EIA but this test did 
not detect core, p24 and p55 antibodies, until after day 115 on the 
next available sample at day 308, although they were visible on a 
western blot on day 61 • Antibodies to the other proteins developed 
slowly. This may be attributed to the imraunosuppressed state of the 
patient.
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Figure 2.7. Confirmation of HIV-1 seropositivity by western 
blot (1:20) in serial samples fran a transfusion 
recipient (Tx).
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In addition a similar response was shown in a series of sanples 
from a homosexual patient whose contact date was unknown but was 
thought to be 3-4 weeks prior to the first sample tested in the 
January (Fig.2.8, Table 2.14 (patient Ho)). He presented with 
symptoms classified as CDC stage I, i.e. that of a seroconversion 
illness. The first weakly reactive ELISA signal revealed p24 and 
gp160/120 on a WB, and the Abbott Confirmatory EIA envelope bead was 
negative. A sample two days later was positive by ELISA and now 
showed 3 bands by western blot (p24, p55, gp160/120) and a positive 
envelope bead on the Confirmatory EIA. There was a noticeably 
quicker development of all markers and the preseance of antibody to all 
the major proteins of HIV, in this otherwise healthy individual, in 
comparison to the imnunosuppressed patient described above.
The predominant feature is the presence of antibody to the high 
molecular weight glycoproteins even in those with the p24 plus p55 
motif which could be associated with a false positive reaction.
Once the criteria were established, decisions regarding 
positivity could be made with confidence based on the available 
clinical information, laboratory screening and confirmatory data.
False Positives
Fig.2.9 illustrates the type of false positive reactions seen on 
a WB; these are samples from blood donors, many of whom have donated 
repeatedly and yet have shown neither an increase or change in the 
number of bands on a WB nor development of a genuine antibody profile 
to HIV-1.
B1 and B2 (Fig.2.9) are from the same donor, 9 months apart and 
are reactive in two of the screening tests. B3 and B4 are from the 
same donor, 3 months apart and are negative by the then current 
screening tests. However, donations prior to these have been 
reactive by the previous routine screening test and the policy of the 
BTS is to follow-up these donors until they are negative by all tests 
and produce no viral bands on a WB at 3 consecutive visits. This is 
the same situation for samples B5-B7; they are negative by ELISA in 
the three donations over 6 months, and the WB pattern is unaltered.
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Figure 2.8. Confirmation of HIV-1 seropositivity by western 
blot (1:20) in serial samples from a homosexual 
patient (Ho).
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Figure 2.9. False positive reactivities on western blot (1:20)
82
B8-B11 shew no change in WB in the sane donor over a period of 18 
months. However these samples are negative by all the current 
screening tests and would not have been blotted had they not been part 
of a follow-up programme of previous reactives. False positive bands 
have now been noted in other regions, gp41, gp160/120 to that of the 
pattern originally observed, i.e. a single band or a combination in 
the p17, p24 or p55 regions. In the routine western blots performed 
in 1990 on the Code 4 donors, i.e. those initially reactive on ELISA 
screening and repeatedly showing bands on a WB, it was found that 189 
out of 392 such donors (48.2%) had bands visible, 24 of whom had 3 
bands. Hie most common antigen to which reactivity was detected was 
p24 in 60.3% of cases followed by p64 (25.4%), p53, p55, p17 (18%) 
with only 2.6% of donors reacting with p31 (Dr. B.C. Dew, personal 
communication).
It was clear from the above studies that bands could be detected 
on WB of donor sera whether or not they reacted in a screening test. 
Therefore it was decided to determine the frequency of WB false 
positives in the normal blood donor population, i.e. a population 
which had been screened and shown to be ELISA unreactive. A sample 
of 50 blood donors (in 5 lots of 10 consecutive donors), negative by 
the screening test, were thus blotted at a dilution of 1:20. Hiirty 
of the fifty (60%) were found to have bands in viral regions most 
commonly at p53 and/or p55 and p24. These donations passed through 
the system, oblivious to the presence of bands on a WB and were 
processed in the usual way. A western blot does not appear to be the 
ideal choice for confirmation of these low risk samples. Hie 
continued presence of WB bands on these follcw-up samples from donors 
means that these donations are removed each time from the blood bank 
and unused. Hie cost to the blood bank supply is high since many 
individuals have continued donating in good faith, but their donation 
is flagged each time as a biological false positive until it is 
negative by all tests on three consecutive occasions. Some such 
donors have donated since screening began in October 1985 and very few 
(5%) have re-entered the blood bank pool. Hieir donation prior to 
October 1985 would never have been screened for anti-HIV 1 and would 
have been processed in the normal way. In addition each new
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screening test picks out a new set of reactives which are then 
followed-up, thus Increasing the number of unused donations.
Diluted Samples
An interesting difference was noted in the western blot pattern 
of the dilutions discussed in Table 2.5 and the pooled QC sera in 
Table 2.6. Fig. 2.10 illustrates what happens when single samples 
are diluted (in normal human serum). Antibody reactivity to a single 
protein remains on serial dilution. However multiple bands of low 
intensity were noted on the WB of the biochemistry quality control 
sera (Fig.2.11). This was pooled material and therefore it was 
assumed that a dilution effect similar to that in Fig.2.10 would be 
seen. It is not known why this WB pattern should be so, perhaps 
there is more than one infected donor in the pool.
Western Blot and Disease Progression
Follow-up samples were obtained regularly from HIV-1 Ab positive 
patients attending an out-patient clinic at Ruchill Hospital and in 
some patients a change in WB pattern was noticed as time progressed. 
Could the usefulness of WBs be expanded? Was a change predictive of 
infectivity or of disease progression? The predominant feature was a 
decreased reactivity to the p24 core protein and this correlated with 
the presence of HIV-related symptoms. This is shown in Fig.2.12 in a 
number of patients who first presented with symptoms.
When the time course of HIV infection was followed in individual 
patients, the decrease in core antibody over time was noted 
(Fig.2.13). It appears, therefore, that as time progresses and with
the onset of symptoms, there is a resulting decrease in anti-p24. In 
certain (extreme) cases, only anti-env and no anti-core is visible on 
a WB. This correlated with a negative result in the core bead 
(Abbott Confirmatory EIA) in symptomatic patients, although this ELISA 
result becomes negative in most of these patients before a decrease in 
anti-p24 on the blot. The lack of sensitivity of this ELISA is 
useful and it plays a role as a prognostic indicator of disease
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Figure 2.13 Temporal decline of HIV-1 anti-p24 observed on 
western blots (1:100) frcm a homosexual with 
AIDS-related complex (ARC).
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progression whereas WB is an expensive and time-consuming test to 
perform routinely for this purpose.
Reading Western Blot Results
Laser densitometry can be used to read the developed 
nitrocellulose strips. This was attempted a number of years ago 
(courtesy of Professor H. Pennington, Department of Bacteriology, 
Forresterhi 11 Hospital, Aberdeen) (data not shewn). It was found not 
to be of significant use to justify the purchase of such expensive 
hardware. Two problems in particular were noted; the reader 
requires an even background of staining to establish a baseline, this 
is not always possible with the blots and secondly the area under the 
peak, produced when the laser beam passes through the coloured bands, 
is related to the width of the band rather than the depth of colour 
and therefore does not represent a measure of the intensity of the 
Ab-Ag reaction. Western blots have always been read by eye and a 
scoring system + to ++++ used to determine the intensity of the Ab-Ag 
reaction.
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DISCUSSION
Hie need far a confirmatory test is self-evident because of the 
initial rate of false positives obtained when antibody screening 
commenced. A correct result is obviously Important to a patient's 
physical and mental wellbeing. Therefore a confirmatory testing 
service has been in operation since screening began.
An ideal confirmatory test should have a high sensitivity and 
specificity, use an independent methodology from the screening test, 
examine the antibody reaction to a range of viral proteins, be able to 
detect all strains of HIV-1 and ideally detect all classes of 
antibody, i.e. IgG, IgM and IgA.
The test of preference at the HRL has been, and remains the 
western blot. The development of a commercial Western Blot kit for 
HIV-1 meant ease of use since quality control had already been 
performed. This is important because of the subjective nature of WB 
interpretation. As with many of the tests examined in this Chapter, 
the assay improved over the time in use at the HRL. The western blot 
has improved mainly due to enhanced envelope glycoprotein detection. 
The transfer of glycoproteins to NC has always been notoriously 
difficult, probably due to their bulky sugar side chains. However 
the higher molecular weight glycoproteins, gp160 and gp120, are now 
clearly distinguished as two separate bands.
The strong ELISA reactives present no problem in confirmation on 
any test system, showing multiple bands of intense reactivity on a 
WB. However the occurrence of weak ELISA reactives meant that the 
criteria of positivity had to be established to distinguish a genuine 
positive from that of a false positive (FP). The spread of HIV 
infection in the DA population tested in 1986 and the follow-up of the 
unfortunate recipient of an infected transfusion allowed the 
development of markers to be examined and assisted in determining a 
minimum expected result for a sample to be considered positive at the 
HRL, i.e. that of the presence of 3 viral specific bands, one of which 
must be the high molecular weight envelope glycoprotein.
Various criteria from different sources have been established 
over the years. The initial p24 and/or gp41 requirement has most
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certainly been updated (126), A report by the Consortium for 
Retrovirus Serology Standardisation in 1988 stated that four different 
"standard" criteria were being used (172). These included:
( i) presence of antibodies to p24, p31 and gp41 or gp160/120 
(DuPont);
( ii) presence of antibodies to at least one gene product from 
each of gag, pol and env (American Red Cross);
(iii) presence of antibodies to any two of p24, gp41 and
gp160/120 (Association of State and Territorial Public 
Health Laboratory Directors (ASTPHUD), Department of 
Defense) and
( iv) presence of antibodies to at least p24 or p31 plus gp41 
or gp160/120 (Consortium for Retrovirus Serology 
Standardisation.
The latter was the minimum accepted since No. (i) would exclude 
many of the AIDS patients in whom the anti-p24 reactivity has been 
reduced. Hcwever No. (i) is probably most used since this is the 
recommended criterion of the FDA licensed kit. In a report on the use 
and interpretation of WB in the serodiagnosis of HIV-1 infection, the 
CDC recommended the use of the ASTPHLD criterion which gave the highest 
percentage of positives and the lcwest percentage of indeterminate 
results (130). The criterion described and used at the HRL in 
conjunction with clinical information and follow-up where indicated, 
has presented no problems in HIV confirmation and serodiagnosis. 
This criteria has been updated recently to a requirement of four 
bands, two of which must be gp120 and gp160 as these proteins are now 
routinely visually distinct as two separate bands on a developed WB. 
The lack of a pol gene product requirement in the HRL criteria is 
because antibody to these proteins developed late in the 
seroconversion case, patient Tx (Table 2.14).
Care has to be taken in reading the blots and making comparisons 
because of the variation between batches and the subjective nature of 
interpretation. A western blot is only as good as the antigen 
preparation on the strip, i.e. a high quality, clean antigen source is
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a necessary requirement, A sanple can react only with the proteins 
present on the nitrocellulose so each viral protein needs to be 
represented in sufficient quantity with minimal cellular components, 
to give a clean background. Problems were encountered when DuPont 
supplied strips of inferior quality from their manufacturing plant in 
Singapore. Interpretation was made difficult due to the presence of 
multiple nan-viral bands and high background on colour development. 
It is important to note that the proteins are not in their native 
state as they have been disrupted with detergent. This may affect 
antibody binding since linear epitopes rather than conformational 
epitopes will be recognised. The transfer of glycoproteins from 
polyacrylamide gels to nitrocellulose is also notoriously difficult, 
resulting in smeared bands.
The occurrence of false positive bands at equivalent positions 
to that of the viral proteins aroused suspicion in these patients and 
tended to discredit WB ("Indeterminate" category). These individuals 
who have been followed up showed no development of markers and in many 
cases retained the same reactivities over a period of time. This is 
understandably of great concern in blood-donor screening. Donors 
with such indeterminate reactions are excluded from the blood bank 
(but not from donating) until 3 consecutive donations are completely 
negative by all screening and confirmatory tests. This rarely 
occurs, only 5% of such donors in the West of Scotland, and current 
proposals to change this are being considered. Genesca et al. (173) 
found that 20% of ELISA negative blood donors produced an 
indeterminate WB pattern. Recipients of such blood donations also 
showed indeterminate patterns and there was not always a correlation 
of band specificities in a donor-recipient pair. No donors or 
recipients seroconverted for HIV-1 and none were shown to contain 
HIV-1 gag and env sequences by polymerase chain reaction (PGR). Thus 
this FP reactivity is likely to be nan-viral in origin. What are 
these false positive (FP) reactions? Are they HLA antigens which 
co-migrate with viral proteins when the disrupted viral infected cells 
are run on a gel? This may be the case in certain patients and has 
been demonstrated by Blcraberg and Klasse (125). A limited amount of 
WB testing was performed with a mock-infected H9 cell line but with no
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conclusive results as to the nature of the FP reaction (data not 
shown). It may be explained by cross-reaction to other retroviral 
sequences particularly that of the group specific antigen or gag 
protein(s); a legacy of ancient retroviral sequences or of those yet 
undiscovered. Up to June 1988 all the code 4 donors at the Regional 
Transfusion Centre, Law Hospital, i.e. those indeterminate or 
unconfirmed donors with a reactive or previously reactive ELISA, result 
and in some cases FP western blot bands were tested and found to be 
HIV-2 seronegative. In the literature reference has been made to 
certain species of anti-human IgG conjugates and anti-species IgGs 
reacting with the p24 cn HIV-1 western blots (125,174).
It appears that each ELISA test detects its own set of false 
positive reactions for one reason or another and hence it is 
important to use a confirmatory test with a different source of 
antigen from that used in the screening test otherwise the false 
positive ELISA reaction will also be mirrored by the confirmatory 
test. This has always been the practice at the HRL.
The DuPont kit has emerged as the best of the western blot 
assays (125) and was the first test of this nature to be licensed by 
the Food and Drug Administration (FDA), USA. In the early days the 
use of a radioinmunoprecipitation assay (RIPA) was advised to 
complement the western blot since it was better at detecting 
anti-envelope reactivity. This was important in those with an 
isolated anti-p24 reactivity and could be used to establish a genuine 
early infection from a FP. However enhanced envelope glycoprotein 
detection has improved the blots. Recent reports (175,176) have 
shewn that gp41 farms multimers and viral lysate antigen preparations 
were found to contain this multimeric form, which has the same 
mobility as gp160. Anti-gp41 reacts at this site. This may give 
rise to false identification of reactivities. The use of monoclonal 
antibodies shewed that true gp160 and gp120 material was present on 
the DuPont WBs (176). Reference laboratories rely on this quality 
control work being carried out at source before the kit is supplied 
commercially. In addition several drawbacks to the technique of
RIPA, e.g. the use of radio-active label and the requirement for 
cultures of HIV-infected cells, would have been prohibitive in many
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laboratories.
Hie DuPont WB is still widely used despite the introduction of 
recombinant imraunoblot assays (RIBA). These were found not to be 
significantly more sensitive or specific than the viral lysate WB. 
But recently the RIBA strips have incorporated a recombinant protein 
from HIV-2/ most commonly a gp36(env) epitope, e.g. Pepti-LAV 1/2 
(Diagnostics Pasteur), LiaTek HIV 1 + 2  (Innogenetics N.V., Belgium) 
etc. This allows simultaneous testing of those samples which react 
on the combination ELISAs. Since the current screening tests now 
detect antibody to HIV-1 and HIV-2, it is necessary to confirm the 
presence of either anti-HIV 1 or anti-HIV 2 or both, i.e. dual 
infection. Hie viral lysate HIV-1 WB (DuPont) is the first line 
confirmatory test following a repeatable positive ELISA result. This 
is supplemented with an HIV 1+2 RIBA strip and where necessary an 
HIV-2 viral lysate WB. This provides a comprehensive means of 
identification of the infecting virus and confirmation of the antibody 
screen.
It was previously thought that additional information relating 
to stage of infection in an HIV-1 Ab positive could be read from a WB 
and in this way the WB would be predictive of a change in clinical 
status. Hie intensities of the bands are soared + to ++++ and the 
number of bands present are recorded. A number of patterns have been 
noted; e.g. (1) in seroconversion, high intensity reactions to few 
bands particularly p17, p24 and gp160, gp120, (2) high intensity
reaction to all bands in the 1 strong positives*, generally the 
asymptomatic seropositives, (3) loss of anti-core antibodies generally 
in patients with disease progression and (4) in some cases of AIDS low 
intensity reactions to several proteins. In addition the pooled sera 
showed multiple reactivities of low intensity which was unusual. Hie 
WB has no predictive role since clinical AIDS is often manifest before 
a reduction in anti-core reactivity. However experience in observing 
such patterns enables the user to be confident in the interpretation 
of results.
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SCREENING AND CONFIRMATION: CONCLUSIONS
The continuing advances in technology have benefitted the 
development and improvement of both the anti-HIV screening and 
confirmatory tests. This has allowed the use of alternative sources 
of antigen, e.g. the manufacture of recombinant antigens or synthetic 
peptides and the incorporation of a similar related virus, HIV-2, into 
the testing regime. In the future, related viruses including HFLV-I 
and -H may be added to the solid phase of an ELISA test such that a 
retrovirus screen is initially performed. Further testing with 
monospecific ELISAs, i.e. specific for one virus and confirmatory 
assays would be used to establish the nature of the reactivity of a 
test serum on such a screen.
The rapid improvement in sensitivity and specificity of the 
commercial ELISAs meant that they very quickly matched the 
confirmatory test, the western blot. There exists the school of 
thought that use of a multiple ELISA testing system could meet the 
needs of a confirmatory test (177). Tests of varying methodologies, 
e.g. competitive, direct, particle-agglutination and different sources 
of antigen, e.g. viral lysate, synthetic peptides, recombinant 
proteins, could be used in sequence. Any non-specific reaction in 
one test would not be repeated in a different test. The success of 
this procedure depends on all the ELISAs having a very high 
sensitivity and routinely quality controlled to maintain this. It is 
known in practice that different tests do detect certain samples, 
particularly those of genuine weak positives from a seroconversion, 
better than others. The use of various ELISAs of single specificity 
is now increasingly recommended to distinguish HIV-1 and HIV-2 
seropositivity in specimens reacting in the first-line combination 
tests, and in this way reduce the number of samples tested on western 
blots or recombinant inniunoblots, which are more expensive and more 
time-consuming to perform.
The WB has continued to be the method of choice in finally 
confirming seropositivity, certainly for HIV-1 at the HRL. There has 
been very little experience of using WB to confirm anti-HIV 2
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seropositivity, as there has been no HIV-2 infection found in the 
population under test at the HRL, The WB has improved over time, 
particularly with respect to envelope glycoprotein detection, and 
efforts must be maintained to achieve the maximum performance from 
these strips. It may be necessary, in the future, to increase the 
sensitivity of the detection system using technologies such as 
radiolabelled conjugate or a chemiluminescent substrate.
It is evident that as ELISA technology is pushed to the limits 
of sensitivity, the confirmatory tests mist keep ahead. Hie 
provision of an antibody profile and the specificity of western 
blotting still undoubtedly remain useful.
Another current challenge is to distinguish between anti-HIV 1 
and anti-HIV 2 reactivity after an initial screen by the HIV-11-2 
combi tests. Hie nature of the antibody cross-reactions does make it 
more difficult to determine the true result. HIV-2 antibodies bind 
most readily to the core proteins and to a lesser degree with the 
envelope proteins of HIV-1 (117). However HIV-1 antibodies react 
mainly with the gag and pol gene products and do not recognise HIV-2 
env gene products. So-called monospecific ELISAs do detect
antibodies to both viruses and thus it is important to have good 
confirmatory systems.
There are viral lysate WB kits commercially available for both 
HIV-1 and HIV-2 and it is encouraging to visualise the antibody 
profile to back up an ELISA result. Also available are combination 
imnunoblots where recombinant or synthetic peptides from HIV-1 and 
HIV-2 are painted onto a nitrocellulose support. Although more rapid 
than a WB they have been disappointing in use. Hie obvious advantage 
is in being able to distinguish between HIV-1 and HIV-2 in one step. 
However the major drawback in those kits currently available is the 
lack of HIV-2 specific peptides on the strip and often a positive 
HIV-2 Ab result is based on reactivity to a single epitope, most 
commonly that of the transmembrane glycoprotein gp36. It is hoped 
that in the future, further epitopes or peptides from HIV-2 will be 
included in these recombinant imnunoblots and that their test 
peforraance will improve to match or even better that of the viral 
lysate WB.
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Minor alterations and fine tuning of tests continue to maximise 
the performance of ELISAs and WBs in HIV Ab screening.
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CHAPTER 3
EPIDOIIOLOGY OF RETROVIRUS INFECTION IN GLASGOW 
AND THE WEST OF SCOTLAND
INTRODUCTION
Hie advent of an antibody screening test allowed the majority of 
those infected with HIV to be identified. The importance of 
screening the blood donor population for a virus which is transmitted 
by blood and blood products is apparent. However, alternative
testing sites had to be made available to discourage members of any 
risk groups from using blood donating centres to determine their HIV 
status and therefore to reduce the chance of an infectious donation 
passing through the system undetected. The implementation of 
antibody screening at the Hepatitis Reference Laboratory (HRL) in 
April 1985 together with the opening of the Counselling Clinic in 1986 
provided this service for Glasgow and the West of Scotland. Testing 
is performed on a voluntary basis.
To fulfil an epidemiological role, i.e. to assess the prevalence 
of HIV in the population, the laboratory is dependent on receiving 
samples from those individuals considered to be at risk of infection. 
Screening of only those individuals who wish to know their status can 
bias the prevalence figures in two ways; an underestimate if the 
majority of tests are performed on patients in the 1 worried-well' 
category which generally comprises those at least risk, or an 
over-estimate when high rates are found in low numbers of the at-risk 
population. However, trends in prevalence amongst groups that are 
available for testing provide some estimate of hew HIV infection is 
spreading in the population.
Early epidemiological studies in the USA examined the risk 
groups of patients with AIDS. This identified those most at risk 
from acquiring HIV: transfusion recipients of blood and blood
products including haemophiliacs, intravenous drug abusers, 
homosexuals, Haitians, Hispanics and sexual contacts of these groups.
94
The results presented in this Chapter implicate the same groups at 
risk in the area of testing covered by the HRL (with the exception of 
Haitians and Hispanics, who have not been tested in our population).
MATERIAL AND METBDDS
As a prelude to the introduction of screening of all blood 
donations by the Blood Transfusion Service (BTS), HIV-1 testing first 
began at the HRL in October 1984 using an innrunof luorescence 
technique. Pre-prepared slides coated with LAV infected and 
uninfected H9 cells (Pasteur) were used on selected patients. More 
extensive screening became possible with the advent of an ELISA test 
system (Abbott, Appendix 2) in April 1985. Some retrospective
testing of sera from at risk groups was performed at this time.
Samples were received from: infectious disease (ID) clinics,
genito-urinary medicine (GUM) clinics, the counselling clinic, general 
practitioners, drug rehabilitation centres, prisons and young 
offenders institutions, hospital in-patients, the regional haemophilia 
centres and the BTS.
On introduction of routine screening an attempt was made in the 
laboratory to assign a risk group code or reason for testing code to 
all specimens sent to the laboratory for HIV antibody testing. The 
codes had to be simple and sufficiently specific to provide 
well-defined population groups. The following codes have been in use 
since April 1985:
DA admitted drug abuser
Ho homosexual
Bi bisexual
c m  - contact of risk groups
R risk (unspecified)
WW worried well
Hra haemophiliac
VISA - for work abroad
INS - for insurance purposes
Most information was made available regarding the DAs and they
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have formed the best defined group in this study.
In November 1988, the Communicable Diseases (Scotland) Unit 
(CDSU) produced a surveillance form seeking information from patients 
on risk group and the reason for testing, for all HIV tests requested 
in Scotland (CDS Denominator Study). This provided additional 
detailed information on the risk groups being tested and their 
contacts. The patients details on the forms are put into a computer 
under code and therefore provide a database of information on all 
samples received for HIV testing. The clerical officers employed to 
do this also make follow-up telephone calls to seek missing relevant 
patient information if this is not included in the initial form 
completed by the requesting clinician.
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RESULTS
A, HIV-1 SEROPREVALENCE:
TOTAL NUMBERS IN GLASGOW AND THE WEST OF SCOTLAND WITH 
RISK GROUP BREAKDOWN
Table 3.1 ^icws the total numbers screened per year and the total 
numbers reported HIV-1 antibody positive (including those known to be 
positive elsewhere). In addition 30 haemophiliacs, including both 
children and adults, were found to be positive before 1985 (see 
Chapter 5).
The HIV Reference service at the HRL covers six health board 
areas including Greater Glasgow, Argyll and Clyde, Lanarkshire, 
Ayrshire and Arran, Dumfries and Galloway and Forth Valley, with a 
total population estimated at 2,751,650 in June 1987 (CDS Weekly 
Report: back cover). In these six health boards no samples are
reported positive without confirmation at the HIV Reference Unit at 
the Regional Virus Laboratory.
Over the 63 months, from April 1985 to the end of June 1990, a 
total of 23,857 specimens have been examined in the Hepatitis 
Reference Laboratory (HRL), Ruchill Hospital. The number of total 
seropositives in the population screened is 398, a prevalence of 
1.7%. However, this figure is misleading and is of little 
significance. The total number screened is artificially high because 
it includes repeat specimens from patients, reference samples from the 
Blood Transfusion Service (BTS), sent in triplicate and latterly 
multiple saliva specimens from known HIV-1 antibody positives, for a 
special study. The total number can also be considered artificially 
low as it does not include negative samples screened at laboratories 
in the Region carrying out their own tests.
In addition the sample population is not uniform year to year as 
it is influenced through publicity campaigns by the Government using 
television commercials, the press and bill poster advertising, leading 
to an increase in the numbers tested in the "worried well" category at 
that time, i.e. those most worried but generally at least risk
TABLE 3.1
Total number of HIV-1 seropositives detected each year from 
April 1985 to June 1990*
Year
Total Nos. 
screened
Total Nos, 
positive
Pre 1985 - 30
1985 (Apr-Dee) 881 66
1986 3,010 95
1987 5,228 82
1988 5,937 53
1989 5,484 44
1990 (Jan-Jun) 3,317 28
Total 23,857 398
* This includes 30 haemophiliacs found to be antibody 
positive prior to 1985 by retrospective testing
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(Fig.3.1). The number of drug abusers tested remained fairly 
constant during 1986 and most of 1987. It has since dropped to a new 
level but remains constant, currently testing an average of 43 drug 
abusers per month in 1990. Therefore the numerator in the prevalence 
quotient is very accurate as all potential positives are referred to 
the HRL but the denominator is inaccurate and becomes more so as 
increasing numbers of laboratories introduce screening. Hence the 
need for the CDSU Denominator Study to provide an accurate denominator 
for the quotient.
A breakdown of the figures in Table 3.1 demonstrates the 
contribution made by each risk group each year to the total number of 
reported seropositives (Table 3.2). These figures represent the new 
positive cases, i.e. only those whose sera were confirmed as positive 
at the HRL for the first time and had not been confirmed and diagnosed 
as seropositive elsewhere. To complement this are the figures in 
Table 3.3, showing those who have come to live in the health board
areas under test but who have been diagnosed as seropositive
elsewhere.
The DAs and the Hos are the major contributors to the total 
seropositives. The numbers of Ho and Bi seropositives per quarter 
and the incidence of diagnosed infection per quarter in the DAs from 
April 1985 to the end of June 1990 is shown in Table 3.4. An
increase was noted in the Glasgow population of DAs in 1986. The
prevalence of infection increased from 1.7% in the first quarter to 
5.8% in the last quarter of 1986. The percentage positive remained 
high at the start of 1987 but subsequently decreased and has remained 
at this new level (less than 2%) over the following years. A further 
4 seropositive Glasgow DAs in 1987 and 4 DAs in 1990 were confirmed at 
the HRL although initial screening was performed in two other 
laboratories in the city.
The Ho/Bi totals in Table 3.4 record all the confirmed Ho and Bi 
seropositives in Glasgow and the West of Scotland area covered by 
testing at the 3 laboratories in the city. A consistent number of 
Ho/Bi were detected each year after 1985. There was little 
information available regarding the prevalence of HIV-1 infection in 
this population until the CDS Denominator Study began.
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TABLE 3.4 Hie number of newly diagnosed infections per quarter in 
high risk groups in Glasgow and the West of Scotland 
during the period April 1985 to June 1990.
No. DAs
seropositive in 
Year Glasgow and the
and No. DAs West of Scotland* No. Ho and Bi
Quarter tested (Greater Glasgow only) seropositive
1985
A-J 154 3 (0) 6
J-S 257 5 (0) 5
O-D 195 24 (5) 10
1986
J-M
A-J
J-S
O-D
177
222
246
329
8
16
9
24
(3)
(4) 
(6)
(19)
1987
J-M
A-J
J-S
O-D
314
224
216
170
14
8
4
2
(1 1)
(7)
(2)
(0)
1988
J-M
A-J
J-S
O-D
163
163
165
138
(2)
(2)
(3)
(3)
1989
J-M
A-J
J-S
O-D
178
136
148
114
(1)
(2)
(0)
(0)
1990
J-M
A-J
139
99
(0)
(1)
* Prevalence can be assessed in the drug abusers and represents only 
those tested at the HRL. A further total of 9 DAs (8 from Greater 
Glasgow) tested at two other virus laboratories in Glasgow but 
confirmed at the HRL complement these figures to give the total of 
147 shown in Table 3.2
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In sunmary the results suggest that the pattern of infection in 
Glasgow has changed over the 63 months since routine screening began. 
In 1985/ from our sampled population/ HIV-1 infection was more 
predominant in the homosexual group than the Glasgow drug abusers. 
In 1986 this pattern was reversed and the prevalence of infection in 
the DA population increased 3.4 fold to the end of the year. In 
general since this time/ the number of seropositive DAs has decreased 
(until the start of 1990)/ the number of Hos (including Bis) has 
remained constant but there has been an increased contribution from 
other risk groups, particularly in those exposed abroad, which 
includes a high percentage of African nationals.
1. SEROPOSITIVE DRUG ABUSERS
Total in Glasgow and the West of Scotland
In Table 3.2 the drug abusing seropositives contribute 49.3% of 
the total. Hie numbers are highest in 1985, 1986 and 1987 then 
decline.
1985
The laboratory received samples from various health boards and 
it was noted that in 1985 most of the seropositives were sent from the 
Forth Valley Health Board. Indeed only 5 out of the 32 found 
positive in 1985 were kncwn to reside in Glasgow (Table 3.5). At 
this time serum samples were sent for testing from Comton Vale Prison 
near Stirling, the only women*s prison in Scotland. Fifteen out of 
the 21 seropositive females were from there. However, enquiries as 
to the home addresses of these patients revealed that 11 came from 
Edinburgh and 4 from Dundee. All of the remaining six seropositives 
lived in the West of Scotland and included one from Ayrshire and Arran 
Health Board area who had been in France for the previous three years 
and one from a drug rehabilitation centre in Tarbert who had 
connections with Edinburgh. The remaining four females were from
TABLE 3.5
HIV-1 seroprevalence in drug abusers 
tested at the Hepatitis Reference Laboratory.
No.seropositives 
No. DAs in Glasgow and No.seropositives
Year tested West Scotland M/F Glasgow only M/F
1985
(Apr-Dee) 606 32 11M/21F 5 1M/4F
1986 974 57 33M/24F 32 20M/12F
1987 924 28 10M/18F 20 5M/15F
1988 629 12 10M/2F 10 8M/2F
1989 576 6 6M 3 3M
1990
(Jan-Jun) 238 3 3M 1 1M
Total 3,944 138 73M/65F 71 38M/33F
*1987 4 1M/3F 4 1M/3F
*1988 1 1M
*1990 4 2M/2F 4 2M/2F
Total 147 77M/70F 79 41M/38F
* Samples sent from two other virus laboratories in the city 
for confirmation.
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Greater Glasgow, one of whom had been in Edinburgh and had returned to 
her home in Glasgow, probably early in 1985.
One of the male DAs tested positive in 1985 was known to reside 
in Glasgow. Two others were from another Glasgow hospital and 
another was in prison here, however in all 3 cases their area of 
residence was unknown. Another patient came from the Forth Valley 
area. Six of the male seropositive DAs found in this year had 
Edinburgh connections: three via Dumfries, one via Lanarkshire and
two via a drug rehabilitation centre in Cardross, Argyll and Clyde.
1986
In 1986 the pattern changed and 56% of the DAs found 
seropositive in that year were Glasgow residents. In that year, 
three out of 15 samples found positive from Comton Vale Prison were 
Glasgow residents (seven ex-Edinburgh, three ex-Dundee, one 
ex-Aberdeen and one unknown). A further nine seropositive female DAs 
were from Glasgow. Seven of the 33 male seropositives were from 
Edinburgh, one from the USA, five whose connections were unknown and 
20 from Glasgow.
1987
Idle Edinburgh contribution to the total decreased further in 
1987. Five of the 10 male seropositives detected at the HRL in this 
year were from Glasgow. The male DA referred for confirmation from 
another Glasgow hospital had been found dead. One male was in
prison, the remaining four were sent from hospitals in the outlying 
health board areas covered by the HRL; one who was known to have 
Edinburgh connections, one from Stirling and two with connections 
further afield, in London and Amsterdam. Eighteen of the 21 
seropositive females were from Glasgow, three of the requests were 
sent from Comton Vale and the remainder were sent from several 
sources within the city including the counselling clinic, Ruchill 
Hospital, and three referred for confirmation. One other positive 
report from Comton Vale was a female from Aberdeen. The two 
remaining seropositives were resident in health board areas in the 
West of Scotland.
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After this time very few specimens were received from Oomton 
Vale Prison. Most testing of DAs was from within Glasgow via G.P's, 
hospital out-patients, drug rehabilitation units and the counselling 
clinic, which opened at Ruchill Hospital in December 1986.
The contribution of Glasgow DAs to the total continued to be 
high in 1987 but the total number found was reduced and the overall 
prevalence (3%) was less than in the previous year (Table 3.5).
1988
In 1988, 10 of the 12 seropositives at the HRL were Glasgow 
residents, five of whom ware tested via the Counselling Clinic. One 
DA was in the drug rehabilitation ward at Ruchill Hospital and another 
had been admitted to the hospital with an acute hepatitis B infection. 
Two of the other three Glasgow seropositives were sent for testing 
from Glasgow hospitals and the remaining one was tested via the 
forensic laboratories. The remaining two include one male prisoner 
and one male DA from Lanarkshire tested via his GP.
1989
Only 6 seropositives were diagnosed in 1989, 3 of these came 
from health boards outwith Greater Glasgow. Two of the remaining 
three were patients in the drug rehabilitation ward in Ruchill and the 
other patient was a prisoner.
1990
When the figures for the other Glasgow laboratories are included 
in the total it can be seen that as many DAs were found seropositive 
in the first half of 1990 as were detected in total in 1989. Five 
out of the seven seropositives in 1990 resided in Glasgow; two of 
these were found deceased (probably drug related). One new infection 
was noted in this year in a female DA who was seronegative on testing 
in December 1989, but subsequently seroconverted in May 1990.
Early Infections in Glasgow Drug Abusers
Fifteen of the 32 Glasgow DAs found positive in 1986, one from
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1985, and five out of 24 seropositives in 1987 had previous specimens 
in 1984, 1985 or 1986 that contained no detectable antibody to HIV-1 
(Table 3.6). Many of the remainder showed serological evidence of 
recent infection by ELISA and western blot. A test for HIV-1 antigen 
(Abbott Diagnostics) in 16 specimens taken up to 16 months prior to 
the first positive antibody result was reactive in only two (four and 
five months prior to antibody detection). These results were 
unconfirmed due to insufficient sample remaining for a neutralisation 
test.
A total of five drug abusers (1M/4F) resident in Glasgow were 
detected in 1985. The earliest case was a female DA who had 
previously been in Edinburgh, had returned home to Glasgow and was 
found to be HIV-1 antibody positive in the first sample available for 
testing in February 1985. In the last quarter of 1985, two females 
and one male DA were found seropositive and were known to have shared 
needles with the first case mentioned above. In addition, another 
female DA was found retrospectively to have seroconverted during 
October to November 1985, but remained undetected with the screening 
test used at that time until a serum sample was taken a year later, in 
October 1986. She has now been included in the 1985 figures.
HIV-1 infection appears to have entered the drug abusing 
population in Glasgow during the latter part of 1985, early 1986 and 
subsequently spread. Seroconversions are still occurring in this 
risk group but they are now a rare occurrence; three DAs in 1988 and 
one DA in 1990 were known to have previously seronegative samples 
(Table 3.6). In two of these cases, several samples had been taken 
prior to their first seropositive results, implying that they were 
considered to be at high risk of acquiring HIV-1 infection, since a 
drug-abusing sibling was HIV-1 seropositive in both cases.
Spread of Infection
An examination of the area of residence of the Glasgow 
seropositive DAs shews that the majority came from the G20-G23 
postcode areas (Table 3.7). These are areas long associated with 
drug abuse. In addition other clusters of positives have been found
TABLE 3.6
Timing of HIV-1 antibody serooonversicns in 
drug abusers in Glasgow.
Last Ab. Meg. First Ab. Fos. Time Interval
Sex/Age Month/Year Month/Year (Months)
F22 10/85 11/85 1
FI 9 12/85 5/86 5
M20 3/86 7/86 4
M21 12/84 8/86 20
Ml 9 5/85 10/86 17
F19 11/85 10/86 11
F16 6/86 11/86 5
M32 5/86 11/86 6
F31 7/85 11/86 16
F24 6/86 11/86 5
FI 8 4/86 12/86 8
M20 2/86 12/86 10
Ml 8 7/86 12/86 5
M22 8/85 12/86 16
M19 10/85 12/86 14
F22 4/86 12/86 8
F25 9/86 2/87 5
F25 10/86 2/87 4
F23 3/87 5/87 2
FI 6 4/86 6/87 14
F20 11/84 12/87 37
F30 3/87 2/88 11
M24 6/86 9/88 27
M29 2/88 11/88 9
F23 12/89 5/90 5
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in discrete pockets around the city in areas where drug abuse itself 
is known to be a problem, e.g. in Castlerailk, G45 and Easterhouse, 
G32-34.
The first seropositives at the end of 1985 were found to have 
addresses in the G20s. This was also the location of at least 17 of 
the 32 Glasgow DAs in 1986. In this year a few seropositives were 
detected in other areas in Glasgow. One female patient who lived on 
the outskirts of Glasgow was known to have travelled into the city for 
drugs. In 1987 there was a greater contribution from the Gorbals 
area (G5) and the G30s in the east end of Glasgow. It is of interest 
to note the changing pattern of the origin of requests sent to the 
laboratory. In 1986, eight seropositives were found either in the 
young offenders institution at Glenochil, Stirling, or the remand unit 
at Longriggend, Lanarkshire. Three were from Comton Vale Prison, 11 
from Glasgow hospitals, six from G.P's and four from the drug 
rehabilitation units at Kilraahew House and Woodilee in Glasgow. In 
1987, half the seropositives were found through either the Counselling 
Clinic based at Ruchill Hospital (opened in December 1986) or through 
the Infectious Diseases clinics there. Five specimens were sent from 
other Glasgow hospitals, three from G.P's, three from Comton Vale 
Prison and one from Woodilee. After this time, most seropositives 
were detected through the Counselling Clinic, the drug rehabilitation 
ward at Ruchill Hospital or from other Glasgow hospitals.
In other health board areas the first HIV seropositives were 
found in 1985 in Forth Valley, Lanarkshire, Dumfries and Galloway and 
Ayrshire and Arran. In all cases, except the latter, these 
seropositives had connections with Edinburgh; in Ayrshire and Arran
this female DA reported in 1985 had previously been in France. In
1986, two female DAs who resided in the Argyll and Clyde Health Board 
area were found antibody positive. They presented for testing 
through Comton Vale Prison in one case and through the Infectious 
Diseases Unit at Ruchill Hospital in the other.
In 1986 there was considerable concern in Glasgow at the trend
shewn in drug abusers found positive. The number of positive DAs 
increased each quarter through 1986 and there was speculation that the 
same trend would occur here as in Edinburgh and the graph (Fig.3.2)
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would continue in an upward fashion. However, this has proved not to 
be the case and the number of seropositives diagnosed continues at a 
low level, on average 2-3 DAs per quarter. There has been no
sustained increase in Glasgow in comparison to the Edinburgh 
experience.
Prior Hepatitis B Infection in Drug Abusers
Past or current exposure to hepatitis B (HBV) was found in 70% 
of all DAs tested and in 93% of the HIV-1 seropositives in Glasgow in 
1985 (178). In the following year 69% of HEV-1 seronegative DAs and 
81.2% of the seropositive Glasgow DAs had evidence of past HBV 
infection (179). A similar high prevalence (85.7%) was found in 
seropositive DAs tested in 1987.
2. SEROPOSITIVE HCMOSEXDALS/BISEXDALS
Total in Glasgow and the West of Scotland
The homosexual and bisexual population contribute 30.5% to the 
total positives (Table 3.2). This includes 1 Ho/DA and 2 Bi/DA. 
Their numbers are further swollen by the 35 seropositives in Table 3.3 
who were known to be positive elsewhere but who have moved into the 
area or come home for treatment.
The prevalence in the Ho population (including Bi and Ho/DA) can 
be better assessed since the CDS Denominator Study was set-up at the 
end of 1988. Tests performed on Ho/Bi from Glasgow (Table 3.8) show 
that between 4% and 6% of those tested in 1990 are seropositive; this 
is more than double the prevalence in the DA population tested, 
however the actual figures are snail.
When HIV-1 screening began in Glasgow, homosexuals were the 
predominant risk group found seropositive. The number of new 
positives decreased in subsequent years but the total pool of 
infection has been increased by those positives known elsewhere. New
TABLE 3.8
Year
1989 
J-M 
A-J 
J-S 
O-D
1990 
J-M 
A-J
Homosexual and bisexual risk group screening 
during 1989 and 1990 (Jan-Jun).*
Nos. Ho/Bi 
Screened (Ho/Bi) Nos. Positive (%)
66
50
63
60
50Ho/16Bi 
40Ho/1 OBi 
49Ho/14Bi 
52Ho/ 8Bi
2
1 (1Bi)
2 
1
(3.0)
(2.0) 
(3.2) 
(1.7)
67
49
52Ho/15Bi 
35H6/14Bi
4 (2Ho/2Bi) (6.0)
2 (1Ho
1H6/DA ) (4.1)
* The numbers represent only the testing performed 
at the HRL from Ho/Bi in Glasgow.
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cases are still being diagnosed, about 2-3 per quarter, generally 
through the genito-urinary medicine clinics. In general the 
homosexual population are known to be a more widely travelled group, 
being older than most DAs and have a different socio-economic 
background. Eight of the antibody positives who were diagnosed 
elsewhere were from England, three from the USA, one from as near as 
Edinburgh and one from as far away as New Zealand.
Early Infection in the Bo/Bi Population
Over the first 5 years of screening only 3 cases of 
seroconversion were observed in homosexuals presenting for screening. 
Serum samples were available 6 days, 9 days and 2 months prior to the 
confirmed detection of anti-HIV 1 • The presence of antigen was 
confirmed in only one patient.
The first seropositive found on screening at the HRL was a 
homosexual; the patient presented clinically with AIDS and had been 
ill since 1984. His partner was also HIV-1 antibody positive. 
Evidently HIV-1 infection has been in this population in the West of 
Scotland for a number of years prior to 1984-1985. In addition 
evidence of AIDS-associated infections were found on a post-mortem of 
a patient who had received a blood transfusion in 1983. One of the 
donors was a homosexual and was known to be HIV-1 seropositive on 
testing at the HRL in 1985. HIV-1 infection was in the blood donor 
population at least as early as 1983.
Ho/Bi and HIV-1 Disease
There is evidence to suggest that the homosexual population has 
been infected with HIV-1 for a longer period of time than the DAs. 
In many cases, the newly diagnosed seropositives presented with signs 
of progression of HIV infection.
1985
The clinical status was known in 11 out of the 23 seropositives 
in 1985; five were asymptomatic at presentation, four had PGL and two
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had AIDS.
1986
In 1986, seven were asymptomatic at presentation: of these seven, 
one progressed to PGL, one to ARC, one to AIDS and four whose clinical 
state is unknown. Three presented with PGL, two of whom developed 
AIDS and have since died and one other patient presented with AIDS.
1987
In 1987, five out of the 13 whose status was known presented 
with AIDS all of whom died 1-19 months later, two presented with ARC, 
one died 13 months later with ARC, the other died 19 months later 
having developed AIDS. Six were asymptomatic at presentation, one of 
whom developed ARC 22 months later, two have progressed to PGL and the 
clinical state of the remaining three is unknown.
1988
Seven asymptomatic patients presented in this year, two of whom 
are know to have progressed. Two had a documented seroconversion 
illness when diagnosed, four appeared with symptoms and clinical 
status was unknown in the remaining four.
1989
Out of a total of 12 seropositives reported, three patients were 
asymptomatic at presentation, two had symptoms of progressive illness, 
and there was no information regarding the clinical status of the 
other seven patients.
1990
Three of the seven seropositives reported in this year from 
Glasgow and the West of Scotland appeared with symptoms; one with 
weight loss, fatigue etc. and the other two with recurrent chest 
infections. There was no clinical information given about the 
remaining four patients.
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3. HIV-1 SEROPOSITIVE BLOOD PRODUCT AND BLOOD TRANSFUSION
RECIPIENTS
The knowledge that blood product recipients were at high risk of 
acquiring HIV prompted the retrospective testing of haemophiliacs in 
1985. Since this group of patients were monitored regularly for 
hepatitis, serum samples were available from up to ten years prior to 
this date in some cases (see Chapter 5). One hundred and eleven 
adults attending the Regional Haemophilia Centre at Glasgow Royal 
Infirmary (GRI) and 57 children attending the Royal Hospital for Sick 
Children (RHSC) were tested? 14 adults and 16 children were 
seropositive prior to 1985? two of whom have now been lost to 
follcw-up in this area. Three of the Oil seronegative adults and one 
adult attending another Glasgow hospital and not previously tested 
here, were subsequently found to be seropositive on routine screening 
in 1985. There were no new cases in the haemophilia population after
1985, due to the introduction of heat-treated concentrates in late 
1984 and blood donor screening in October 1985.
Blood transfusions were attributed risk factors in three 
patients reported in 1986 and in one patient first tested and 
confirmed in 1989. In the latter case, the infected transfusion was 
given prior to the introduction of anti-HIV 1 screening. In August
1986, two patients who became HIV antibody positive received blood 
products from the same donor? concentrated red blood cells in one 
case and platelets in the other. At the time of donation in August 
1986, no antibodies to HIV were detected in the donor serum even by 
western blot. However 86 days later in October 1986 the donor was 
found to be seropositive. In addition the same donor had given blood 
in May 1986, but all recipients of this donation were seronegative. 
The infectious donation was tested for the presence of HIV antigen 
(Abbott) when a test became available in 1987 and gave a borderline 
result. Lack of specimen prevented further confirmation of this 
result.
107
4. HETEROSEXUAL HIV INFECTION INCLUDING PERSONS EXPOSED ABROAD
HIV infection in the heterosexual West of Scotland population 
contributed only 5 cases (1.7%) to the total new seropositives; three 
of the five cases are females, one whose sexual partner is African, 
the remaining two cases involved contact with a bisexual man. One of
the seropositive males reported heterosexual contact with a risk
group. In addition, of the 3 others who were kncwn elsewhere (Table 
3.3), 2 were female, one of whan had been a contact of a male drug 
abuser in Greece. The remaining case was a male, known in the USA,
who had come home for treatment. Heterosexual contact is also
specified in five of the 17 cases who were exposed abroad.
All those listed under the 1 exposure abroad' oolurm in Table 3.2 
had their exposure in Africa. All except one are male. Twelve are 
African nationals; four Ugandans, three Tanzanians, three Zambians, 
one South African and one African of unknown origin. Three of the 
African nationals are known to have died in Glasgow and several are 
students who will most probably return home eventually. Table 3.9 
shows the location or place of contact of these seropositives; it can 
be seen that both Uganda and Zambia are areas of note regarding HIV-1 
infection. Male to female and female to male transmission of the 
virus occurs, but there is little evidence to suggest that HIV is 
epidemic in the heterosexual population in the West of Scotland nor 
that it is spreading in this area outwith sexual contacts of known 
risk groups.
5. HIV-1 IN OTHER RISK CATEGORIES
Four of the 7 listed under 'other' (Table 3.2) had unspecified 
contacts with HIV antibody positives. The remaining three are 
sisters, whose parents were both found to be HIV seropositive. it is 
not known hew the parents were infected, but an older child is HIV 
antibody negative. The three subsequent children may have been 
infected through vertical transmission from mother to child. In
TABLE 3.9
Sex, age and origin of HIV-1 seropositive African nationals 
and West of Scotland heterosexuals infected through contact abroad.
Year
Heterosexua Is: 
Exposure Abroad African National
1985
1986
1987
M21 - Central Africa
M38
M31
Africa
Zambia
F28 - Tanzania 
M28 - Zambia d
1988 M37 - Africa
M67 - Zambia and Zimbabwe
M38 - Zambia**
M41
M39
M28
M30
M31
Uganda 
Uganda d 
Uganda 
Uganda * 
Zambia
1989 M38 
M29 
M2 5
Zambia 
* African' 
Tanzania
1990 M35 - Tanzania 
M25 - Uganda 
M35 - South Africa
* - diagnosed seropositive elsewhere
§ - infected through a blood transfusion 
d - deceased
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addition three children in the West of Scotland bom to HIV-1 positive 
mothers became antibody negative 12-18 months after birth and have 
remained so, bo date. They have not been included in the figures as 
they are not currently increasing the pool of infection.
6. HIV-1 SEROPREVALENCE IN THE BLOOD DONOR POPULATION
The BTS began screening every blood donation for HIV antibodies 
from October 14th 1985. A text of exclusion clauses was produced for 
every blood donor to read in order that those in any risk group or a 
contact of any such group would be dissuaded from donating.
Initial ELISA tests lacked specificity and were subject to false 
positive results. To avoid the trauma of notifying donors as such, 
confirmatory testing was instigated at the appropriate Reference 
Laboratories. The function of these Reference Laboratories was to 
provide additional but separate methods of testing those sera found 
repeatedly reactive by the BTS screening ELIS As. The HRL at Ruchill 
Hospital, Glasgow, serves as a Reference Laboratory for three Regional 
Transfusion Centres (RTC) that of Glasgow and the West of Scotland, 
the North of Scotland and Northern Ireland.
Table 3.10 shews the number of confirmed seropositives detected 
each year and the risk category of these donors from the Glasgow and 
West of Scotland BTS. Of these 18 positive donors, (16 male and two 
female), five were new donors, five had donated previously but prior 
to the introduction of testing and eight donors who had been tested 
previously and were anti-HIV negative. Less than 0.01% of all donors 
tested are positive and 2.5 in 100,000 donations tested are positive 
(Dr. B.C. Dew, personal communication).
B. PREVALENCE OF OTHER RETROVIRUSES IN GLASGOW AND
THE WEST OF SCOTLAND
1. HTLV-I AND HELV-II
A limited amount of screening for anti-HTLV 1 and anti-HELV II
TABLE 3.10
Risk group breakdown of HIV-1 seropositive blood donors in Glasgow 
and the West of Scotland for the period October 1985 to June 1990.
Year DA Ho HET Other AJnk Total
1985
Oct-Dec - 0
1986 2 3 1 6
1987 1 1 1 3
1988 2 2
1989 2 2 1 5
1990
Jan-Jun 2 2
Total 4 10 2 2 18
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has been carried out on sera from HIV-1 high risk patients and in the 
blood donor population.
No drug abusers have been found to be either HELV-I or HTLV-II 
seropositive ever four years of testing (Table 3.11). In addition 
anti-HIV 1 positive (n=33) and anti-HIV 1 negative (n=32) 
haemophiliacs were tested. No patient was found to be HTLV-I or -II 
seropositive.
In 1989, 5000 random blood donors were screened at the Glasgow 
and West of Scotland BTS, using the three test kits available at the 
time (Abbott, Du Pont and Serodia). The purpose of the study was to 
determine the specificity of anti-HTLV screening tests. Thirty-four 
(0.7%) were found to react repeatedly in one or more ELISA. None of 
the 34 were confirmed positive by either a western blot assay (DuPont 
and Abbott Laboratories, Chicago) or a radioimraunoprecipitation assay 
(RIPA) performed by Abbott Laboratories, Chicago.
There is no evidence of HTLV-I or -II infection in the blood 
donor population in the West of Scotland or in the IVDAs, a group 
considered to be at risk at this time.
2. HIV-2
Anti-HIV 2 screening has been routinely performed at the HRL 
since the development and launch of the combination anti-HIV 1 /2 
ELISAs in 1989. To date, no clinical sample has been found to 
contain antibody to HIV-2 in Glasgow and the West of Scotland.
TABLE 3.11
Results of antibody screening for HELV-I/-II
HILV-I/-II Ab.
Year No. DAs Tested No. Positive
1987 82 0
1988 205* 0
1989 274 0
1990 40 0
* This figure includes 16 HIV-1 antibody positives
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DISCUSSION
The climate of public opinion and the attitudes of those most at 
risk have changed ever the years, whether influenced by the media or 
by peer pressure. At times it has been acceptable to be tested and 
knew one's HIV status and at other times, the general feeling of those 
at risk has been that they don't want to know. This has influenced 
the total number of test requests and the number from the high risk 
populations coming into the laboratory.
An attempt has been made to examine the epidemiology of HIV-1 
infection in Glasgow and the West of Scotland; who is infected and 
how many are infected? Assuming that the sanple populations
available for testing are representative of the populations at risk, 
the results presented here show the extent of HIV infection in this 
area up to the end of June 1990.
Several problems are associated with epidemiological
surveillance of this type of disease. In the opinion of the general
public there was and still is very much a stigma attached to being 
infected with HIV-1; it was seen to be primarily a
sexually-transmitted disease and only certain members, the more 
undesirable numbers, of society could be infected, excepting the 
haemophiliacs and other blood product recipients who are regarded as 
innocent victims. The main problem is admitting to being a member of 
a risk group. The prevalence of seropositives in the different risk 
groups cannot be assessed when there are no baseline figures for the 
numbers at risk; the information presented here is predominantly 
about the DAs since they were the most frequently openly identified on 
request cards, whereas the homosexuals often did not volunteer the 
information regarding their risk activity or this information was not 
included on the request card.
Another problem in epidemiological surveillance is the
possibility of double reporting, e.g. patients attending GUM clinics 
who are assigned an identification number can be recorded as 
seropositive and then appear at the Infectious Diseases (I.D.) clinics
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or other as a named patient. By removing the numbers of patients 
known elsewhere or previously, where this information is available, 
from the total numbers of seropositives, an attempt has been made to 
keep this duplication to a minimum.
A. PREVALENCE OF HIV-1
The general pattern of infection is similar here as elsewhere in 
that the same risk groups can be identified as susceptible to 
infection, these are: intravenous drug abusers, homosexuals,
bisexuals, blood product recipients, haemophiliacs and heterosexual 
contacts of these groups, also children of HIV-1 seropositive mothers. 
The variation in prevalences in the different risk groups and in 
different areas are influenced by the date of introduction of the 
virus into the ocmmunity and by the frequency of behaviours promoting 
transmission. The overall impression in the groups at risk, who have 
been tested here is that the homosexuals have been infected for 
longer, since, to date, many have signs of progression of HIV-1 
related disease and there is an indication in some cases that HIV-1 
infection has been "imported" from the USA early in the epidemic. 
Serological evidence (Chapter 5) indicates that infection appeared in 
the Glasgow haemophiliac population as early as 1981 and also was 
"imported" from the USA. Seroconversion occurred in the DA
population in Glasgow in late 1985 through 1986, and only new, four or 
five years on, do this group manifest signs of HIV disease. A 
diagnosis of AIDS has been recorded in all risk groups in the West of 
Scotland implying that tjq group, no matter the manner in which they 
were infected, escapes the possibility of disease.
Intravenous Drug Abusers
The most interesting data collected is that concerning the drug 
abusers. The DA population in the region is currently estimated at 
between 8-12,000 (180). The data presented here suggests that HIV-1 
infection in Glasgow is not widespread, in marked contrast to the
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extent of the problem in Edinburgh, where greater than 30% were found 
seropositive (181,182), Since routine screening began, almost 4,000 
specimens from DAs have been tested at the HKL (Table 3.5). The 
prevalence is low,currently 1.2% of the total tested are HIV-1 
antibody positive. Sampling may be a problem, since only those who 
wish to knew their HIV-1 status can be tested. The problem may lie 
in those not wishing to be screened. However a larger number of 
positives would have been expected in this pool, if the problem was 
genuinely worse.
An HIV seroprevalence and behavioural study was introduced in 
May 1990 to screen DAs anonymously; to sample 500 DAs each year for 5 
years at various sites within Glasgow and compare the behaviour of the 
seronegatives and the seropositives (Dr. D.J. Goldberg, CDSU, personal 
communication). Salivette samples and blood spots were collected and 
tested by GACELISA. Of over 500 screened in the first year 10 were 
found positive, however 3 of these were from Edinburgh and therefore 
should never have been included in the study, leaving 7 Glasgow 
seropositives (1.4%). This is further evidence that HIV-1 infection 
has not spread widely in Glasgow drug abusers. However HIV-1 is 
still spreading albeit slowly as new seroconversions are detected 
occasionally.
Reports in the literature in 1984-85 found varying rates of 
seropositivity in certain populations of DAs across Europe and the 
USA. Table 3.12 indicates the percentage positive in this population 
in different areas and in some cases, details of the increased 
prevalence with time as HIV infection entered and spread in the 
population(s) examined (101,178,179,181-189).
In the United Kingdom (UK) the total numbers of HIV infected DAs 
has increased as time has progressed. The total seropositives 
reported in the whole of the UK up to the end of June 1990 was 14,090, 
of which 1903 (13.5%) were DAs and 7208 (51.2%) were Ho/Bi males 
(145). If the Scotland total of seropositive DAs (926), to the same 
date, are subtracted, only 977 HIV-1 antibody positive DAs remain for 
the rest of the UK. Therefore Scotland has contributed 48.7% of all 
the seropositive DAs reported. Something different has happened in 
this population in Scotland compared to the rest of the UK. In the
TABLE 3.12
Early reports of the percentage of seropositive DAs in 
populations across the UK, Europe and the USA.
UK
Europe
USA
Percentage
positive Year Location Reference
1.5 1983 London (183)
2.5 1984 England (184)
6.4 1985 London (184)
51 1983-85 Edinburgh (181)
38 1985 Edinburgh (182)
0.5 1985 Glasgow (178)
3.2 1986 Glasgow (179)
4 1983 Southern Bavaria (185)
6 1984 Southern Bavaria (185)
36 1984 Zurich (101)
11 1983 Spain (186)
40 1984 Spain (186)
48 1985 Spain (186)
44 1984-85 Austrian Tyrol (187)
6 1980 Italy (188)
10 1981 Italy (188)
15 1982 Italy (188)
31 1983 Italy (188)
53 1984 Italy (188)
76 1984 Italy (188)
29 1981-82 New York (189)
50 1984 New Jersey (189)
87 1984 Manhattan (189)
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14 reporting units in England, the percentage of total seropositives 
which were DAs ranged from 6% in the North East Thames region to 18.7% 
in East Anglia since reporting began, up to the end of June 1990 
(Table 3.13). By comparison the figures from the Glasgow reporting 
unit are high, as are those from 4 out of the other 5 reporting units 
in Scotland. When the numbers of DA seropositives from outwith 
Greater Glasgow are removed from the total, the figure drops to 24%, 
i.e. 79 out of 328. This is still higher than any reporting unit in 
England. However 61% of the Scotland DA total were reported from 
Edinburgh and only 16% from Glasgow. Why is the situation in Glasgow 
so different from Edinburgh, which is situated only 70 km to the east 
when other indicators in this population are similar?
There was a 51% prevalence reported in the Edinburgh DAs between 
1983 and 1985 (Table 3.12). Robertson et al. (181) found that HIV-1 
infection entered this group late 1983, early 1984 and then spread 
rapidly; seroconversion was also noted in 33 of the 83 antibody 
positives. There was no indication to suggest that seropositivity 
was related to the duration of drug abuse but there was a correlation 
with the frequency of sharing needles and syringes. Both the 
frequency of sharing and injection practices led to the rapid spread 
of HIV-1 in Edinburgh (91% of seropositives reported frequent sharing 
versus 71% in the seronegatives). Testing at a separate site in 
Edinburgh in 1985 showed 38% were infected (182). Evidence of 
hepatitis B (HBV) infection (i.e. presence of hepatitis B surface 
antigen or antibody to hepatitis B core antigen) was , found in 62% of 
all patients tested, and in 90% of the HIV-1 seropositives. This 
extent of exposure to HBV is consistent with a longer history of drug 
abuse and a greater frequency of sharing. Needle sharing is the 
predominant risk activity by which HIV-1 is spread in this population 
as HIV-1 seropositivity is lew in their sexual contacts (190), and so 
a high rate of past or current HBV would not be unexpected.
A similar study in Glasgow in 1985 found 4.5% of DAs tested were 
HIV antibody positive (178). However the results presented here 
indicate that less than 1% were Glasgow based (Table 3.12). In 1986 
this rose to 6% in the last quarter. However this increase was not 
sustained, as was expected, when other similar populations were
TABLE 3.13 emulative regional totals of HIV-1 seropositives 
detected in the UK to the end of June 1990.**
Region
Nos. Seropositive 
All Risk Groups DAsj[%l
England: Northern
Yorkshire
Trent
East Anglia 
NW Thames 
NE Thames 
SE Thames 
SW Thames 
Wessex 
Oxford
South Western 
West Midlands 
Mersey
North Western 
Channel Islands
343
375
371
198
4,194
2,383
1,547
361
296
380
289
432
178
671
23
58
46
49 
37
315
151
175
31
37
50 
40 
25 
15 
68
6
(16.9)
(12.3)
(13.2)
(18.7) 
( 7.5) 
( 6.3)
(11.3) 
( 8.6) 
(12.5) 
(13.2)
(13.8) 
( 5.8) 
( 8.4) 
(10.1) 
(26.1)
Wales 171 7 ( 4.1)
Northern
Ireland 74 7 ( 9.5)
Scotland: Aberdeen
Dundee
Edinburgh
Glasgow
Inverness
SNBTS
45
235
1,074
328
11
41
15 (33.3) 
177 ( 75) 
565 ( 53) 
147*(44.8)
1 (9.1)
16 ( 39)
*79 of whom were from Greater Glasgow
** Source of data: PHLS AIDS Centre - Gonnrunicable Disease Surveillance
Centre, and Communicable Diseases (Scotland) Unit. Unpublished quarterly 
surveillance tables No.8, September June 1990 Table 9 (145) and 
Cannunicable Diseases (Scotland) Weekly Report, AIDS News Supplement A155, 
JtfLy 1990; 90/28 (206).
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examined, e.g. in Italy (188) and Spain (186) (Table 3.12). High 
rates of previous expsoure to HBV were found in the HIV-1 seropositive 
and seronegative Glasgow DAs during 1985 and 1986 similar to that 
reported from the two testing sites in Edinburgh during 1985 
(181,182). This suggests that Glasgow DAs were sharing needles 
widely at this time. The higher prevalence of hepatitis B in the 
HIV-1 seropositives compared to the seronegatives in both cities is 
consistent with greater sharing in the former and hence an increased 
likelihood of coining into contact with the virus.
In a study of geographical distribution of HIV and HBV among DAs 
in Glasgow between 1986 and the end of June 1989 the records of acute 
HBV and HIV infection, from 3 virus laboratories in Glasgow, were 
studied (M. Peedle, personal communication). Acute HBV infection was 
found in all 41 post-code areas studied (the post-code areas were 
placed in 10 groups according to geographical proximity) but 
predominantly in the G20-G23 areas in the North of the city and G31-34 
in the East of the city. HIV infection was found in all but 4 groups 
(16 postal code areas). It was also highest in the areas described 
above for HBV, suggesting that the same risk factors are present. A 
greater number of DAs were screened in these post-codes than elsewhere 
and HIV-1 infection was present in 4.5-7% of the total DAs tested in 
these areas over the period 1986-June 1989.
It was noted that acute hepatitis B occurred in areas where 
there is as yet no HIV infection. Since HBV is spread in a similar 
but more efficient manner, is it only a matter of time before HIV 
infection appears in these drug abusing groups? One year on from 
this study no spread has occurred yet in these areas. However the 
number of DAs tested from such postcodes has been small. These areas 
are further out from the city centre of Glasgow and the residents are 
in a higher socio-economic group, perhaps high risk behaviour occurs 
less often. Information from the CDS surveillance database dicws 
that HIV test requests from DAs have been received from all but five 
Glasgow postal codes. The majority are from the G20-G22 areas. 
This is the area closest to Ruchill Hospital and may reflect a higher 
usage of the Counselling Clinic and the Needle Exchange Centre in the 
hospital, where testing would be encouraged or a heightened awareness
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in the local General Practitioners attending such patients.
In 1986 two general practice populations of intravenous heroin 
users from Edinburgh and Glasgow were studied in an attempt to explain 
the variation in HIV-1 seroprevalence between the two cities (191). 
The groups were taken to be socially comparable, similar in behaviour 
and representative of DAs in the community. It was found that apart 
from the different dates of arrival of the virus into the two 
communities the only other difference was that both the number of 
people sharing needles and syringes and the number of occasions when 
equipment was shared per month were significantly higher in Edinburgh.
HIV-1 entered the drug abusing population in Edinburgh during 
the last quarter of 1983, early 1984, and spread rapidly. Was this a 
reflection on the extent of sharing and frequency of sharing needles 
and syringes at this time or an effect of the virulence of the virus
in a susceptible population? The latter proposal can only be
speculated upon but there is information available regarding the 
former to suggest that frequent sharing occurred, with multiple 
contacts involved, similar to the "shooting galleries" described in 
the USA (181,191). An epidemic of heroin use was also noted between 
1982 and 1984 which would increase the numbers in the susceptible 
population (192). That such an explosion of infection occurred in 
Edinburgh over such a short time period suggests that a group of 
highly infectious DAs were sharing with large nunbers of other DAs and 
that these contacts were in turn sharing with a further set of DAs and 
so forth. If all this happened when virus load in any one patient 
was at its greatest this would help to explain the rapidity of spread. 
The highest titres of virus have been shown to be present early in 
infection (87,88) and serological evidence is suggestive of recent 
HIV-1 infection in a number of the seropositives in Edinburgh at this 
time (181).
Glasgow is a far larger city than Edinburgh in terras of
population and area. It also has 3-4 times the number of injecting
DAs, currently estimated at 8-12,000 (180); however the drug users 
are generally found in discrete areas with very little mixing between 
these areas. The results have shown isolated pockets, e.g. G20, G21 
post-code areas which have high rates of infection. The
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comparatively late arrival of the virus helped the situation here in 
that publicity and targeting of the risk groups was beginning. 
Although the actual numbers infected in 1986 are snail, the increase 
was marked at this time.
The mechanisns of transmission of HIV-1 infection are influenced 
by sharing needles; whether the "works" (needle and syringe) are 
cleaned between contacts, the time between contacts and by certain 
injection practices, particularly that of "washout" which involves 
flushing any remaining drug left in the syringe with one's blood. 
However, there also has to be at least one infected person present 
since needle sharing among uninfected individuals is essentially safe 
with respect to transmitting HIV-1 infection. The infectivity of the 
index case also plays a role in transmission of the virus. It 
appears that infectivity varies between individuals and within an 
individual over time.
At the end of 1986, a .marked increase in positive DAs was 
noted in Glasgow but this was not significant.. There may be many 
reasons far this. The low number of seropositives meant that there 
was less chance of coming into contact with an infected DA. Perhaps 
a 'threshold' number of seropositives or number of potentially 
infectious exposure events have to occur to promote virus 
transmission. In Glasgow, therefore it appears that sharing
practices are probably quite different from those in Edinburgh, 
involving smaller numbers of known contacts at any one time.
Much hearsay evidence suggests that geographically distinct 
pockets of drug abusers in the city do not inter-mix. In contrast, 
the majority of Edinburgh DAs who became seropositive all come from 
the same locale, and probably took drugs together, sharing the same 
needle and syringe.
The availability of needles and syringes has been greater since 
that time both through the selling of needles and syringes by 
pharmacists or by needle exchange. A study by Goldberg et al (193). 
examined the sales of needles and syringes to DAs by a single 
pharmacist in the G22 area from March 1987. Around 1000-2000 per 
month were sold. The increase in sales appeared to coincide with the 
decrease in HIV-1 seropreva lence in 1987; but this is likely to be
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only one of the contributing factors as the downward trend was already 
happening. In addition, needle exchange centres were established in 
1987 following the success achieved in Amsterdam with this set-up 
(194). This provided DAs with a clean set of 1 works* in exchange 
for dirty needles and syringes and was also an opportunity to offer 
information about HIV risks. Three such centres are currently 
running in Glasgow.
Results from these exchange programmes established throughout 
England and Scotland have shown encouraging changes of behaviour. 
There was a worry that increasing the availability of needles and 
syringes would only encourage more sharing as this is associated with 
a feeling of community among DAs. However an educational input 
regarding risk behaviours and hew and why this should be changed 
appears to have had the desired effect. The needle exchanges 
provided counselling about drug use, advice on safer sex, needles, 
syringes and condoms thereby providing the DAs with the means with 
which to change their behaviour. The results of a question-based 
survey of the DAs attending over two points in time showed that many 
clients had adopted low or lower risk behaviour; there had been a 
decrease in syringe sharing and changes in sexual behaviour, although 
the non-use of condoms had increased (195).
A follow-up study on a group of Edinburgh DAs has shown that in 
addition to a reduction in sharing episodes, with fewer people 
involved they are also injecting less frequently, irrespective of 
serological status (196). The data also shewed that the risk 
behaviour of the seronegatives was initially less than the 
seropositives. These trends continued when a second follow-up of the 
same individuals was carried out (197). This is encouraging as it 
shews that DAs are capable and willing to modify their behaviour. 
Changes in sexual behaviour in the same group were also noted with a 
reduction in the number of sexual contacts per year; there was also a 
trend towards single, long-term relationships. This is important 
since these heterosexual DAs, especially those female drug abusers who 
prostitute to finance their drug habit, are a major reservoir for the 
introduction of the virus into the non-drug abusing heterosexual 
population. This problem is considerable in Glasgow. Goldberg et
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al. (198) showed that 26 out of 35 HIV-1 seropositive female DAs, 
diagnosed between 1985 and 1987, engaged in regular prostitution, with 
two others suspected of such practices. Thus it appears that the 
spread of HIV-1 in Glasgow shows a similar pattern to that of other 
cities in the OK and Europe, where an initial snail increase in spread 
of infection was observed which subsequently steadied and the 
seropreva lence remains low. However the story in Edinburgh is quite 
different and nowhere else has such a rapid increase been seen.
HIV-1 is still spreading in the DAs, although at a slower rate 
now than previously. The current incidence is low, less than 2% of 
those tested are positive. This is similar in other areas, even in 
Edinburgh where the number of new positive DAs detected per quarter 
has dropped from 11 in the second quarter of 1989 to 2 in the second 
quarter of 1990 (data extracted from CDS surveillance reports). The 
DAs as a group are a difficult population to manage or control, to 
target publicity and even to administer routine medical treatment. 
However, it is clear that help and advice must continue to ensure that 
they are constantly aware of the threat of picking up HIV-1 and to 
encourage behavioural change, however snail. There is no room for 
complacency as the potential threat of igniting an explosion of HIV-1 
infection in the DA population is always present. The pool of 
currently infected DAs could act as a potent spark and hence the need 
for continued monitoring of both behaviour and infection status in 
this population
The Homosexual and Bisexual Population
The homosexual and bisexual populations (including Ho/Bis who 
also abuse drugs) contribute 52% of the total seropositives in the UK 
and make up 81% of the cases of AIDS up to the end of June 1990 (145). 
In contrast to the DAs, Scotland's contribution of seropositive Ho/Bis 
to the UK total is only 4.2%. In Glasgow 30.5% of the recorded 
seropositives are Ho/Bi (Table 3.2).
The homosexual and bisexual populations are a less well-defined 
cohort in the West of Scotland and very often this risk activity is 
not admitted when HIV-1 screening is requested. Therefore less
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information is readily available. Hcwever, a consistent number of 
homosexuals have been diagnosed seropositive each year since screening 
commenced. There was initially high numbers of homosexuals detected 
in the first year of screening so much of the spread had occurred in 
the early 1980s, especially through travel. The Ho, being a more
widely travelled group, were in contact earlier with at-risk groups in 
countries where HIV-1 infection was already widespread. In
subsequent years the numbers in this pool were swollen by 
seropositives, diagnosed elsewhere, but returning home for treatment 
etc. (Table 3.3).
An interesting observation was made in 1987; an increased number 
of test requests were received from patients, predominantly in the Ho 
risk group who first presented with symptoms indicative of HIV-related 
disease. On western blot decreased reactivity to core proteins, 
especially p24, was noted in these patients compared to the 
a symptcma tics.
No major increase in numbers has been observed but new cases are 
being detected, on average 2-3 per quarter, predominantly via the GUM 
clinics situated in other hospitals in the city or through clinical 
presentation, usually an atypical pneumonia.
AIDS began in the USA in the homosexual population and the first 
case in Glasgow was a member of this group. In San Francisco and
other parts of the USA, they are a large, well-publicised and open 
group. Many have been followed up in cohort studies to assess the 
risks regarding various homosexual practices, to examine changes in 
behaviour, length of time of progression to AIDS, etc.
Several studies have shewn that the receptive partner is the one 
at greatest risk (199) since damage to the rectal mucosa (the lining 
of the rectum) is the main means by which HIV-1 can enter the blood 
stream. Langerhans cells in the rectal epithelium have been proposed 
as a vehicle far transmission of HIV-1 firstly into lyraph-nodes and 
then into the circulation (200). Practices increasing trauma to the 
epithelial layer will obviously increase the risk of acquiring HIV-1. 
In addition, in those patients with multiple partners the chances of 
coming into contact with an infected person multiplies.
Publicity and advertising has been targeted at all risk groups
120
especially the homosexuals, whose behaviour it was believed, could be 
more easily influenced. A reduction in the number of cases of other 
sexually transmitted diseases, implying a trend towards lower risk 
behaviour, was noted in GUM clinics in London (201) and Stockholm in 
1986 (202). However recently this trend has been reversed in 
homosexual populations elsewhere (203). Despite the risks being 
well-known and easy access to information and advice, new cases are 
still being detected. Once again a campaign of information must be 
maintained to repeatedly inform this population of the risks 
associated with such a lifestyle.
Blood Donors and Blood Product Recipients
A total of 30 haemophiliacs both children and adults were found 
positive retrospectively, the earliest being in 1981, and a further 4 
(3 of whom were known to have had previous negative samples) were 
detected in 1985. No new infections in the haeraophilacs, tested at 
the HKL, were diagnosed after 1985 due to the introduction of heat- 
treated factor concentrates which has proved to be successful in 
preventing transmission of the virus by this route. The haemophiliac 
seropositives are described and discussed more fully in Chapter 5.
Epidemiological evidence from studies in the early 1980s 
inplica ted the transfusion of blood and blood products as a means of 
transmission of HIV-1 • Identification of infected blood donors and 
removal of their donations from the blood bank, was seen as an 
important way to prevent the spread of HIV-1 infection into the 
general population.
However two of the four transfusion recipients were infected as 
a result of a transfusion of blood products from a single infected 
donor in the West of Scotland after antibody screening was introduced. 
Transfusion of any fraction, e.g. platelets, concentrated red cells 
etc. of a blood donation is known to transnit infection (204). This 
donation was found to contain no evidence of HIV-1 antibody by ELISA 
or western blot. Therefore withdrawal of antibody-infected blood is 
insufficient on its own to completely remove the risk of transmission 
of infection. Potential donors have to be repeatedly and continually
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dissuaded if they have indulged to any extent in any risk activity.
These were unfortunate cases, which could have been avoided by 
appropriate donor deferral. Hcwever it appears that same members of 
the population do not perceive themselves as a member of a risk group. 
Fourteen of the 18 blood donors found seropositive in Glasgow and the 
West of Scotland belong to a high risk group; 5 of the 18 were new 
donors and 8 of the 18 seroconverted. These persons should not be 
donating blood and the provision of alternative testing sites, such as 
the Counselling Clinic at Ruchill Hospital was to prevent this. 
Either these donors did not consider themselves as ’high-risk* members 
of the ooranunity with respect to HIV-1 infection or the appeal of 
absolute anonymity made them use the BTS as a source for testing.
The Heterosexual Population
The heterosexual spread of HIV-1 is becoming an important risk 
factor in the epideniiologica 1 surveillance of HIV-1 infection. In 
Africa, this is the predominant mode of spread with equal numbers of 
infected males and females in the sexually active age groups (134). 
In the USA the heterosexual epidemic is growing quickly, largely as a 
result of spread by DAs (205).
In the UK (excluding Scotland) heterosexual contact accounts for 
6.9% of the total seropositives up to the end of June 1990 (145). 
This includes those whose exposure was abroad and in some cases in 
countries where the spread of HIV-1 is largely through heterosexual 
contact (World Health Organisation pattern II countries). In 
addition 5.8% of the AIDS cases are in this category (145).
In Scotland the figures to the end of June 1990 are similar, 
7.9% of the seropositives and 7.7% of all AIDS cases specified 
heterosexual contact (141,206). In Glasgow, 10 out of the 298 
seropositives (3.4%) had heterosexual contact, 5 persons in this 
country and 5 persons in Africa.
Male to female transnission occurred in 3 cases. In several 
studies on the risk of transmission from male to female, a variety of 
factors have been suggested to increase the risk of transmission, and 
these are described by Holraberg et al. (147). For example, duration
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of relationship and frequency of contact, a history of STDs, T4 count 
and stage of infection in the index male, the practice of anal 
intercourse etc. A combination of one or more of these factors may 
be important in different risk groups since it is interesting to note 
that the prevalence in the wives of haemophiliacs and 
transfusion-associated infections is lew in comparison to the sexual 
contacts of other risk groups (150). In addition no household member 
who is not a sexual contact of an HIV-1 infected person has been shown 
to seroconvert (150).
Seven cases of female to male transmission were reported,
however five of these were in Africa where the mechanisms for
transmission in this way operate efficiently. Female to male 
transmission of HIV-1 has been reported, and it is likely that the 
same factors as those mentioned above operate to promote transmission 
of infection in this direction.
The numbers found seropositive on testing at the HRL are small 
and to date these have been contacts of high risk groups. This lack 
of spread outwith the risk group contacts so far is supported by the 
low numbers of seropositives in the blood donor population. In
addition a sero-epideraiological survey performed anonymously on
Guthrie card samples from newborn babies in Scotland, to measure the 
extent of HIV-1 infection in females of reproductive age has revealed 
few seropositives, no additional cases who were not already knewn and 
no positives in the West of Scotland (207). It is perhaps too early 
to realise the extent of spread into the general heterosexual 
population. This epidemic may develop more slcwly since
heterosexuals change partners less often then homosexuals. HIV-1 
infected prostitutes, heterosexual DAs and bisexuals are potential 
reservoirs for spread of infection and spread from these sources is 
occurring. Continued awareness of this threat is achieved by high
profile advertising. An increasing number of anonymous screening and 
epidemiological studies are new underway to monitor the spread of 
infection and identify any novel at-risk groups.
The 'exposure abroad1 category in Tables 3.2 and 3.5 includes 5 
males who had heterosexual contact in various parts of Africa 
(mentioned above) 12 African nationals, 11 of whom were male, and 2
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males who presented here but were known elsewhere; one of whan was a 
Ugandan and the other, a British citizen had received a blood 
transfusion in Zambia.
The CDS surveillance figures for testing African nationals 
reveal that over 18 months of testing, between 1989 and the end of 
June 1990, a total of 9 were tested, and 6 have been found positive. 
This includes only those sarqples where the information regarding 
nationality had been given or found on follcw-up telephone calls. It 
is interesting to note that greater than half of those from countries 
in Africa with high rates of HIV-1 infection, presenting here for 
testing, are positive, illustrating the nature of the epidemic in the 
African continent.
Other and Unknown Risk Categories
The remaining seropositives to be discussed are those listed 
under 'other' and 'unknown'. Four of the seven others have had 
unspecified contacts with HIV-1 seropositives, two males with AIDS 
contacts, one male with a female seropositive and one female with a 
male seropositive. All these patients have been lost to follow-up, 
but it is tempting to speculate that all four may genuinely be a 
result of heterosexual spread of HIV.
The remaining three females are the children of HIV-1 
seropositive parents aged between 5 months and 4 years. An older 
sibling was anti-HIV negative when tested at this time. The oldest 
daughter presented with pneumonia and was subsequently diagnosed with 
AIDS. It is unclear hew the parents were infected (although drug 
abuse has been implicated) or which one was infected first. The 
mechanism of vertical transmission of HIV-1 is unknown but can occur 
across the placenta, perinatally or post-natally through exposure to 
breast milk. Intrauterine transmission is the most likely mode (148) 
and HIV-1 has been shewn to be present in foetal tissues as early as 
15 weeks gestation (208). To reduce the chances of infection 
post-del i very, breast feeding is contra-indicated in HIV-1 
seropositive mothers as HIV-1 has been isolated from breast milk (39).
Over the 63 months of screening, to the end of June 1990, a
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total of 23 seropositives have been found in whom no risk group was 
notified. Very little can be said about this group. It is not 
known whether this is a failure on the part of the requesting 
clinician to record sane information or whether it is unwillingness on 
the part of the patient to admit to a risk category. Six of the 
* unknowns' were female, one of whom was the wife of a seropositive 
male. Hie is also in the same category and both have been mentioned 
previously as the parents of three seropositive children. The threat 
of increased spead into the heterosexual population means that 
continued epidemiologies 1 surveillance is important to identify the 
risk groups of patients in this other/unknown category.
Seropositives Diagnosed Elsewhere
Those patients diagnosed HIV-1 antibody positive elsewhere 
contribute 19% to the total seropositive figures. They have been 
discussed in the relevant risk groups. These persons are not 
seropositive as a result of transmission in this area, however they 
are adding to the pool of infection. It is interesting to note that 
the homosexuals make up half of this total and this is more than 
double the numbers of known positive DAs. This supports the claim 
that Hos are more widely travelled, since in many cases, it is stated 
that they have come for treatment, presumably having been infected 
much earlier elsewhere.
B. PREVALENCE OF OTHER RETROVIRUSES
HTLV-I and HTLV-II
No persons have been found to be HTLV-I or -II seropositive in 
the West of Scotland. This is not too surprising since few sporadic 
cases occur and HTLV-I is generally confined to endemic areas of the 
world; south west Japan, the Caribbean and scrae parts of Africa (18). 
Very few natives of these areas reside in the West of Scotland. 
Hcwever, HTLV-I and -II infection have been identified in intravenous 
drug abusers and blood transfusion recipients in the USA, Europe and
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Latin America.
HTLV-I and -II are transmitted in a similar fashion to HIV-1 and 
HIV-2, i.e. per ina tally, sexually and parenterally by sharing 
contaminated needles and syringes and by transfusion of infected blood 
products. In endemic areas the perinatal acquisition of HTLV-I, 
mostly through breast feeding, is an important transmission route.
No routine screening of blood donors for HTLV-I and -II antibody 
is performed in the UK, at the time of writing, although it is 
anticipated in the future. Transmission of HTLV-I infection by blood 
transfusion in Japan and the USA has been associated with a 48% to 
82% seroconversion rate in the recipients (209). However there have 
been no reports of transfusion-associated ATL thus far, but it may be 
too early to assess the problem due to the long incubation period to 
HTLV-I associated disease. Small studies in USA and Europe have been 
performed to assess the prevalence in the donor population. Almost 
all carriers of HTLV-I were found to be of Afro-caribbean or Japanese 
origin. The current evidence suggests that the risk of HTLV-I 
infection through blood transfusion is lew, although not negligible in 
some areas.
In America, the reported prevalence of anti-HTLV I in blood 
donors is about 0.025% (209) similar to that for HIV-1. This is 
lower in European studies; in France the reported seropreva lence is 
0.011% (210) and in London 0.00036% (211). In other European 
countries no anti-HTLV I positive blood donors were found (212). 
Larger scale studies require to be performed to assess the true 
prevalence. To further lower the risks it may be necessary to ask 
persons of Afro-caribbean or Japanese origin to defer from donating 
blood, especially locally since there are relatively fewer persons of 
such nationalities living in the West of Scotland.
There have been reports of HTLV infection in DAs, particularly 
HTLV-II infection. In 1984 Tedder et al.(26) found 4 out of 113 DAs 
were HILV antibody positive, 3 of the 4 had high titres of antibody to 
HTLV-II. HTLV-I has also been reported in Italian drug addicts (213) 
and in the USA (27). In the latter study, 21 out of 23 HTLV 
polymerase chain reaction (PCR) positive DAs were shown to be infected 
with HTLV-II. No evidence of HILV infection was found in the DA
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population tested in the West of Scotland.
Dual infection with HIV-1 is not unooranon in certain risk groups 
and may be inportant in the progression to disease; indeed in one 
study a cohort of IVDAs from Miami, Florida, who were infected with 
both HIV-1 and HTLV-I/-II were three tines more likely to die from 
AIDS during the follow-up period than those infected with HIV-1 only 
(214). Once in a population such as the drug abusers, these 
retroviruses spread in a similar fashion to, but probably less 
efficiently, than HIV since seropreva lence is seal to increase with 
age suggesting cumulative exposure. In contrast, a very low 
seropreva lence of HTLV-I has been found in homosexual men tested in 
the USA and selected from areas with a high incidence of HIV-1 
infection (215). No testing has been performed on this HIV high-risk 
group in the West of Scotland.
Currently these retroviruses present no challenge in diagnostic 
screening or to medical care in the West of Scotland.
HIV-2
No persons in the sample population at the HRL since March 1989 
nor at the West of Scotland Regional Transfusion Centre (RTC) since 
June 1990 have been found to be seropositive. There have been 12 
reports of HIV-2 infection (2 in blood donors) in the UK, to the end 
of December 1990 (74). Nine of these 12 patients had a connection 
with Africa, mainly West Africa. Reports of HIV-2 infection around 
the world are few suggesting a limited extent of spread. Most cases 
have a connection with West Africa. In Europe, France and Portugal 
have the highest numbers (216) and it is interesting that both these 
countries have past colonial associations with West Africa.
HIV-2 is transmitted in a similar fashion to HIV-1. Although 
HIV-2 appears to be confined to certain populations at the moment it 
is likely that seropreva lence will increase if the virus is allowed to 
spread in a susceptible population or spread to new populations 
through increased global travel. An AIDS-like illness is the 
clinical outcome, however there are reports suggesting a longer 
incubation time to disease in HIV-2 infection (75). This may reflect
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lower pathogenicity of this virus which appears to have existed in its 
current host, man, for much longer than HIV-1. Infection with both 
HIV-1 and HIV-2 can occur but it is unclear how dual infection will 
affect disease progression (76). Counselling, advice and donor 
deferral policies for HIV-1 can be extended and expanded to include 
those at risk for HIV-2 infection.
CONCLUSIONS
Currently HIV-1 infection in the West of Scotland is confined to 
members of the high risk groups defined in epidemiological studies 
performed at the start of the epidemic in the USA. However there is 
no room for complacency since HIV-1 is starting to spread outwith the 
confinements of these groups, a second wave of infection in the 
heterosexual population has begun (217), initially through sexual 
contacts of the high risk population and in those returning from 
certain areas of the world especially Africa, where the main mode of 
spread is by heterosexual contact.
Potential routes of transmission are many and varied since HIV-1 
has been isolated from blood, semen, cervical secretions, breast-railk, 
cerebro-spina 1 fluid, tears and saliva (34-39). But the major routes 
are parenterally through blood or sexually via semen and to a much 
lesser extent, cervical secretions. Hie major vehicle of
transmission is most probably the virus-infected cell rather than free 
virus (218). Virus titre is unlikely to reach sufficiently high 
concentration in these other body fluids to be transmissible.
There has been no evidence of any unusual modes of spread 
despite reports of the survival of HIV-1 in bed bugs (219) and the 
isolation of HEV-1 from contact lenses in 4 ARC or AIDS patients 
(220). Arthropod cells were found to be unable to support HEV-1 
replication although the virus has been shown to bind to Drosophilia 
cells resulting in non-productive infection (221). In a study of 
routes of transmission in Belle-Glade, Southern Florida (222) there 
was no evidence for spread of HEV-1 by insects nor was arthropod-borne
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infection responsible for spread in Africa (134). Acupuncture and 
the use of dirty needles was implicated in HIV-1 infection in a French 
male but this was not a definite association despite detailed 
questioning of the patient (223). Non-sexual household contacts are
at negligible risk (150). Fischl et al. (224) found no risk in
hugging, kissing and sharing of kitchen and bathroom facilities in 
household contacts of adults with AIDS. There have been reports of 
HIV-1 infection in health-care workers (148), either through 
needlestick injury or splashes of infected body fluids onto raucous 
membranes or non-intact skin. The incidence of cases infected this 
way is low but it is not zero and therefore great care must be 
exercised in administering medical help or in handling the body fluids 
from an infected patient.
It has been observed that not all contacts of a seropositive 
individual become infected despite frequent and repeated contact, 
therefore other factors must play a role in determining the 
infectivity of the index case and how likely they are to pass on 
infection and similarly in determining susceptibility to infection in 
the contact. These factors may relate to properties of the infecting 
virus strain, the host's immune response to it, genetic factors and 
behavioural features. There is no test for infectivity and therefore 
no indication as to time or duration of infectiousness. However, 
there is a correlation between presence of antigen in serum and virus 
infectivity with advanced disease stage. This suggests an increased 
risk in the ability to transmit HIV-1 in ARC and AIDS patients. 
Serum antigenaeraia does not necessarily imply infectivity of virus but 
does indicate increased viral replication and therefore a higher 
circulating virus load in the bloodstream. In addition, early in 
infection, prior to antibody seroconversion, serum antigenaemia 
(85,86) and plasma viraeraia (87,88) have been shewn. Contacts have 
been infected when the index case has been in this window period 
implying infectious virus is present, such a case has been described 
in the West of Scotland (97).
Changes in immunological parameters either as a direct result of 
HIV-1 infection or other infections, especially a low T4 lymphocyte 
count may affect the rate of transmission.
129
Certain factors in the contact must also play a part. Any 
degree of immunosuppression or chronic activation of the inmune system 
by other infectious diseases increases susceptibility (143). An 
increased risk of being infected by sexual contact was found in those 
with other sexually-transmitted diseases particularly those causing 
genital ulceration and bleeding thereby facilitating the entry of 
HIV-1 into the blood stream.
Transmission dynamics of HIV-1 vary in different geographical 
locations and depend on risk activity, co-factors, e.g. use of 
nitrites by Hos, numbers of contacts, frequency and duration of 
contact etc. It is therefore essential that people are constantly 
reminded to adopt lcw-risk behaviour and that advice and education are 
continually provided to prevent further spread of HIV-1 and other 
retroviruses spread in a similar way.
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CHAPTER 4
MARKERS OF DISEASE PROGRESSION IN A COHORT OF 
HIV-1 SEROPOSITIVES
INTRODOCnON
Acquired Iranune Deficiency Syndrome, AIDS, is the end stage of 
HIV infection, and is characterised by a number of clinical, 
immunological and serological markers. It may take up to 10 or 15 
years after initial infection with the virus, to develop AIDS; this 
incubation period varies amongst individuals and it is not yet known 
if all infected persons will eventually progress to disease. A 
number of stages have been defined; these have been suranarised into 
classification systems. Those most commonly in use are the Centre 
for Disease Control (CDC) classification (137) and the Walter Reed 
staging (136). There are 4 OX! stages labelled CDC I to CDC IV and 6 
stages in the waiter Reed system. The members of the HIV 
seropositive cohort followed up at Ruchill Hospital, Glasgow, have 
been staged by the CDC classification system. In the presence of 
laboratory evidence of HIV-1 infection clinical signs, e.g. weight 
loss, lyraphadenopathy, oral candidiasis etc. and laboratory measured 
observations , e.g. thrombocytopenia, anaemia etc., are used to define 
each stage of the disease. In broad terras CDC I corresponds to an 
acute seroconversion illness, CDC II refers to asymptomatic patients, 
CDC III is those who are progressing with signs of persistent 
generalised lyraphadenopathy (FGL). CDC IV is subdivided IVA to IVE; 
CDC IVA and IVC^  are the pre-AIDS or AIDS-related complex (ARC) stage 
and CDC IVB, IVCj, IVD, IVE refer to full-blcwn AIDS, incorporating 
various manifestations, opportunistic infections, neurological signs 
and certain cancers.
There is no cure for AIDS, but a number of drugs, particularly 
nucleoside analogues are beneficial and available for treatment. The 
main drug available AZT, 31 -azido-31 -deaxythyinidine, also know as 
Retrovir or Zidovudine (Burroughs Wellcome) is a thymidine analogue 
which inhibits the action of reverse transcriptase (RT) of HIV-1 by 
chain terminating DNA synthesis (225) and thus inhibits viral
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replication. This drug was initially licensed only for use in ARC 
and AIDS patients. Current trials (MRC/INSERM Concorde Trial) are 
investigating its use at earlier stages of infection. Early 
intervention with AZT, despite its haeraatologica 1 toxicity, could 
prove useful in delaying the onset of further symptoms. This would 
allow the other medical problems encountered by these patients to be 
kept under control.
A number of markers indicative of inmune activation and viral 
replication have been examined in other studies to assess their 
inporta nee as indicators of clinical progression. Those most 
commonly measured include HIV-1 antigen, anti-p24, £2~raicroglobulin 
(^ >^ -wg) neopterin ,<x- and interferon, interleukin-2 (IL-2), T4, T8 
cell counts (absolute levels and ratios) and immunoglobulin levels 
(IgG, IgA, etc.)(154,158). During the course of HIV-1 infection, 
described in Chapter 1.2, the predominant virological changes seen 
include loss of p24 antibody and detection of antigen, mainly p24, in 
the serum (104-107). Immunological disturbances such as inverted 
T4/T8 ratios and increased levels of immune markers, e.g. IL-2 and
all signify progression of disease.
In this study three serological markers, p24 antigen, anti-p24 
and (3>2~mg, were measured on sequential samples to examine what 
changes, if any, correlated with onset of symptoms and/or poor 
prognosis in a group of HIV-1 seropositive patients who regularly 
attended the Infectious Diseases (ID) clinics at Ruchill Hospital.
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MATERIAL AND METHODS
STUDY POPULATION
Hie patients described are HIV-1 serqpositives attending the ID 
physicians either at out-patient clinics or as in-patients at Ruchill 
Hospital.
TESTS
Antigen: HIV-1 antigen (Ag) was measured in serum samples
using the Abbott HIV-1 Antigen EIA (Abbott Diagnostics), Appendix 2. 
Hie specificity of any positive result was confirmed by neutralisation 
using human anti-HIV as a blocking antibody. When positive, the 
antigen level was measured using the Du Pont HIV p24 Core Antigen 
ELISA (Appendix 2). Hie Du Pont assay is quantitative: optical
density readings from a series of dilutions, made from a 200 pg/ml 
standard, are plotted on a graph. Hie concentration of antigen in 
the test sample can be read directly from the standard curve and in 
this way the levels of Ag in a patient's blood can be monitored.
Hie DuPont test specifically binds p24 Ag since the solid phase 
of the assay is coated with antisera of high specificity and affinity 
for p24. Hie Abbott test can detect both envelope and core antigens 
but is mare sensitive for the care Ag. Hiis is partly determined by 
the specificity of the rabbit anti-HIV conjugate used.
Antibody: Anti-p24 was measured using the Abbott HIV-1
Anti-Core EIA (Appendix 2). Hiis assay uses identical reagents to 
the core bead test which is part of the ENVA03R HIV-1 EIA, described 
previously (Chapter 2).
^ 2-microglobulin: Levels of jB^ -microglobulin were measured
using the Abbott j^ 2-microglobulin RIA (Abbott Diagnostics) a 
competitive radioimmunoassay for the detection and quantitation of
in serum, plasma or urine. ^  ^ie tost samples competes
133
with I-labelled ^ 2 “^  far sites on the anti- (nwuse
monoclonal)-0 0ated solid phase. The amount of bound label is 
inversely proportional to the concentration of p 2-10^  bn the test 
samples. A standard curve is obtained by plotting the percentage 
bound radioactivity versus the logarithm of the concentration of
a set of standards. The concentration of ^  the best specimens
can be determined from the graph.
TERMINOLOGY
Hie terras CDC II and asymptomatic, CDC III and VGL, CDC IV A
and ARC, CDC IV B and/or IV Cj and/or IV D 
(IV B/Gj/D) and/or IV E and AIDS can be interchanged. The CDC terras 
will be used in the tables and the words ARC, AIDS etc. will be 
written in the text. There is a certain degree of subjective 
clinical interpretation and judgement on the part of the physicians in 
classifying the patients into disease categories and this should be 
taken into consideration. Patients may be symptomatic for a period 
of time before being staged in order to meet the criteria.
and/or CDC IV CL (IV A/C^ )
134
RESULTS
A. SEROLOGICAL MARKERS IN HIV-1 SEROPOSITIVES
Detection of HIV-1 Antigen
Samples from seropositive patients, predominantly in the 
homosexual risk category, were tested for HIV-1 antigen by EIA.
Initial assessment of a snail number of patients showed a 
correlation between the presence of antigen (Ag) and progression of 
HIV-1 infection (Tables 4.1). Eighty-four per cent of symptomatic 
patients (PGL, ARC and AIDS) were reactive compared to 5.6% of 
asymptomatic patients.
For the purposes of the rest of this study, a patient described 
as being antigen positive is defined as having a positive Ag result, 
i.e. reactive by ELISA and confirmed by neutralisation, at least once, 
as many of the symptomatic patients have been treated with AZT. In 
most patients this reduced the level of serum Ag below the detection 
limits of the test.
Detection of HIV-1 Anti-p24
It was noted that certain patients who were confirmed HIV-1 
antibody positive by ELISA and WB, were negative for core antibody. 
This occurred in two situations; in the initial stages of HIV-1 
infection or at the advanced stages of disease. In some patients 
followed sequentially over time, anti-p24 became negative by EIA. 
This corresponded with production of antigen and in some cases a 
clinical change. This is illustrated in several patients in Table
4.2. Therefore an attempt was made to establish the time from loss 
of anti-p24 to development of antigenaemia and/or AIDS.
J^-Microglobulin Levels in HIV-1 Seropositives
Initially a number of samples from both HIV seropositive and 
seronegative risk groups were tested. The results are shown in Table
TABLE 4.1
HIV-1 antigen results on a sample of patients 
at different stages of disease
GDC Stage No. Reactive No. Non-reactive Total
CDC II 1 17 18
(asymptomatic)
CDC III 
(PC3L)
CDC IV
(ARC an3 AIDS)
10 12
Total 17 20 37
P a t i e n t s  a t  s t a g e s  CDC I I I  a n d  CDC I V  w e r e  
a m a lg a m a t e d  a n d  t h e  c h i - s q u a r e d  t e s t  w a s  p e r f o r m e d  
t o  i n v e s t i g a t e  t h e  a s s o c i a t i o n  o f  r e a c t i v i t y  i n  t h e  
a n t i g e n  t e s t  w i t h  s t a g e  o f  d i s e a s e .  T h e  c h i - s q u a r e d  
t e s t  s h o w s  t h a t  t h e r e  i s  a  s i g n i f i c a n t  a s s o c i a t i o n ,  
( X 2, = 2 3  . 0 2  , p < 0 . 0 1 )  . T h e  a s y m p t o m a t i c  p a t i e n t s  a r e  
a s s o c i a t e d  w i t h  n o n - r e a c t i v i t y  a n d  t h e  s y m p t o m a t i c  
p a t i e n t s  a r e  a s s o c i a t e d  w i t h  r e a c t i v i t y  i n  t h e  
a n t i g e n  t e s t .
TABLE 4.2
L o s s  o f  p24 a n t ib o d y  i n  H IV -1  s e r o p o s i t i v e s
Patient Date p24 Ab p24 Aq
G5 12/86 +
12/87 - -
4/88 - Bd*
11/88 - +
4/89 - +
Mc20 7/86 _ _
3/87 + -
8/87 + Bd
9/88 + -
10/88 NT# +
12/88 + +
2/89 - +
M9 5/87 + —
10/88 + -
1/89 - -
12/89 NT -
3/90 - +
P7 3/88 +
8/88 + +
3/89 + +
4/89 - +
S6 3/86 + NT
10/86 - -
1/87 - +
11/87 - NT
7/88 - +
4/89 - +
T1 12/86 _ _
5/88 - -
10/88 ( + ) -
3/89 + -
8/89 - -
2/90 ( + ) +
CDC S ta g e
II
II
II
III
III
II
II
II
III
III
III
III
II
II
III
III
III
II
IV A
IVA
IVA
II
II
III
IVCp
IVCo
IVC2
II
II
II
II
II
*B d  = B o r d e r l i n e  
#NT = N o t  t e s t e d
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4.3. A difference was noted in both the mean value and the
range. The mean (plus 2 standard deviations) level, determined
on specimens from normal individuals is 2.0mg/l for serum (Instruction 
Manual, j^-Microglobulin RIA, Abbott Diagnostics). It can be seen 
that the mean level is higher for each group of seropositives and was 
greater than the value determined for the normal population. Table 
4.4 shows the mean levels 011 a number of HIV seropositive
patients whose OX! stage was known. A higher mean level is observed 
in those whose HIV-1 infection has progressed and is highest in those 
with AIDS. A wide range of values is obtained in 3 out of the four 
categories, even in those seropositives who were asymptomatic when 
tested. The numbers tested does reflect more than one sample from 
some patients.
Thus serial f>2"Wf3 values from HIV-1 seropositives attending the 
ID clinics at Ruchill Hospital were measured to determine the role of 
^-mg as an indicator of disease progression.
B. ASSESSMENT OP MARKERS IN THE RUCHILL COHORT
The markers described in the earlier part of this Chapter 
(section A), i.e. p24 antigen (Ag), anti-p24 (Ab) and jB2-microglobulin 
(fe-rog), were examined along with clinical information in a core group 
of patients who regularly attended the ID clinics at Ruchill Hospital 
and were defined as the Ruchill cohort.
The Ruchill Cohort
Up to the end of June 1989 a total of 133 patients were 
initially described in the cohort, 14 have been lost to follow-up. Of 
the remaining 119, 19 have died during the period of the study: 16
with AIDS or HIV related conditions and 3 others, all from drug 
overdoses. Table 4.5 shows the breakdown of the risk groups and CDC 
staging at initial presentation of the members in the cohort. The 
homosexuals (and bisexuals) are the largest contributing risk group 
and presented at different stages of disease. Seventeen of the 19 
patients presenting with advanced HIV disease (ARC or AIDS) were
TABLE 4.3
Mean f ^ - m i c r o g lo b u l i n  l e v e l s  (m g /1 )  i n  
s e r o n e g a t iv e  a n d  s e r o p o s i t i v e  r i s k  g ro u p s  f a r  H IV
H IV -1  A b  N e g a t iv e  H IV -1  A b  P o s i t i v e
No r i s k 1 .5 7
H o m o se xu a l 1 .6 3  (0 .0 8 5 )* 3 .2 8  (0 .185)
D ru g  a d d ic t 1 .8 2  (0 .0 8 5 ) 3 .4 8  (0 .445 )
H a e m o p h il ia c 2 .1 2 (0 ,0 9 4 ) 3 .1 1  (0.151)
N o. t e s t e d 128 63
R ange  0 .7 2  -  3 .8  m g /1  1 .5 5  -  6 . 5  m g /1
*  S t a n d a r d  e r r o r  o f  t h e  m e a n
j u s i n g  a  t w o  s a m p le  t  t e s t  w i t h  a  95%  c o n f i d e n c e  l e v e l  
j t h e  m e a n  / 2 - m i c r o g l o b u l i n  l e v e l s  f o r  e a c h  r i s k  g r o u p  
i a r e  s i g n i f i c a n t l y  d i f f e r e n t > ( p < 0 .0 5 ) .
TABLE 4.4
Mean levels of l^-n^Groglobulin (mg/1) and 
relationship with HIV-1 disease
Clinical Status No. Tested* Mean (mg/1) Range
(XC II 77 2.9 1.3 -> 4.7
(Asymptomatic)
CDC III 
(PGL)
25 3.0 1.0 -> 6.5
CDC IV A/C2 
(ARC)
33 3.2 2.4 -> 4.3
CDC IV B/G|/D/E 33 4.6 2.6 -> 8.4
(AIDS)
♦Nos. tested in each category (II -> IV) are samples taken from 
26, 9, 8 and 13 patients respectively.
No statistical evaluation was performed on these 
results due to the small number of patients in each 
disease category.
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homosexuals (and bisexuals). The earliest recruits in the cohort had 
a diagnosis of AIDS in 1985 and in one case this was backdated to 
1984. The most recent member was recruited in February 1989, a 
homosexual man with ARC.
Table 4.6 shows the number of patients who have clinically 
progressed during the period of follow-up. The majority, 93 out of 
119 i.e. 78.2%, of the patients were asynptoraatic at presentation, 
one-third of these progressed, two-thirds of these were homosexuals. 
Sixity-one remained asymptomatic over the period of time studied (this 
figure includes two patients who died from drug overdoses). The most 
interesting patients to examine are those that progressed.
Clinical progression, CP, was noted in a total of 40 patients 
(Table 4.6):
- 32 progressed from being asymptomatic to PGL (n=15), to ARC 
(n=13) or to AIDS (n=4)
- 4 progressed from PGL to ARC (n=1) or AIDS (n=3), and
- 4 progressed from ARC to AIDS.
A breakdown of the risk groups reveals that 29 of the 40
patients are homosexuals or bisexuals (including 1 homosexual
drug-abuser), 10 are drug abusers and the remaining patient, a
recipient of an infected platelet transfusion.
Nine of the 13 patients presenting with AIDS were deceased by
the end of June 1989, one person died within a month of presentation;
the longest survived 27 months with a diagnosis of AIDS. The mean 
survival time was 13.3 months. The remaining 4 have survived 9 to 19 
months to the end of June 1989. It is interesting to note that the 
longest surviving patients with AIDS at Ruchill Hospital (not included 
in the cohort) has been ill since 1986 and is still alive with AIDS up 
to the time of writing (June 1991).
Serological Markers and Their Link with Disease Stage
Two parameters, anti-p24 and p24 antigen, were examined in
patients in the cohort from each disease category, at the end of June 
1989, or at the time of death where appropriate (Fig.4.1). Loss of 
anti-p24, in this section, refers to a negative result in the Abbott
TABLE 4.5
Risk groups and O X  staging at presentation of the 
cohort members attending Ruchill Hospital.
Risk Group
Nos. Presenting
at CDC Stage: Ho/Bi DA Ho/DA T* Het/Oth Unk Total
CDC I I 40 47 93
CDC I I I
CDC A /C 2 
(ARC)
CDC IV  B /G | /D  
(A ID S )
11 13
63* 47* 1 6* 119
* deceased patients : 14 Ho/Bi
4 DA
1 Het/Oth
TABLE 4.6
Numbers of patients who progressed clinically during 
the period of follow-up to the aid of June 1989
Nos. Progressing to CDC Stage:
Nos. Presenting
at CDC Stage: III IV A/C?(ARC) IV B/Ci/D(AIDS) Total
II 93 15 13 4 32
III 7 - 1 3 4
IV A/C2 6 - - 4 4
15 14 11 40
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HIV-1 Anti-Core EIA, Hie association between loss of p24 antibodies 
(Ab) and appearance of p24 antigen (Ag) in serun, with advancing 
disease can be seen: 83.9% of asynptoraatic patients were p24 Ab
positive compared to 14.3% in those with AIDS. In contrast 81% of 
those with AIDS were antigenaemic compared to 5.4% in the asymptomatic 
group. Thus the majority (82%) of asymptomatic patients were p24 Ab 
positive and Ag negative but the reverse was true in ARC and AIDS 
patients where it was more usual (76%) to be p24 Ab negative/Ag 
positive. A dramatic change in Ab/Ag status occurs in progression 
from PGL to ARC or AIDS.
Those patients who progressed during the period of follow-up 
were examined more closely to establish which, if any, of the above 
markers changed first, which preceded a clinical change and what 
predictive role the measurement of ft 2~m9 played in disease 
progression.
Virological Progression
Virological progression, VP, defined by a loss of p24 Ab and/or 
production of Ag, was observed in a total of 23 patients up to the end 
of June 1989 in the cohort. A change in a further three patients was 
noted after this time, to the time of writing (two in July/August 1989 
and one in February 1990) and these are included in the results giving 
a total of 26 patients from the cohort of 119 patients.
Five patterns related to changes in markers have been observed:
( i) Loss of Ab pre-appearance of Ag (13 patients)
( ii) Loss of Ab post-appearance of Ag (4 patients)
(iii) Loss of Ab and appearance of Ag together (2 patients)
( iv) Loss of Ab alone (3 patients)
( v) Appearance of Ag alone (4 patients)
Thirteen of the 19 patients (68.4%) with changes in both markers, i.e. 
those who became Ab-/Ag+ showed a decline in Ab prior to detection of 
Ag. HIV-1 antigen was detected on average 14.1 months (range 3-28 
months) after the first anti-care EIA negative result.
A small percentage of these patients (4 out of 19 i.e. 21%) had 
detectable Ab a number of months after antigenaemia (pattern (ii)) and
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in two patients the first changes were recorded in the same sample 
(pattern (iii)). Patients shewing patterns (iv) and (v) may not have 
been followed up for a sufficient length of time since they could be 
potential members of patterns (i) and (ii) respectively. Hie above 
markers are associated with a bad prognosis, 15 of these patients 
progressed clinically and will be described below.
Clinical Progressors
Those patients identified in Table 4.5 as showing clinical 
progression (CP) were examined more closely to determine which markers 
if any changed pre- or post-observation of progressive disease. Hie 
patients have been grouped according to their clinical status to 
facilitate analysis of the relationship between VP and CP.
A total of 15 of the 40 patients with CP were noted to have a 
change in one or more of the markers discussed above (Table 4.7) over 
the period of follcw-up, to the end of June 1989.
Group PI Asymptomatic -> PGL (n=15)
Five of the 15 who progressed from asymptomatic to PGL became 
Ab negative (by ELISA) and four of these patients also developed 
antigen. Of the nine marker changes, five occurred after clinical 
diagnosis, 2 changed at the same time and 2 changed prior to 
diagnosis. In none of the patients did both markers change prior to 
the clinical change. The remaining 10 patients in this group are 
still Ab+/Ag-. Progression to PGL may represent a minimal clinical 
change in these patients.
Group P2 Asymptomatic -> ARC (n=13)
Seven of the 13 patients progressing to ARC showed virological 
progression (VP). Two of these patients had a documented episode of 
time with PGL. All 7 patients became antigenaeraic, however only 5 
became anti-core negative. Both markers changed prior to the 
clinical diagnosis of ARC in 4 patients; in the two patients 
retaining Ab, both were Ag positive prior to clinical change, in Mc13 
this was post CP to PGL (Table 4.7). The remaining patient, P7,
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developed Ag as the clinical change was noted and subsequently (8 
months later) lost anti-p24. Four of the remaining 6 were Ab+/Ag- 
and 2 were Ab-/Ag+ at presentation.
Group P3 Asymptomatic -> AIDS (n=4)
Only one of the four patients who developed AIDS from being 
initially asymptomatic during follow-up was noted to have VP. A 
negative anti-p24 EIA result and a positive p24 Ag result was 
recorded, 25 and 5 months respectively, prior to diagnosis of AIDS. 
In the other three CPs one was Abf/Ag-, one was Ab-/Ag? (where sample 
size was insufficient to determine Ag status) and the remaining 
patient was Ab+/Ag+ at presentation.
Group P4 PGL -> ARC (n=1)
There was no recorded VP in the one patient member of this 
group. He was Ab-/Ag+ throughout the period of study.
Group P5 PGL -> AIDS (n=3)
Two of the three patients with CP to AIDS from PGL also had 
changes in both Ab and Ag status. The remaining patient was Ab-/Ag+ 
at presentation. In one patient, L2 (Table 4.7) a loss of anti-p24 
was recorded 22 months prior to the diagnosis of AIDS and antigenaemia 
occurred 11 months after loss of Ab, i.e. 11 months pre-diagnosis. 
Production of Ag was the first recorded change in patient SI 3, 23 
months prior to diagnosis of AIDS, anti-p24 was subsequently negative 
by EIA, 13 months later.
Group P6 ARC -> AIDS (n=4)
No VP was noted in the 4 patients in this group. All were 
Ab-/Ag+ at presentation.
Clinical Non-Progressors
Virological changes were noted in 11 of the clinical 
non-progressors, i.e. those patients who presented and remained in the 
same CDC category; eight from Group NP1, two from Group NP2, nil from
140
Group NP3 and one from Group NP4 (Table 4.8).
Group NP1 Asymptomatic (n=61)
A total of eight patients showed VP; in 5 patients both Ab 
and Ag changed and all demonstrated a pattern (i) VP, two patients 
lost Ab alone, i.e. pattern (iv) and one patient became Ag positive 
(pattern (v)). The majority of patients (48 out of 61) were Ab+/Ag- 
as would be expected in asymptomatic patients. Three presented 
Ab-/Ag- and in the remaining two patients there was insufficient sera 
to complete the tests.
Group NP2 PGL (n=3)
In Group NP2 patients; one patient became Ab-/Ag+, 12 months 
after first presentation (pattern (iii)) and the only change in the 
other patient was the appearance of Ag, 28 months after presentation 
(pattern (v)). The only other member of this group is Ab+/Ag-.
Group NP3 ARC (n=2)
No VP was observed in this group. One patient was already 
Ab-/Ag+ at presentation and the other remains Ab+/Ag-.
Group NP4 AIDS (n=13)
Five months after presenting with AIDS, one patient became 
Ab-/Ag+ (pattern (iii)). He died 8 months later. Six patients 
presented with Ab-/Ag+ status, the pattern most commonly associated 
with advanced disease and two patients showed the reverse, i.e. 
Ab+/Ag-. Four other patients were Ab-/Ag-.
In summary, in the groups of patients with a noted clinical 
change, i.e. groups P1-P6, a total of 15 patients were observed to 
have a change in one or more of the viral markers, anti-p24 or p24 Ag, 
over the period of follow-up testing at the HRL. Twelve patients 
changed with respect to both markers, i.e. loss of anti-p24 by EIA and 
production of Ag, 2 patients developed antigen only and one patient 
became anti-p24 negative only (Table 4.9). In only 5 of the above 
noted 15 patients did both markers change prior to the observation of 
CP. It is interesting to note that the time span of events was
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similar. Anti-core declined on average 18.6 months (range 10-25 
months) prior to diagnosis of clinical change and Ag appeared on 
average of 6 months (range 5-10 months) prior to the clinical 
progression. Loss of p24 Ab preceded Ag by a mean of 12.6 months 
(range 3-20 months). Pour of these patients are in Group P2 and have 
developed ARC and one patient developed AIDS (Group P3). In addition 
3 patients in Group PI showed virological change after the clinical 
diagnosis of PGL. Thesedata fits with that in Fig 4.1 where the most 
dramatic change in marker status was observed in those patients with 
ARC compared to these with PGL.
In addition a further 10 patients presented with one or both 
markers already changed and subsequently progressed (up to 26 months 
later). The most rapid progression was seen in GroupP6 patients who 
were diagnosed AIDS within 6 months of presentation.
To complement this the remaining 15 patients with observed 
disease progression showed no alteration in Ab or Ag status and 
remained Ab+/Ag-. Ten belonged to Group PI, four to Group P2 and one 
to Group P3. It can be seen that the initial stages of progression, 
i.e. asymptomatic to PGL appear to be less associated with any viral 
changes and represent a minimal clinical change with respect to the 
ongoing pathogenic effects of the virus.
Only limited conclusions can be made regarding time(s) to 
progression and the significance of changes in markers. Progression 
of HIV-1 disease is indeed associated with changes in p24 Ab and Ag; a 
total of 25 out of the 40 patients (62.5%) in this cohort who 
developed symptoms had a change in one or both indicators. The most 
common pattern of VP observed was pattern (i) i.e. loss of Ab before 
the production of Ag. However the observation that 15 patients 
progressed with no viral changes and 10 (excluding Mc8 (Table 4.8)) 
showed viral changes and no clinical advancement means that these 
markers are not the absolute or only important factors involved in the 
disease process and are not prognostic in all patients.
No consensus of timing of the clinical and virological changes 
could be established to allow a putative time-course of events and 
therefore an indication of when disease might occur and at what stage 
intervention with drug therapies may be used to best effect in
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delaying onset of symptoms and prolonging life.
Screening for such markers gives the clinicians more information 
regarding the status of the patient at any one point, particularly the 
measurement of Ag levels which is especially useful in patients on AZT 
treatment.
Serial j^-Microglobulin Measurements
The serun concentration of ^ -nig was measured routinely in the 
cohort of seropositives. The results presented in Table 4.10 show 
some examples of patients where an apparent rise preceded or was noted 
at the time of onset or progression of symptoms. In some patients 
this increase was sustained but in others a decrease was noted. 
Using the same groups described in the previous section on virological 
markers, the reslJlts were as follows:
jS 2~Microglobulin in Clinical Progressors
Group PI Asymptomatic -> PGL (n=15)
Over the period of follow-up, only 3 patients showed a rise in 
concentration, in 2 patients this preceded clinical change (P5, 
M9) (Table 4.10) and in one patient this was after CP. Ten patients 
consistently had levels <3mg/l and two patients had levels >3mg/l. 
There was no correlation with CP.
Group P2 Asymptomatic -> ARC (n=13)
The majority of patients had average j^ -nig levels >3mg/l. 
TWo patients had a raised level pre-CP, 3 at the time of CP and 2 
patients post-CP. In 3 patients with consistently high levels this 
was unrelated to any clinical changes.
Group P3 Asymptomatic -> AIDS (n=4)
Two patients in this group had high levels throughout and 
therefore there was no correlation with disease progression. One 
patient showed a rise after the diagnosis of AIDS. An increase 
through the course of disease was noted in the remaining patient (B2,
TABLE 4.10
Patient
M9
P5
Mc5 
Mc13
B2
* A rise
Serial f 2“rn9 concentrations in patients with a change in
clinical status*
CDC
Date mg/i p24 Ab p24 Ag Stage
3/86 2.5 + II
5/87 2.2 + -
6/88 3.1 <+) -
10/88 3.0 (+) -
1/89 NT - Ill
5/89 3.1 - -
12/89 2.9 - -
3/90 2.4 - +
6/87 2.95 NT II
12/87 4.7 NT -
2/88 NT NT Ill
3/88 4.5 NT -
7/88 6.5 + -
11/88 4.2 NT -
3/89 2.95 +(6/89) -
8/88 4.1 - + II
12/88 4.0 - + III
3/89 2.7 -(5/89) IVC2(2/89)
10/89 1.8 NT
3/87 3.5 NT NT II
11/87 5.4 +
1/88 4.7 + - III
9/88 NT + +
12/88 NT NT NT III+IVC2
1/89 3.9 + +
12/85 2.2 NT NT II
1/86 NS NS NS III
8/86 2.2 NT
6/87 6.5 NT - ?IVA
12/87 NT NT IVB
2/88 3.4 NT
4/88 5.0 NT
8/88 4.1 +
2/89 3.0 + - IVC^ d
in concentration is observed prior to or at clinical progression
§ On AZT treatment; NT - not tested? NS - no sample; d - deceased
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Table 4.10). The largest spike in concentration occurred prior to 
the diagnosis of AIDS. No VP was noted in this patient. This was 
the first drug abuser in the cohort to develop AIDS and she died three 
months later.
Group P4 FGL -> ARC (n=1)
Hie one member of this group had a ^ -mg concentration ranging 
from 1.6-3.9rag/l over the period of follcw-up, there was no 
correlation with progressing disease.
Group P5 PGL -> AIDS (n=3)
There was no association of levels with clinical changes
in the three patients in this group. One patient had particularly 
high levels (between 5-8.5mg/l). He was diagnosed with AIDS within 
two months of presenting at the ID clinic, and his /^ -rog levels were 
measured after this time.
Group P6 ARC -> AIDS (n=4)
Hie highest levels were noted in this group; where the mean 
value was >6mg/l in three patients. Hie remaining patient had an 
average value of 2.9mg/l. A concentration of 3.4mg/l was noted prior 
to clinical change but this decreased below 3mg/l after the diagnosis 
of AIDS.
jS 2”Microglobulin in Clinical Non-Progressors
Group NP1 Asymptomatic (n=61)
Four out of the 8 patients who had changes in virological 
markers (Table 4.8) had concentrations around 3mg/l, two of whom
had levels persistently >3rag/l. Hie remaining four had normal 
levels. There was no association with VP, nor was an increase 
observed over the follcw-up period. Hie majority (32) of the 
remaining patients all had levels consistently <2.5mg/l. Fluctuating 
values were noted in nine patients, where at least one value was 
higher than 3mg/l, in some cases this corresponded with an infection, 
e.g. herpes. A concentration of 3mg/l or greater was observed in 8
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patients. (Four patients have not been tested).
Group NP2 PGL (n=3)
All three patients had /^-mg ooncentrations within the normal 
range (2mg/l or less) and there was no evidence of a rise in 
concentration.
Group NP3 ARC (n=2)
An apparent decrease in concentration of was observed in
one patient who became Ag negative after beginning AZT treatment.
Group NP4 AIDS (n=13)
Only 4 out of the 11 patients tested had mean values >4rag/l. 
Hie remaining seven had mean values around 3rag/l.
Hie main observation from the results as noted in Section A is 
that j?>2 “rn5 concentration is increased in those with more advanced 
disease. It can be seen that a value of 3rag/l is a better lower 
limit than 2mg/l for indication of disease since at least 56% of the 
asymptomatic patients (Group NP1) had values around the 2mg/l level 
and in all other groups the levels were higher. In most cases once
the level rose above 3mg/l it remained high, independent of
clinical status. In those groups where a clinical change was 
diagnosed (Groups P1-P6), no obvious changes in levels were
observed.
A decrease in was noted in 3 patients in particular; one
patient with ARC who had levels >3mg/l before developing AIDS showed 
an apparent decrease in after diagnosis of AIDS. Two patients,
one from Group P2 and one from Group NP3 had high levels initially 
when they were also Ag positive. Serun antigen became undetectable 
in these patients once treatment with AZT was commenced and an 
apparent decrease in (2> 2_m9 was observed. A contrast was also 
observed in the levels of ^ 2~ra^  ^  GrouP ^ 4  patients (those appearing 
with AIDS) and Group P6 patients (those developing AIDS). In the 
latter patients, the highest concentrations of were observed
(>6mg/l). Hcwever in the AIDS patients, average values between
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3-5mg/l were obtained.
Only 11 of the 40 patients with CP showed a rise in an^ in
only 5 such patients did this precede CP therefore no correlation of 
CP and >^2~nx^  was found in the Ruchill cohort, hcwever it should be 
noted that rapid progression with respect to CDC staging occurred in 
some patients because they had only attended the clinics once they 
were ill and baseline values were more difficult to ascertain. 
Further follow-up of those patients currently asymptomatic may yield 
better results regarding /^-mg as a prognostic indicator of disease 
progression.
Time to Progression
Seroconversion was documented in 17 members of the cohort; 13 
DAs, 3 Hos and a transfusion recipient (Table 4.11). Two of the DAs 
died from overdoses and have not been included. Five of the seven 
seropositive for 3 years (1986-1989) showed either CP (n=2), VP (n=1) 
or both (n=2). In contrast there was only one clinical progressor 
and one patient with VP in the eight patients seropositive for 2 years 
or less. Hie ages of the patients at seroconversion were similar and 
no correlation with progression can be made.
Summary
Six out of the 11 clinical progressors with a rise in ^ >2~w^ 
concentration also had virological progression, five of whom also had 
changes in both viral markers. Therefore a total of only five out of 
the 40 patients with clinical progression demonstrated all the 
predicted changes in markers. However closer examination reveals 
that no patients in this cohort showed a change in all 3 markers prior 
to clinical progression, four had a change in 2 markers prior to CP 
and these were most commonly the virological markers.
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DISCUSSION
Hie antibody ELISA screening and confirmatory tests to detect 
HIV infection, described in Chapter 2, are not a test for AIDS. AIDS 
is the end-stage disease resulting from infection with HIV-1 (and 
HIV-2) and the classification of a patient as such has to fulfil a 
number of criteria as described by the Centre for Disease Control 
(GDC), Atlanta, USA. These criteria do include a positive HIV 
antibody test result, along with other clinical and laboratory 
information. In this Chapter, three tests have been examined to 
establish their use as indicators of advancing disease.
VIROLOGICAL CHANGES
Two inportant changes in serum chemistry of viral markers have 
been established from studies of patients at various stages of HIV-1 
disease; a temporal decline or loss of core Ab and appearance of 
serum Ag. However, the causal relationship between the two and with 
the progression of disease has not been fully elucidated.
HIV- 1  Antigen
HIV-1 Ag is detected in patients with advancing disease (85) and 
most probably represents a switch from latent or low level replication 
to active or high level replication of virus. Plasma viraemia has 
been detected throughout all stages of infection in most, if not all, 
patients (33,100). Higher titres of virus are present in those with 
more advanced disease. Hcwever the presence of Ag in serum is 
generally associated with the onset of the clinical symptoms of AIDS 
(104,105,107) and this was found in the group of patients tested in 
the HRL. Only free serum Ag, i.e. the quantity of Ag in excess of 
that bound in immune complexes, was measured in these patients. The 
predominant viral antigens detected in serum are viral core proteins.
The result of productive viral infection where high levels of 
viral protein synthesis are occurring may be sufficient on its own to 
induce the cytopathic effect of HIV-1 infection, thus leading to a
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drop in T4 helper cells which in turn allows opportunistic infections 
to flourish unhindered. The appearance of detectable levels of Ag in 
serum may signal this switch to lytic infection and thus it is not 
surprising to detect Ag in the ARC and AIDS patients more often than 
in those with PGL or the a symptoraa tics.
The switch or combination of events that triggers high levels of 
viral protein synthesis remains to be fully elucidated. Most 
mechanisms involve stimulation of T cells since HIV-1 is not produced 
by quiescent T cells (226). This may occur in a variety of ways. 
Various factors in the host, e.g. certain HLA haptotypes have been 
associated not only with seroconversion but also with disease 
progression through inniune activation (162). Cellular, host
regulatory proteins such as nuclear factor kappa B (NF-KB) have been 
shown to bind to enhancer sequences in the proviral DNA and to 
activate transcription from the HIV-1 long terminal repeat (LTR) 
resulting in low level proviral transcription leading to the 
expression of the viral regulatory proteins tat, rev and nef (43). 
Induction of NF-KB is a result of inmune stimulation by the gene 
products of other viruses, e.g. HELV-I, herpes viruses (161), or by 
certain cytokines e.g. tumour necrosis factor (162) and T cell 
mitogens. Other DNA-binding proteins constitutively expressed in the 
host may also play a similar role e.g. Sp1 (227). In addition, it 
has been shown in vitro that different isolates of HIV-1 can vary in 
their replicative capacity, cytopathic effect (syncytium-inducing 
capacity) and host range and that these differences may affect 
clinical progression (163,228). Therefore a particular variant may 
be selected for, in vivo, which confers certain properties and affects 
disease outcome. As jo et al. (228) isolated virus strains with a 
higher replicative capacity in patients with HIV-related disease than 
those from asymptoraatics. Tersraette et al. (163) showed that a more 
rapid progression and shorter survival time occurred in those patients 
with high-replicating, highly cytopathic isolates compared to either 
high-replicating, non-cytopathic strains or low-replicating, 
non-cytopathic strains. This may help to explain why same persons 
with AIDS in the Ruchill cohort remain antigen negative if a 
low-replicating, cytopathic strain is the dominant circulating strain
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in vivo and why some a symptcraa tics develop antigen if a
high-replicating, non-cytopathic strain is selected in vivo. The 
combination of a competent immune system able to cope with high levels 
of virus and the in vivo selection of non-cytopathic viral strains may 
retard disease progression even when serum Ag is detected.
HIV-1 Anti-p24
The other most notable serological features was that of a
decline in core antibodies in symptomatic patients both by specific 
anti-core ELISA (Abbott) and by western blotting (92,101-103). This 
was observed in the patients presenting at various disease stages at 
Ruchill Hospital. The anti-core EIA (Abbott) is less sensitive than 
the western blot assay and in most cases although the EIA result was 
negative, core antibodies were still visible on a western blot. 
Western blotting is an expensive and time-consuming test to perform 
and it is primarily used in the initial confirmation of a positive 
antibody test and not in follow-up screening. Hcwever, on the 
occasions when a series of samples from patients showing symptoms of 
disease progression were blotted together, a decline in any one or 
more of the core antibodies, p55, p24, p17, has been observed. This 
lack of sensitivity of the ELISA was not considered a hinderanoe as it 
was a measurement of Ab change that was being sought, not an absolute 
value.
A decrease in, and loss of, anti-p24 occurs with a rise in
levels of serum p24 Ag after the change from latency to productive 
HIV-1 infection and has been shewn to precede the onset of AIDS by up 
to 27 months (103) and precede antigenaemia by 12-18 months (106). 
This may be a result of coraplexing the rising concentration of viral 
antigens released in quantity from infected cells destroyed by the 
virus as Ab-Ag complexes are found in AIDS patients (229). Other 
mechanisms must be involved; 7.9% of the ARC and AIDS patients in the 
Ruchill cohort were anti-p24 positive in the presence of serun antigen 
(Fig.4.1). It is interesting to note that decline in anti-p24 occurs 
in a much smaller percentage of persons with disease progression in 
Central Africa (230). A good iranune response to p24 may be
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protective against the development of AIDS car may indicate a better 
prognosis in infected patients. Recently Cheingsong-Popov et al. 
(231) found an association between antibody response at seroconversion 
and clinical outcome; specifically those patients with an initial low 
titre of anti-p24 progress more rapidly to ARC or AIDS and are more 
likely to develop serum antigenaeraia than those with an initial high 
titre anti-p24 response. (Higher titres of gp120 antibody at 
seroconversion were also associated with clinical progression). They 
postulated that a high dose of infecting virus may lead to more rapid 
progression by binding to T cell receptors. In this way the T cell- 
dependent B cell response is depressed resulting in low levels of 
antibody production. Hcwever this would be expected to affect the 
antibody levels to other antigens. It is more probable that 
progressive defects in the immune system as a consequence of viral 
persistence may result in a decreased synthesis of specific anti-p24 
by B lymphocytes. In those individuals retaining anti-p24 throughout 
disease there may be specific host factors, e.g. human leukocyte 
antigens which maintain immune competence in spite of high titres of 
viral antigen. Much remains to be understood about the inmune 
complexities of infection with HIV-1. A discussion of the complex 
interactions between cells of the inmune system and their role in HIV 
infection is beyond the scope of this thesis.
One patient in the Ruchill cohort is particularly interesting; 
throughout follow-up testing he had one of the highest levels of serum 
antigen recorded when he developed AIDS. He maintained this despite 
treatment with AZT. In addition he remained care antibody positive 
by EIA and western blot.
In a small number of patients the reappearance of anti-p24 in 
patients assumed to have become negative has been observed. This has 
been noted in some patients on anti-viral therapy and may reflect a 
decrease in antigen production associated with AZT treatment. In 
others the test CD fluctuates above and below the ELISA cut-off, 
making the assessment of the first anti-p24 negative result difficult. 
In such patients this probably illustrates a declining anti-p24 titre 
but it may also reflect differences in intra-assay test performance.
Decline in anti-p17 has been suggested to be an even earlier
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narker of disease progression (232). This has not been measured 
specifically in this study, but the Abbott anti-core ELISA does detect 
epitopes at the carboxy terminus of the p17 protein. The loss or 
decline in anti-p24 was the more prominent observation on western 
blots.
HIV-1 Ag, Anti-p24 and the Time Course of Infection
Thus the majority of patients fit the putative time course of 
events in HIV-1 disease described in Chapter 1 (Fig. 1.2) and discussed 
above, i.e. loss of Ab as Ag appears. The Ag measured in this study 
is free serum Ag and does not include Ag bound in complexes. The 
reduced sensitivity of the anti-core ELISA means a negative result nay 
be obtained when care Ab is still present. Thus a comparable graph 
for the Ruchill cohort using these test results would show actual loss 
of Ab before Ag appears, described in the results as pattern (i).
Results of anti-p24 and p24 antigen measurements from patients 
in the Ruchill cohort at different stages of disease do show a strong 
association of antibody negative/antigen positive (Ab-/Ag+) status and 
AIDS and the reverse, i.e. antibody positive/antigen negative 
(Ab+/Ag-) status in asymptomatic patients (Fig.4.1). However this is 
not absolute; Ag is not detectable in 100% of AIDS patients, only 81% 
in the Ruchill cohort had detectable Ag at some point during follow-up 
and a snail percentage (14.3%) retained core Ab. In this cohort all 
combinations of Ab and Ag have been noted in those with AIDS or 
developing AIDS during follcw-up, i.e. Ab-/Ag+, Ab-/Ag-, Ab+/Ag+ and 
Ab+/Ag-. Similarly a number of asymptomatic patients (5.4%) were
antigenaemic and 16% were anti-core negative when tested. Therefore 
these markers could never form part of the criteria for diagnosis of 
AIDS, but they could be prognosticslly useful where a change, referred 
to here as virological progression, might implicate onset of disease.
^2-MICROGLOBOLIN
The remaining serum marker measured in this study was the j^-mg 
concentration. ^2~ia^  is an 11.8 Kd protein present on the surface of
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all nucleated cells (233). It constitutes an invariant light chain 
of an Imnunoglobulin-type molecule and is associated with an HLA heavy 
chain at the cell membrane. In healthy subjects, f$2~wQ turnover is 
constant with circulating serun levels of 2mg/l in adults, although 
the level does increase with age. It is eliminated via the kidneys 
and in the absence of any impairment of renal tubular function, which 
is associated with elevated levels, an increased level indicates
an activated immune process, e.g. in various autoimmune disorders or 
neoplastic disease. Thus an increased serum concentration
reflecting increased lymphocyte turnover may be a marker of immune 
activation in HIV-1 infection, this would lead in turn to increased 
viral replication. This is true of other acute viral infections 
especially cytomegalovirus (CMV). Higher than normal levels were 
observed in patients with AIDS or suspected AIDS (234) and has been 
shewn to rise during HIV-1 infection (235). This was also found in 
patients at various stages of disease and from various risk groups 
tested at the HRL. When members of HIV-1 risk groups were tested, a 
higher mean f$2~m3 value was noted in those who were HIV-1 
seropositive. The mean levels in the seronegatives compares with 
that established in studies of healthy adults and thus a modified 
cut-off level of 3mg/l may be a better indicator in the HIV-1 
seropositive patients.
In agreement with other reports (234,235) higher mean values 
were observed in patients with mare advanced disease. It is 
interesting to note the broad range of values obtained in at least 3 
out of the 4 disease categories. Could this be suggestive of an 
intercurrent acute infection or perhaps indicative of disease 
progression?
SEROLOGICAL CHANGES LINKED TO CLINICAL PROGRESSION
As the understanding of the disease and the pathogenic effects 
of the virus has increased a link between the risk of developing 
disease and changes in a number of measurable laboratory parameters 
was observed. A wide range of viral, immunological and other related 
markers have been measured in cohort studies to establish their
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usefulness in a predictive role, either individually or as a 
combination of criteria. Such studies were performed to establish a 
model for progression to determine those HIV-1 infected persons most 
likely to benefit from early intervention of drug treatment. At 
least four laboratory markers have been shown to predict AIDS in 
asymptomatic, seropositive homosexual men (236). These were; T4 
count, p24 Ag, serum 3rd serum neopterin. Moss et al. (235)
shewed that the chances of developing AIDS were increased when 
was raised and T4 counts had dropped belcw 400 x 10^ /1 (where a normal 
value is 800-900 x 10^ /1). An increased risk of developing AIDS is 
associated with the production and persistence of serum Ag 
(99,235,237). Alla in et al. (237) found it to be a better marker 
than the absolute T4 count in predicting disease onset. Loss of core 
antibody was also noted and was linked more to the production of 
antigen than as a marker on its cwn, such that a care Ab negative, 
antigen positive status developing in a patient implied that they were 
mare likely to progress to AIDS.
An attempt was made to link changes in the 3 markers described 
in this Chapter with the clinical progression in the Ruchill cohort to 
assess the prognosis of HIV-1 infection. A number of patients in the 
Ruchill cohort (twenty-six in total) were observed to have virological 
progression. Clinical progression was recorded in fifteen of these 
twenty-six patients. The predictive value of the Ag and Ab tests in 
this situation was assessed carefully. In general virological 
progression could be associated with clinical progression. Hcwever 
there were too many exceptions to this rule, e.g. some patients whose 
HIV-1 disease state advanced, did so without ever having detectable Ag 
and/or losing Ab. It appears that p24 Ab and Ag are not sufficiently 
reliable markers to be of clinical predictive value. In a cohort of 
homosexual men, de Wolf et al. (107) showed that loss of core Ab, 
appearance of Ag and a drop in T4 counts preceded AIDS by a mean of 
21.3 (8.9), 17.7 (8.8) and 15.7 (8.9) months respectively. However 
the standard deviations, shewn in parentheses, allow for a wide range 
in time-span of events. A similar time-scale could be seen in five 
patients in the Ruchill cohort where loss of Ab preceded serum Ag by 
an average 12.6 months (range 3-20 months) and Ag preceded onset of
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symptoms by 5 months in 4 patients and 10 months in the remaining 
patient. Only one patient in the group had developed AIDS, the 
others had progressed to ARC. The main conclusion would be that such 
changes in markers would imply not only an increased likelihood of 
developing AIDS but also a more rapid progression. A fundamental 
flaw in the use of serum Ag as a marker is that it is not produced by 
or detectable in all patients who eventually progress.
It should be noted that more recently measurement of Ag has 
become less useful as a marker of progression as anti-viral therapy, 
e.g. AZT, can now be given to patients at earlier stages of 
progression rather than to AIDS patients alone. Thus a degree of 
clinical deterioration in association with a falling T4 count has 
prompted treatment in a number of patients before serum Ag has been 
detected. AZT inhibits the viral reverse transcriptase ard the level 
of serum Ag, in most patients on treatment, becomes undetectable. 
Those patients designated Ag positive in this study had at least one 
serum sample reactive and confirmed in the Ag test as many of the ARC 
and AIDS patients have been on various dose regimes of AZT therapy, at 
various intervals, throughout the follow-up period. Thus some 
patients subsequently retested as non-reactive, in others the antigen 
level appeared to fluctuate around the detection limits of the test 
and in others AZT apparently had no effect (data not shewn). Hcwever 
the appearance of antigen can still indicate a poor prognosis as there 
is evidence to indicate the emergence of AZT-resistant viral strains, 
so-called escape mutants, in some patients on prolonged therapy. The 
reduced sensitivity to AZT, in vitro, is associated with mutations in 
the reverse transcriptase gene (238). In addition a small number of 
patients, either asymptomatic or with PGL, have been enrolled in the 
MRC-INSERM Concorde trial since 1989. This is a randomised, 
double-blind, placebo-controlled trial to study the efficacy of AZT in 
reducing disease progression and prolonging life in asymptomatic or 
PGL patients. The identity of the patients involved is unknown to 
the laboratory and thus some patients will be receiving treatment 
which could prevent Ag production.
In the Ruchill cohort there was little evidence of an increase 
in f$2~wQ concentration as a predictor of CP. Although this is a
154
non-specific marker there is an association of higher levels with more 
advanced disease, but only a total of 11 out of the 40 CPs had a rise 
in ^ 2“®? at some time during the course of HIV-1 infection. However 
the increase was noted at earlier stages of progression, i.e. from 
asymptomatic to PGL or ARC. TMs may not be surprising as it has 
been noted that many patients showed a rapid clinical progression 
after their first attendance, i.e. they had attended the clinic as 
symptoms began to appear and were therefore on the brink of a 
progressive diagnosis, and so a baseline f^-mg concentration was 
obtained from one measurement only. Nevertheless there is an 
indication that earlier intervention with treatment may delay the 
onset of AIDS and prolong life. There was evidence that 
decreased during AZT treatment in these patients (239). If AZT is 
slowing the disease process by halting viral replication the 
subsequent reduction in inmune stimulation, i.e. decrease in T cell 
and macrophage turnover of mirrored by a return to normal
j^-mg concentration. Lower levels were noted in the patients
presenting with AIDS versus those developing AIDS. Perhaps long-term 
AZT treatment in the AIDS patients has stabilised the disease process 
and the pathogenicity of the virus resulting in less inmune activation 
and steadier >^2~10^  levels. Hcwever it is probable that the
destruction and resultant decrease in T4 cell numbers may play a role. 
It has been suggested that serum measurement would be a better
marker than serum antigen for estimating the antiretroviral activity 
of drugs as not all patients produce detectable antigen (240).
The most interesting group of patients to follow will be group 
NP1. Four of the eight patients in this group who had progressed 
virologically showed higher levels than most of the asyraptoraatics, an 
additional 8 patients without VP also had raised levels. jS 2-10?
has been found to be a useful predictor of impending disease in other 
cohort studies (235,241,242). In seropositive homosexual men, it was 
strongly correlated with the risk of progression to AIDS and was the 
best single predictor of progression in the parameters measured in the 
San Francisco General Hospital cohort study (235). Similarly Fahey 
et al. (241), in an extensive study of eight cellular and serological 
indexes, found that p2_n^  (arjd neopterin) reflected prognosis equally
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as well as T4 counts and could predict the future rate of decrease in 
T4 cells. A more recent study on a cohort of haemophiliacs (242)
infected from the same batch of FVIII in whom the times of
seroconversion were well-documented, shewed that ^2~ro^  leve^s >3mg/l 
had been attained at least one year before symptoms developed. They 
concluded that although most markers measured reflected the disease 
process, concentration appeared to predict the onset of
symptoms. The mechanisms responsible for the elevated levels of 
>^2~ia3 are n°t fully understood. Constant immune stimulation via 
lyraphokines etc., reflected in raised levels of fi 2~m^/ over t*rae 
increase the production of HTV frcm infected cells. The production 
of virus may reach a threshold level, above which syncytia or giant 
cells form killing off infected and uninfected T4 cells, thus
resulting in decreased T4 counts. At the start of the AIDS epidemic
the first marker measured was the T4 cell count; the observed inmune 
deficiency was a consequence of the reduction in this cell population. 
Although useful for plotting the course of disease, i.e. low counts 
before development of AIDS, the T4 count has never been established as 
a useful predictor of disease progression on its own. However, used 
in combination with concentrations a better estimate of the risk
of progression can be made (154).
A variety of other markers, e.g. IgA concentration, neopterin, 
levels of interferon and interleukin, T8 counts etc. which reflect 
immune disturbances and various aspects of viral pathogenic mechanisms 
have been measured in other studies (241,242). Neopterin has been 
found to be similar in usefulness to (241). Hcwever it appears
that no single marker can predict disease onset on its own. 
Predicting who will progress to AIDS, despite the numerous markers is 
clearly not simple and some attempt has been made in this Chapter to 
link the changes in laboratory parameters with clinical staging. In 
the Ruchill cohort no conserved or distinct pattern of change 
associated with clinical progression has been identified, except that 
loss of antibody was the first marker change in the majority of 
patients. There was no finite or definitive time between loss of 
core Ab and progression to disease, production of Ag and progression 
or level of serum during progression. In many circumstances
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close, careful, clinical observation is as useful a predictor of 
disease progression than the results of laboratory measurements. The 
underlying theme is the individuality of response in the different 
patients. Persons respond in different ways to this viral infection, 
and even in the small number of patients described here, there are 
many exceptions to confound any rules or associations that might be 
made. However, general trends have been shown, e.g. production of Ag 
in the later stages, rise in although these are not true
for every patient. Thus most markers reflect the disease process 
rather than predicting onset. Appearance of change in one or more 
markers in a person may only indicate an increased likelihood of 
developing disease quicker than in persons with less evidence of 
virological or imraunological change. Moss and Bacchetti (154) have 
defined an algorithm, based on five variables, for estimating the 3 
year probability of progression to AIDS from their studies on the San 
Francisco General Hospital (SFGH) cohort of homosexual men. In this 
way a combination of markers are used to predict progression; this is 
likely to be more reliable than observations based on single 
measurements.
The Ruchill cohort have been followed up for a relatively short 
period of time; many patients only presented at clinics as symptoms 
appeared and these patients, mainly homosexuals, had obviously been 
seropositive for a number of years. Sixty-seven percent of those who 
progressed were homosexuals which supports the suggestion in Chapter 3 
that members of this group have been infected with HIV-1 for longer 
than other risk groups tested in the West of Scotland except the 
haemophiliacs, who are discussed in Chapter 5. Hcwever, the late(r) 
arrival of the virus in the drug abusing members of the cohort (as 
discussed in Chapter 3) means that continued follow-up of these 
patients may yield further interesting results. As earlier
intervention with drug therapies, irrespective of disease stage, is 
now permitted it would be interesting to see if this prolongs the 
progression to AIDS and prolongs life in those with AIDS compared to 
current estimated incubation times.
No good data regarding time to progression is available from the 
Ruchill cohort. Longer follow-up is required in those who
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serooonverted during the period of the study. Hcwever a greater 
number (9 out of 16) had progressed to ARC or AIDS by the end of June 
1989 in those first recorded seropositive at the HRL in 1985-86 
compared to 2 out of 10 reported seropositive in 1987-88. This is 
not unexpected but is of limited predictive use since the dates of 
seroconversion are unknown. Ideally information about incubation 
times for progression require follcw-up of a cohort in whom the dates 
of infection are known; studies involving transfusion recipients and 
some haemophiliac cohorts can be successful in this respect.
CONCLUSION
Thus as time passes, the development of AIDS has increasingly 
become the inevitable outcome of HIV-1 infection. Disease
progression is determined by many factors and co-factors, properties 
of both the host and the virus, some of which have been discussed 
here. Viral and immunological markers indicative of viral
pathogenesis and disease progression have been identified, e.g. 
anti-p24, p24 Ag, ^-mg. No single marker has been found to be 
predictive but a combination of laboratory data and clinical 
observations can be used with caution and experience to assess the 
prognosis in an individual patient.
Studies on viral and imnunological markers, as described here, 
leads to a greater understanding of the mechanisms of viral latency 
and pathogenesis also the immune system and its response to HIV-1 • 
Such advances may help in the design of vaccines and in better 
targetting of anti-viral drugs. AIDS is a terminal disease and much 
hope for the sufferers lies in better treatment and possibly also the 
use of vaccine in the HIV-1 infected patients.
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CHAPTER 5
HIV-1 INFECTION IN HAEMOPHILIACS,
GLASGOW AND THE WEST OF SCOTLAND.
INTRODUCTION
Haemophilia, a disorder of blood clotting, is genetically 
inherited as a sex-linked recessive characteristic. It affects the 
male population predominantly and occurs only in females who are 
homozygous for this trait, i.e. possessing two copies of the defective 
gene. Heterozygous females act as carriers. One of the
blood-clotting proteins (factors), is either absent or has a markedly
reduced activity. This is most commonly Factor VIII (FVIII) or 
antihaeraophilia factor which causes haemophilia A (HmA) also called 
classical haemophilia with an incidence of 12 in 100,000 males. 
Factor IX (FIX) deficiency or haemophilia B (HraB) is rarer, affecting 
1 in 30,000 males. This is also known as Christmas Disease after 
Stephen Christmas, the first patient in whom it was described. Other 
blood clotting disorders exist, e.g. von Willebrand's disease, but
these are less common than the above mentioned disorders.
These patients periodically require transfusion with the
defective protein to complement the series of clotting factor proteins 
in their blood. This is in the form of a concentrate which is 
extracted from human plasma, pooled from 2,000 to 20,000 blood 
donations. Hie severity of the two major forms of haemophilia does 
vary and therefore requirement of factor concentrate is different. 
In severe haemophilia the in vivo activity of the FVIII protein is 
less than one per cent (moderate 1-5% and mild >5%). Thus severe 
haemophiliacs require greater quantities of the factor. In the 
United Kingdom, about 5,000 persons suffer from haemophilia, 2,000 of 
whom have severe haemophilia. Haemophilia can be crippling both in 
terms of orthopaedic disabilities, due to bleeding into joints and in 
social problems, e.g. in maintaining employment. Intensive treatment 
with blood products from an early age was shown to lead to an improved 
quality of life. Transfusions of freshly donated blood/plasma or 
fresh frozen plasma, as a hospital in-patient, was the only treatment
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for these disorders until 1964 and the discovery of a method of 
concentrating FVIII in blood. Treatment with this product allowed 
the patients greater freedcm since they could be treated at home. In 
1973 the UK government allowed human blood products to be imported; 
lyophilised concentrates became readily available and the majority of 
supplies came from manufacturers in the USA. These commercial 
concentrates supplemented the locally produced FVIII.
Hcwever the Scottish National Blood Transfusion Service 
(SNBTS) has been self-sufficient for many years and Scottish 
haemophiliacs have been treated almost totally with locally produced 
FVIII since 1981.
In the past, transfusion of blood products has been associated 
with the risk of viral transmission particularly in inmunosuppressed 
patients or in patients receiving large doses. Post-transfusion 
hepatitis was recognised more than ten years ago (243,244), 
particularly that caused by a non A  non B (NANB) agent, now identified 
as hepatitis C virus (HCV)(245) and hepatitis B virus (HBV) from 
FVIII and FIX concentrates. The acute illness may be mild, even 
sub-clinical but the risk of long-term chronic damage to the liver, by 
these hepatotropic agents, may be as high as 21% (246).
A new threat, that of infection with the AIDS virus, appeared 
in the early 1980s when epidemiological data established that 
transfusion of blood and blood products represented one of the major 
routes of transmission of HIV. Haemophiliacs were thus identified as 
a high-risk population (247). Hence the blood supply had to be made 
safer to reduce the risk of transmission by this route. What could 
be done to achieve this?
Past experience with HCV and HBV identified three major ways. 
Firstly, donor selection; active dissuasion of members of identified 
high-risk groups from donating blood. Secondly, treatment with 
chemical agents or heat to inactivate the transmissible agent without 
destroying the activity of the factor concentrate. The AIDS virus 
was found to be extremely heat labile in the liquid phase (248), but 
heat treatment of factor concentrates in the liquid phase rapidly 
reduces their biological activity and so they are preferentially 
heat-treated in the lyophilised state. Lack of seroconversion in
160
haemophiliacs treated with heat-treated factor concentrate indicated 
the success of this procedure (249). Lastly, the development of 
sensitive and specific assays for detection of viral markers in order 
to exclude infected donations. There was now a real possibility that 
transmission by this route could be eliminated.
The haemophiliac population form a well-defined group in which 
to study the natural history of HIV infection, particularly since the 
introduction of heat-treated concentrate in October 1984 and the 
implementation of blood-donor screening in October 1985, has 
significantly reduced the likelihood of further seroconversions in 
this population.
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MATERIAL AMD METHODS
SUBJECTS
In the West of Scotland, haemophilia patients attend two 
centres; children up to the age of 14 years attend clinics at the 
Royal Hospital for Sick Children (RHSC), Glasgow and adults (15 years 
old and ever) attend the Regional Haemophilia Centre (RHC) at Glasgow 
Royal Infirmary (GRI).
HIV-1 SCREENING
Antibody: Initial screening for anti-HIV 1 in serum samples
was performed in 1985, using the Abbott HTLV-III EIA (Abbott 
Laboratories) described in Appendix 2. This was the first commercial 
test kit available. Seropositives were confirmed by indirect 
iiununofluorescence at this time. Subsequent samples from these 
patients have been tested using one of the other screening ELISAs 
described in Appendix 2 and by western blotting (DuPont).
Antigen: Screening for HIV-1 antigen by both the Abbott
HIV-1 antigen EIA and the Du Pont HIV p24 core antigen ELISA (Appendix 
2) commenced in March 1987.
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RESULTS
ANTIBODY IN HAEMOPHILIACS
Serum samples from 111 haemophiliacs registered at the RHC, 
GRI and from 57 haemophiliacs treated at RHSC who were regular 
attenders were tested for HIV-1 antibodies (Table 5.1), 
Retrospective samples (stared as serum at -20°C) from the 31 
seropositives who have been followed up were then examined to 
determine the approximate dates of seroconversion, where possible, or 
the dates of the first antibody positive sample (Fig. 5.1).
Fifteen out of the 31 seropositives were infected with HIV-1 
prior to or during 1982. No patient was found to be seropositive in 
samples taken prior to 1980. The earliest positive case was detected 
in 1981 in patient 20? patient 5 was shewn to seroconvert in that 
year. The first sample from patient 5 in June 1981 was negative by 
ELISA, IF and western blotting but 4 months later, in October a 
follow-up sample was weakly positive by ELISA, negative by IF, and 
produced gag, pol and env bands, on an early version western blot 
(i.e. those with no high molecular weight proteins on the strips) 
(Table 5.2).
The latest seroconversions occurred in 1985 in four patients. 
Patients 7, 15 and 16 ware antibody negative in the last quarter of 
1984, patient 16 was also seronegative in January 1985. However, all 
three were sercpositive when next tested, in the last quarter of 1985. 
Patient 25 was first found seropositive in January 1985 having been 
seronegative in August 1984.
A total of 9 out of the 31 patients (29%) were positive on the 
first specimen available for testing. Therefore the precise date of 
infection could not be determined. The remaining 22 patients had 
previous specimens, where the time interval between the last negative 
and the first positive specimen ranged from 104 days (patient 5) to 
772 days (patient 26), excluding patients 2 and 20, where the time 
interval was of the order of 4 or 5 years. ELISA and western blot 
data indicated that 7 patients were at an early stage of HIV infection 
in their first positive sanples (Table 5.2). Samples tested within 6
TABLE 5.1
HIV-1 seroprevalence in the haemophilia population 
in Glasgow and the West of Scotland.
NO. Tested No. Positive (%)
Adults
(15 years and over) 111 17* (15.3)
Children
(14 years and under) 57 16* (28.1)
168 33 (19.6)
* One adult and one child lost to follow-up
Patient
Age at 
first 
antibody 
positive
N o . 1977 1978 1979 198 0  1981 1982 1983 1984 1 985 serum
( a )  1 • 11
3 • 14
4 • 51
6 • 15
9 • 16
11 • 14
18 • 24
28 • 5
29 • 6
(b) 2 0 • 37
5 0  • 15
7 0 • 46
8 0 0 0 0 0 0 • 31
10 0 0 0 0 • 21
12 0 • 30
13 0 • 14
14 0 • 16
15 0 0 • 36
16 0 0 0 O • 19
17 0 0 0 0 0 0 • 42
19 O • 13
20 0 • 20
21 0 0 • 10
22 0 0  • 12
23 0 • 7
24 0  • 7
25 0 0 0 • 10
2 6 * 0 • 8
2 7 * 0 • 7
3 0 * 0 0 • 8
3 1 * 0 0 • 8
Totals 2 13 7 5 4
FIG. 5.1 History of seroconversion in serial samples from 31 
haemophiliacs from Glasgow and the West of Scotland.
0 = anti-HIV 1 negative 
• = anti-HIV 1 positive
Patients 16 and 18 have haemophilia B, the remainder 
have haemophilia A.
* = Patients 26 and 27 are twin brothers and patients
30 and 31 are twin brothers.
(a) = Haemophiliacs where first available sample is 
HIV-1 antibody positive.
(b) = Seroconversions in haemophiliacs
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months after the estimated seroconversion date showed weakly positive 
reactions with the tests available at this time. The estimated 
seroconversion date is taken as the mid-point in time between the last 
seronegative result and the first seropositive result. Most of the 
serooonversions appear to have occurred between 1981 and 1983.
Patients 16 and 18 suffered from Bn B and received FIX 
concentrate; the remaining 29 had HnA, 28 of whom were severe 
haemophiliacs. In addition, patients 7 and 12 had inhibitor, that is 
anti-FVTII antibodies and thus were treated with a commercial product 
of American origin. There are two sets of twins in this cohort; 
patients 26 and 27 and patients 30 and 31 (Fig.5.1).
The age of the patients at the time of their first antibody 
positive sample ranged from 5 to 51 years. This includes 10 children 
infected when 10 years of age or younger. When initial screening was 
performed, a higher percentage of seropositives was found in the 
patients attending the RHSC (28.1%) compared to 15.3% in the adults 
attending GRI. At the end of June 1990 the average length of time of 
seropositivity is 7 years (range 5 to 9 years), where 87% have been 
positive for a minimum of 6 years.
ANTIGEN IN HAEMDPHILIACS
No HIV-1 antigen was found in sera from 15 patients taken 
prior (4-18 months) to their first antibody positive sample. In 
addition 1983-84 samples from 20 antibody negative haemophiliacs were 
tested, retrospectively, for antigen as they were believed to have 
been treated with a batch of FVIII thought to be infected with HIV-1 
(Dr. R. Madhok, personal communication). No sample contained antigen 
but 4 patients are now known to have seroconverted; one in 1983 
(patient 10) and 3 later in 1985 (patients 7, 15 and 16). No further 
information on this batch or its origin is available.
Serum p24 antigen levels were monitored regularly in the 31 
seropositive haemophiliacs. Over the 5 year follow-up period, 8 
patients (25.8%) were found to have detectable levels of antigen 
repeatedly in their serum. In patient 1 the presence of HIV-1 
antigen was reactive and confirmed on only one sample in January 1990.
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He has subsequently tested negative. The remaining patients are 
antigen negative up to the end of June 1990 (patient 9 moved to London 
during 1988 and was antigen negative up to this time).
Antigen Positive Group
The time interval to antigenaemia ranged from 16 months to 93 
months in these 8 patients (mean 48.9 months) (Table 5.3). However 
the precise dates of infection in these patients are unknown and so 
this can only represent the rainiiaun time interval. The four patients 
who were HIV-1 seropositive in 1982 showed widely differing times to 
antigenaemia/ from 22 to 92 months, i.e. in the order of 2-8 years; 
two patients who seroconverted in 1983 developed HIV-1 antigen almost 
four-and-a-half years later. Patient 8, first found seropositive in 
1984, had detectable HIV-1 antigen 29 months later and the most rapid 
progression was observed in patient 7 who seroconverted during 1985 
and had detectable serum antigen 16 months later.
A correlation between age at first antibody positive test and 
progression to antigenaemia was suggested. The oldest patient in 
this group, patient 7, aged 46 years when first found to be 
seropositive, progressed most rapidly to antigenaemia whereas the 
younger patients took 4 to 5 times longer.
The production of antigen (Ag) was associated with other
changes in serum chemistry. Decline in reactivity to core proteins 
was demonstrated in all of these patients by ELISA (Abbott HIV-1 
Anti-Core EIA, Appendix 2) and in some patients by western blotting. 
In 4 patients, ELISA results shewed the typical profile of a loss in 
anti-p24 levels preceding antigenaemia by 5 and 16 months in patients 
13 and 7 and by 30 and 42 months in patients 28 and 1. Patients 8
and 18 became anti-p24 negative by EIA at the same time as Ag was
detected in serum. Patients 27 and 31 were more atypical in that 
they were anti-core positive by ELISA on developing antigenaemia 
(Table 5.4) and became anti-p24 negative 34 and 28 months later.
Western blot data differed: all patients shewed anti-p24 on a
blot at sane point in time, a decrease was noted in patient 7 during 
1989, patient 8 between 1988 and 1989, patient 13 and patient 31 
between 1986 and 1988. Patient 13 experienced a decrease in anti-p24
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on becoming antigen positive during 1987, this decreased further on 
progression of clinical illness until death (Fig.5.2). Low levels of 
anti-p24 were detected in patient 28 throughout the period of 
follow-up. The lack of anti-p24 in the 1984 and 1985 specimens may 
reflect the lower sensitivity of the early version western blots used 
at the beginning of this study. Neither patient 8 nor patient 13 had 
anti-p17 and a decrease in anti-p17 response was noted in patients 7 
and 31 • There was no evidence of change on a western blot in patient 
1 and 27.
Patient 18 was unusual (Fig.5.3). Gore antibodies were 
present in the first sample available for testing in April 1982; by 
the end of 1982, however, the patient became anti-p24 negative. The 
loss of anti-p24 preceded development of antigen by a maximum of 22 
months. This status quo (anti-p24 negative, p24 antigen positive) 
remained until 1988, when antibodies to p24 reappeared, detected by 
western blot and by ELISA. The anti-p24 response has been retained 
through 1989 and 1990 despite the presence of serum antigen.
Anti-env response was retained and unchanged by ELISA and 
western blot in all patients.
Antigen Negative Group
The remaining 22 patients are HIV-1 antigen negative up to the 
end of June 1990. The mean duration of HIV-1 seropositivity to this 
time is 7 years (range 5-9 years) where 11 out of the 22 have been 
seropositive for 8 years or more.
An anti-p24 response was detected in all 22 patients by ELISA. 
However, 2 patients (patients 12 and 15) showed a weaker reactivity in 
the anti-p24 ELISA and this has been interpreted as a decline in core 
antibody. Patient 15 has since become antigen positive after June 
1990.
^-MICROGLOBOLIN IN HAEMOPHILIACS
Serum ft 2-microglcbulin ( was measured in a group of 
HIV-1 seropositive and seronegative haemophiliacs (Table 5.5). In
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Figure 5.2 Temporal decline of HIV-1 anti-p24 observed on 
western blots from patient 13 up to the time 
of his death in July 1987.
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healthy individuals, values up to 2 mg/1 are accepted as normal 
(Abbott 2~n[iicroglobulin RIA Test procedure, Expected Value p11). 
Although the ranges are wide far both groups certain differences 
between the two have been noted: 57% of antibody negative
haemophiliacs have values <2 mg/1 in contrast to only 7% in the 
antibody positive group. In this latter group 48.3% have levels 
>3mg/l but only 6.7% of the seronegative patients have levels as high 
as this
^-microglobuUn levels were measured in serial samples fron 
the HIV-1 antigen positive group and age-matched HIV-1 seropositive 
controls up to the end of June 1989 (Table 5.6). In 5 out of the 8 
Ag negative seropositives the ^ -mg was seen to rise (>3mg/l) 4 to 5 
years after being found to be HIV-1 Ab-positive; in one patient (26) 
the time interval was only 2 years. However this increase was not 
always maintained. Three patients remained within the normal range 
of leve s^ even 8 years after being HIV-1 Ab positive.
In the Ag positive group, /^-mg levels have been in the normal 
range in 2 patients and always raised, i.e. >3mg/l in another 4 
patients throughout the time period of follcw-up, and therefore did 
not correlate with the appearance of Ag. In one of these patients 
the ^ 2~ra^  levels were recorded in the last few months of his life when 
he was Ag positive and symptomatic. An increase in level was noted 
in the 2 remaining patients, and this corresponded with the detection 
of serum Ag in both cases. Hie levels of /^-mg rot appear to 
correlate with Ag status, nor with the age of the patient, nor the 
length of time seropositive. No virological progression was observed 
at any subsequent time in these Ag negative patients with an 
increasing concentration. However patient 17 has progressed
clinically to ARC. Thus the measurement of P>2~m3 Novels, in the 
small sample of patients studied was found to have a limited 
association with virological progression.
Since the end of 1989, concentration has been measured
routinely in all HIV-1 seropositive haemophiliacs. In the 25 
patients with two or more values only 6 patients have an average value 
}3mg/l where 4 of these patients are members of the antigen positive 
group (patients 7, 8, 27 and 28). A further 5 patients have mean
TABLE 5.5
Serum p2“micro9^ °fc)U^ in levels (mg/1) in HIV-1 seronegative and 
seropositive haemophiliacs
HIV antibody Mean value Range
status No. tested mg/1 mg/1
Positive 29 3.11(0.151)* 1.55 - 4.9
Negative 30 2.12^ .094) 1.4 - 3.8
* Standard error of the mean
Using a two sample t test with a 95% confidence 
level the mean /S^-microglobulin level for the HIV-1 
antibody positive haemophiliacs is significantly 
different from that of the HIV-1 antibody negative 
haemophiliacs,(p<0.05) .
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values >2.5mg/l, two of whom are also in the antigen positive group 
(patients 13 and 31).
Details of clinical status were obtained and an assessment 
made about the role of the above markers, anti-p24, Ag and in
disease progression in the adult HIV-1 seropositive haemophilacs in 
Glasgow and the West of Scotland.
CLINICAL STATUS
Clinical information was available on the haemophiliacs 
attending the RHC at GRI (Dr. G.D.O. Lowe, personal communication). 
Up to the end of June 1990, 22 HIV-1 seropositives attended this 
centre. (One individual, patient 9, moved away in 1988 and another 
individual, patient 23, formerly at the RHSC was now of an age to 
attend the adult centre). Eleven patients have become symptomatic 
(Table 5.7); 3 with PGL, 5 with ARC (1 deceased) and 3 with AIDS (1
deceased and 1 subsequently died in February 1991). Patient 5 
developed PGL after the end of the period of follow-up, in September 
1990, and then progressed to ARC (May 1991). He has been included in 
the group of clinical progressors. In the patients progressing to 
ARC and AIDS time to progression ranged from 3 years to 10 years. 
This represents the minimum time to progression. The first patients 
found seropositive (patients 5 and 20) took the longest to progress,
i.e. 9 and 10 years respectively. In contrast, the last
seroconverter, patient 7 in 1985, had developed ARC within 3 years. 
The remaining 11 are asymptomatic with one on prophylactic treatment
with AZT and/or pentamidine because of a falling T4 count (and 4
others after June 1990, to the time of writing).
Clinical Progressors
p24 Antibody and Antigen
Six of the adult patients who progressed clinically shewed 
virological changes associated with disease advancement (patients 1, 
7, 8, 13, 18 and patient 15 after June 1990, Table 5.7). Five 
patients developed antigen and lost p24 antibody; the other patient,
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patient 15, showed an apparent decline in anti-p24 and became antigen 
positive in September 1990, one year after being diagnosed with ARC. 
Where a change in both markers was noted, this occurred prior to the 
diagnosis of HIV-related symptoms in all 5 cases. Loss of anti-p24 
preceded symptoms by 2 to 4 years in 4 patients, where one of these 
patients was always anti-core negative by ELISA. The remaining 
patient, patient 18, was most unusual and was described previously; 
anti-core reappeared 4 years after being undetectable by ELISA. 
HIV-1 antigen was detected 2 months prior to developing PGL in one 
patient and up to 2 years before the diagnosis of ARC in 3 other 
patients. In patient 18, antigen had first been detected 5 years 
prior to progression. The remaining 5 patients showed no changed in 
virological markers. All 11 patients in this group began AZT 
treatment at or shortly after diagnosis of HIV-related disease.
ft 2-microglobulin
The ^ -mg levels in the 4 haemophiliacs (patients 7, 8, 13 and 
18) who had regular measurements taken over the time span of 
progression show differing results (Table 5.8). In patient 7 a rise 
was noted after antigen was detected prior to the development of ARC; 
however this patient always had levels >3mg/l. The level
increased to >4mg/l almost a year after the diagnosis of ARC. In 
patient 8 the concentration of rose above 3mg/l after becoming
antigen positive and remained stable at this level although the 
patient progressed clinically. >^2~W^  e^vels in patient 13 were very 
high, but these measurements were taken in the last few months of his 
life when rapid clinical progression occurred following a salmonella 
septicaemia as a result of a surgical procedure becoming infected. 
No obvious changes in concentration were detected in patient 18
with an average concentration of 2.4mg/l despite being symptomatic and 
antigen positive. In the remaining 7 patients with clinical 
progression routine levels were measured, following the
diagnosis of HIV-related symptoms. All but one patient had a mean 
concentration $2.6rag/l. One patient (patient 20) did have a j^ -rag 
concentration >3mg/l prior to the diagnosis of ARC but he had been 
symptomatic for four years. A rise in l^-mg concentration above
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3rag/l was also observed in patient 17 prior to developing ARC; this 
subsequently decreased.
Clinical Non-Progressors
There is no evidence of virological progression or an increase in 
^-rag levels, where more than 2 measurements have been made, in 10 out 
of the 11 patient members of this group despite being HIV-1 
seropositive for up to 9 years.
Summary
Thus p24 antibody and antigen are the markers that have 
changed and usually a number of years in advance of any clinical 
diagnosis of HIV-1 disease in half of the total number., of patients 
studied. This may signify a more rapid onset of disease than those 
with no virological progression. The predictive role of
^2-microglcbu 1 in levels in disease progression is less obvious but does 
appear to be associated with the disease process in half of the 
individuals with clinical progression. There is no evidence of 
rising levels in the group who have not progressed clinically even in 
those with other warning signs of disease onset, i.e. a falling T4 
count.
Age at seroconversion has been associated with disease 
progression and this has been noted in this haemophiliac population. 
All except one of the patients over 30 years of age have progressed to 
symptomatic disease and have progressed more quickly than the younger 
patients. In the group of clinical non-progressors who have been 
seropositive for 7 or 8 years, a falling T4 count has been noted in 5 
patients and hence prophylactic treatment started (Dr. Lowe, personal 
communication). These patients are the oldest members of this group 
(Table 5.9).
TABLE 5.9
Data on the asymptomatic haemophiliacs listed in age 
order from youngest to oldest
Date of First 
HIV-1 Seropositive No. of Years AZT
Patient Result Seropositive to Commenced
No. (Month/Year) June 1990 (Month/Year) Age
21 2/83 7 NA 10
22 5/82 8 NA 12
19 11/82 8 NA 13
11 2/83 7 NA 14
3 2/83 7 11/90 14
6 12/82 8 1/91 15
14 11/82 8 ?/91* 16
16 11/85 5 NA 19
10 6/83 7 1/90 21
12 9/82 8 10/90 30
2 3/84 6 NA 37
* Patient moved to a new centre and put on AZT some time 
between January-June 1991 •
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DISCUSSION
The emergence of another blood-borne virus put the 
haemophiliacs at great risk due to their requirement for transfusion 
of blood products, which have been pooled from up to 20,000 donors. 
Evidently the greater the quantities of factor concentrate used, the 
greater the risk of infection. Studies in the UK (250) and elsewhere 
(251) have demonstrated that the greatest percentage of seropositives 
occurs in those patients with HmA. This is also true in the West of 
Scotland patients where the majority, 29 out of 31 seropositives 
(93.5%) suffered from HraA. All HmA patients except one had severe 
haemophilia and were therefore large users of FVIII. Of the two HraB 
patients; one, patient 16, was a moderate user of FIX concentrate, 
the other, patient 18, was also receiving blood products in 
Manchester. The probable reasons for this increased prevalence in 
HraA over HraB are twofold. Firstly, the greater the quantities of 
factor concentrate used by an individual -kin* Yii^ her the probability of 
being transfused with an infected batch. This was observed in a 
higher percentage of HIV-1 seropositives detected in the child 
haemophilia population who have a different treatment policy, using 
greater quantities of factors than the adults. Secondly, the 
differences in the extraction and purification of FVIII and FIV from 
pooled blood may affect the risk of acquiring HIV. FVIII concentrate 
is prepared from the cryoprecipitate of frozen-thawed plasma (252), 
where any viral particles coraplexed with inraunoglobulins are also 
likely to be found. FIX concentrate is further purified from the 
supernatant of frozen-thawed plasma by adsorption on a DEAE 
ion-exchange column (253) and in this way HIV may be excluded fran FIX 
concentrate.
In 1984 the use of heat-treated concentrate (60°C for 72 hr.) 
was advocated in an attempt to prevent further infections. This was 
not entirely satisfactory. There were reports of seroconversions in 
haemophiliacs after receiving commercial heat-treated FVIII (254). 
However this may reflect inadequate treatment of the concentrate to 
reduce the infectious titre of virus since certain groups were 
successful in preventing further seroconversions (249). But in most
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countries, by this date, the damage had been done. Hie indication 
from several reports published in 1984 of high rates of infection 
amongst haemophiliacs, supported this (Table 5.10).
Although the numbers did vary between different continents and 
between countries within these continents, the highest rates were 
found in the USA, where AIDS was first described. In a sample of 
Scottish haemophiliacs (256) including the population of patients on 
which this study was based, 15.6% were found to be seropositive. Hie 
present figure including children in the population of 250 
haemophiliacs in the West of Scotland is 12.4%.
In this study, samples prior to 1985 were available, because 
of the regular monitoring of hepatitis status in these patients, so it 
could be shown that HIV infection was acquired in almost 
three-quarters (71%) of the total seropositives before the end of
1983. An increase in prevalence in the early 1980s, e.g. from 0% in 
1980 to 53% in 1984 (257) was shown in other European haemophiliacs
(258). A higher prevalence of seropositives was noted in the 
haemophiliac children (28.1%) compared to the adults (15.3%) tested at 
this time in the West of Scotland. This is most probably associated 
with the more liberal approach to FVIII usage at the RHSC with the 
almost exclusive use of FVIII manufactured in the U.S.A.
Detection of seropositives in this group as early as 1981 
coincident with the emergence of the AIDS epidemic among homosexual 
men and intravenous drug abusers in the U.S.A., but not with the AIDS 
epidemic in the UK, implicates the import and use of foreign blood 
products, of American origin, at this time. In addition
Cheingsong-Popov et al. (183) found 0% prevalence of anti-HIV 1 in a 
sample of more than 1,000 unselected blood donors from one transfusion 
centre in the UK in 1984, however there is evidence to suggest HIV-1 
seropositivity in certain risk groups in the population in Glasgow and 
the West of Scotland as early as 1983 but whether such persons donated 
blood at this time is unknown (Chapter 3).
A positive association between the use of commercial FVIII and 
increased incidence of seropositivity was shewn by Melbye et al. 
(256): 40% of haemophiliacs treated with either FVIII alone or in
combination with locally produced FVIII were positive compared with
TABLE 5.10
Seroprevalence reports in other haemophilia 
populations in 1984
Country
Seroprevalence
% Reference
Georgia, U.S.A. 
Massachusetts, U.S.A. 
Denmark
South Bavaria, Germany 
United Kingdom 
West of Scotland
72
66
59
53
34
15.6
Ramsay et al. (255)
Kitchen et al. (251)
Melbye et al. (256)
Gurtler et al. (257)
Gieingsong-Popov et al,
Melbye et al. (256)
(183)
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6,7% in those using only local FVIII. Since 1981 haemophiliacs in 
Scotland have been treated mainly with FVIII concentrate produced by 
the Scottish National Blood Transfusion Service (SNBTS) at the Protein 
Fractionation Centre (PPC) in Edinburgh. Such practice, in addition 
to the different treatment policies practiced in different regions may 
explain the relatively low prevalence of HIV infection in Scottish 
haemophiliacs. However one of the seropositive cases described here 
received only local concentrate. This patient, 10, was first found 
to be seropositive in June 1983 (but seronegative in July 1982) 
suggesting that he was infected during 1982 or early 1983. This 
confirms the presence of HIV infection in the blood donor population 
in Scotland in 1982/83. Although an attempt was made at identifying 
the batch of concentrate responsible, no other haemophiliac 
seroconverted as a result (Dr. R. Madhok, personal communication). 
The remaining seropositives received significantly greater quantities 
of commercial concentrates than the seronegatives (Dr. R. Madhok, 
personal communication) and this is therefore the likely source of 
infection especially in those seropositive prior to the introduction 
of heat treated concentrate. In Edinburgh, 18 out of a cohort of 32 
haemophiliacs all treated with the same infected batch of FVIII 
seroconverted. Cuthbert et al. (242) showed that the main
difference between the two groups was that greater quantities of the 
FVIII were given to the seropositives.
Three cases were documented as being seropositive for the 
first time in the latter part of 1985. The results suggest that they 
were infected during 1985. This would be after the introduction of 
heat treated concentrate in December 1984. However, they may have 
received an infected batch earlier: they were recipients of an
inplica ted batch of FVIII during 1983. Perhaps the virus remained 
dormant in their peripheral blood lymphocytes or in an alternative 
reservoir, e.g. monocytes or macrophages, (lymphocytes) having avoided 
the inraune system, until activated by some other co-factor e.g. 
another virus. Perhaps repeated exposures, even in snail doses, to 
factor concentrate, and the allogeneic proteins it contains, triggered 
expression of latent virus into active infection. Consequently it 
implies that each time a haemophiliac has treatment, he is in danger
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of switching on viral expression. That T cells are antigenically 
primed, and proliferate on exposure to some component of FVIII 
concentrate has been shewn in a small study by Mattheson et al. (259).
Why did some haemophiliacs become infected while others 
treated with the same batch have no apparent evidence of infection? 
Certainly some members of the population appear to be more susceptible 
to infection with HIV although the mechanisms involved have yet to be 
determined; in haemophiliacs the effect of FVIII on the immune system 
may play a role. Repeated exposure to pooled blood products, from 
many donors, is associated with the development of T4/T8 abnormalities
(259). Factor VHI appears to cause inmune suppression, perhaps 
those patients with the severest abnormalities in lynphocyte 
sub-populations and immune response may be at greater risk of 
acquiring HIV infection. Indeed Ludlara et al. (260) followed a 
cohort of haemophiliacs all treated with the same batch of 
contaminated FVIII and suggested that haemophiliacs with a 
helper/suppressor T cell ratio <1.5 were more susceptible to 
infection. Patients with haemophilia B are noted to have fewer 
lymphocyte subset abnormalities and a lower prevalence of antibody to 
HIV. There have also been reports (162,261 ) associating HLA 
phenotype particularly A1, B8, DR3, with an increased risk of
seroconversion.
Other interesting questions arise: have the haemophiliacs
been treated with infectious virus or have these patients synthesised 
antibodies to viral proteins disrupted during the preparations of 
concentrate and are therefore effectively vaccinated? This latter 
suggestion is probably unlikely since haemophiliacs do get AIDS; 50% 
of this cohort of adults developed signs of HIV-related disease
progression.
The presence of HIV antigen in serum prior to seroconversion
has been reported in haemophiliacs (86, 262) and in other risk groups
(85). However in this cohort of patients with previous seronegative 
specimens available for testing there was no confirmed antigenaemia 
present. Alla in et al. (86) reported 22.5% and Siraraonds et al. (262) 
42% of haemophiliacs with antigenaemia prior to seroconversion; 
Alla in et al. (86) found Ag in serum up to 9 months prior to
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seroconversion. However presence of antigen at this stage in 
infection is a transient phenomenon and the random timing of the 
samples in this cohort may have precluded its detection.
The presence of antigen early in infection would be expected 
to coincide with an acute or primary infection with the virus. There 
have been reports (82) to suggest that a seroconversion illness occurs 
less often in haemophiliacs in contrast to other risk groups (77-81). 
Only 1 out of 22 case records examined (Dr. Madhok, personal 
communication) revealed an illness consistent with primary infection.
At the opposite end of the spectrum of infection, progression 
of HIV disease has been associated with changes in levels of certain 
markers in blood. Decline in anti-core, production of HIV-1 antigen, 
decrease in T4 cell counts and raised serum jf^ -microglobulin levels 
have all been associated with progression in haemophiliacs 
(237,242,263) as in other risk groups (104-107,235). A change in Ab 
and Ag status was observed in 8 out of the 31 patients (25.8%) up to 
the end of June 1990. Five of these patients received treatment in 
the early 1980s at the RHSC, and three are currently patients there, 
where FVIII usage has always been liberal. Therefore they probably 
received greater doses than the adults whose treatment tended to be 
given only if they had a major bleed. Such frequent treatment may 
promote disease advancement. In the haemophiliac children there are 
two sets of HIV-1 seropositive twins (patients 26 and 27 and patients 
30 and 31). One brother from each pair is antigen positive but the 
sibling, in both cases, has shown no signs of virological progression 
yet. If these twins are genetically identical this suggests that 
co-factors other than genetic factors influence progression of 
illness.
No obvious pattern emerges from the 8 members of the antigen 
positive group as to which marker, p24 antibody or p24 antigen, 
changes first or incubation times heralding change. In 4 patients 
loss of antibody preceded antigen detection by up to 3.5 years and in 
a further two patients the first virological change was the appearance 
of antigen followed by decline and loss of anti-p24 up to 2.5 years 
later. In the remaining two patients an antibody negative/antigen
positive, Ab-/Ag+, pattern was observed at the same sampling time.
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The reappearance of anti-p24 in one of the latter patients is 
interesting and may demonstrate some recovery of B-cell function 
resulting in an increase in antibody production. This may be in 
response to increased viral synthesis or de novo antibody synthesis 
directed against a different epitope of the p24 core protein. 
Perhaps antibodies to certain core epitopes could not be detected by 
the standard screening and confirmatory tests, until sane selection 
pressure altered the dominant circulating virus strain in this 
patient.
Time to production of HIV-1 antigen also varied fran less than
2 years up to 8 years after HIV-1 antibody seroconversion. The most
rapid time to development of antigen was observed in patient 7 who was 
one of the last haemophiliacs to seroconvert in 1985. In addition, 
he was also the oldest of the 8 patients showing virological
progression. Previous reports have suggested a positive correlation 
of age at seroconversion with disease progression (155,158,159).
This probably reflects a decrease in the capabilities of the immune 
system to resist the pathogenic effects of HIV-1. Prolonged factor 
VIII usage and clinical conditions, e.g. chronic liver disease 
associated with older haemophiliacs may lead to chronic antigen 
stimulation and/or impaired antigen processing and thus promote 
disease advancement.
Core Ab and p24 Ag along with other markers have frequently 
been used to determine rapid onset of symptomatic infection. Eleven 
out of the 22 patients in whom clinical information was available 
became symptomatic over the period of follow-up; 50% of these 
patients had become Ab-/Ag+, the pattern most conraonly found in 
symptomatic patients (as discussed in Chapter 4), prior to any 
clinical diagnosis. One additional patient became anti-p24 negative 
but the remainder showed no signs of virological progression. No 
change in either of the viral markers was observed in the asymptomatic 
patients. Thus Ag production and loss of anti-care does occur in 
symptomatic haemophiliacs but not in all such patients. These 
markers may signify early progression and rapid disease onset. The 
changes may not necessarily precede symptoms; in most patients 
HIV-related signs and symptoms are present for a period of time before
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a clinical diagnosis is made so as to meet the criteria of disease 
classification. Alla in et al. (237) found that HIV-1 Ag was a better
marker than absolute T4 cell counts in predicting the appearance of 
symptomatic infections in a group of French haemophiliacs. Eyster 
et al. (263) showed that p24 antigenaemia predicted a poor prognosis 
and was a more specific but less sensitive marker than T4 cell counts; 
46% of their haemophiliac patients with AIDS never developed 
detectable antigenaemia, an equivalent finding in the symptomatic 
patients in this study. It is interesting to note that there was no 
suggestion of progressing disease in the asymptomatic patients using 
the viral markers p24 Ab and Ag. Instead the first observation, 
possibly indicative of some ongoing disease process was a falling T4 
count (Dr. Lowe, personal communication). This was more instructive 
to the physicians; when this occurred prophylactic anti-viral therapy 
was commenced early in the hope of retarding the disease process. 
Continued testing for Ag is less useful in these asymptomatic patients 
now on AZT treatment.
/^ -roicroglobulin, a nonspecific marker of inmune activation, 
was also measured in the HIV-1 seropositive haemophiliacs but was 
found to have little prognostic value. An increase in 
concentration was seen in a total of 9 out of the 16 HIV-1 
seropositives in whom serial testing was performed before 1989; five 
of the 8 antigen negatives and 4 of the 8 antigen positives (2 others 
in the latter group repeatedly had levels higher than 3mg/l). 
However the increase observed in the antigen negative patients was not 
maintained although one of the patients is known to have developed 
ARC. Hie temporary rise in in the haemophiliacs nay be related
to other stimulatory effects on the imnune system, e.,g. through the 
regular treatment with blood products. However a raised level still 
remains a feature of HIV-1 infection as only 2 out of the 30 
seronegative haemophiliacs tested had levels >3mg/l.
As a predictor of disease progression, five out of the 11 
haemophiliacs who developed HIV-related disease had a rise in /^-mg 
concentration prior to diagnosis. In contrast no patient who 
remained asymptomatic shewed an increasing concentration, even
in those patients with the suspicion of clinical progression due to a
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falling T4 count. Thus an association exists between raised p2~m9 
concentration and progressive HIV disease. However this is not 
definitive or absolute as variation occurs between different patients. 
A recent study (242) in a cohort of well characterised Edinburgh 
haemophiliacs infected from a cannon batch of FVIII (260) examined a 
variety of markers of imnune status including T4 and T8 cell counts 
and ^2-microglobulin. Serial T4 counts decreased as disease
progressed, a coranon finding in all cohort studies and a 
well-established feature of the viral pathogenicity. However plasma 
^2-ng concentration not only reflected the presence of clinical disease 
but was useful in predicting the onset of symptomatic infection. In 
the Edinburgh study it was persistently raised (>3mg/l) in all nine, 
i.e. 100%, of the symptomatic seropositives, compared to 45.4% (5 out 
of 11) in the Glasgow haemophiliacs. In 5 out of the 9 Edinburgh 
patients this rise had been noted at least one year prior to 
development of symptoms; this was similar in Glasgow, a rise was 
noted less than 1 year before the diagnosis of ARC in the relevant 5 
patients. In a San Francisco cohort of homosexuals (235), ^ -mg was 
the single, most useful predictor of disease progression, however this 
was not found to be the case in the Hm patients studied here.
The time to progression of disease is more difficult to assess 
in patients where the date of infection is not precisely known. In 
the Glasgow haemophiliacs the time interval ranged from 3 years to 10 
years (mean 5.9 years) in the 8 patients progressing to ARC or AIDS. 
This represents the minimum time in some patients and in other 
patients the time since the date of the estimated seroconversion. 
Twenty-seven per cent progressed to ARC within 6 years of their first 
antibody positive result or seroconversion, with 14% developing AIDS 
in less than 6 years. This compares with estimates when included 
with the rest of the OK haemophiliacs (264), in the American (155) and 
Swedish Bn (156), and in other risk groups, e.g. homosexuals (157). 
However progression in the Edinburgh haemophiliac cohort appears to be 
quicker; with 27.7% having developed AIDS (and a total of 55.5% with 
ARC or AIDS) within 5 years (242). The reasons for this are unclear 
and may be directly related to the quantities of the infected batch 
received by these individuals. The overall picture suggests that
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progression to AIDS is generally slow. Such progression can be 
delayed still further with the early intervention of drug therapies 
particularly AZT which directly inhibits viral replication by 
inhibiting the viral reverse transciptase enzyme.
Several reports in the literature have noted older age at 
seroconversion as an important co-factor in clinical progression 
(155,158,164). This is also true of the Hm population studied here. 
In the United Kingdom Haemophiliac Centre survey (264) a five-fold 
greater risk of developing AIDS within 5 years of seroconversion was 
observed in patients aged over 45 at the earliest HIV-1 seropositive 
report. Patient 7, aged 46 years at seroconversion and who was one 
of the last patients to become infected developed ARC within 3 years 
and AIDS within 4 years (Table 5.7). The majority of the other 
patients over 30 years of age at initial reporting had also developed 
ARC or AIDS within 5 or 6 years. The younger patients took twice as 
long to progress. This probably reflects a reduction in both 
lymphocyte numbers and immune competence in the older patients after 
years of treatment and chronic antigenic stimulation. The role of 
other factors and their contribution to progression is not fully 
understood. Chronic liver disease, for many years a problem in Hra 
may contribute to AIDS-related diseases. Haemophiliacs infected with 
cytomegalovirus have been found to progress more rapidly (265). 
Infection with other viruses, particularly hepatitis C, may also have 
a role to play.
Determinants of progression to disease are likely to be 
rnultifactorial. Most markers reflect the disease process rather than 
being predictive of clinical change. The more markers that are 
examined, the more evident it becomes that patients vary as 
individuals and only general trends can be established. There is no 
single marker which oould be used diagnostics lly to predict onset of 
symptoms with absolute certainty. However, it appears that one of 
the most useful parameters is the T4 count; a falling T4 count is 
highly indicative of impending disease and a level below 200 cells/ 1 
is associated with a very poor prognosis and prophylactic treatment is 
new instigated at this stage.
HIV-1 infection in the haemophiliac population is now
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essentially preventable and this would appear to be so, as no new 
seropositives have been detected since late 1985, after the 
introduction of heat-treated FVIII and blood donor screening. Sadly, 
however, the evidence shows that the incidence of AIDS in this group 
is increasing as time progresses and the time-bcrab of HIV-1 infection 
ticks away. Hope lies in the improvement of drug therapy and the 
early intervention of treatment in order to maintain a reasonable 
quality of life in these patients.
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CHAPTER 6
GENERAL DISCUSSION
A pestilence isn't a thing made to man's measure; 
therefore we tell ourselves that pestilence is a 
mere bogy of the mind, a bad dream that will pass 
away. But it doesn't pass away and, frcra one bad 
dream to another, it is men who pass away.....
Albert Camus, 'Hie Plague'.
Ten years have passed since the apparent start of the AIDS 
epidemic in 1981 and the deaths of the first cases of AIDS. 
Retrospective evidence reveals sporadic cases in the 1970s and earlier 
(266). Hie emergence of the human immunodeficiency virus family has 
plundered research resources, activated the minds of clinicians, 
epidemiologists and research scientists the world over, killed 
thousands and decimated certain African populations. NO other virus 
or virus-related disease has seen such a boom in research in such a 
short time. Our knowledge and perspective of the HIV family and AIDS 
has advanced faster than any known modem infectious agent. However, 
many questions still remain to be answered.
Not least of all is the question of the origin of the virus.
Several pointers suggest it emerged in Africa where a number of
related lentiviruses in both monkeys and man have been found, e.g.
SIV , SIV , HIV-2 etc. and perhaps others as yet undiscoveredmac agm
which sit close together on a phylogenetic tree. Sufficient 
homology exists for these viruses to be related but they are 
sufficiently different at the genomic level to be different types and 
not just variants. There is also the suggestion from the greater 
extent of variation in African isolates compared to American isolates 
that the virus has been in Africa for longer (50). One can only 
speculate as to hew the virus got to America and elsewhere, perhaps 
via commercial trade in the past car more recently via sailors and 
travellers. In the initial stages of the epidemic, the finger was 
pointed at African viruses as being the progenitor of the AIDS virus. 
This created bad feeling between African and American medical and
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scientific communities and led to an underplaying of the extent of the 
problem in Africa and the true extent of the problem in some areas of 
Africa remains unknown.
Hie virus had time to run its full course of infection to AIDS 
before the problem was evident. Hie initial spread of HIV-1 
infection therefore occurred as a silent epidemic throughout the 1970s 
in Africa and America. Hie extent of the spread at that time become 
apparent in the upsurge of cases of AIDS in these continents during 
the late 1970s, early 1980s. Hie first case of AIDS in the West of 
Scotland was in a homosexual man whose diagnosis was back-dated to
1984. There is also evidence to suggest that HIV-1 was in the blood 
donor population here as early as 1983. Thus the virus was 
introduced into the population in the West of Scotland in the early 
1980s coincident with the emergence of the AIDS epidemic in the U.S.A. 
How did the virus get here? Originally this was through travel to 
areas with high rates of infection or through the Import of infected 
blood products.
Hie boundaries of international travel have expanded over the 
last two decades and places previously inaccessible are now open to 
travel for the purposes of both tourism and business. In addition 
greater numbers of persons are now members of the itinerant population 
and thus the opportunity for spread and inter-mixing of infectious 
agents increases.
Population groups such as the homosexuals, which comprise many 
professional persons in older age groups, probably have greater 
opportunity to travel. HIV-1 infection in the homosexual population 
in the West of Scotland was initially imported; a result of contact 
in the early 1980s with infected partners in areas with high rates of 
infection such as North London in the U.K. and the west coast of the 
United States. Hiis was the time of gay liberation and the fight for 
gay rights, particularly in the U.S.A. Homosexuals could be more 
open and still be accepted by the community. So it was only natural 
that homosexuals would go and indulge in places where attitudes were 
more relaxed. Unfortunately conditions were also prime for the 
transmission of an infectious agent such as HIV-1.
In the haemophiliac population, the virus was undoubtedly
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introduced by the use of contaminated factor concentrate from the 
U.S.A. Most transmission to haemophiliacs had occurred by 1982-83. 
Fortunately the requirement for imported products in Scotland is low 
as Scotland has its own Protein Fractionation Centre and is usually 
self-sufficient in FVIII and FIX. Consequently, Scotland has one of 
the lowest reported seroprevalence rates in haemophiliacs in the 
world. However, eventually even the locally produced FVIII became 
contaminated (260).
Seroconversion to anti-HIV 1 was observed in the drug abuser 
population in Glasgow and the West of Scotland from the end of 1985, 
through 1986 and into 1987. The drug abusers in Glasgow are 
generally members of the lower socio-economic groups and are therefore 
less likely to indulge in international travel. It was speculated 
that the virus arrived in Glasgow from Edinburgh in 1985 via a female 
drug abuser. Several of her needle-sharing contacts subsequently 
became seropositive in that year. Samples from these patients are 
currently being sequenced following PCR amplication by Dr. P. Sinroonds 
(university of Edinburgh) to establish the relatedness of the
infecting viral strain. A sequence in the fourth hypervariable
region (V4) of the OMP gene could determine relatedness (52). Such 
molecular epidemiology may prove or disprove that the Edinburgh strain 
of the virus did infect the Glasgow drug abusers initially and whether
the same strain is still spreading. However, it is unlikley that
this was the only source of infection.
The data presented indicate that the same groups are at risk in 
Glasgow and the West of Scotland as elsewhere, i.e. homosexuals 
(including bisexuals), drug abusers and haemophiliacs. Infection of 
haemophiliacs was halted after 1985 and there has been no evidence to 
suggest that they have contributed to further spread of the virus in 
the area. However the same is not true for the homosexuals and the 
drug abusers.
The drug abusers represent almost half of the newly diagnosed 
seropositives in this area, and the homosexuals about one-third. The 
actual numbers do not reflect the dynamics of spread of HIV-1 
infection. The seroprevalence in the homosexual population is 
difficult to assess because they are a hidden group within the
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population. It is clear from continued screening that the epidemic 
in the homosexual population here is still being boosted by persons 
returning to Glasgow having been infected elsewhere. In addition 
evidence of the silent epidemic, resulting from transmission in the 
early or mid-1980s is becoming apparent in the increasing numbers of 
patients whose first presentation is with an opportunistic infection 
and full-blown AIDS.
In contrast the drug abusers have a higher profile in this area 
and more readily admit to their risk activity. Hie problem of drug 
abuse in Glasgow is enormous and much attention has been focused on 
treatment and management of such individuals in the past decade. 
Medical problems, from septic abscesses to heart-valve replacements, 
associated with drug abuse itself are a greater threat to the abusers 
themselves and a greater drain on medical resources at the moment than 
the effects of HIV-1 infection. The prevalence of HIV-1 is currently 
low, <2% in the population screened and the indication is that most of 
this is 'home-grown', i.e. a result of spread within Glasgow. To 
find such a low level was encouraging; perhaps the factors promoting 
transmission are working less efficiently in this group. However 
sero-epideraiological studies rely not only on appropriate sampling but 
also on sensitive and specific laboratory tests.
Hie laboratory diagnosis of infection has to be accurate, 
particularly when dealing with such an emotive subject as HIV. An 
extensive choice of screening ELISAs has been available since the 
first screening test was developed in 1984. Hiis has been a huge 
commercial venture for many of the large pharmaceutical and chemical 
companies, some of whom had never before been involved in diagnostic 
virology but jumped on the bandwagon to develop and/or market a 
screening test far anti-HIV 1. However the performance of the 
majority of tests was and has continued to be satisfactory, both in 
screening high prevalence populations, i.e. high risk groups and low 
prevalence populations, i.e. blood donors.
There is no doubt that screening tests have greatly improved. 
In five years there have been three generations of assays reflecting 
technological advances; from viral lysate-based tests to recombinant 
protein-coated solid phases and more recently, amplified detection
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systems, resulting in tests with a high degree of sensitivity.
Initially the screening tests were not without their problems and 
the specificity of an ELISA reactive sample was further tested by 
western blot, the confirmatory test of choice at the HRL. In no
other area of diagnostic virology has so much effort been spent on 
establishing a confirmatory system. The performance of the
ooranercial DuPont Western Blot assay was maximised for use in the HRL 
using seroconversion samples, samples from those recently infected and 
also false reactives found on screening low prevalence populations. 
Criteria were established so that genuine reactivities were 
distinguished frcm false reactives and thus HIV-1 infection could be 
reliably diagnosed. The advances made in screening and confirmation 
means that the diagnosis of HIV-1 infection is sensitive, specific and 
reliable. That those infected are reliably identified is supported 
by the results from current anonymous screening studies. A 
seroprevalence and behavioural study on the local Glasgow drug abusing 
population has confirmed the same seroprevalence rate as that in the 
drug abusers who were screened voluntarily. This also suggests that 
the extent of spread of HIV-1 infection in the Glasgow drug abusers is 
much less than expected from experiences elsewhere in Scotland, the 
U.K. and worldwide.
What is the future for screening and confirmatory tests? The 
current screening tests detect anti-HIV 1 and anti-HIV 2 and problems 
arise in distinguishing between these reactivities or in confirming a 
dual reaction. There is sufficient homology between the viral 
proteins for them to cross-react on individual ELISA systems and on 
the viral lysate WBs. Single-specificity ELISAs need to be developed 
using Immunodominant epitopes that are not conserved between the 
viruses. If only very short sequences of amino acids are required 
for antibody recognition this may increase the choice of epitopes 
available from each virus.
Confirmation is made easier by the more recent availability of 
strip assays containing recombinant or synthetic peptides from both 
viruses. Thus ELISA reactivity can be determined in one test. 
However only one epitope far HIV-2 is present on the currently 
available tests; greater confidence in reporting HIV-2 seropositivity
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would be achieved by including more HIV-2 epitopes. No marked 
increase in sensitivity was noted in the recombinant iranunoblot strips 
and this may reflect the lack of conformational epitopes in such 
material. It is becoming increasingly more difficult to match or 
better the improvement in the screening test performance 
characteristics with the currently available confirmatory tests, even 
with new advances such as cherailuminescent substrates, etc. for use in 
WBs.
HIV-1 infection continues to spread slcwly in the West of 
Scotland. It is interesting to note that prevalence within a 
risk-group varies geographically suggesting that local factors 
contributing to the spread of the virus do vary substantially. This 
is most obvious in the drug abusing communities in Glasgow and 
Edinburgh. In Edinburgh, high rates of infection were recorded and 
this was associated with an increased pool of heroin abusers in the 
early 1980s who frequently shared needles and syringes, with multiple 
contacts at each sharing episode. Conditions were perfect for the 
spread of the virus. Evidence from the early case control studies in 
the U.S.A. show that it requires only one individual, who is highly 
infectious and indulging in risk behaviour, to promote spread of the 
virus within a community —  the so-called Orange County connection 
(267,268). This was a homosexual, Canadian, airline steward with 
multiple partners in different areas of the united States who was 
identified as the link between a number of the first cases there. It 
was fortunate that no similar explosion of infection occurred in the 
West of Scotland; this was due in part to the later arrival of the 
virus in this drug abusing community and also to other behavioural 
factors, i.e. less sharing and less often than their Edinburgh 
counterparts (191). Advertising, television and press publicity 
campaigns began in late 1986 and 1987 but it is difficult to assess 
whether this reached the high-risk groups and had the desired effect 
or whether changes in attitudes and behaviour had already begun.
The appearance of AIDS and HIV-1 infection has shaken society and 
its previously held values causing individuals to examine moral issues 
and their own lifestyle. It has brought homosexuality and drug abuse 
out of the closet. Sadly, social attitudes are in general not
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sympathetic to such lifestyles; there is still a stigma associated 
with being HIV seropositive. HIV is transmitted through intimate 
contact, either sexually, via blood or from mother to child, however 
it is not selective in its target population contrary to what was 
originally believed. It is not a gay-person’s disease and these 
attitudes will have to change if further spread of the virus is to be 
prevented. It is clear that once the virus is introduced into 
certain populations and given the right conditions it will spread. 
The dynamics of the epidemic are changing elsewhere with spread into 
the heterosexual population. This suggests that all sexually active 
adults are at risk of acquiring infection. How long before this 
takes off in the West of Scotland is unknown. Currently heterosexual 
spread here is low and is a result of contact of high risk groups; 
only 10 of the 298 newly diagnosed seropositives, i.e. 3.4% reported 
heterosexual contact. Five were infected while staying in the 
African continent, the other five were contacts of risk groups here, 
e.g. bisexual men. Recent results from an anonymous HIV survey of 
all babies bom in Glasgow during 1990 shew no evidence of HIV
infection in any child indicating no general heterosexual spread at 
this time (207).
Factors governing the transraissibility of the virus, i.e. both 
the infectivity of the donor and susceptibility of the recipient may
also play a role in viral pathogenesis and disease progression.
Since the beginning of the epidemic, infection with HIV-1 has 
confronted the scientific community with several important questions. 
Who will progress to AIDS? - does everyone infected proceed to
end-stage disease? When does progression occur? Why does 
progression occur? and what are the factors promoting disease 
advancement and viral pathogenesis and can they be halted? As time 
progresses the epidemic of AIDS will incur more fatalities as present 
studies indicate that HIV-related disease and AIDS is the eventual 
outcome for infected persons. This can be seen in the Glasgow and 
West of Scotland adult haemophiliacs studied here; 50% have now been 
classified with HIV-disease, a further 22.7% are on prophylactic drug 
therapies because of a falling T4 count. Hcwever the incubation time 
to disease is longer than first thought. Gloomy predictions in the
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e a r ly  d a y s  o f  th e  e p id e m ic  s u g g e s te d  n o t  o n ly  r a p id  p ro g r e s s io n  t o  
A ID S , w it h in  3 o r  4 y e a rs  o f  b e in g  a n t ib o d y  p o s i t iv e ,  b u t  a ls o  a 
s h o r te r  l i f e s p a n ,  i , e .  d e a th  w i t h in  a y e a r  a f t e r  d ia g n o s is  o f  A ID S . 
F o llo w -u p  o f  th e  a d u lt  h a e m o p h ilia c  p o p u la t io n  in  th e  W e s t o f  S c o tla n d  
show ed a  m in im um  p ro g r e s s io n  t im e  t o  ARC o r  A ID S  o f  4 t o  5 y e a rs  in  
th e  o ld e r  p a t ie n ts  w it h  u p  t o  10 y e a rs  in  th e  o th e r  p a t ie n t s .  T h e  
d a te s  o f  in f e c t io n  o f  a l l  b u t  a fe w  m em bers o f  th e  R u c h l l l  c o h o r t  a re  
unknow n a nd  th u s  n o  a s s e s s m e n t o f  t im e  t o  p ro g re s s io n  o f  d is e a s e  c a n  
b e  made in  th e s e  p a t ie n t s ,  i . e .  in  th e  h o m o s e x u a l a n d  d ru g  a b u s in g  
p o p u la t io n s  in  G la s g o w  a n d  th e  W e s t o f  S c o tla n d .
E v id e n c e  o f  p ro g r e s s io n  w as e x a m in e d  b y  d e te c t io n  o f  a  c h a n g e  in  
m a rk e rs  w h ic h  w e re  th o u g h t t o  b e  p r e d ic t iv e  o f  d is e a s e  p ro g r e s s io n . 
Two v i r o lo g ic a l  m a rk e rs , H IV -1  A g  a n d  H IV -1  a n t i- c o r e  a n d  a n  
im m u n o lo g ic a l m a rk e r , j f ^ - n i ic r o g lo b u lin  w e re  e x a m in e d . I n  th e  g ro u p  
o f  c l i n i c a l  p ro g re s s o rs ^  c h a n g e s  in  o n e  o r  b o th  v i r a l  m a rk e rs  w as n o te d  
in  a s im i la r  p e rc e n ta g e  o f  m em bers in  th e  R u c h i l l  c o h o r t  (6 2 .5 % ) a n d  
th e  h a e m o p h ilia  c o h o r t  (5 4 .5 % ) a lth o u g h  th e  a c tu a l n u m b e rs  a re  s m a ll.  
T h e se  p re c e d e d  th e  d ia g n o s is  o f  c l i n i c a l  c h a n g e  i n  a l l  b u t  o n e  
h a e m o p h ilia  p a t ie n t .  N o  c o n s is te n c y  b e tw e e n  ^ e v e l s  a n d  d is e a s e
p ro g re s s io n  w as fo u n d . No p a t ie n t  in  th e  R u c h ill  c o h o r t  a n d  o n ly  tw o  
h a e m o p h ilia  p a t ie n ts  d e m o n s tra te d  a c h a n g e  in  a l l  th r e e  m a rk e rs  p r io r  
t o  c l i n i c a l  p ro g r e s s io n . T h e  m o s t conm on c h a n g e s  o b s e rv e d  w e re  th e  
v i r o lo g ic a l  m a rk e rs  p a r t i c u la r ly  lo s s  o f  a n t i- p 2 4 .
No d e f in i t iv e  p r o f i l e  o f  t im e  t o  ch a n g e  in  m a rk e rs  a n d  
p ro g re s s io n  o f  d is e a s e  c o u ld  b e  e s ta b lis h e d .  I n  b o th  th e
h a e m o p h ilia c  a d u lt s  a n d  th e  R u c h i l l  c o h o r t  n o  o n e  o r  c o m b in a tio n  o f  
m a rk e rs  w as fo u n d  t o  b e  a lw a y s  r e l ia b ly  p r e d ic t iv e  in  d e te rm in in g  w ho 
p ro g re s s e d  o r  th e  t im e  t o  d is e a s e  p ro g re s s io n . A lth o u g h  a n  
a s s o c ia t io n  o f  lo s s  o f  A b , p ro d u c t io n  o f  A g , in c re a s e  i n  ^ 2 -m ^  -^e v e ^  
w ith  c l i n i c a l  p ro g re s s io n  w as n o te d , th e  c h a n g e s  o b s e rv e d  m e re ly  
r e f le c te d  th e  im ra u n o p a th o g e n e s is  o f  H IV -1  a nd  th e  o n g o in g  d is e a s e  
p ro c e s s . T h a t in d iv id u a l  p a t ie n ts  re s p o n d e d  in  in d iv id u a l w a ys  
becam e th e  conm on th e m e  a n d  th e r e fo r e  o n ly  g e n e ra l t r e n d s  c o u ld  b e  
e s ta b lis h e d .
I n  p r a c t ic a l  te r ra s , a s tu te  p h y s ic ia n s  and  n u r s in g  s t a f f  w ho kn o w  
th e  p a t ie n ts  a s  in d iv id u a ls  a re  m are  l i k e l y  t o  b e  a w a re  o f  a c h a n g e
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b e fo re  a n y  la b o r a to r y  p a ra m e te r  in d ic a te s  p ro g r e s s io n . T he
m e a su re m e n t o f  th e  m a rk e rs  d e s c r ib e d  h e re  g iv e s  e x t r a  in fo r m a t io n  t o  
th e  p h y s ic ia n s  r a th e r  th a n  b e in g  p r e d ic t iv e  o n  t h e i r  ow n . T he  f u t u r e  
r e m it  o f  A g  a n d  t e s t in g  i s  m o re  l i k e l y  t o  b e  in  m o n ito r in g  th e
e f f e c t s  o f  a n t i - v i r a l  th e ra p y  a s  a d e c re a s e  i n  A g  a n d  ^ e v e -^s
o b s e rv e d  in  p a t ie n ts  o n  AZT t r e a tm e n t.  M o n ito r in g  o f  le v e ls
w i l l  b e  m o re  s u c c e s s fu l in  t h i s  r e s p e c t  b e c a u s e  n o t a l l  p a t ie n t s  
d e v e lo p  d e te c ta b le  se rum  A g  th ro u g h  th e  c o u rs e  o f  d is e a s e .
I t  i s  s t i l l  a m a tte r  o f  d e b a te  a s  t o  w h ic h  m a rk e rs  b e s t p r e d ic t  
d is e a s e  o n s e t;  d i f f e r e n t  m a rk e rs  a re  fo u n d  t o  b e  m ore  o r  le s s  u s e fu l 
in  th e  c o h o r t  s tu d ie s  r e p o r te d  in  th e  l i t e r a t u r e  b u t  jf ^ - r o ic r o g lo b u lin  
m e a su re m e n t e m e rg es a s  o n e  o f  th e  b e s t  p r e d ic to r s  (2 3 5 ,2 4 1  ) .  No 
o u ts ta n d in g  m a rk e r w as s ig n i f ic a n t  in  o u r  tw o  p a t ie n t  c o h o r ts .  No 
o n e  m a rk e r i s  p ro b a b ly  s u f f i c ie n t  o n  i t s  ow n t o  p r e d ic t  r a te s  o f  
p ro g re s s io n  a n d  M oss a n d  B a c c h e t t i d e s c r ib e  a n  a lg o r ith m  b a s e d  o n  f i v e  
v a r ia b le s  t o  e s tim a te  th e  p r o b a b i l i t y  o f  p ro g r e s s io n  (1 5 4 ) . T r y in g  
t o  a s s e s s  w hen a s ig n i f ic a n t  c h a n g e  i s  a b o u t t o  o c c u r  in  s u c h  a 
d y n a m ic  s y s te m  a s  th e  im m une s y s te m  e s p e c ia l ly  o n e  s u p p o r t in g  a 
c h r o n ic  v i r a l  in f e c t io n  s u c h  a s  H IV -1  i s  v e r y  d i f f i c u l t .  S p ik e s  o f  
H IV -1  a n t ig e n  a nd  in c re a s e s  in  im m une m a rk e rs  o c c u r  in  re s p o n s e  t o  
o th e r  s t im u l i ,  e .g .  b a c t e r ia l  in f e c t io n s .  T h e  m o le c u la r  s w itc h  in  
H IV -1  w h ic h  in c re a s e s  th e  t r a n s c r ip t io n  a n d  t r a n s la t io n  o f  th e  
s t r u c t u r a l  g e n e s  i s  th e  r e v  p r o te in  ( th e  r e g u la to r  o f  e x p re s s io n  o f  
v i r i o n  p r o t e in s ) .  H o w e ve r t h i s  in v o lv e s  a c o m p le x  in t e r a c t io n  
in v o lv in g  o th e r  p r o te in s  a n d  s o p h is t ic a te d  fe e d b a c k  c o n t r o l lo o p s , a 
d is c u s s io n  o f  w h ic h  i s  b e y o n d  th e  s c o p e  o f  t h i s  th e s is .  P e rh a p s  a 
th r e s h o ld  le v e l o f  s t r u c t u r a l  p r o te in  s y n th e s is  a n d  s u b s e q u e n t v i r a l  
r e le a s e  i s  r e q u ir e d  b e fo re  a n y  c y to p a th ic  e v e n ts  o c c u r  a nd  th e r e fo r e  
an  i n t r a c e l lu la r  m a rk e r o f  v i r a l  a c t iv a t io n ,  p o s s ib ly  a t  th e  m o le c u la r  
le v e l ,  m ay b e  a m ore  s p e c i f ic  in d ic a t o r .
M o re  in fo r m a t io n  c o u ld  s t i l l  b e  e x t r a c te d  fro m  o u r  in f e c te d  
p o p u la t io n  in  th e  W est o f  S c o tla n d . T h e re  i s  a n  a d v a n ta g e  in  th e  
e p id e m ic  h e re  b e in g  s e v e r a l y e a rs  b e h in d  o th e r  p o p u la t io n s  a n d  th e  
h o p e  o f  p ro lo n g e d  s u r v iv a l f o r  s u c h  p a t ie n t s  i s  g r e a te r  a s  a d v a n c e s  in  
t r e a tm e n t e t c .  a re  m ade. D a ta  o n  T 4  c e l l  c o u n ts  a nd  o th e r  
im m u n o lo g ic a l p a ra m e te rs  w as a ls o  c o lle c te d  in  b o th  th e  R u c h ill  c o h o r t
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a n d  th e  h a e m o p h ilia c  c o h o r t  a n d  a s t a r t  w i l l  b e  m ade t o  a s s e s s  th e  
r o le  o f  th e s e  m a rk e rs  o n  t h e i r  own a n d  in  a s s o c ia t io n  w it h  th e  m a rk e rs  
m e a su re d  h e re . M o s t m em bers o f  th e  R u c h i l l  c o h o r t  w e re  r e c r u it e d  a s  
th e y  a tte n d e d  th e  ID  c l i n i c  fo l lo w in g  a s e r o p o s it iv e  r e s u l t .  T h is  i s  
n o t  id e a l a nd  in  th e  f u t u r e  a b e t t e r  d e f in e d  c o h o r t  w it h  c le a r  
c r i t e r i a  f o r  e n t r y  i s  r e q u ir e d  t o  e s ta b lis h  a  r o u t in e  s a m p lin g  a nd  
s c re e n in g  p rog ram m e f o r  m a rk e rs .
F a c to r s  p ro m o tin g  d is e a s e  p ro g re s s io n  a re  m any a n d  v a r ie d  
in v o lv in g  i n t r i n s i c  q u a l i t ie s  o f  th e  v i r u s ,  e .g .  c y t o p a t h ic i t y  o f  th e  
in f e c t in g  s t r a in  a n d  th e  h o s t  re s p o n s e  t o  i t ,  e .g .  n e u t r a l is in g  
a n t ib o d ie s ,  in t e g r a l  fe a tu r e s  o f  th e  h o s t ,  e .g .  a g e , HLA p h e n o ty p e  
e t c .  a n d  b e h a v io u r  p a t t e r n s  o f  th e  h o s t ,  e .g .  c o n t in u a t io n  o f  r is k  
a c t i v i t y .  A l l  th e s e  q u a l i t ie s  w i l l  g o v e rn  th e  in d iv id u a l i t y  o f  
re s p o n s e . Some o f  th e s e  fa c t o r s  c a n  b e  m e a su re d  t o  d e te rm in e  th e  
l ik e l ih o o d  o f  p ro g r e s s io n  b u t  n o  a lt e r a t io n s  c a n  b e  m ade t o  a f f e c t  
d is e a s e  o u tc o m e . T h e  m o s t m a rke d  fe a tu r e  in  th e  h a e m o p h ilia  
p o p u la t io n  s tu d ie d  h e re  w as th e  a s s o c ia t io n  o f  o ld e r  a g e  a t  
s e ro c o n v e rs io n  w ith  d is e a s e  p ro g r e s s io n . Why t h i s  i s  s o  re m a in s  
u n c le a r  b u t  p ro b a b ly  r e f le c t s  some a s p e c t o f  th e  im m une s y s te m . 
O th e r  f a c to r s ,  e .g .  b e h a v io u r ,  c a n  b e  m o d if ie d  a n d  th e  r e s p o n s ib i l i t y  
f o r  s u c h  r e s ts  w ith  th e  in d iv id u a l .
A  s lo w e r  r a t e  t o  i n i t i a l  p ro g re s s io n  w as n o te d  in  th e  a d u lt  
h a e m o p h ilia  c o h o r t  co m p a re d  t o  th e  m em bers o f  th e  R u c h i l l  c o h o r t  in  
whom a n  e s tim a te d  t im e  o f  s e ro c o n v e rs io n  w as k n o w n . T h is  m ay r e f le c t  
re p e a te d  a n t ig e n ic  s t im u la t io n  o f  th e  h o s t w ith  H IV -1  o r  o th e r  
m ic r o b ia l a g e n ts  in  th o s e  d ru g  a b u s e rs  a n d  h o m o s e x u a ls  w ho c o n tin u e  
t h e i r  h ig h  r is k  a c t i v i t i e s  w h ic h  m ay b r in g  th e m  in t o  c o n ta c t  w it h  su ch  
a g e n ts . I n  c o n t r a s t  th e  h a e m o p h ilia c s  h a v e  n o t  b e e n  re -e x p o s e d  to  
H IV -1 , a f t e r  th e  in t r o d u c t io n  o f  h e a t- t r e a te d  f a c t o r  p ro d u c ts ,  th u s  
p r e s e r v in g  a m ore  in t a c t  in m u n e  s y s te m  f o r  lo n g e r .
I s  i t  o n ly  a m a tte r  o f  t im e  b e fo re  a l l  th o s e  in f e c te d  w ith  H IV -1  
d e v e lo p  A ID S ? T h is  i s  d i f f i c u l t  t o  a s s e s s  a s  th e r e  a re  m em bers o f  
b o th  c o h o r ts  w ho re m a in  a s y m p to m a tic , b u t  how  lo n g  t h i s  w i l l  b e  s o  i s  
u n kn o w n . A  s tu d y  o f  n o n -p ro g re s s o rs  may b e  u s e fu l t o  e x a m in e  w h a t 
fe a tu r e s  o f  t h e i r  im m une re s p o n s e  t o  th e  v ir u s  a re  p r o t e c t iv e  a n d  w h a t 
c lu e s  c o u ld  b e  u s e fu l i n  d e s ig n in g  tr e a tm e n t.  L if s o n  e t  a l .  (2 6 9 )
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e x a m in e d  im m u n o lo g ic a l c h a r a c t e r is t ic s  in  s u c h  a  g ro u p  o f  p a t ie n ts  a n d  
fo u n d  a r a is e d  T 8  c o u n t m ay h e lp  t o  c o n t r o l  v i r a l  r e p l ic a t io n  a n d  
d e la y  p ro g re s s io n  t o  A ID S . F u r th e r  s tu d ie s  h a v e  show n a  la c k  o f
e n h a n c in g  a n t ib o d ie s  f o r  H IV  in  n o n -p ro g re s s a rs . I n  a d d it io n ,  a n d  
w h a t m ay b e  th e  m o s t im p o r ta n t fe a tu r e  o f  a l l  i s  th e  n a tu re  o f  th e  
in f e c t in g  s t r a in  o f  v i r u s .  A  le s s  v i r u le n t  s t r a in  m ay b e  a s s o c ia te d  
w ith  la c k  o f  d is e a s e  p ro g r e s s io n .  I f  t h i s  i s  s o , c o u ld  s u c h  a s ta te  
b e  in d u c e d  in  p e rs o n s  in f e c te d  w ith  a h ig h ly  v i r u le n t  s t r a in ?
M uch w o rk  re m a in s  t o  b e  d o n e  f o r  g r e a te r  u n d e rs ta n d in g  o f  how  th e  
p a th o g e n ic  e f f e c t s  o f  th e  v i r u s  a re  a c h ie v e d , how  th e  v ir u s  m a in ta in s  
la te n c y ,  th e  n a tu re  o f  th e  im m une re s p o n s e  t o  th e  v ir u s  e t c .  I f  
H IV -1  i s  t r u l y  th e  c a u s e  o f  A ID S , a  v ie w  c h a lle n g e d  b y  D r . P . D u e s b e rg  
( 2 7 0 ) , th e n  th e  b o u n ty  o f  k n o w le d g e  a lr e a d y  a v a ila b le  a b o u t th e  
m o le c u la r  m e ch a n ism s  o f  th e  v i r u s  w i l l  p r o v id e  th e  n e c e s s a ry  
in fo r m a t io n  f o r  d e s ig n  a n d  m a n u fa c tu re  o f  a n t i - v i r a ls  a n d  v a c c in e s .
T en  y e a rs  o n  a n d  n a n  c o n tin u e s  t o  p a s s  a w a y . I n  th e  W est o f  
S c o tla n d , A ID S  h a s  o c c u r re d  p re d o m in a n tly  in  th e  h o m o s e x u a l p o p u la t io n  
(4 3 % ). H cw e ve r s ig n s  a nd  sym ptom s o f  H IV -1  d is e a s e  p ro g re s s io n  a re  
new  b e g in n in g  t o  a p p e a r in  th e  d ru g  a b u s e rs . H IV -1  in f e c t io n  i s  
s t i l l  s p re a d in g  in  th e  p o p u la t io n  a lb e i t  a t  a  s lo w e r  r a t e .  A lth o u g h  
i t  i s  e n c o u ra g in g  t h a t  c e r t a in  in d ic a to r s  a re  c h a n g in g , i . e .  lo n g e r  t o  
p ro g re s s io n  o f  d is e a s e  a n d  th o s e  w ith  A ID S  a re  l i v in g  lo n g e r  th e  o n ly  
h o p e  f o r  th e  H IV -1  in fe c te d  p e rs o n s  (H IP s ) a n d  th e  p e o p le  w ith  A ID S  
(PW As) r e s t s  w it h  th e  d e v e lo p m e n t o f  s u it a b le ,  e f f e c t iv e  a n t i - v i r a l  
th e ra p y  a n d  v a c c in e .  P h ase  1 t r i a l s  o f  v a c c in e  m ade fro m  re c o m b in a n t 
e n v e lo p e  p r o te in s  a re  c u r r e n t ly  u n d e rw a y  b u t  i t  i s  b e yo n d  th e  sco p e  o f  
t h i s  th e s is  t o  d is c u s s  v a c c in e  d e s ig n  a n d  e f f ic a c y  t r i a l s .
T h is  d is c u s s io n  h a s  fo c u s e d  o n  H IV -1  a n d  A ID S  s in c e  n o  m em bers o f  
th e  p o p u la t io n  i n  G la sg o w  a n d  th e  W e s t o f  S c o tla n d  h a v e  b e e n  fo u n d  
s e r o p o s it iv e  f o r  e it h e r  H F L V -I, H T L V -II o r  H IV -2 .
A ID S  h a s  ro c k e d  th e  w o r ld  l i k e  n o  o th e r  m o d e m  e p id e m ic . A ID S  
a n d  H IV -1  in f e c t io n  h a v e  d u p lic a t io n s  f o r  th e  w h o le  o f  s o c ie ty .  A  
m a s s iv e  g lo b a l in p u t  o f  re s o u rc e s  a n d  s c i e n t i f i c  re s e a rc h  c o n tin u e s  
a n d  s lo w ly  b u t  s u r e ly  a d v a n c e s  a re  b e in g  m ade. I t  i s  in t e r e s t in g  t o  
s p e c u la te  t h a t  in  th e  f u t u r e  a s y m b io t ic  r e la t io n s h ip  m ay d e v e lo p  
b e tw e e n  hum an im m u n o d e fic ie n c y  v i r u s  a n d  m an, s u c h  t h a t  in  g e n e ra t io n s
191
t o  c a n e  H IV -1  m ay becom e n a n -p a th o g e n ic  in  i t s  h o s t /  h o w e v e r c a r r ie r s  
m ay re m a in  in  th e  p o p u la t io n  a n d  c o n tin u e  t o  c o n t r ib u te  t o  s p re a d  o f  
in f e c t io n  a lb e i t  a t  a  m uch lo w e r  r a t e .
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APPENDIX 1.
D e s ig n  o f  E L IS A  t e s t s  (M o rtim e r  e t  a l .  (1 0 8 ))
TYPE Is INDIRECT ASSAY
J-Ag + A b  > j-A g -A b  + Ab.ENZ > |~Ag-Ab-Ab. ENZ + Substrate
Product
V ir u s - s p e c if ic  a n t ib o d ie s  in  a p a t ie n t * s  se ru m  b in d  t o  v i r a l  a n tig e n s  
c o a te d  o n to  a s o l id  p h a s e  ( e .g .  p o ly s ty r e n e  b e a d  o r  m ic r o t i t r e  w e l l ) .  
F o llo w in g  a w ash  s te p  a s e c o n d  s p e c ie s  a n t ib o d y  ( u s u a lly  g o a t o r  
r a b b i t )  c o n ju g a te d  t o  a n  enzym e i s  a d d e d . T h is  re c o g n is e s  a n d  b in d s  
t o  th e  F c  p o r t io n  o f  hum an in m u n o g lo b u  l i n  G ( Ig G ) .  A ny bound  
c o n ju g a te d  a n tib o d y  w i l l  b e  d e te c te d  b y  a  c o lo u r  ch a n g e  o n  th e  
a d d it io n  o f  s u b s tr a te  a n d  t h i s  i s  d i r e c t ly  p r o p o r t io n a l t o  th e  a m o un t 
o f  a n t ib o d y  in  th e  t e s t  s e ru m . T he  r e s u lt s  a re  re a d  b y  eye  o r  in  a 
s p e c tro p h o to m e te r .
TYPE II: COMPETITIVE ASSAY
I-A g +
A b
A b.E N Z
fA g -A b  + S u b s tra te
fA g -A b . ENZ + S u b s tra teoilP r d u c t
B o th  th e  t e s t  s p e c im e n  a n d  hum an a n ti-H IV -e n z y m e  c o n ju g a te  co m p e te  f o r  
b in d in g  s i t e s  o n  th e  a n tig e n -c o a te d  s o lid  p h a s e . V ir u s - s p e c if ic  
a n t ib o d ie s  p re s e n t in  th e  t e s t  se rum  w i l l  p re v e n t b in d in g  o f  th e  
a n t ib o d y  c o n ju g a te  a n d  n o  c o lo u r  ch a n g e  w i l l  fo rm  o n  th e  a d d it io n  o f  
s u b s t r a te .
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TYPE IV: SANDWICH ASSAY
M o d if ie d  f o r  th e  D e te c t io n  o f  A n tig e n
j-Ab + A g  > J-Ab-Ag+Ab.ENZ > J-Ab-Ag-Ab.ENZ + Substrate
P ro d u c t
V i r a l  a n t ig e n  i n  th e  t e s t  se ru m  fo rm s  a  b r id g e  b e tw e e n  im m o b ilis e d  
a n t ib o d y  o n  th e  s o l id  p h a s e  a n d  th e  a n t ib o d y  c o n ju g a te d  t o  enzym e. A  
c o lo u r , c h a n g e  i s  p ro d u c e d  o n  th e  a d d it io n  o f  s u b s tr a te  i f  a n t ig e n  i s  
p re s e n t i n  th e  t e s t  se ru m .
Modifications (Type I and Type IV)
M o d if ic a t io n s  t o  e n h a n ce  d e te c t io n  in c lu d e  u s in g  a  d e te c to r  a n tib o d y  
w h ic h  i s  la b e lle d  w ith  a  b io t in  m o ie ty . Enzym e i s  c o n ju g a te d  t o  
a v id  in  ( o r  s t r e p t a v id in )  w h ic h  h a s  a  h ig h  a f f i n i t y  f o r  b io t in .  I n  
t h i s  w ay a  tw o -s te p  d e te c t io n  s y s te m  c a n  b e  u s e d .
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APPENDIX 2
R e t r o v ir u s  a n t ib o d y  s c re e n in g  a nd  c o n f ir m a to r y  t e s t s ,  
a n t ig e n  te s t s  a nd  s u p p le m e n ta ry  t e s t s .
NAME TYPE
HIV-Screening
A b b o tt L a b o r a to r ie s
1 s t  G e n e ra tio n :
A b b o tt H T L V - II I  E IA  I
2 n d  G e n e ra tio n :
A b b o tt R e c o m b in a n t 
H IV -1  E IA  I
A b b o tt R e c o m b in a n t 
H IV -1 /H IV -2  E IA
W e llc o m e  D ia g n o s tic s  
1 s t  G e n e ra tio n :
W e llc o z y m e
A n ti-H T L V  I I I  E IA  I I
2 n d  G e n e ra tio n :
W e llc o z y m e  H IV  
M o n o c lo n a l E IA  I I
SO LID  PHASE CONJUGATE D ILU T IO N
D u P o n t:
D ip s t ic k  A s s a y
D ia g n o s t ic s  P a s te u r  
( a n t i - H I V  2 )
E LA V IA  A c -A b -A k  I I
V i r a l  L y s a te  
H9/H T L V - I I Ib  
Ce l l  L in e
rDNA# ( E . c o l i)  
H IV -1  c o re  and  
e n v  a n tig e n s
rDNA ( E . c o l i)  
H IV -1  c o re  and  
e n v  p lu s  H IV -2 
e n v  a n tig e n s
V i r a l  L y s a te  
c a p tu re d  o n to  
a n t i- H IV  1 
c o a te d  w e lls
V i r a l  L y s a te  
(CEM C e ll L in e )  
c a p tu re d  o n to  
m ouse m o n o c lo n a l 
a n t i- H IV
U nknow n
V ir a l  L y s a te  
D u a l W e ll:  V i r a l  
A g  c o a te d  -  
c e l lu la r  a nd  
se rum  A g c o a te d
A n ti-H u m a n  
Ig G  (G o a t)-H R P *
A n ti-H u m a n  
Ig G  (G o a t)-H R P
A n ti-H u n a n  
Ig G  (G o a t)-H R P
A n t i- H IV  
(H um an)-H R P
A n t i- H IV  
(H um an) -  HRP
U nknow n
A n ti-H u m a n  
Ig G  (G o a t)-H R P
1 :4 0 0
1 :4 0
1 :4 0
N e a t
N e a t
1 :4 0
1:100
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NAME TYPE S O U P  PHASE
H T LV  SC R EENING
A b b o tt L a b o r a to r ie s
A b b o tt H E LV -1 E IA  I  V i r a l  L y s a te
H O T -102 -2B  
c e l l  l i n e
H IV -1  C O N FIR M A TIO N
A b b o tt L a b o r a to r ie s
A b b o tt ENVAOQR D u a l B ead
H IV -1  E IA  I I  1 .rD N A # (E .o o li)
( fo r m e r ly  th e  A b b o tt e n v  a n t ig e n
C o n firm a to r y  E IA )
2 .rD N A  ( E . c o l i )  
c o re  a n t ig e n s
D u P o n t
W e s te rn  B lo t  K i t  
f o r  th e  D e te c t io n  
o f  Ig G  A n t ib o d ie s  
t o  H IV -1
I  V i r a l  L y s a te  
H 9 / f f lL V - I I I B
H IV -1  A N T IG E N  D E TEC TIO N
D u P o n t NEN 
H IV  p24  c o re
A n tig e n  E L IS A  IV  A n t i- H IV
(R a b b it)
A b b o tt la b o r a to r ie s  
A b b o tt H IV -1
A n tig e n  E IA  IV  A n t i- H IV
(Hum an)
CONJUGATE
A n ti-H u m a n  
Ig G  (G o a t)-H R P
E n v  A n t i- H IV  
(H um an)-H R P *
C o re  A n t i- H IV  
(H um an)-H R P
1 .B io t in y la te d  
A n ti-H u m a n  
Ig G  (G o a t)
2 .A v id in -H R P
1 . B io t in y la te d  
A n t i- H IV  p24  
(Hum an)
2 .S tre p ta v id in -H R P
1 .A n t i- H IV  
(R a b b it)
D ILU TIO N
1 :4 0
N e a t
N e a t
1:100
N e a t
N e a t
2 . A n t i- R a b b it  
Ig G  (G o a t)-H R P
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NAME
SUPPLEMENTARY TESTS
A b b o tt H IV -1  
A n t i- C o re  E IA
A b b o tt
P 2 -m ic ro g lo b u  1 in  R IA
TYPE SO LID  PHASE CONJUGATE D ILU TIO N
I I  rDN A ( E . c o l i)  
c o re  a n tig e n s
C o re  A n t i- H IV  
(H uraan)-H R P
N e a t
I I  M ouse m o n o c lo n a l 
a n t i - f e -  
r a ic r o g lo b u lin
1 25 I - la b e l le d
2 - m ic r o g lo b u lin
1:10
HRP: h o rs e ra d is h  p e ro x id a s e
rD N A : re c o m b in a n t DNA
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v ir u s  in f e c t io n  in  tw o  c o h o r ts  o f  h o m o s e x u a l m en : n e u t r a l is in g  
s e ra  a n d  a s s o c ia t io n  o f  a n t i- g a g  a n t ib o d y  w ith  p ro g n o s is .
Lancet 1 9 8 7 ; i :  1 1 9 -1 2 2 .
1 0 4 . L a n g e  JM A, P a u l D A, H u ism an  HG. e t  a l .  P e r s is te n t  H IV  
a n tig e n a e m ia  a n d  d e c lin e  o f  H IV  c o re  a n t ib o d ie s  a s s o c ia te d  w ith  
t r a n s i t io n  t o  A ID S . B r .  M e d . J .  1 9 8 6 ; 2 9 3 : 1 4 5 9 -1 4 6 2 .
1 0 5 . P e d e rs e n  C , N ie ls e n  CM, V e s te rg a a rd  B F , G e r s to f t  J ,  K ro g s g a a rd  K , 
N ie ls e n  J O . T e m p o ra l r e la t io n  o f  a n tig e n a e m ia  a n d  lo s s  o f  
a n t ib o d ie s  t o  c o re  a n t ig e n s  t o  d e v e lo p m e n t o f  c l i n i c a l  d is e a s e  
in  H IV  in f e c t io n .  B r .  M e d . J .  1 9 8 7 ; 2 9 5 : 5 6 7 -5 6 9 .
1 0 6 . F o r s te r  SM, O s b o rn e  IM , C h e in g s o n g -P o p o v  R . e t  a l .  D e c lin e  o f
a n t i- p 2 4  a n t ib o d y  p re c e d e s  a n tig e n a e m ia  a s  c o r r e la te  o f  p ro g n o s is  
in  H IV -1  in f e c t io n .  AIDS 1 9 8 7 ; 1 : 2 3 5 -2 4 0 .
1 0 7 . d e  W o lf F , L a n g e  JM A, H o u w e ilin g  JT M . e t  a l .  A p p e a ra n c e  o f
p r e d ic to r s  o f  d is e a s e  p ro g re s s io n  in  r e la t io n  t o  th e  d e v e lo p m e n t 
o f  A ID S . AIDS 1 9 8 9 ; 3 : 5 6 3 -5 6 9 .
1 0 8 . M o r tim e r  P P , P a r ry  J V , M o r tim e r  J Y . W h ich  a n ti-H T L V  I I I / L A V  
a s s a y  f o r  s c re e n in g  a n d  c o n f ir m a to r y  te s t in g ?  L a n c e t  1 9 8 5 ; 
i i :  8 7 3 -8 7 6 .
1 0 9 . R e e s in k  HW, L e l ie  F N , H u ism an  JG . e t  a l .  E v a lu a t io n  o f  s ix  
enzym e im m u no assa y  f o r  a n t ib o d y  a g a in s t  hum an im m u n o d e fic ie n c y  
v i r u s .  Lancet 1 9 8 6 ; i i :  4 8 3 -4 8 6 .
1 1 0 . K u h n l P , S e id l S , H o lz b e rg e r  G . HLA-DR4 c a u s e  p o s it iv e  H T L V - II I  
a n t ib o d y  E L IS A  r e s u lt s .  Lancet 1 9 8 5 ; i :  1 2 2 2 -1 2 2 3 .
1 1 1 . W e iss  SH , M ann D L , M u rra y  C , P o p o v ic  M . HLA-DR a n tib o d y  a n d  
H T L V - I I I  a n t ib o d y  E L IS A  t e s t in g .  Lancet 1985; i i :  157.
1 1 2 . H u n te r  J B , M e n ito v e  J E . HLA a n t ib o d y  d e te c te d  b y  E L IS A  H T L V - I I I  
a n t ib o d y  k i t s .  L a n c e t  1 9 8 5 ; i i :  3 9 7 .
1 1 3 . J u n g k in d  D L , D iR e n z o  S A , Y oung  S J . E f f e c t  o f  u s in g  h e a t-  
in a c t iv a t e d  se ru m  w ith  th e  A b b o tt hum an T - c e l l  ly m p h o tro p ic  v ir u s  
ty p e  I I I  a n t ib o d y  t e s t .  J .  C l in .  M ic r o b io l .  1 9 8 6 ; 2 3 : 3 8 1 -3 8 2 .
1 1 4 . T a y lo r  H L , M o r tim e r  P P , M o u ls d a le  H J , P a r ry  J V , K e n n e d y  D A,
L is t e r  P A . E v a lu a t io n  o f  S ix  C o m m e rc ia l A n t i- H IV  K i t s .
Public Health Laboratory Service and Department of Health and 
Social Security. S T D /8 7 /1 6  M ay 1 9 8 7 .
1 1 5 . S p e ilb e r g  F , K a beya  CM, R y d e r RW. F ie ld  t e s t in g  a n d  c o m p a ra tiv e  
e v a lu a t io n  o f  r a p id ,  v is u a l ly  re a d  s c re e n in g  a s s a y s  f o r  a n t ib o d y  
t o  hum an im m u n o d e fic ie n c y  v i r u s .  L a n c e t  1 9 8 9 ; i :  5 8 0 -5 8 4 .
1 1 6 . L e l ie  P N , R e e s in k  HW, H u ism an  H . E v a lu a t io n  o f  th r e e  s e c o n d -
206
g e n e ra t io n  a n d  th r e e  c o n f ir m a to r y  a s s a y s  f o r  a n t ib o d ie s  t o  hum an 
in n iu n o d e f ic ie n c y  v i r u s .  V o x . S a n g . 1 9 8 8 ; 5 4 : 8 4 -9 1 .
1 1 7 . D e n is  F , L e o n a rd  G , S a n g a re  A . e t  a l .  C o m p a ris o n  o f  10  enzym e 
im m u n o a ssa ys  f o r  d e te c t io n  o f  a n t ib o d y  t o  hum an in m u n o d e fic ie n c y  
v i r u s  ty p e  2 in  W e st A f r ic a n  s e ra . J .  C l in .  M ic r o b io l .  1 9 8 8 ; 
2 6 : 1 0 0 0 -1 0 0 4 .
1 1 8 . P a r ry  J V , M o r tim e r  P P , M a cD o n a ld  C A , K e nn e dy  D A . An e v a lu a t io n  
o f  tw e lv e  c o m m e rc ia l a n t i- H IV  k i t s .  D e p a r tm e n t o f  H e a lth  
p u b lic a t io n  S T D /9 0 /2 7 . L o n d o n : S u p p lie s  T e c h n o lo g y  D iv is io n ,
D e p a rtm e n t o f  H e a lth  1 9 9 0 .
119  P a r ry  J V , M o r tim e r  P P , M a cD o n a ld  C A , K e nn e dy D A . E v a lu a t io n  o f  
c o m m e rc ia l a n t i- H IV  k i t s  : S u p p le m e n t r e p o r t  t o  S T D /9 0 /2 7 . A n t i -  
H IV  2 s e n s i t i v i t y  o f  n in e  c o m b in e d  a n t i- H IV  1 /H IV  2 k i t s .
PH LS V ir u s  R e fe r e n c e  L a b o r a t o r y  a n d  D e p a r tm e n t o f  H e a lth  
M D D /9 0 /55  N ovem ber 1 9 9 0 .
1 2 0 . C a r ls o n  J R , Y ee J ,  H in r ic h s  SH, B ry a n t M L, G a rd n e r MB, P e d e rs e n  
NC. C o m p a ris o n  o f  in d i r e c t  im rru n o flu o re s c e n c e  a n d  w e s te rn  b lo t  
f o r  d e te c t io n  o f  a n ti-h u ra a n  im m u n o d e fic ie n c y  v i r u s  a n t ib o d ie s .
J .  C l in .  M ic r o b io l  1 9 8 7 ; 2 5 : 4 9 4 -4 9 7 .
1 2 1 . A lb  J .  E v a lu a t io n  o f  a new  c o n f ir m a to r y  a s s a y  f o r  a n t ib o d ie s  
a g a in s t  ly m p h a d e n o p a th y -a s s o c ia te d  v ir u s  (L A V )/h u m a n
T - ly m p h o tro p ic  v i r u s  ty p e  I I I  (HPLV I I I ) .  V o x . S a n g . 1 9 8 6 ;
5 1 : 2 3 3 -2 3 5 .
1 2 2 . T e rs ra e tte  M, L e l ie  PN, v a n  d e r  P o e l C L . e t  a l .  C o n firm a tio n  o f  
H IV  s e r o p o s i t iv i t y :  c o m p a ris o n  o f  a n o v e l ra d io in m u n o -  
p r e c ip i t a t io n  a s s a y  t o  in m u n o b lo t t in g  and  v i r u s  c u lt u r e .
J .  M e d . V i r o l .  1 9 8 8 ; 2 4 : 1 0 9 -1 1 6 .
1 2 3 . L e l ie  PN, v a n  d e r  P o e l C L , R e e s in k  HW. I n t e r p r e t a t io n  o f  
is o la te d  H IV  a n t i- p 2 4  r e a c t i v i t y  in  w e s te rn  b lo t  a n a ly s is .
L a n c e t  1 9 8 7 ; i :  6 3 2 .
1 2 4 . T o w b in  H , S ta e h e lin  T , G o rd o n  J .  E le c t r o p h o r e t ic  t r a n s fe r  o f  
p r o te in s  fro m  p o ly a c r y la m id e  g e ls  t o  n it r o c e l lu lo s e  s h e e ts : 
p ro c e d u re  a nd  some a p p lic a t io n s .  P r o c .  N a t l .  A c a d . S c i .  USA 
1 9 7 9 ; 7 6 : 4 3 5 0 -4 3 5 4 .
1 2 5 . B lo ra b e rg  J ,  K L a sse  R J . S p e c i f ic i t ie s  a n d  s e n s i t i v i t ie s  o f  th r e e  
s y s te m s  f o r  d e te r m in a t io n  o f  a n t ib o d ie s  t o  hum an in m u n o d e f ic ie n c y  
v i r u s  b y  e le c t r o p h o r e t ic  irarauno b lo t t in g .  J .  C l in .  M ic r o b io l .  
1 9 8 8 ; 2 6 : 1 0 6 -1 1 0 .
1 2 6 . C e n tre  f o r  D is e a s e  C o n t r o l.  P r o v is io n a l P u b lic  H e a lth  S e rv ic e  
in te r - a g e n c y  re c o m m e n d a tio n s  f o r  s c re e n in g  d o n a te d  b lo o d  a n d  
p la s m a  f a r  a n t ib o d y  t o  th e  v i r u s  c a u s in g  a c q u ire d  im m uno­
d e f ic ie n c y  s y n d ro m e . M o r b id .  M o r t a l .  W e e k ly  R e p . 1 9 8 5 ; 3 4 : 1 -5 .
1 2 7 . B ib e r f ie ld  G , B re d b e rg -R a d e n  U , B o t t ig e r  B . e t  a l .  B lo o d  d o n o r
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s e ra  w it h  f a ls e - p o s i t iv e  w e s te rn  b lo t  r e a c t io n s  t o  hum an im m uno­
d e f ic ie n c y  v i r u s .  L a n c e t  1 9 8 6 ; i i :  2 8 9 -2 9 0 .
1 2 8 . C o u ro u c e  A -M , M u lle r  J - Y ,  R ic h a rd  D . F a ls e  p o s it iv e  w e s te rn  b lo t  
r e a c t io n s  t o  hum an im m u n o d e fic ie n c y  v ir u s  in  b lo o d  d o n o rs .
L a n c e t  1 9 8 6 ; i i :  9 2 1 -9 2 2 .
1 2 9 . v a n  d e r  P o e l C L , R e e s in k  HW, T e rs m e tte  M , L e l ie  PN, H u ism an  H ,
M i edema F . B lo o d  d o n a tio n s  r e a c t iv e  f a r  H IV  in  w e s te rn  b lo t  
b u t  n o n - in fe c t iv e  in  c u lt u r e  a n d  r e c ip ie n t s  o f  b lo o d . L a n c e t  
1 9 8 6 ; i i :  7 5 2 -7 5 3 .
130. C e n tre  f o r  D is e a s e  C o n t r o l.  I n t e r p r e t a t io n  a nd  u s e  o f  th e  
w e s te rn  b lo t  a s s a y  f o r  s e ro d ia g n o s is  o f  hum an im m u n o d e fic ie n c y  
v ir u s  ty p e  1 in f e c t io n s .  Morbid. Mortal. Weekly Rep. 1989;
38: S7.
1 3 1 . C e n tre  f o r  D is e a s e  C o n t r o l.  P n e u m o c y s tis  p ne um on ia  -
L o s  A n g e le s . Morbid. Mortal. Weekly Rep. 1 9 8 1 ; 3 0 : 2 5 0 -2 5 2 .
1 3 2 . C e n tre  f o r  D is e a s e  C o n t r o l.  K a p o s i's  sa rco m a  a n d  P n e u m o c y s tis
p n e u m o n ia  am ong h o m o s e x u a l men -  New Y o rk  C it y  a n d  C a l i f o r n ia .  
Morbid. Mortal. Weekly Rep. 1 9 8 1 ; 3 0 : 3 0 5 -3 0 8 .
1 3 3 . C e n tre s  f o r  D is e a s e  C o n tr o l T a s k  F o rc e  o n  K a p o s i's  S arcom a a n d  
O p p o r tu n is t ic  I n f e c t io n s .  E p id e m io lo g ic  a s p e c ts  o f  th e  c u r r e n t  
o u tb re a k  o f  K a p o s i's  sa rco m a  a n d  o p p o r tu n is t ic  in f e c t io n s .
N . E n g l.  J .  M e d . 1 9 8 2 ; 3 0 6 : 2 4 8 -2 5 2 .
1 3 4 . Q u in n  T C , M ann JM , C u rra n  JW , P io t  P . A ID S  in  A f r ic a :  a n
e p id e m io lo g ic  p a ra d ig m . S c ie n c e  1 9 8 6 ; 2 3 4 : 9 5 5 -9 6 3 .
1 3 5 . M a th u r-W a g h  U , E n lo w  RW, S p ig la n d  I .  e t  a l .  L o n g itu d in a l s tu d y  
o f  p e r s is t e n t  g e n e r a lis e d  lym p ha d en op a  th y  in  h o m o se xu a l m en: 
r e la t io n  t o  a c q u ir e d  in m u n o d e f ic ie n c y  s y n d ro m e . L a n c e t  1 9 8 4 ; 
i :  1 0 3 3 -1 0 3 8 .
1 3 6 . R e d f ie ld  R R , W r ig h t D C , T ra n e n t E C . H ie  W a lte r  R eed s ta g in g  
c la s s i f ic a t io n  f o r  H IL V - I I I /L A V  in f e c t io n .  N . E n g l.  J .  M e d . 
1 9 8 6 ; 3 1 4 : 1 3 1 -1 3 2 .
1 3 7 . C e n tre  f o r  D is e a s e  C o n t r o l.  R e v is io n  o f  th e  CDC s u r v e illa n c e  
c a s e  d e f in i t io n  f a r  a c q u ire d  im m u n o d e fic ie n c y  s y n d ro m e .
Morbid. Mortal. Weekly Rep. 1987; 36: 1S.
1 3 8 . S e rw adda  D , M ugerw a RD, Sewankam bo N K. e t  a l .  S lim  d is e a s e : a 
new  d is e a s e  in  U ganda a nd  i t s  a s s o c ia t io n  w ith  H T L V - II I  in f e c t io n .  
L a n c e t  1 9 8 5 ; i i :  8 4 9 -8 5 2 .
139. C e n tre  f o r  D is e a s e  C o n t r o l.  U p d a te : a c q u ire d  im m u n o d e fic ie n c y  
syn d ro m e  -  U n ite d  S ta te s .  Morbid. Mortal. Weekly Rep. 1986;
3 5 : 1 7 -2 1 .
1 4 0 . W o rld  H e a lth  O r g a n is a t io n .  A c q u ire d  im m u n o d e fic ie n c y  synd rom e
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(A ID S ) -  D a ta  a s  a t  30 J u n e  1 9 9 0 . W k ly .  E p id e m . R e c . 1 9 9 0 ;
6 5 : 2 0 5 -2 1 2 .
1 4 1 . A c q u ire d  im m une d e f ic ie n c y  syn d ro m e  (A ID S ) -  U n ite d  K in g d o m .
A ID S  News S u p p le m e n t, CDS W e e k ly  R e p o r t  1 9 9 0 ; CDS 9 0 /2 7 :
A /1 5 4 .
1 4 2 . C u rra n  JW , J a f f e  HW, H a rd y  AM, M o rga n  V3M, S e lik  R , D o n d e ro  T J . 
E p id e m io lo g y  o f  H IV  in f e c t io n  a n d  A ID S  in  th e  U n ite d  S ta te s .  
S c ie n c e  1 9 8 8 ; 2 3 9 : 6 1 0 -6 1 6 .
1 4 3 . P ie t  P , P lu n m e r F A , M h a lu  F S , L a ra b o ra y  J - L ,  C h in  J ,  Mann JM .
A ID S : a n  in t e r n a t io n a l p e r s p e c t iv e .  S c ie n c e  1 9 8 8 ; 2 3 9 :
5 7 3 -5 7 9 .
1 4 4 . B e rk e lm a n  R L , H eyw ard  W L, S te h r-G re e n  J K , C u rra n  JW . E p id e m io lo g y  
o f  hum an im n u n o d e fic ie n c y  v ir u s  in f e c t io n  a n d  a c q u ire d  im m uno­
d e f ic ie n c y  s y n d ro m e . A m . J .  M e d . 1 9 8 9 ; 8 6 : 7 6 1 -7 7 0 .
1 4 5 . PHLS A ID S  C e n tre . C o m m u n ica b le  D is e a s e  S u r v e illa n c e  C e n tre , a nd  
C o m m u n ic a b le  D is e a s e s  (S c o tla n d )  U n it .  U n p u b lis h e d  q u a r te r ly  
s u r v e il la n c e  ta b le s  N o .8 , S e p te m b e r J u n e  1 9 9 0 .
1 4 6 . C o m m u n ic a b le  D is e a s e s  (S c o tla n d )  U n it .  R e v is e d  p re s e n ta t io n  o f  
th e  r e g u la r  sum m ary ta b le s  o n  r e p o r te d  A ID S  c a s e s  a n d  H IV -1  
a n t ib o d y - p o s it iv e  p e rs o n s . A ID S  News S u p p le m e n t, CDS W e e k ly  
R e p o r t  1 9 9 1 ; CDS 9 1 /0 2 : A 1 8 1 .
1 4 7 . H o lm b e rg  SD , H o rs b u rg h  CR J r ,  W ard JW , J a f f e  HW. B io lo g ic  
f a c t o r s  in  th e  s e x u a l tr a n s m is s io n  o f  hum an Im m u n o d e fic ie n c y  
v i r u s .  J .  I n f e c t .  D is .  1 9 8 9 ; 1 6 0 : 1 1 6 -1 2 5 .
1 4 8 . A d v is o r y  C o m m itte e  o n  D a n g e ro u s  P a th o g e n s . H IV - th e  c a u s a tiv e  
a g e n t o f  A ID S  a nd  r e la te d  c o n d it io n s .  S econd  r e v is io n  o f
g u  i d le  l in e s .  A p p e n d ix  2 . C row n C o p y r ig h t. J a n u a ry  1 9 9 0 .
1 4 9 . E u ro p e a n  C o lla b o r a t iv e  S tu d y . C h ild r e n  b o m  t o  women w ith  
H IV -1  in f e c t io n :  n a tu r a l h is t o r y  a n d  r is k  o f  t r a n s m is s io n .
L a n c e t  1 9 9 1 ; 3 3 7 : 2 5 3 -2 6 0 .
1 5 0 . P e te rm a n  T A , S to n e b u m e r R L , A lle n  J R , J a f f e  HW, C u rra n  JW .
R is k  o f  hum an im m u n o d e fic ie n c y  v ir u s  tra n s m is s io n  fro m  h e te ro ­
s e x u a l a d u lt s  w ith  t r a n s fu s io n - a s s o c ia te d  in f e c t io n s .  JAMA 
1 9 8 8 ; 2 5 9 : 5 5 -5 8 .
1 5 1 . M e d le y  G F , A n d e rs o n  RM, C ox DR, B i l l a r d  L .  In c u b a t io n  p e r io d  
o f  A ID S  in  p a t ie n ts  in fe c te d  v ia  b lo o d  t r a n s fu s io n .  N a tu r e  
1 9 8 7 ; 3 2 8 : 7 1 9 -7 2 1 .
1 5 2 . L u i K - J ,  D a rrc w  WW, R u th e r fo rd  GW. A  m o d e l-b a s e d  e s tim a te  o f  
th e  m ean in c u b a t io n  p e r io d  f o r  A ID S  in  h o m o s e x u a l m en. S c ie n c e  
1 9 8 8 ; 2 4 0 : 1 3 3 3 -1 3 3 5 .
1 5 3 . J a s o n  J ,  L u i K - J ,  R a g n i MV, H e s s o l N A , D a rrc w  WW. R is k  o f
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d e v e lo p in g  A ID S  in  H IV - in fe c te d  c o h o r ts  o f  h a a n o p h ilic  and  
h o m o s e x u a l m en. JA M A  1 9 8 9 ; 2 6 1 : 7 2 5 -7 2 7 .
1 5 4 . M oss A R , B a c c h e t t i P . N a tu r a l h is t o r y  o f  HTV in f e c t io n .  A ID S  
1989? 3 : 5 5 -6 1 .
1 5 5 . E y s te r  ME, G a il MH, B a lla r d  J O , A l-M o n d h iry  H , G e o d e rt J J .
N a tu r a l h is t o r y  o f  hum an in m u n o d e f ic ie n c y  v ir u s  in f e c t io n s  in  
h a e m o p h ilia c s : e f f e c t s  o f  T - c e l l  s u b s e ts , p la t e le t  c o u n ts  a n d
a g e . A n n . I n t e r n .  M e d . 1987? 1 0 7 : 1 -6 .
1 5 6 . G ie s e c k e  J ,  S c a lia -T o m b a  G , B e rg lu n d  0 , B e m to rp  E , S ch u lm a n  S , 
S t ig e n d a l L .  In c id e n c e  o f  sym ptom s and  A ID S  in  146 S w e d is h  
h a e m o p h ilia c s  a n d  b lo o d  t r a n s fu s io n  r e c ip ie n t s  in fe c te d  w ith  
human im m u n o d e fic ie n c y  v i r u s .  B r .  M e d . J .  1988? 2 9 7 : 9 9 -1 0 2 .
1 5 7 . R u th e r fo rd  GW, L if s o n  AR , H e s s o l NA. e t  a l .  C o u rs e  o f  H IV -1  
in f e c t io n  in  a c o h o r t  o f  h o m o se xu a l and  b is e x u a l m en: a n  11 y e a r  
fo l lo w  u p  s tu d y . B r .  B le d . J .  1 9 9 0 ; 3 0 1 : 1 1 8 3 -1 1 8 8 .
1 5 8 . G e o d e rt J J ,  K e s s le r  CM, A le d o r t  LM . A p ro s p e c t iv e  s tu d y  o f  
hum an im m u n o d e fic ie n c y  v i r u s  ty p e  1 in f e c t io n  and  th e  d e v e lo p m e n t 
o f  A ID S  in  s u b je c ts  w it h  h a e m o p h ilia . N . E n g l.  J .  B le d . 1 9 8 9 ; 
3 2 1 : 1 1 4 1 -1 1 4 8 .
1 5 9 . L e e  C A, P h i l l ip s  A , E lf o r d  J .  H ie  n a tu r a l h is t o r y  o f  hum an 
im m u n o d e fic ie n c y  v i r u s  in f e c t io n  in  a h a e ra o p h ilic  c o h o r t .
B r .  J .  H a e m a to l. 1 9 8 9 ; 7 3 : 2 2 8 -2 3 4 .
1 6 0 . K a p la n  J E , S p ira  T J , F is h b e in  D F , Bozem an L H , P in s k y  P F , 
S c h o n b e rg e r L B . A  s ix - y e a r  fo llc w - u p  o f  H IV - in fe c te d  h o m o s e x u a l 
men w ith  lym p h a d e n o p a  t h y .  JAB1A 1 9 8 8 ; 2 6 0 : 2 6 9 4 -2 6 9 7 .
1 6 1 . L a u re n c e  J .  M o le c u la r  in t e r a c t io n s  among h e rp e s  v ir u s e s  a n d  
th e  hum an in m u n o d e f ic ie n c y  v ir u s e s .  J .  I n f e c t .  D is .  1 9 9 0 ;
1 6 2 : 3 3 8 -3 4 6 .
1 6 2 . O sb o rn  L ,  K in k e l S , N a b e l G J . T um our n e c ro s is  f a c t o r  a lp h a  a n d  
in t e r le u k in  1 s t im u la te  th e  hum an in m u n o d e f ic ie n c y  v i r u s  e n h a n c e r 
b y  a c t iv a t io n  o f  th e  n u c le a r  f a c t o r  K B . P r o c .  N a t l .  A c a d . S c i 
USA 1986? 8 9 : 2 3 3 6 -2 3 4 0 .
1 6 3 . T e rs n e tte  M , L a n g e  JM A , d e  G oede REY. e t  a l .  A s s o c ia t io n  b e tw e e n  
b io lo g ic a l p r o p e r t ie s  o f  hum an in m u n o d e f ic ie n c y  v i r u s  v a r ia n ts  a n d  
r is k  f o r  A ID S  and  A ID S  m o r t a l i t y .  L a n c e t  1 9 8 9 ; i :  9 8 3 -9 8 5 .
1 6 4 . K a s lo w  R A , D u g u e sn o y  R , V an  R aden M. e t  a l .  A 1 , CW7, B 8 , DR3 HLA 
a n tig e n  c o m b in a tio n  a s s o c ia te d  w ith  r a p id  d e c lin e  o f  T - h e lp e r  
ly m p h o c y te s  in  H IV -1  in f e c t io n .  L a n c e t  1 9 9 0 ; 3 3 5 : 9 2 7 -9 3 0 .
1 6 5 . P a r ry  J V , P e r ry  KR , M o r tim e r  P P . S e n s it iv e  a s s a y s  f o r  v i r a l
a n t ib o d ie s  in  s a liv a :  a n  a lt e r n a t iv e  t o  te s t s  on  s e ru m . L a n c e t
1 9 8 7 ; i i :  7 2 -7 5 .
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1 6 6 . M o r tim e r  P P , M o u ls d a le  H J , O ld ha m  L J ,  P a r ry  J V , P e r e ira  MS, 
M o r tim e r  J Y . E v a lu t io n  o f  te n  c o m a e rc ia l a n ti-H T L V  I I I / L A V  a s s a y  
k i t s .  P u b l ic  H e a lth  L a b o r a t o r y  S e r v ic e  a n d  D e p a r tm e n t o f  
H e a lth  a n d  S o c ia l  S e c u r i t y  S T B /8 6 /1 4  M a rch  1 9 8 6 .
1 6 7 . G r i l ln e r  L ,  L a n d q v is t M , J o h a n s s o n  M , S ch u lm a n  S . F a ls e  n e g a tiv e  
r e s u lt  b y  th e  W e llo o z y m e  a n t i- H IV  a s s a y  in  t e s t in g  a n  H IV  p o s i t iv e  
h a e m o p h ilia c . L a n c e t  1 9 8 7 ; i :  1 2 0 0 -1 2 0 1 .
1 6 8 . T a y lfo r th  H -L , M o u ls d a le  H J , M o r tim e r  P P . B lo o d  d o n o r  s c re e n in g  
b y  W e llco m e  a n t i- H IV  k i t s .  L a n c e t  1 9 8 7 ; i :  6 3 1 -6 3 2 .
1 6 9 . M o rga n  J ,  T a te  R , F a r r  A D , U rb a n ia k  S J . P o te n t ia l s o u rc e  o f  
e r r o r  in  H T L V - II I  a n t ib o d y  t e s t in g .  L a n c e t  1 9 8 6 ; i :  7 3 9 -7 4 0 .
1 7 0 . B a r r  A , Dow BC , A m o t t  J ,  C ra w fo rd  R J , M it c h e ll  R . A n ti-H T L V  
I I I  s c re e n in g  s p e c i f i c i t y  a nd  s e n s i t i v i t y .  L a n c e t  1 9 8 6 ; i :
1 0 3 2 .
1 7 1 . B a c k e r U , W e in a u e r F , G a th o f G , E b e r le  J .  H IV  a n t ig e n  s c re e n in g  
in  b lo o d  d o n o rs . L a n c e t  1 9 8 7 ; i i :  1 2 1 3 -1 2 1 4 .
1 7 2 . H ie  C o n s o rtiu m  f o r  R e t r o v ir u s  S e ro lo g y  S ta n d a rd is a t io n .
S e r o lo g ic a l d ia g n o s is  o f  hum an im n u n o d e fic ie n c y  v ir u s  in f e c t io n  
b y  w e s te rn  b lo t  t e s t in g .  JAM A 1 9 8 8 ; 2 6 0 : 6 7 4 -6 7 9 .
1 7 3 . G ene se a  J ,  S h ih  JW -K , J e t t  BW, H e w le t t  IK ,  E p s te in  J S , A l t e r  H J .
W hat d o  w e s te rn  b lo t  in d e te r m in a te  p a t te r n s  f o r  hum an im m uno­
d e f ic ie n c y  v ir u s  m ean in  E IA - n e g a tiv e  b lo o d  d o n o rs ?  L a n c e t  
1 9 8 9 ; i i :  1 0 2 3 .
1 7 4 . B jo r c k  L ,  B lo ra b e rg  J .  S tre p to c o c c a l p r o te in  G : A  s e n s it iv e  
t o o l  f a r  d e te c t io n  o f  a n t ib o d ie s  t o  hum an im n u n o d e f ic ie n c y  v ir u s  
p r o te in s  in  w e s te rn  b lo t  a n a ly s is .  E u r .  J .  C l in .  M ic r o b io l .  
1 9 8 7 ; 6 : 4 2 8 -4 2 9 .
1 7 5 . P in te r  A , H onnen W J, T i l l e y  S A . e t  a l .  O lig o m e r ic  s t r u c t u r e  
o f  g p 4 1 , th e  tra n s ra e m b ra n e  p r o te in  o f  hum an im n u n o d e f ic ie n c y  
v ir u s  ty p e  1 . J .  V i r o l .  1 9 8 9 ; 6 3 : 2 6 7 4 -2 6 7 9 .
1 7 6 . Z o lla -P a z n e r  S , G a m y  MK, H onnen W J, P in te r  A . R e in te r p r e ta t io n
o f  hum an im n u n o d e f ic ie n c y  v ir u s  w e s te rn  b lo t  p a t te r n s .
N . E n g l.  J .  M e d . 1 9 8 9 ; 3 2 0 : 1 2 8 0 -1 2 8 1 .
1 7 7 . M it c h e ll  SW, M 'B o u p  S , M in g le  J .  e t  a l .  F ie ld  e v a lu a t io n  o f  
a lt e r n a t iv e  H IV  t e s t in g  s t r a te g y  w it h  a r a p id  ira nu n o  b in d in g  
a s s a y  a nd  a n  a g g lu t in a t io n  a s s a y . L a n c e t  1 9 9 1 ; 3 3 7 : 1 3 2 8 - 
1 3 3 1 .
1 7 8 . F o l le t t  EAC, M c In ty re  A , O 'D o n n e ll B , C le m e n ts  GB, D e s s e lb e rg e r  U . 
H T L V - II I  a n tib o d y  in  d ru g  a b u s e rs  i n  th e  W e st o f  S c o tla n d : th e  
E d in b u rg h  c o n n e c tio n . L a n c e t  1 9 8 6 ; i :  4 4 6 -4 4 7 .
1 7 9 . F o l l e t t  EAC, W a lla c e  L A , M oC ruden E A B . H IV  a n d  HBV in f e c t io n
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in  d ru g  a b u s e rs  in  G la s g o w . Lancet 1987; i :  920.
1 8 0 . S t r a th c ly d e  R e g io n a l C o u n c il.  H IV  in f e c t io n  a n d  A ID S : to w a rd s
a n  in te ra g e n c y  s t r a te g y  in  S t r a th c ly d e .  G la s g o w  1 9 8 8 .
1 8 1 . R o b e rts o n  J R , B u c k n a ll AB V, W e ls b y  PD . e t  a l .  E p id e m ic  o f  A ID S
r e la te d  v ir u s  (H T L V - III/L A V )  in f e c t io n  am ong in t ra v e n o u s  d ru g
a b u s e rs . B r .  M e d . J .  1 9 8 6 ; 2 9 2 : 5 2 7 -5 2 9 .
182. P e u th e re r  J J ,  Edm ond E , S iraraands P , D ic k s o n  J D , B a th  G E. H IL V - I I I  
a n t ib o d y  in  E d in b u rg h  d ru g  a d d ic t s .  Lancet 1985; i i :  1129-1130.
1 8 3 . C h e in g s o n g -P o p o v  R , W e is s  R A , D a lg le is h  A . e t  a l .  P re v a le n c e  
o f  a n tib o d y  t o  hum an T - ly m p h o tro p ic  v ir u s  ty p e  I I I  in  A ID S  and  
A ID S - r is k  p a t ie n ts  in  B r i t a in .  Lancet 1 9 8 4 ; i i :  4 7 7 -4 8 0 .
1 8 4 . M o rtim e r PP, V a n d e rv e ld e  EM, J e s s o n  W J, P e r e ir a  MS, B u rk h a rd t F . 
H T L V - II I  a n tib o d y  in  S w is s  a n d  E n g lis h  in t ra v e n o u s  d ru g  a b u s e rs . 
L a n c e t  1 9 8 5 ; i i :  4 4 9 -4 5 0 .
1 8 5 . G u r t le r  LG , W e rn ic k e  D , E b e r le  J ,  Z o u le k  G , D e in h a rd t F , S ch ranm  W. 
In c re a s e  in  p re v a le n c e  o f  a n t i- H T L V - I I I  in  h a e m o p h ilia c s . Lancet 
1 9 8 4 ; i i :  1 2 7 5 -1 2 7 6 .
1 8 6 . R o d rig o  JM , S e rra  MV, A g u ila r  E , d e l O lm o J A , G im eno  V , A p a r is i L . 
H IL V - I I I  a n t ib o d ie s  in  d ru g  a d d ic ts  in  S p a in . L a n c e t  1 9 8 5 ; i i :  
1 5 6 -1 5 7 .
1 8 7 . F u ch s  D , B le c h a  H 3 , D e in h a rd t F . e t  a l .  H ig h  fre q u e n c y  o f  HTLV I I I  
a n t ib o d ie s  am ong h e te rs o s e x u a  1 d ru g  a b u s e rs  in  th e  A u s t r ia n  T y r o l.  
L a n c e t  1 9 8 5 ; i :  1 5 0 6 .
1 8 8 . A n g a ra  n o  G , Pa s to r e  G , M onno L ,  S a n ta n to n io  T , L u ch e n a  N ,
S c h ir a ld i 0 . R a p id  s p re a d  o f  H T L V - I I I  in f e c t io n  am ong d ru g  
a d d ic ts  in  I t a l y .  L a n c e t  1 9 8 5 ; i i :  1 3 0 2 .
1 8 9 . Landesraan SH, G in z b u rg  HM, W e is s  SH . T he  A ID S  e p id e m ic .
N . E n g l.  J .  M e d . 1 9 8 5 ; 312  5 2 1 -5 2 5 .
1 9 0 . B r e t t le  RP, B is s e t  K , B u rn s  S . e t  a l .  Human im m u n o d e fic ie n c y  
v ir u s  a nd  d ru g  m is u s e : th e  E d in b u rg h  e x p e r ie n c e . B r .  M o d . J .
1 9 8 7 ; 2 9 5 : 4 2 1 -4 2 4 .
1 9 1 . R o b e rts o n  J R , B u c k n a ll ABV, W ig g in s  P . R e g io n a l v a r ia t io n  in  
H IV  a n tib o d y  s e r o p o s i t iv i t y  in  B r i t i s h  in t ra v e n o u s  d ru g  u s e rs . 
L a n c e t  1 9 8 6 ; i :  1 4 3 5 -1 4 3 6 .
1 9 2 . R o b e rts o n  JR , S k id m o re  C . A ID S  a n d  in t ra v e n o u s  d ru g  u s e .
B r .  M e d . J .  1 9 8 7 ; 2 9 4 : 5 7 1 .
1 9 3 . G o ld b e rg  D , W a tson  H , S tu a r t  F , M i l l e r  M , G ru e r  L ,  F o l l e t t  E . 
P harm acy s u p p ly  o f  n e e d le s  a n d  s y r in g e s  -  th e  e f f e c t  o n  s p re a d  
o f  H IV  in  in tra v e n o u s  d ru g  m is u s e rs . I n :  A b s tr a c ts  fro m  th e  
IV International Conference on AIDS V o l. 2 . J u n e  1 2 -1 6 , 1 9 8 8 ,
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S to c k h o lm , S w eden : M e d ic a l P u b lis h in g  G ro u p , 1 9 8 8 : 8521 ( a b s t r . ) :
3 8 9 .
1 9 4 . B u n in g  E C , O o u tin h o  R A , v a n  B ru s s e l GHA, v a n  S a n te n  GW,
v a n  Z a d e lh o f f  AW. P re v e n tin g  A ID S  in  d ru g  a d d ic ts  in  A m s te rd a m . 
L a n c e t  1 9 8 6 ; i :  1 4 3 5 .
1 9 5 . D onoghoe  MC, S tira s o n  G V, D o la n  K , A l l d r i t t  L .  C hanges in  H IV  r is k  
b e h a v io u r  in  c l ie n t s  o f  s y r in g e -e x c h a n g e  schem es in  E n g la n d  a n d  
S c o tla n d . A ID S  1 9 8 9 ; 3 : 2 6 7 -2 7 2 .
1 9 6 . R o b e rts o n  J R , S k id m o re  C A , R o b e r ts  J J K . H IV  in f e c t io n  in  in t r a ­
v e n o u s  d ru g  u s e r s :  a fo llo w - u p  s tu d y  in d ic a t in g  c h a n g e s  in  r i s k -
ta k in g  b e h a v io u r . B r .  J .  A d d ic t .  1 9 8 8 ; 8 3 : 3 8 7 -3 9 1 .
1 9 7 . S k id m o re  C A , R o b e rts o n  J R , R o b e r ts  J J K . C ha ng es in  H IV  r i s k -  
ta k in g  b e h a v io u r  am ong in tra v e n o u s  d ru g  u s e r s :  a se co n d  fo l lo w - u p .  
A ID S  News S u p p le m e n t. CDS W e e k ly  R e p . 1 9 8 9 ; CDS 8 9 /0 3 : A 8 7 .
1 9 8 . G o ld b e rg  D J , G re e n  S T , K in g d o m  JC P , C h r is t ie  PR . H IV  in f e c t io n  
am ong fe m a le  d ru g -m is u s in g  p r o s t i t u t e s  in  G re a te r  G la s g o w . A ID S  
News S u p p le m e n t. CDS W e e k ly  R e p . 1 9 8 8 ; CDS 8 8 /1 2 : A 4 8 .
1 9 9 . K in g s le y  L A , D e te ls  R , K a s lo w  R . e t  a l .  R is k  fa c to r s  f o r  
s e ro c o n v e rs io n  t o  hum an in m u n o d e f ic ie n c y  v i r u s  am ong m a le  
h o m o s e x u a ls . L a n c e t  1 9 8 7 ; i i :  3 4 5 -3 4 9 .
2 0 0 . N ie d e c k e n  H , L u tz  G , B a u e r R , K re y s e l HW. L a n g h e rh a n s  c e l l  a s  
p r im a ry  t a r g e t  a n d  v e h ic le  f o r  tr a n s m is s io n  o f  H IV . L a n c e t  1 9 8 7 ; 
i i :  5 1 9 -5 2 0 .
2 0 1 . C a m e  C A, W e lle r  IV D , J o h n s o n  AM. e t  a l .  P re v a le n c e  o f  a n t ib o d ie s  
t o  hum an im m u n o d e fic ie n c y  v i r u s ,  g o n o rrh o e a  r a te s ,  and  c h a n g e d  
s e x u a l b e h a v io u r  in  h o m o s e x u a l men in  L o n d o n . L a n c e t  1 9 8 7 ; i :  
6 5 6 -6 5 8 .
2 0 2 . v a n  K ro g h  G , H e lls t r a n  L , B o t t ig e r  M. D e c lin in g  in c id e n c e  o f  
s y p h i l is  am ong h o m o s e x u a l men in  S to c k h o lm . L a n c e t  1 9 8 6 ; i i :  
9 2 0 -9 2 1 .
2 0 3 . v a n  d e n  H oek JA R , v a n  G r ie n s v e n  G JP , O o u tin h o  R A . In c re a s e  in
u n s a fe  h o m o s e x u a l b e h a v io u r . L a n c e t  1 9 9 0 ; 3 3 6 : 1 7 9 -1 8 0 .
2 0 4 . W ard  JW , D eppe  D A , Sam son S . e t  a l .  R is k  o f  hum an im m uno­
d e f ic ie n c y  v i r u s  in f e c t io n  fro m  b lo o d  d o n o rs  w ho la t e r  d e v e lo p e d
th e  a c q u ire d  in m u n o d e f ic ie n c y  s y n d ro m e . A n n . I n t e r n .  M e d .
1 9 8 7 ; 1 0 6 ; 6 1 -6 2 .
2 0 5 . M oss AR . A ID S  a n d  in tra v e n o u s  d ru g  u s e : th e  r e a l  h e te ro s e x u a l
e p id e m ic . B r .  M e d . J .  1 9 8 7 ; 2 9 4 : 3 8 9 -3 9 0 .
2 0 6 . Human im m u n o d e fic ie n c y  v i r u s  (H IV ) in f e c t io n ,  S c o tla n d . Q u a r te r ly  
r e p o r t  t o  30 J u n e  1 9 9 0 . A ID S  News S u p p le m e n t, CDS W e e k ly  R e p . 
1 9 9 0 ; CDS 9 0 /2 8 : A 1 5 5 .
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2 0 7 . T a p p in  DM, G ird w o o d  RWA, F o l l e t t  EAC , K ennedy R , B ro w n  A J , 
C o c k b u rn  F . P re v a le n c e  o f  m a te rn a l H IV  in f e c t io n  i n  S c o tla n d  
b a s e d  o n  u n lin k e d  a n o nym ou s t e s t in g  o f  n e w b o rn  b a b ie s . L a n c e t  
1 9 9 1 ; 3 3 7 : 1 5 6 5 -1 5 6 7 .
2 0 8 . S p re c h e r S , S o u m e n k o ff G , P u is s a n t F , D e g u e ld re  M. V e r t ic a l  
tr a n s m is s io n  o f  H IV  in  1 5 -w e e k  f e t u s .  L a n c e t  1 9 8 6 ; i i :  2 8 8 -2 8 9 .
2 0 9 . W illia m s  A E , F a n g  C T , S la ra e n  D J . e t  a l .  S e ro p re v a le n c e  a nd  
e p id e m io lo g ic a l c o r r e la te s  o f  H E L V -I in f e c t io n  in  U .S . b lo o d  
d o n o rs . Science 1 9 8 8 ; 2 4 0 : 6 4 3 -6 4 6 .
2 1 0 . C o s te  J ,  L e ra a ire  JM , B a r in  F , C o u ro u o e  A -M . H T L V - I / I I  in  F re n c h  
b lo o d  d o n o rs . L a n c e t  1 9 9 0 ; 3 3 5 : 1 1 6 7 -1 1 6 8 .
2 1 1 . S a lk e r  R , T o s s w ill JH C , B a rb a ra  J A J . e t  a l .  H IL V - l/1 1  a n t ib o d ie s  
in  UK b lo o d  d o n o rs . Lancet 1 9 9 0 ; 3 3 6 : 3 1 7 .
2 1 2 . S o r ia n o  V , T o r  J ,  M on zcn  M , G ra u s  JM , C lo te t  B , R ib a s -M u n d o  M . 
H T L V -I in  S p a in . Lancet 1 9 9 0 ; 3 3 6 : 6 2 7 -6 2 8 .
2 1 3 . G ra d ilo n e  A , Z a n i M , B a r i l l a r i  G . e t  a l .  H T L V -I a n d  H IV  
in f e c t io n  in  d ru g  a d d ic t s  in  I t a l y .  L a n c e t  1 9 8 6 ; i i :  7 5 3 -7 5 4 .
2 1 4 . P age  J B , L a i S , C h itw o o d  DD, K lim a s  NC, S m ith  PC, F le tc h e r  MA. 
H T L V - I / I I  s e r o p o s i t iv i t y  a n d  d e a th  fro m  A ID S  am ong H IV -1  
s e r o p o s it iv e  in t ra v e n o u s  d ru g  u s e r s .  L a n c e t  1 9 9 0 ; 3 3 5 :
1 4 3 9 -1 4 4 1 .
2 1 5 . M anns A , O braras I ,  D e te ls  R . e t  a l .  S e ro p re v a le n c e  o f  human 
T - c e l l  ly m p h o tro p ic  v i r u s  ty p e  I  am ong h o m o s e x u a l m en in  th e  
U n ite d  S ta te s .  N . Engl. J .  M e d . 1 9 8 8 ; 3 1 9 ; 5 1 6 -5 1 7 .
2 1 6 . H o rs b u rg h  CR J r ,  H o lm b e rg  SD . T h e  g lo b a l d is t r ib u t io n  o f  hum an 
im m u n o d e fic ie n c y  v i r u s  ty p e  2 (H IV -2 )  in f e c t io n .  Transfusion 
1 9 8 8 ; 2 8 : 1 9 2 -1 9 5 .
2 1 7 . PHLS W o rk in g  G ro u p . P re v a le n c e  o f  H IV  a n t ib o d y  in  h ig h  a nd  le w  
r i s k  g ro u p s  in  E n g la n d . Br. M e d . J .  1 9 8 9 ; 2 9 8 : 4 2 2 -4 2 3 .
2 1 8 . L e v y  J A . T he  t r a n s m is s io n  o f  A ID S : th e  c a s e  o f  th e  in fe c te d  
c e l l .  JAM A 1 9 8 8 ; 2 5 9 : 3 0 3 7 -3 0 3 8 .
2 1 9 . L y o n s  S F , J u p p  PG, S c h o u b  B D . S u r v iv a l o f  H IV  in  th e  common 
b e d b u g . Lancet 1 9 8 6 ; i i :  4 5 .
2 2 0 . T e rv o  T , L a h d e v ir ta  J ,  V a h e r i A , V a l le  S -L , S u n i J .  R e c o v e ry  
o f  H T L V - II I  fro m  c o n ta c t  le n s e s . L a n c e t  1 9 8 6 ; i :  3 7 9 -3 8 0 .
2 2 1 . S r in iv a s a n  A , Y o rk  D , B o h a n  C . L a c k  o f  H IV  r e p l ic a t io n  in  
a r th ro p o d  c e l l s .  L a n c e t  1 9 8 7 ; i :  1 0 9 4 -1 0 9 5 .
2 2 2 . C a s tro  KG, L ie b  S , J a f f e  HW. e t  a l .  T ra n s m is s io n  o f  H IV  in
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B e lle  G la d e , F lo r id a :  le s s o n s  f o r  o th e r  o o ra n u n itie s  in  th e
U n ite d  S ta te s .  S c ie n c e  1 9 8 8 ; 2 3 9 : 1 9 3 -1 9 7 .
2 2 3 . V it t e c o q  D , M e t t e ta l J F , R o u z io u x  C , B a ch  J F , B o uch o n  J P .
A c u te  H IV  in f e c t io n  a f t e r  a c u p u n c tu re  t r e a tm e n ts .  N . E n g l.
J .  M e d . 1 9 8 9 ; 3 2 0 : 2 5 0 -2 5 1 .
2 2 4 . F is c h l MA, D ic k in s o n  GM, S c o t t  G B, K lira a s  N , F le tc h e r  MA,
P a rk s  W. E v a lu a t io n  o f  h e te ro s e x u a l p a r tn e r s ,  c h ild r e n  and  
h o u s e h o ld  c o n ta c ts  o f  a d u lt s  w ith  A ID S . JA M A  1 9 8 7 ; 2 5 7 : 
6 4 0 -6 4 4 .
2 2 5 . M its u y a  H , W e in h o ld  K J , F urm an P A . S 'A z id o -S 1 
d e c x y th y ra id in e  (BW A 5 0 9 U ): An a n t i v i r a l  a g e n t t h a t  in h ib i t s
th e  i n f e c t i v i t y  a n d  c y to p a th ic  e f f e c t  o f  hum an T -  ly m p h o tro p ic  
v i r u s  ty p e  I I I / ly m p h a d e n o p a th y - a s s o c ia te d  v i r u s  in  v i t r o .
P r o c .  N a t l .  A c a d . S c i .  USA 1 9 8 5 ; 8 2 : 7 0 9 6 -7 1 0 0 .
2 2 6 . C u lle n  B R , G re e n e  WC. R e g u la to ry  p a th w a y s  g o v e rn in g  H IV -1  
r e p l ic a t io n .  C e l l  1 9 8 9 ; 5 8 : 4 2 3 -4 2 6 .
2 2 7 . J o n e s  K A , K adonaga  J T , L u c iw  P A , T j ia n  R . A c t iv a t io n  o f  th e  
A ID S  r e t r o v ir u s  p ro m o te r  b y  c e l lu la r  t r a n s c r ip t io n  f a c t o r ,  S p1 . 
S c ie n c e  1 9 8 6 ; 2 3 2 : 7 5 5 -7 5 9 .
2 2 8 . A s jo  B , M o r fe ld t-M a n s o n  L ,  A lb e r t  J .  e t  a l .  R e p lic a t iv e  
c a p a c ity  o f  h im a n  in m u n o d e f ic ie n c y  v i r u s  fro m  p a t ie n ts  w ith  
v a r y in g  s e v e r it y  o f  H IV  in f e c t io n .  L a n c e t  1 9 8 6 ; i i :  6 6 0 -6 6 2 .
2 2 9 . M o rro w  WJW, W h a rto n  M , S t r ie k e r  R B , L e v y  J A . C ir c u la t in g  
in m u n e  c o m p le x e s  in  p a t ie n t s  w ith  a c q u ire d  im m une d e f ic ie n c y  
syn d ro m e  c o n ta in  th e  A ID S -a s s o c ia te d  r e t r o v ir u s .  C l in .  
Im m u n o l. In m u n o p a th o l.  1 9 8 6 ; 4 0 : 5 1 5 -5 2 4 .
2 3 0 . B a r in  F . A ID S  v a c c in e  p r e d ic t io n s .  N a tu r e  1 9 8 7 ; 3 2 8 : 2 1 .
231 • C h e in g s o n g -P o p o v  R , P a n a g io t id i C , B cw co ck  S , A ro n s ta m  A ,
W a d sw o rth  J ,  W eber J .  R e la t io n  b e tw e e n  h u m o ra l re s p o n s e s  t o  
H IV  g a g  a n d  e n v  p r o te in s  a t  s e ro c o n v e rs io n  a n d  c l i n i c a l  o u tco m e  
o f  HEV in f e c t io n .  B r .  M e d . J .  1 9 9 1 ; 3 0 2 : 2 3 -2 6 .
2 3 2 . L a n g e  JM A, d e  w o lf  F , K ro n e  W JA, D a n n e r S A , O o u tin h o  R ,
G o u d s ra it J .  D e c lin e  o f  a n t ib o d y  r e a c t i v i t y  t o  o u te r  v i r a l  c o re  
p r o te in  p 1 7 i s  a n  e a r l i e r  s e r o lo g ic a l m a rk e r o f  d is e a s e  
p ro g re s s io n  in  hum an im m u n o d e fic ie n c y  v i r u s  in f e c t io n  th a n  
a n t i- 2 4  d e c lin e .  A ID S  1 9 8 7 ; 1 : 1 5 5 -1 5 9 .
2 3 3 . K a r ls s o n  F A , W ib e ll L ,  E v r in  P E . B 2 - m ic r o g lo b u lin  in  
c l i n i c a l  m e d ic in e . S c a n d . J .  c l i n .  L a b .  I n v e s t .  1 9 8 0 ; 4 0 , 
S u p p l. 1 5 4 : 2 7 -3 7 .
2 3 4 . Z o lla -P a z n e r  S , W ill ia m  D , E l-S a d r  W, M arm or M, S ta h l R . 
Q u a n t ita t io n  o f  / ^ - m ic r o g lo b u l in  a n d  o th e r  im m une 
c h a r a c t e r is t ic s  in  a p ro s p e c t iv e  s tu d y  o f  men a t  r i s k  f o r
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a c q u ire d  im m une d e f ic ie n c y  s y n d ro m e . JAM A 1 9 8 4 ; 2 5 1 :
2 9 5 1 -2 9 5 5 .
2 3 5 . M oss AR , B a c c h e tt i P , O sm ond D . e t  a l .  S e r o p o s it iv i t y  f o r
H IV  a n d  th e  d e v e lo p m e n t o f  A ID S  o r  A ID S  r e la te d  c o n d it io n :
th r e e  y e a r  fo llo w - u p  o f  th e  San F ra n c is c o  G e n e ra l H o s p ita l
c o h o r t .  B r .  M e d . J .  1 9 8 8 ; 2 9 6 : 7 4 5 -7 5 0 .
2 3 6 . M oss AR . P r e d ic t in g  w ho  w i l l  p ro g re s s  t o  A ID S . B r .  M e d . J .  
1 9 8 8 ; 2 9 7 : 1 0 6 7 -1 0 6 8 .
2 3 7 . A l la  in  J - P , L a u r ia n  Y , P a u l D A . e t  a l .  L o n g -te rm  e v a lu a t io n
o f  H IV  a n tig e n  a nd  a n t ib o d ie s  t o  p 2 4  a n d  gp41 in  p a t ie n ts  w ith  
h a e m o p h ilia . N . E n g l.  J .  M e d . 1 9 8 7 ; 3 1 7 : 1 1 1 4 -1 1 2 1 .
2 3 8 . L a r d e r  B A , Kemp SD . M u lt ip le  m u ta tio n s  in  H IV -1  re v e rs e  
t r a n s c r ip ta s e  c o n fe r  h ig h - le v e l r e s is ta n c e  to  z id o v u d in e  (A Z T ). 
S c ie n c e  1 9 8 9 ; 2 4 6 : 1 1 5 5 -1 1 5 8 .
2 3 9 . N a th w a n i D , G reen  S T , W a lla c e  L ,  H a r r io t  R . S erum  
/$2 - n d c r o g lo b u lin  le v e ls  a n d  z id o v u d in e  th e ra p y . Im m u n o l 
a n d  I n f e c t .  D is .  1 9 9 0 ; 1 :  7 7 -7 8 .
2 4 0 . J a c o b s o n  MA, A b ram s D I ,  V o lb e rd in g  P A . e t  a l .  S erum  
^ - m ic r o g lo b u l in  d e c re a s e s  in  p a t ie n ts  w ith  A ID S  o r  ARC 
t r e a te d  w ith  a z id o th y r a id in e . J .  I n f e c t .  D is .  1 9 8 9 ; 1 5 9 : 1 0 2 9 - 
1 0 3 6 .
2 4 1 . F a h e y  J L , T a y lo r  JM 3 , D e te ls  R . e t  a l .  T he  p ro g n o s t ic  v a lu e  o f  
c e l l u la r  and  s e r o lo g ic  m a rk e rs  in  in f e c t io n  w ith  hum an im m uno­
d e f ic ie n c y  v ir u s  ty p e  1 . N . E n g l.  J .  M e d . 1 9 9 0 ; 3 2 2 : 1 6 6 -1 7 2 .
2 4 2 . C u th b e r t R JG , L u d la ra  C A , T u c k e r  J .  e t  a l .  F iv e  y e a r  p ro s p e c t iv e  
s tu d y  o f  HEV in f e c t io n  in  th e  E d in b u rg h  h a e m o p h ilia c  c o h o r t .
B r .  M e d . J .  1 9 9 0 ; 301 : 9 5 6 -9 6 1 .
2 4 3 . C ra s k e  J ,  D i l l i n g  N , S te r n  D . A n  o u tb re a k  o f  h e p a t i t is  a s s o c ia te d  
w it h  in tra v e n o u s  in je c t io n  o f  f a c t o r - V I I I  c o n c e n tra te . L a n c e t  
1 9 7 5 ; i i :  2 2 1 -2 2 3 .
2 4 4 . H ru b y  M, S c h a u f V . T r a n s fu s io n - r e la te d  s h o r t - in c u b a t io n  h e p a t i t is  
in  h a e ra o p h ilic  p a t ie n t s .  JAM A 1 9 7 8 ; 2 4 0 : 1 3 5 5 -1 3 5 7 .
2 4 5 . C hoo  Q -L , K uo G , W e in e r A J , O v e rb y  L R , B ra d le y  EW, H o u g h to n  M . 
I s o la t io n  o f  a cDNA c lo n e  d e r iv e d  fro m  a b lo o d -b o rn e  n o n -A , n o n -B  
v i r a l  h e p a t i t is  g en om e. S c ie n c e  1 9 8 9 ; 2 4 4 : 3 5 9 -3 6 2 .
2 4 6 . H ay CRM, P re s to n  F E , T r ig e r  DR, U nd e rw oo d  JC E . P ro g re s s iv e
l i v e r  d is e a s e  in  h a e m o p h ilia : a n  u n d e rs ta te d  p ro b le m . L a n c e t
1 9 8 5 ; i :  1 4 9 5 -1 4 9 8 .
2 4 7 . C e n tre  f o r  D is e a s e  C o n t r o l.  P n e u m o c y s tis  c a r i n i i  p ne um on ia  
am ong p e rs o n s  w ith  h a e m o p h ilia  A . M o r b id .  M o r t a l.  W e e k ly  R e p . 
1 9 8 2 ; 3 1 : 3 6 5 -3 6 7 .
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2 4 8 . M cD o ug a l J S , M a r t in  L S , O o rt SP , M ozen M , H e ld e b ra n t CM, E v a t t  B L . 
T h e rm a l in a c t iv a t io n  o f  th e  a c q u ire d  im n u n o d e f ic ie n c y  syn d ro m e  
v i r u s ,  hum an T  ly m p h o tro p ic  v i r u s - I I I / ly m p h a d e n o p a th y -a s s o c ia te d  
v i r u s ,  w ith  s p e c ia l r e fe re n c e  t o  a n t i- h a e m o p h ilic  f a c t o r .
J .  C l in .  I n v e s t .  1 9 8 5 ; 7 6 : 8 7 5 -8 7 7 .
2 4 9 . B e m to r p  E . N o e v id e n c e  o f  H IV  tr a n s m is s io n  a f t e r  lo n g - te rm
fo llo w - u p  o f  h a e m o p h ilia c s  t r e a te d  w ith  h e a t - t r e a te d  f a c t o r  V I I I  
c o n c e n tra te  o f  A m e ric a n  o r ig in .  L a n c e t  1 9 8 7 ; i i :  2 8 3 .
2 5 0 . A ID S  G ro u p  o f  th e  U n ite d  K in gd om  H a e m o p h ilia c  C e n tre  D ir e c to r s .  
P re v a le n c e  o f  a n t ib o d y  t o  HTLV I I I  in  h a e m o p h ilia c s  in  th e  UK.
B r .  M e d . J .  1 9 8 6 ; 2 9 3 : 1 7 5 -1 7 6 .
2 5 1 . K itc h e n  LW, B a r in  F , S u lliv a n  J .  e t  a l .  A e t io lo g y  o f  A ID S : 
a n t ib o d ie s  t o  hum an T - c e l l  le u k a e m ia  v ir u s  ( ty p e  I I I )  in  
h a e m o p h ilia c s . N a tu r e  1 9 8 4 ; 3 1 2 : 3 6 7 -3 6 9 .
2 5 2 . A ro n s o n  D L . F a c to r  V I I I  ( a n t ih a e m o p h ilic  g lo b u l in ) .  Sem
T h ro m b . H e m o s t. 1 9 7 9 ; 6 : 1 2 -2 7 .
2 5 3 . A ro n s o n  D L . F a c to r  IX  c o m p le x . S em . T h ro m b . H e m o s t. 1 9 7 9 ;
6 : 2 8 -4 3 .
2 5 4 . W h ite  GC I I ,  M a tth e w s  T5J, W e in h o ld  K J . e t  a l .  H T L V - I I I  
s e ro c o n v e rs io n  a s s o c ia te d  w ith  h e a t - t r e a te d  f a c t o r  V I I I  
c o n c e n tr a te .  L a n c e t  1 9 8 6 ; i :  6 1 1 -6 1 2 .
2 5 5 . R am say R B , P a lm e r E L , M cD ouga l J S . e t  a l .  A n tib o d y  t o  ly ra p h - 
a d e n o p a th y -a s s o c ia te d  v ir u s  in  h a e m o p h ilia c s  w ith  a n d  w ith o u t  
A ID S . L a n c e t  1 9 8 4 ; i i :  3 9 7 -3 9 8 .
2 5 6 . M e lb y e  M , F ro e b e l K S , M adhok R . e t  a l .  H T L V - I I I  s e r o p o s i t iv i t y  
in  E u ro p e a n  h a e m o p h ilia c s  e xp o se d  t o  f a c t o r  V I I I  c o n c e n tra te  
im p o r te d  fro m  th e  USA. L a n c e t  1 9 8 4 ; i i :  1 4 4 4 -1 4 4 6 .
2 5 7 . G u r t le r  LG , W e rn ic k e  D , E b e r le  J ,  Z o u le k  G , D e in h a rd t F ,
S ch ranm  W. In c re a s e  in  p re v a le n c e  o f  a n t i- K P L V - I I I  in  
h a e m o p h ilia c s . L a n c e t  1 9 8 4 ; i i :  1 2 7 5 -1 2 7 6 .
2 5 8 . M a th e z  D , L e ib o v itc h  J ,  S u lta n  Y , M a is o n n e u v e  P . L A V /H T L V - III 
s e ro c o n v e rs io n  a n d  d is e a s e  in  h a e ra p h ilia c s  t r e a te d  in  F ra n c e .
N . E n g l.  J .  M e d . 1 9 8 6 ; 3 1 4 : 1 1 8 -1 1 9 .
2 5 9 . M a th e s o n  D S, G re e n  B J , P oon M -C , Bowen T J , F r i t z l e r  M J, H o a r D I.
T  ly m p h o c y te s  fro m  h a e m o p h ilia c s  p r o l i f e r a t e  a f t e r  e x p o s u re  t o  
f a c t o r  V I I I  p r o d u c t .  V o x . S a n g . 1 9 8 6 : 5 1 : 9 2 -9 5 .
2 6 0 . L u d la ra  CA, T u c k e r  J ,  S te e l CM. e t  a l .  Human T - ly m p h o tro p ic  
v i r u s  ty p e  I I I  ( H T L V - I I I )  in f e c t io n  in  s e ro n e g a tiv e  h a e m o p h ilia c s  
a f t e r  t r a n s fu s io n  w ith  f a c to r  V I I I .  L a n c e t  1 9 8 5 ; i i :  2 3 3 -2 3 6 .
2 6 1 . S te e l CM, L u d la ra  C A , B e a ts o n  D . e t  a l .  HLA h a p lo ty p e  A1 B8 DR3
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a s  a r i s k  f a c t o r  f o r  H IV - r e la te d  d is e a s e . L a n c e t  1 9 8 8 ; i :  
1 1 8 5 -1 1 8 8 .
2 6 2 . S im a o n d s  P , L a in s o n  F A L , C u th b e r t R , S te e l CM, P e u th e re r  J F , 
L u d la m  C A . H IV  a n tig e n  a n d  a n tib o d y  d e te c t io n :  v a r ia b le  
re s p o n s e s  t o  in f e c t io n  in  th e  E d in b u rg h  h a e m o p h ilia c  c o h o r t .
B r .  H e d . J .  1 9 8 8 ; 2 9 6 : 5 9 3 -5 9 8 .
2 6 3 . E y s te r  ME, B a lla r d  J O , G a il MH, Drum m ond J E , G o e d e rt J J .  
P r e d ic t iv e  m a rk e rs  f o r  th e  a c q u ire d  in m u n o d e f ic ie n c y  syn d ro m e  
(A ID S ) in  h a e m o p h ilia c s : p e r s is te n c e  o f  p24  a n t ig e n  a n d  le w
T4 c e l l  c o u n t.  A n n . I n t e r n .  M e d . 1 9 8 9 ; 1 1 0 : 9 6 3 -9 6 9 .
2 6 4 . D a rb y  S C , R iz z a  OR, D o ll  R , S p o o n e r R JD , S t r a t to n  IM , T h a k ra r  B . 
In c id e n c e  o f  A ID S  a nd  e x c e s s  o f  m o r t a li t y  a s s o c ia te d  w ith  H IV
in  h a e m o p h ilia c s  in  th e  U n ite d  K in g d o m : r e p o r t  o n  b e h a lf  o f  th e
d ir e c t o r s  o f  h a e m o p h ilia  c e n tr e s  in  th e  U n ite d  K in g d o m .
B r .  M e d . J .  1 9 8 9 ; 2 9 8 : 1 0 6 4 -1 0 6 8 .
2 6 5 . W e b s te r A , L e e  CA, C ook DG. e t  a l .  c y to m e g a lo v iru s  in f e c t io n  
a n d  p ro g re s s io n  to w a rd s  A ID S  in  h a e m o p h ilia c s  w it h  hum an im m uno­
d e f ic ie n c y  v ir u s  in f e c t io n .  L a n c e t  1 9 8 9 ; i i :  6 3 -6 6 .
2 6 6 . G a rry  R F , W it te  MH, G o t t l ie b  AA e t  a l .  D o c u m e n ta tio n  o f  a n  A ID S  
v i r u s  in f e c t io n  in  th e  U n ite d  S ta te s  in  1 9 6 8 . JAM A 1 9 8 8 ; 2 6 0 : 
2 0 8 5 -2 0 8 7 .
2 6 7 . C e n tre  f o r  D is e a s e  C o n tr o l.  A  c lu s t e r  o f  K a p o s i1 s  sa rco m a  a n d  
P n e u m o c y s tis  c a r in n i p ne um on ia  am ong h o m o s e x u a l m a le  r e s id e n ts
o f  L o s  A n g e le s  a n d  O ra n g e  C o u n t ie s , C a l i f o r n ia .  M o r b id .  M o r t a l .  
W e e k ly  R e p . 1 9 8 2 : 3 1 : 3 0 5 -3 0 7 .
2 6 8 . S h i l t s  R . A nd th e  b an d  p la y e d  o n . S t .  M a r t in 's  P re s s , New Y o rk , 
1 9 8 7 .
2 6 9 . L if s o n  A R , B u c h b in d e r S P , S h e p p a rd  HW. e t  a l .  L o n g - te rm  hum an 
im m u n o d e fic ie n c y  v ir u s  in f e c t io n  in  h o m o s e x u a l a n d  b is e x u a l men 
w ith  n o rm a l CD4+ ly m p h o c y te  c o u n ts : im m u n o lo g ic  a nd  v i r o lo g ic  
c h a r a c t e r is t ic s .  J .  I n f e c t .  D is .  1 9 9 1 ; 1 6 3 : 9 5 9 -9 6 5 .
2 7 0 . D u e s b e rg  PH . Human im m u n o d e fic ie n c y  v ir u s  a n d  a c q u ire d  im m uno­
d e f ic ie n c y  s y n d ro m e : c o r r e la t io n  b u t  n o t c a u s a tio n . P r o c .  N a t l .  
A c a d . S c i .  USA 1 9 8 9 ; 8 6 : 7 5 5 -7 6 4 .
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